<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Interventions for dialysis patients with hepatitis C virus (HCV) infection - Prabhu, AR - 2023 | Cochrane Library</title> <meta content="Interventions for dialysis patients with hepatitis C virus (HCV) infection - Prabhu, AR - 2023 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007003.pub3/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Interventions for dialysis patients with hepatitis C virus (HCV) infection - Prabhu, AR - 2023 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007003.pub3/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD007003.pub3" name="dc.identifier" scheme="DOI"/> <meta content="Interventions for dialysis patients with hepatitis C virus (HCV) infection" name="citation_title"/> <meta content="Attur Ravindra Prabhu" name="citation_author"/> <meta content="Kasturba Medical College Manipal, Manipal Academy of Higher Education" name="citation_author_institution"/> <meta content="aravindraprabhu@gmail.com" name="citation_author_email"/> <meta content="Indu Ramachandra Rao" name="citation_author"/> <meta content="Kasturba Medical College Manipal, Manipal Academy of Higher Education" name="citation_author_institution"/> <meta content="Shankar Prasad Nagaraju" name="citation_author"/> <meta content="Kasturba Medical College Manipal, Manipal Academy of Higher Education" name="citation_author_institution"/> <meta content="Eti Rajwar" name="citation_author"/> <meta content="Prasanna School of Public Health, Manipal Academy of Higher Education" name="citation_author_institution"/> <meta content="Bhumika T Venkatesh" name="citation_author"/> <meta content="Prasanna School of Public Health, Manipal Academy of Higher Education" name="citation_author_institution"/> <meta content="Sreekumaran Nair N" name="citation_author"/> <meta content="Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER) (Institution of National Importance Under Ministry of Health and Family Welfare, Government of India)" name="citation_author_institution"/> <meta content="Ganesh Pai" name="citation_author"/> <meta content="Kasturba Medical College Manipal, Manipal Academy of Higher Education" name="citation_author_institution"/> <meta content="Nageswara P Reddy" name="citation_author"/> <meta content="Yashoda Hospitals" name="citation_author_institution"/> <meta content="Deepak Suvarna" name="citation_author"/> <meta content="JSS Medical College" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="4" name="citation_issue"/> <meta content="10.1002/14651858.CD007003.pub3" name="citation_doi"/> <meta content="2023" name="citation_date"/> <meta content="2023/04/25" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007003.pub3/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007003.pub3/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007003.pub3/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Antiviral Agents [therapeutic use]; Chronic Disease; Hepacivirus; *Hepatitis C [drug therapy]; Interferons [therapeutic use]; Recurrence; Renal Dialysis; *Renal Insufficiency, Chronic [drug therapy]; Ribavirin [therapeutic use]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007003.pub3&amp;doi=10.1002/14651858.CD007003.pub3&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007003.pub3&amp;doi=10.1002/14651858.CD007003.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007003.pub3&amp;doi=10.1002/14651858.CD007003.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007003.pub3&amp;doi=10.1002/14651858.CD007003.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007003.pub3&amp;doi=10.1002/14651858.CD007003.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007003.pub3&amp;doi=10.1002/14651858.CD007003.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007003.pub3&amp;doi=10.1002/14651858.CD007003.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007003.pub3&amp;doi=10.1002/14651858.CD007003.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007003.pub3&amp;doi=10.1002/14651858.CD007003.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007003.pub3&amp;doi=10.1002/14651858.CD007003.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007003.pub3&amp;doi=10.1002/14651858.CD007003.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007003.pub3&amp;doi=10.1002/14651858.CD007003.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007003.pub3&amp;doi=10.1002/14651858.CD007003.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007003.pub3&amp;doi=10.1002/14651858.CD007003.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007003.pub3&amp;doi=10.1002/14651858.CD007003.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007003.pub3&amp;doi=10.1002/14651858.CD007003.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007003.pub3&amp;doi=10.1002/14651858.CD007003.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007003.pub3&amp;doi=10.1002/14651858.CD007003.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007003.pub3&amp;doi=10.1002/14651858.CD007003.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007003.pub3&amp;doi=10.1002/14651858.CD007003.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007003.pub3&amp;doi=10.1002/14651858.CD007003.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007003.pub3&amp;doi=10.1002/14651858.CD007003.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007003.pub3&amp;doi=10.1002/14651858.CD007003.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="18M35a5z";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD007003\x2epub3\x26doi\x3d10\x2e1002\x2f14651858\x2eCD007003\x2epub3\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007003\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007003\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","ru","ko","ms","hr","fr","hu","zh_HANS","zh_HANT","ja","id","fa","pl"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD007003.pub3",title:"Interventions for dialysis patients with hepatitis C virus (HCV) infection",firstPublishedDate:"Apr 25, 2023 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Kidney and Transplant Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=18M35a5z&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD007003.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD007003.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD007003.pub3/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD007003.pub3/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD007003.pub3%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD007003.pub3/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD007003.pub3/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD007003.pub3/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD007003.pub3/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD007003.PUB3" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;초록&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;hu&quot;,&quot;title&quot;:&quot;Összefoglalás közérthető nyelven&quot;},{&quot;language&quot;:&quot;id&quot;,&quot;title&quot;:&quot;Saripati tinjauan sistematik&quot;},{&quot;language&quot;:&quot;ja&quot;,&quot;title&quot;:&quot;一般語訳&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;쉬운 말 요약&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pl&quot;,&quot;title&quot;:&quot;Streszczenie prostym językiem&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD007003.pub3/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD007003.PUB3" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD007003.pub3/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD007003.pub3/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>1360 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD007003.pub3" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007003.pub3/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007003.pub3/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007003.pub3/full#CD007003-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007003.pub3/full#CD007003-sec-0096"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007003.pub3/full#CD007003-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007003.pub3/full#CD007003-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007003.pub3/full#CD007003-sec-0014"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007003.pub3/full#CD007003-sec-0015"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007003.pub3/full#CD007003-sec-0041"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007003.pub3/full#CD007003-sec-0088"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD007003.pub3/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007003.pub3/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007003.pub3/appendices#CD007003-sec-0101"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007003.pub3/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007003.pub3/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD007003.pub3/media/CDSR/CD007003/supinfo/CD007003StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD007003.pub3/media/CDSR/CD007003/supinfo/CD007003StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007003.pub3/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007003.pub3/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007003.pub3/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD007003.pub3/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD007003.pub3/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD007003.pub3/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2023 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD007003.pub3/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> <div class="inline-status-wrapper"> <ul class="cochrane-status"> <li aria-label="A new search for studies has been conducted." class="status-item up-to-date custom-tooltip" data-status="newsearch" title="A new search for studies has been conducted."> <a class="btn secondary" href="information#history">New search</a> </li> <li aria-label="There has been an important change to the conclusions of the review." class="status-item up-to-date custom-tooltip" data-status="conclusionchanged" title="There has been an important change to the conclusions of the review."> <a class="btn secondary" href="information#history">Conclusions changed</a> </li> </ul> </div> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Interventions for dialysis patients with hepatitis C virus (HCV) infection</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007003.pub3/information#CD007003-cr-0004"><i class="icon corresponding-author fa fa-envelope"></i>Attur Ravindra Prabhu</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007003.pub3/information#CD007003-cr-0005">Indu Ramachandra Rao</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007003.pub3/information#CD007003-cr-0006">Shankar Prasad Nagaraju</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007003.pub3/information#CD007003-cr-0007">Eti Rajwar</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007003.pub3/information#CD007003-cr-0008">Bhumika T Venkatesh</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007003.pub3/information#CD007003-cr-0009">Sreekumaran Nair N</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007003.pub3/information#CD007003-cr-0010">Ganesh Pai</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007003.pub3/information#CD007003-cr-0011">Nageswara P Reddy</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007003.pub3/information#CD007003-cr-0012">Deepak Suvarna</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD007003.pub3/information/en#CD007003-sec-0108">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 25 April 2023 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD007003.pub3/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD007003.pub3">https://doi.org/10.1002/14651858.CD007003.pub3</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD007003-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD007003-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD007003-abs-0011">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD007003-abs-0018">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD007003-abs-0008">Français</a> </li> <li class="section-language"> <a class="" href="full/ko#CD007003-abs-0004">한국어</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD007003-abs-0013">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD007003-abs-0001" lang="en"> <section id="CD007003-sec-0001"> <h3 class="title" id="CD007003-sec-0001">Background</h3> <p>Hepatitis C virus (HCV) infection is common in chronic kidney disease (CKD) patients on dialysis, causes chronic liver disease, may increase the risk of death, and impacts kidney transplant outcomes. Direct‐acting antivirals have replaced interferons because of better efficacy and tolerability. This is an update of a review first published in 2015. </p> </section> <section id="CD007003-sec-0002"> <h3 class="title" id="CD007003-sec-0002">Objectives</h3> <p>We aimed to look at the benefits and harms of interventions for HCV in CKD patients on dialysis: death, disease relapse, treatment response/discontinuation, time to recovery, quality of life (QoL), cost‐effectiveness, and adverse events. We aimed to study comparisons of available interventions, compared with placebo, control, with each other and with newer treatments. </p> </section> <section id="CD007003-sec-0003"> <h3 class="title" id="CD007003-sec-0003">Search methods</h3> <p>We searched the Cochrane Kidney and Transplant's Specialised Register to 23 February 2023 through contact with the Information Specialist using search terms relevant to this review. Studies in the Register are identified through searches of CENTRAL, MEDLINE and EMBASE, handsearching conference proceedings, and searching the International Clinical Trials Register Portal (ICTRP) and ClinicalTrials.gov. </p> </section> <section id="CD007003-sec-0004"> <h3 class="title" id="CD007003-sec-0004">Selection criteria</h3> <p>Randomised controlled trials (RCTs), quasi‐RCTs, first period of randomised cross‐over studies on interventions for HCV in CKD on dialysis were considered. </p> </section> <section id="CD007003-sec-0005"> <h3 class="title" id="CD007003-sec-0005">Data collection and analysis</h3> <p>Summary estimates of effect were obtained using a random‐effects model, and results were expressed as risk ratios (RR) and their 95% confidence intervals (CI). Confidence in the evidence was assessed using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach. </p> </section> <section id="CD007003-sec-0006"> <h3 class="title" id="CD007003-sec-0006">Main results</h3> <p>Three studies were included in this update, therefore 13 studies (997 randomised participants) met our inclusion criteria. Overall, the risk of bias was judged low in seven studies, unclear in four, low to unclear in one, and high in one study. Interventions included standard interferon, pegylated (PEG) interferon, standard or PEG interferon plus ribavirin; direct‐acting antivirals, and direct‐acting antivirals plus PEG interferon plus ribavirin. </p> <p>Compared to placebo or control, standard interferon may make little or no difference to death (5 studies, 134 participants: RR 0.89, 95% CI 0.06 to 13.23) or relapse (low certainty evidence), probably improves end‐of‐treatment response (ETR) (5 studies, 132 participants: RR 8.62, 95% CI 3.03 to 24.55; I² = 0%) (moderate certainty evidence), and probably makes little or no difference to sustained virological response (SVR) (4 studies, 98 participants: RR 3.25, 95% CI 0.81 to 13.07; I² = 53%), treatment discontinuation (4 studies, 116 participants: RR 4.59, 95% CI 0.49 to 42.69; I² = 63%), and adverse events (5 studies, 143 participants: RR 3.56, 95% CI 0.98 to 13.01; I² = 25%) (moderate certainty evidence). </p> <p>In low certainty evidence, PEG interferon (1 study, 50 participants) may improve ETR (RR 1.53, 95% CI 1.09 to 2.15) but may make little or no difference to death (RR 0.33, 95% CI 0.01 to 7.81), SVR (RR 2.40, 95% CI 0.99 to 5.81), treatment discontinuation (RR 0.11, 95% CI 0.01 to 1.96), adverse events (RR 0.11, 95% CI 0.01 to 1.96) and relapses (21/38 relapsed) (RR 0.72, 95% CI 0.41 to 1.25) compared to standard interferon. </p> <p>In moderate certainty evidence, high‐dose PEG interferon (alpha‐2a and alpha‐2b) may make little or no difference to death (2 studies, 97 participants: RR 4.30, 95% CI 0.76 to 24.33; I² = 0%), ETR (RR 1.42, 95% CI 0.51 to 3.90; I² = 20%), SVR (RR 1.19, 95% CI 0.68 to 2.07; I² = 0%), treatment discontinuation (RR 1.20, 95% CI 0.63 to 2.28; I² = 0%) or adverse events (RR 1.05, 95% CI 0.61 to 1.83; I² = 27%) compared to low‐dose PEG interferon. High‐dose PEG interferon may make little or no difference to relapses (1 study, 43 participants: RR 1.11, 95% CI 0.45 to 2.77; low certainty evidence). There were no significant subgroup differences. </p> <p>Standard interferon plus ribavirin may lead to higher treatment discontinuation (1 study, 52 participants: RR 2.97, 95% CI 1.19 to 7.36; low certainty evidence) compared to standard interferon alone.  </p> <p>In low certainty evidence, PEG interferon plus ribavirin (1 study, 377 participants) may improve SVR (RR 1.80, 95% CI 1.46 to 2.21), reduce relapses (RR 0.33, 95% CI 0.23 to 0.48), slightly increase the number with adverse events (RR 1.10, 95% CI 1.01 to 1.19), and may make little or no difference to ETR (RR 1.01, 95% CI 0.94 to 1.09) compared to PEG interferon alone. The evidence is very uncertain about the effect of PEG interferon plus ribavirin on treatment discontinuation (RR 1.71, 95% CI 0.69 to 4.24) compared to PEG interferon alone. </p> <p>One study reported grazoprevir plus elbasvir improved ETR (173 participants: RR 174.99, 95% CI 11.03 to 2775.78; low certainty evidence) compared to placebo. </p> <p>It is uncertain whether telaprevir plus ribavirin (high versus low initial dose) plus PEG interferon for 24 versus 48 weeks (1 study, 35 participants) improves ETR (RR 1.02, 95% CI 0.67 to 1.56) or SVR (RR 1.02, 95% CI 0.67 to 1.56) because the certainty of the evidence is very low.  </p> <p>Data on QoL, cost‐effectiveness, cardiovascular outcomes and peritoneal dialysis were not available. </p> </section> <section id="CD007003-sec-0007"> <h3 class="title" id="CD007003-sec-0007">Authors' conclusions</h3> <p>In dialysis patients with HCV infection grazoprevir plus elbasvir probably improves ETR. There is no difference in ETR or SVR for combinations of telaprevir, ribavirin and PEG interferon given for different durations and doses. Though no longer in use, PEG interferon was more effective than standard interferon for ETR but not SVR. Increasing doses of PEG interferon did not improve responses. The addition of ribavirin to PEG interferon may result in fewer relapses, higher SVR, and higher numbers with adverse events. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD007003-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD007003-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD007003-abs-0012">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD007003-abs-0019">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD007003-abs-0009">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD007003-abs-0007">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/hu#CD007003-abs-0010">Magyar</a> </li> <li class="section-language"> <a class="" href="full/id#CD007003-abs-0017">Bahasa Indonesia</a> </li> <li class="section-language"> <a class="" href="full/ja#CD007003-abs-0016">日本語</a> </li> <li class="section-language"> <a class="" href="full/ko#CD007003-abs-0005">한국어</a> </li> <li class="section-language"> <a class="" href="full/ms#CD007003-abs-0006">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pl#CD007003-abs-0020">Polski</a> </li> <li class="section-language"> <a class="" href="full/ru#CD007003-abs-0003">Русский</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD007003-abs-0014">简体中文</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD007003-abs-0015">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD007003-abs-0002" lang="en"> <h3>Interventions for dialysis patients with hepatitis C virus (HCV) infection</h3> <p><b>What is the issue?</b> </p> <p>Hepatitis C is a disease of the liver caused by the hepatitis C virus (HCV) which spreads from person to person through blood contact, a result of sharing drug needles and other items contaminated with blood. This virus remains in the body for a long time, and in some it can affect the liver, causing its slow destruction or cirrhosis and liver cancer. Infected people may have weakness, nausea, jaundice and lose weight, and they may have increased liver enzymes and bilirubin. </p> <p>HCV is present worldwide and varies amongst countries with a total of approximately 70 million people having a chronic infection and constitutes 40% of patients with chronic liver disease. People who are on haemodialysis for long periods have a higher chance of getting this infection. Direct‐acting antiviral drugs, which can be taken by mouth, have replaced the previously used interferons for the treatment of HCV infection. Direct‐acting antivirals have better efficacy and tolerability and are effective in almost all patients. The interferons have to be given as injections under the skin and have less efficacy and more side effects. Treatment with direct‐acting antivirals has to be given for 12 weeks as compared to interferons which had to be given for at least 24 to 48 weeks with or without tablets of ribavirin to improve their efficacy. However, ribavirin can accumulate in kidney patients and cause the destruction of red blood cells and anaemia. </p> <p><b>What did we do?</b> </p> <p>Since the publication of our previous review in 2015, newer medicines (direct‐acting antivirals) for the treatment of HCV infection have become available, therefore, we have now updated the evidence to include the efficacy of direct‐acting antivirals. This update searched for new evidence from randomised controlled studies for the treatment of HCV in dialysis patients. </p> <p><b>What did we find?</b> </p> <p>The update found three studies with about 600 patients which could be included in addition to the previous review which had 10 studies all in haemodialysis. The use of the direct‐acting antivirals grazoprevir and elbasvir in combination produces a 100% response by the end of treatment, but follow‐up data is not available, and evidence is not of high quality. The addition of ribavirin to interferon resulted in a better sustained response (being free of the virus in blood after treatment is stopped), decreased chances of disease relapse but more adverse events. Telaprevir along with ribavirin in different doses combined with pegylated (PEG) interferon in different doses and durations produce almost similar end‐of‐treatment and sustained response, but the evidence was not of high quality. PEG interferon was more effective than standard interferon in producing a short‐term response but not a sustained one and both were equally tolerated. Increasing the dose of PEG interferon did not improve response but was tolerated. Limitations of this review are that only a few studies were available with few participants, and patients with serious disease were excluded from previous studies in anticipation of side effects. Hence, the evidence available was not of high quality. Evidence for the newer medicines namely direct‐acting antivirals which have now replaced the use of interferons in the general population was limited and was not of high quality. </p> <p><b>Conclusions</b> </p> <p>This was an update of a review of available treatments for patients on dialysis having HCV infection. Direct‐acting antivirals have now replaced the use of interferons for treatment. Grazoprevir and elbasvir produce an end‐of‐treatment response in almost all patients, but no data is available for a sustained response at follow‐up, and the evidence is not of high quality. Combinations of telaprevir, ribavirin and PEG interferon used in different doses and durations are almost similar in efficacy, and the evidence is not of high quality. PEG interferon is more effective than standard interferon for producing a response by the end of treatment which is not sustained, both being equally tolerated. Increasing doses of PEG interferon does not improve responses, but high and low doses are equally tolerated. The addition of ribavirin produces an improved response even after stopping treatment but has higher adverse events.  </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD007003-sec-0096" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD007003-sec-0096"></div> <h3 class="title" id="CD007003-sec-0097">Implications for practice</h3> <section id="CD007003-sec-0097"> <p>Hepatitis C causes morbidity and death in CKD patients on dialysis and has implications for kidney transplant candidates. This review highlights the small number of studies with only a small number of participants available in most studies. There is a lack of high‐quality evidence in this area, though direct‐acting antivirals are the current preferred choice of therapy over interferons. </p> <p>A combination of direct‐acting antivirals grazoprevir and elbasvir produces end‐of‐treatment responses in nearly all patients and was well tolerated, although the certainty of the evidence is low.  </p> <p>A combination of PEG interferon and ribavirin produces an SVR, with lesser relapses with higher adverse events; the addition of telaprevir produced an end‐of‐treatment response and SVR irrespective of the dose of ribavirin or the duration of therapy.  </p> <p>Standard interferon produces an end‐of‐treatment response which is not sustained but is relatively well tolerated. PEG interferon is better than standard interferon in producing end‐of‐treatment but not SVR. Both are equally tolerated. Increasing doses of PEG interferon does not improve responses but is tolerated.  </p> </section> <h3 class="title" id="CD007003-sec-0098">Implications for research</h3> <section id="CD007003-sec-0098"> <p>This review identifies the potential for conducting further RCTs using direct‐acting antivirals in dialysis patients and testing SVR as a surrogate for long‐term outcomes. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD007003-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD007003-sec-0008"></div> <div class="table" id="CD007003-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Standard interferon versus placebo or control for haemodialysis patients with hepatitis C virus infection</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Standard interferon versus placebo or control for HD patients with HCV infection</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> patients on HD with HCV infection<br/><b>Settings:</b> outpatients<br/><b>Intervention:</b> standard interferon<br/><b>Comparison:</b> placebo or control </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>No. of participants<br/>(RCTs)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="table-header separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p>Risk with p<b>lacebo or control</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p>Risk with s<b>tandard interferon</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Death</b><br/>Follow‐up: 6 to 52 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>17 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>15 per 1000</b><br/>(1 to 224) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.89 </b><br/>(0.06 to 13.23) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>134 (5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Standard interferon may make little or no difference to death compared to a placebo or control  </p> <p>Out of 5 studies only 1 reported death. This evidence should be read with caution due to the low certainty of the evidence </p> <p>In 2 studies data was not available for 18 participants total. Hence, 134/152 were analysed </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Relapse</b><br/>(recurrence after stopping intervention)<br/>Follow‐up: 46 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>1000 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>720 per 1000</b><br/>(280 to 1000) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.72 </b><br/>(0.28 to 1.88) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>1,2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Standard interferon may make little or no difference to the number of relapses compared to placebo or control. This evidence should be read with caution due to the low certainty of the evidence </p> <p>Out of 5 studies only 1 reported relapse. Data was not available in 1 study; 2 studies had no responses in the placebo/control group and could not be analysed, and 1 study did not report follow‐up data </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>End‐of‐treatment response</b><br/>Follow‐up: 6 to 12 months </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population<sup>3</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>RR 8.62 </b><br/>(3.03 to 24.55) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>132 (5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>⊕⊕⊕⊝<br/><b>Moderate</b><sup>1,4</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>Standard interferon probably leads to more end‐of‐treatment response compared to the placebo or control </p> <p>Two studies had events in the control group hence second highest and lowest control group risks also expressed to represent varying levels of risk </p> <p>In 2 studies data was not available for 20 participants</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>34 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>292 per 1000</b><br/>(103 to 832) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate<sup>3</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>59 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>507 per 1000</b><br/>(178 to 1000) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>High<sup>3</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>62 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>539 per 1000</b><br/>(189 to 1000) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Sustained virological response 6 months after stopping treatment</b><br/>Follow‐up: 6 to 12 months </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population<sup>3</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 3.25 </b><br/>(0.81 to 13.07) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>98 (4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝<br/><b>Moderate</b><sup>1,4</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Standard interferon probably makes little or no difference to sustained virological response compared to placebo or control </p> <p>This outcome could not be assessed in 1 study as there was no follow‐up data and data was not available for 18 participants in 2 studies </p> <p>Two studies had events in the control group hence absolute effects for the second highest and lowest control group risks also expressed to represent varying levels of risk </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>116 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>378 per 1000</b><br/>(94 to 1000) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Low<sup>3</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>59 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>192 per 1000</b><br/>(48 to 771) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Treatment discontinuation</b><br/>Follow‐up: 6 to 12 months </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population<sup>3</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 4.59 </b><br/>(0.49 to 42.69) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>116 (4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝<br/><b>Moderate</b><sup>1,4</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Standard interferon probably makes </p> <p>little or no difference in the number of patients discontinuing treatment compared to placebo or control </p> <p>The control group had events in 1 study hence absolute effects at 2 levels of risk were given to represent varying control group risks </p> <p>Data was not available for 1 study and for 18 participants in 2 studies</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>38 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>177 per 1000</b><br/>(19 to 1000) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>High<sup>3</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>222 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>1000 per 1000</b><br/>(109 to 1000) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Adverse events</b><br/>Follow‐up: 24 to 52 months </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population<sup>3</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 3.56 </b><br/>(0.98 to 13.01) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>143 (5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝<br/><b>Moderate</b><sup>1,4</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Standard interferon probably makes little or no difference to the number of patients experiencing adverse events compared to placebo or control </p> <p>The control group had events in 1 study hence absolute effects at 2 levels of risk were given to represent varying control group risks. Data was not available for 9 participants in 1 study </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>31 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>110 per 1000</b><br/>(30 to 400) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>High<sup>3</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>222 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>790 per 1000</b><br/>(218 to 1000) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI)<br/><b>CI:</b> confidence interval; <b>HCV:</b> hepatitis C virus; <b>HD:</b> haemodialysis; <b>RR:</b> risk ratio; <b>RCT:</b> randomised controlled trial </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High certainty:</b> Further research is very unlikely to change our confidence in the estimate of effect<br/><b>Moderate certainty:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate<br/><b>Low certainty:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate<br/><b>Very low certainty:</b> We are very uncertain about the estimate </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>  Number of events is low<br/><sup>2</sup>  One study<br/><sup>3</sup> Based on the second lowest and highest control group risks; events occurred in the control group in some studies for some outcomes hence absolute effects are presented for varying levels of risk </p> <p><sup>4</sup> Risk of bias for random sequence generation was unclear, and allocation concealment was unclear to high </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD007003-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Pegylated interferon alpha‐2a versus standard interferon for haemodialysis patients with hepatitis C virus infection</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>PEG interferon alpha‐2a versus standard interferon for HD patients with HCV infection</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> patients on HD with HCV infection<br/><b>Settings:</b> outpatients<br/><b>Intervention:</b> PEG interferon alpha‐2a <br/><b>Comparison:</b> standard interferon alpha‐2a </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> </b>(95% CI) </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>No. of participants<br/>(RCTs)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p>Risk with s<b>tandard interferon</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p>Risk with <b>PEG interferon</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Death</b><br/>Follow‐up: mean 24 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>40 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>13 per 1000</b><br/>(1 to 312) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.33 </b><br/>(0.01 to 7.81) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>1,2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PEG interferon may make little or no difference to death compared to standard interferon</p> <p>This evidence should be read with caution due to the low certainty of the evidence</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Relapse</b><br/>(recurrence after stopping)<br/>Follow‐up: 72 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>667 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>480 per 1000</b><br/>(273 to 833) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.72 </b><br/>(0.41 to 1.25) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>1,2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PEG interferon may make little or no difference to the number of relapses compared to standard interferon </p> <p>This evidence should be read with caution due to the low certainty of the evidence</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>End‐of‐treatment response</b><br/>Follow‐up: 24 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>600 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>918 per 1000</b><br/>(654 to 1000) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.53 </b><br/>(1.09 to 2.15) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>1,2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PEG interferon may lead to more end‐of‐treatment response compared to standard interferon</p> <p>This evidence should be read with caution due to the low certainty of the evidence</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Sustained virological response 6 months after stopping treatment</b><br/>Follow‐up: 48 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>200 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>480 per 1000</b><br/>(198 to 1000) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 2.4 </b><br/>(0.99 to 5.81) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>1,2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PEG interferon may make little or no difference to the number of patients having sustained virological response compared to standard interferon </p> <p>This evidence should be read with caution due to the low certainty of the evidence</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Treatment discontinuation</b><br/>Follow‐up: 24 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>160 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>18 per 1000</b><br/>(2 to 314) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.11 </b><br/>(0.01 to 1.96) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>1,2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PEG interferon may make little or no difference to the number of patients discontinuing treatment compared to standard interferon </p> <p>This evidence should be read with caution due to the low certainty of the evidence</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events </b><br/>Follow‐up: 24 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>160 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>18 per 1000</b><br/>(2 to 314) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.11 </b><br/>(0.01 to 1.96) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>1,2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PEG interferon may make little or no difference to the number of patients having major adverse events requiring treatment withdrawal compared to standard interferon </p> <p>This evidence should be read with caution due to the low certainty of the evidence</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI)<br/><b>CI:</b> confidence interval; <b>HCV:</b> hepatitis C virus; <b>HD:</b> haemodialysis; <b>PEG:</b> pegylated; <b>RR:</b> risk ratio; <b>RCT:</b> randomised controlled trial </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High certainty:</b> Further research is very unlikely to change our confidence in the estimate of effect<br/><b>Moderate certainty:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate<br/><b>Low certainty:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate<br/><b>Very low certainty:</b> We are very uncertain about the estimate </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Number of events is low </p> <p><sup>2</sup> One study  </p> <p>Zero events in the PEG interferon group for death, treatment discontinuation, and number of participants having adverse events </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD007003-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">High versus low dose pegylated interferon alpha‐2a or alpha‐2b for haemodialysis patients with hepatitis C virus infection</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>High versus low dose PEG interferon for HD patients with HCV infection</b><br/>(separate and combined results of two preparations: alpha‐2a and alpha‐2b) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> patients on HD with HCV infection<br/><b>Settings:</b> outpatients<br/><b>Intervention 1:</b> high dose PEG interferon alpha‐2a (135 µg/week)<br/><b>Comparison 1:</b> low dose PEG interferon alpha‐2a (90 µg/week) </p> <p><b>Intervention 2:</b> high dose PEG interferon alpha‐2b (1 µg/kg/week) </p> <p><b>Comparison 2:</b> low dose PEG interferon alpha‐2b (0.5 µg/kg/week) </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> </b>(95% CI) </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>No. of participants<br/>(RCTs)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p>Risk with <b>low dose PEG interferon </b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p>Risk with <b>high dose PEG interferon </b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell" colspan="7" rowspan="1" scope="col" valign="top"> <p><b>Death</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>PEG interferon alpha‐2a</b><br/>Follow‐up: 24 week </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>23 per 1000</b><sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>132 per 1000</b><br/>(16 to 1000) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 5.66 </b><br/>(0.69 to 46.31) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>81 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>1,2,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>A high dose of PEG interferon probably makes little or no difference to death compared to a low dose of PEG interferon  </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>PEG interferon alpha‐2b</b> </p> <p>Follow‐up: 72 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>0 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>0 per 1000</b> </p> <p>(0 to 0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 2.40</b> (0.11 to 51.32) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>1,2,3</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>PEG interferon (combined)</b> </p> <p>Follow‐up: 24 to 72 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>20 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>86 per 1000</b><br/>(15 to 487) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 4.30</b> (0.76 to 24.33) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>97 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/><b>Moderate</b><sup>1,3</sup> </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="7" rowspan="1" scope="col" valign="top"> <p><b>Relapse (recurrence after stopping treatment)</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>PEG interferon alpha‐2a</b> </p> <p>Follow‐up: 24 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>286 per 1000</b><sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>320 per 1000</b><br/>(114 to 631) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.12 </b><br/>(0.4 to 2.21) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>1,2,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>A high dose of PEG interferon may make little or no difference to the number of patients having a disease relapse compared to a low dose of PEG interferon. In one study there were no events in the control group and could not be analysed </p> <p>This should be viewed with caution due to the low certainty of the evidence</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>PEG interferon alpha‐2b </b> </p> <p>Follow‐up: 72 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>No data</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p> ‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> ‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> ‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> ‐‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>PEG interferon (combined)</b> </p> <p>Follow‐up; 24 to 72 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>286 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>320 per 1000</b><br/>(114 to 631) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 1.12 </b><br/>(0.4 to 2.21) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>43 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>1,2,3</sup> </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="7" rowspan="1" scope="col" valign=""> <p><b>End‐of‐treatment response</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>PEG interferon alpha‐2a</b><br/>Follow‐up: 24 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>488 per 1000</b><sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>581 per 1000</b><br/>(386 to 869) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.19 </b><br/>(0.79 to 1.78) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>81 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>1,2,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>A high dose of PEG interferon probably makes little or no difference to end‐of‐treatment virological response compared to a low dose of PEG interferon </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>PEG interferon (alpha‐2b)</b> </p> <p>Follow‐up: 72 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>0 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>0 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 5.60</b><br/>(0.34 to 93.35) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>1,2,3</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>PEG interferon (combined)</b> </p> <p>Follow‐up: 24 to 72 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>20 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>28 per 1000</b> </p> <p>(10 to 78)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 1.42</b> (0.51 to 3.90) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>97 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/><b>Moderate</b><sup>2,3</sup> </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="7" rowspan="1" scope="col" valign=""> <p><b>Sustained virological response</b> after stopping treatment </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>PEG interferon alpha‐2a</b><br/>Follow‐up: 72 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>349 per 1000</b><sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>394 per 1000</b><br/>(223 to 698) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.13 </b><br/>(0.64 to 2) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>81 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>1,2,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>A high dose of PEG interferon probably makes little or no difference to sustained virological response compared to a low dose of PEG interferon  </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>PEG interferon alpha‐2b</b> </p> <p>Follow‐up: 72 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>0 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>0 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 4.00</b><br/>(0.22 to 72.01) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>1,2,3</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>PEG interferon (combined)</b> </p> <p>Follow‐up: 24 to 72 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>300 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>357 per 1000</b> </p> <p>(204 to 621)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 1.19</b> </p> <p>(0.68 to 2.07)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>97 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/><b>Moderate</b><sup>2,3</sup> </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="7" rowspan="1" scope="col" valign=""> <p><b>Treatment discontinuation</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>PEG interferon alpha‐2a</b><br/>Follow‐up: 24 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>256 per 1000</b><sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>263 per 1000</b><br/>(125 to 550) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.03 </b><br/>(0.49 to 2.15) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>81 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>1,2,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>A high dose of PEG interferon probably makes little or no difference to the number of patients discontinuing treatment compared to a low dose of PEG interferon </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>PEG interferon alpha‐2b</b> </p> <p>Follow‐up: 72 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>286 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>554 per 1000</b><br/>(151 to 1000) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 1.94</b><br/>(0.53 to 7.2) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>1,2,3</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>PEG interferon (combined)</b> </p> <p>Follow‐up: 24 to 72 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>260 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>3112 per 1000</b> </p> <p>(164 to 593)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 1.20</b> </p> <p>(0.63 to 2.28)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>97 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/><b>Moderate</b><sup>2,3</sup> </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="7" rowspan="1" scope="col" valign=""> <p><b>Adverse events</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>PEG interferon alpha‐2a</b><br/>Follow‐up: 24 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>860 per 1000</b><sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>817 per 1000</b><br/>(671 to 990) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.95 </b><br/>(0.78 to 1.15) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>81 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>1,2,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>A high dose of PEG interferon probably makes little or no difference to the number of patients with adverse events compared to a low dose of PEG interferon </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>PEG interferon alpha‐2b</b> </p> <p>Follow‐up: 72 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>286 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>554 per 1000</b><br/>(151 to 1000) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 1.94</b><br/>(0.53 to 7.20) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>1,2,3</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>PEG interferon (combined)</b> </p> <p>Follow‐up 24 to 72 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>780 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>819 per 1000</b> </p> <p>(476 to 1000)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 1.05</b> (0.61 to 1.83) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>97 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/><b>Moderate</b><sup>2,3</sup> </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="7" rowspan="1" scope="col" valign=""> <p><b>Serious adverse events</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>PEG interferon alpha‐2a</b><br/>Follow‐up: 24 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>326 per 1000</b><sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>368 per 1000</b><br/>(202 to 671) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.13 </b><br/>(0.62 to 2.06) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>81 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>1,2,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>A high dose of PEG interferon probably makes little or no difference to the number of patients with serious adverse events compared to a low dose of PEG interferon </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>PEG interferon alpha‐2b</b> </p> <p>Follow‐up: 72 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>286 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>554 per 1000</b><br/>(151 to 1000) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 1.94</b><br/>(0.53 to 7.2) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>1,2,3</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>PEG interferon (combined)</b> </p> <p>Follow‐up: 24 to 72 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>320 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>397 per 1000</b> </p> <p>(230 to 685)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 1.24</b> </p> <p>(0.72 to 2.14)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>97 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/><b>Moderate</b><sup>2,3</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI)<br/><b>CI:</b> confidence interval; <b>HCV:</b> hepatitis C virus; <b>HD:</b> haemodialysis; <b>PEG:</b> pegylated; <b>RR:</b> risk ratio; <b>RCT:</b> randomised controlled trial </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High certainty:</b> Further research is very unlikely to change our confidence in the estimate of effect<br/><b>Moderate certainty:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate<br/><b>Low certainty:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate<br/><b>Very low certainty:</b> We are very uncertain about the estimate </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> One study </p> <p><sup>2</sup> Number of events low </p> <p><sup>3</sup> Risk of bias high for blinding of participants and personnel </p> <p>Two studies compared different preparations of PEG interferon. Hence, each outcome is presented as three entries with results of each RCT and combined analysis result </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD007003-tbl-0004"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Standard interferon plus ribavirin versus standard interferon alone for haemodialysis patients with hepatitis C virus infection</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Standard interferon plus ribavirin versus standard interferon alone for HD patients with HCV infection</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Patient or population:</b> patients on HD with HCV infection<br/><b>Settings:</b> outpatients<br/><b>Intervention:</b> standard interferon plus ribavirin<br/><b>Comparison:</b> standard interferon  </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> </b>(95% CI) </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>No. of participants<br/>(RCTs)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p>Risk with s<b>tandard interferon</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p>Risk with s<b>tandard interferon plus ribavirin</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Death</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>No data</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Relapse</b><br/>(recurrence after stopping) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>No data</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>End‐of‐treatment response</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>No data</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Sustained virological response</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>No data</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Treatment discontinuation</b><br/>Follow‐up: 16 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>163 per 1000</b><br/>(67 to 402) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>484 per 1000</b> </p> <p>(194 to 1000)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 2.97 </b><br/>(1.19 to 7.36) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>1,2</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Adverse events</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>No data</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI)<br/><b>CI:</b> confidence interval; <b>HCV:</b> hepatitis C virus; <b>HD:</b> haemodialysis; <b>RR:</b> risk ratio; <b>RCT:</b> randomised controlled trial </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High certainty:</b> Further research is very unlikely to change our confidence in the estimate of effect<br/><b>Moderate certainty:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate<br/><b>Low certainty:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate<br/><b>Very low certainty:</b> We are very uncertain about the estimate </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup> One study </p> <p><sup>2</sup> Risk of bias unclear </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD007003-tbl-0005"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Pegylated interferon plus ribavirin versus pegylated interferon alone for haemodialysis patients with hepatitis C infection</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>PEG interferon plus ribavirin versus PEG interferon alone for HD patients with HCV infection</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> HD patients with HCV infection <br/><b>Setting:</b> outpatients <br/><b>Intervention:</b> PEG interferon alpha‐2a (135 μg/week) plus ribavirin (200 mg/day) for 48 weeks<br/><b>Comparison:</b> PEG interferon alpha‐2a (135 μg/week) for 48 weeks </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>No. of participants<br/>(RCTs)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with PEG interferon</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with PEG interferon plus ribavirin</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Death</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>No data</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Relapse</b><br/>(recurrence after stopping) </p> <p>Follow‐up: mean 18 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>463 per 1,000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>153 per 1,000</b><br/>(106 to 222) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.33</b><br/>(0.23 to 0.48) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>377 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>1,2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The number of relapses of HCV infection was low in HD patients on PEG interferon with ribavirin therapy. This evidence was reported for HCV 1 and HCV 2 genotypes at 24 weeks and 48 weeks after intervention respectively. This effect should be read with caution because of the low certainty of the evidence </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>End‐of‐treatment response</b><br/>Follow‐up: mean 18 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>867 per 1,000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>876 per 1,000</b><br/>(815 to 945) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.01</b><br/>(0.94 to 1.09) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>377 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>1,2,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The end‐of‐treatment response was more likely in patients treated with PEG interferon with ribavirin, with some limitations for the certainty of the evidence </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Sustained virological response</b><br/>Follow‐up: mean 18 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>383 per 1,000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>689 per 1,000</b><br/>(559 to 846) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.80</b><br/>(1.46 to 2.21) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>377 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Patients on PEG interferon with ribavirin were more likely to have sustained virologic response after treatment. The evidence reported is for both HCV genotype 1 and HCV genotype 2 with 24 weeks and 48 weeks of treatment, respectively </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Treatment discontinuation</b><br/>Follow‐up: mean 18 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>37 per 1,000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>64 per 1,000</b><br/>(26 to 158) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.71</b><br/>(0.69 to 4.24) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>377 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>1,2,3,4</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HD patients with HCV infection on PEG interferon with ribavirin were more likely to discontinue the treatment than patients on PEG interferon monotherapy. However, this evidence should be read with caution, due to the low certainty of the evidence </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events</b><br/>Follow‐up: mean 18 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>819 per 1,000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>901 per 1,000</b><br/>(827 to 975) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.10</b><br/>(1.01 to 1.19) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>377 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HD patients with HCV on PEG interferon with ribavirin therapy had a slightly higher risk of experiencing adverse events when compared to patients on PEG interferon alone. However, this evidence should be read with caution, due to the low certainty of the evidence </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI)<br/><b>CI:</b> confidence interval; <b>HCV:</b> hepatitis C virus; <b>HD:</b> haemodialysis; <b>PEG:</b> pegylated; <b>RR:</b> risk ratio; <b>RCT:</b> randomised controlled trial </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Less number of events </p> <p><sup>2</sup> Only one study was available for analysis; <a href="./references#CD007003-bbs2-0010" title="LuxonBA , MuirAJ , HeneghanMA . Safety and tolerability of pegylated interferon with or without low dose ribavirin for treatment of hepatitis C in hemodialysis patients [abstract no: 1281]. Hepatology2005;42(4 Suppl 1):703-4A. [CENTRAL: CN-00581669] ">Luxon 2005</a> reported pooled outcomes for both groups and could not be meta‐analysed </p> <p><sup>3</sup> Risk estimate includes the null effect </p> <p><sup>4</sup> High risk for blinding of participants  </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD007003-tbl-0006"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">Direct antivirals (grazoprevir and elbasvir) versus placebo for haemodialysis patients with hepatitis C infection</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Direct antivirals (grazoprevir and elbasvir) versus placebo for HD patients with HCV infection</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> HD patients with HCV infection <br/><b>Setting:</b> outpatients, international, multicentre <br/><b>Intervention:</b> Direct antivirals (grazoprevir 100 mg/day and elbasvir 50 mg/day) <br/><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>No. of participants<br/>(RCTs)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with direct‐acting antivirals</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Death</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>No data</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Relapse</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>No data</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>End‐of‐treatment response</b> </p> <p>Follow‐up: mean 28 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>6 per 1,000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>1000 per 1,000</b><br/>(63 to 1000) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR <b>174.99</b><br/>(11.03 to 2775.78) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>173 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low <sup>1,2</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Patients on direct‐acting antivirals were more likely to report an end‐of‐treatment response when compared to patients on placebo Evidence should be considered with caution as the certainty of the evidence is low. </p> <p>Out of 235 participants, those on dialysis (173) were analysed</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Sustained virological response</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>No data</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Treatment discontinuation</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>No data</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Adverse events</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>No data</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI)<br/><b>CI:</b> confidence interval; <b>HCV:</b> hepatitis C virus; <b>HD:</b> haemodialysis; <b>RR:</b> risk ratio; <b>RCT:</b> randomised controlled trial </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Placebo group also received the treatment after 4 weeks of study. Difficult to determine the directness of evidence for end‐of‐treatment response </p> <p><sup>2</sup> Number of events low; wide 95% CI </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD007003-tbl-0007"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 7.</span> <span class="table-title">Pegylated interferon + ribavirin (24 weeks) + initial telepravir (12 weeks) versus pegylated interferon (48 weeks) + initial telepravir (12 weeks) + initial low dose ribavirin (12 + 36 weeks) for haemodialysis patients with hepatitis C infection</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>PEG interferon + ribavirin (24 weeks) + initial telepravir (12 weeks) versus PEG interferon (48 weeks) + initial telepravir (12 weeks) + initial low dose ribavirin (12 + 36 weeks) for HD patients with HCV infection</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> HD patients with HCV infection <br/><b>Setting:</b> outpatients <br/><b>Intervention:</b> PEG interferon + ribavirin (24 weeks) + initial telaprevir (12 weeks)<br/><b>Comparison:</b> PEG interferon (48 weeks) + initial telaprevir (12 weeks) + initial low dose ribavirin (12 + 36 weeks) </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>No. of participants<br/>(RCTs)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with PEG interferon + teleprevir + initial low dose ribavirin (12 + 48 weeks)</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with PEG interferon + telaprevir + ribavirin (36 weeks)</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Death</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>No data</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Relapse</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>No data</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Sustained virological response</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>706 per 1,000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>720 per 1,000</b><br/>(473 to 1,000) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.02</b><br/>(0.67 to 1.56) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low<sup>1,2,3</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HD patients with HCV in the intervention group were more likely to have sustained virological response when compared to control. </p> <p>Evidence should be read with caution due to the very low certainty of the evidence</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>End‐of‐treatment response</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>706 per 1,000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>720 per 1,000</b><br/>(473 to 1,000) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.02</b><br/>(0.67 to 1.56) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low<sup>1.2.3</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HD patients with HCV in the intervention groups were more likely to report end‐of‐treatment response when compared to the control group. Evidence should be read with caution due to the very low certainty of the evidence </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Treatment discontinuation</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>No data</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>No data</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI)<br/><b>CI:</b> confidence interval; <b>PEG:</b> pegylated; <b>HCV:</b> hepatitis C virus; <b>HD:</b> haemodialysis; <b>RR:</b> risk ratio; <b>RCT:</b> randomised controlled trial </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Unclear risk of bias for allocation random sequence generation, allocation concealment, blinding of participants and personnel </p> <p><sup>2</sup> Evidence is reported from a single study for which only an abstract is available </p> <p><sup>3</sup> Low number of events and low sample size. CI including no effect </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD007003-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD007003-sec-0009"></div> <p>Hepatitis C virus (HCV) infection is common in chronic kidney disease (CKD) patients on dialysis, causes chronic liver disease, increases death and impacts kidney transplant outcomes. Direct‐acting antivirals have replaced interferons as the standard of care for HCV treatment due to their higher efficacy and tolerability. We collated evidence for the benefits and harms of interventions for HCV infection in dialysis. This is an update of a review first published in 2015. </p> <section id="CD007003-sec-0010"> <h3 class="title" id="CD007003-sec-0010">Description of the condition</h3> <p>HCV, identified in 1989 (<a href="./references#CD007003-bbs2-0031" title="ChooQL , KuoG , WeinerAJ , OverbyLR , BradleyDW , HoughtonM . Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science1989;244(4902):359-62. [MEDLINE: 2523562]">Choo 1989</a>), is a single‐strand RNA virus with a very high replication rate (10<sup>10</sup> to 10<sup>12</sup> virus/day) (<a href="./references#CD007003-bbs2-0066" title="NeumannAU , LamNP , DahariH , GretchDR , WileyTE , LaydenTJ , et al. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science1998;282(5386):103-7. [MEDLINE: 9756471]">Neumann 1998</a>) and a relatively high mutation rate that impairs an effective immune response (<a href="./references#CD007003-bbs2-0044" title="GomezJ , MartellM , QuerJ , CabotB , EstebanJI . Hepatitis C viral quasispecies. Journal of Viral Hepatitis1999;6(1):3-16. [MEDLINE: 10847126]">Gomez 1999</a>). HCV is found worldwide and is transmitted primarily through intravenous drug use, contaminated blood products, sexual transmission, perinatal, and needle stick injury (<a href="./references#CD007003-bbs2-0033" title="DienstagJL . Chapter 203: Acute viral hepatitis. In: LongoDL , FauciAS , KasperDL , HauserSL , JamesonJL , LoscalzoJ , editors(s). Harrison's Principles of Internal Medicine. 18th edition. Vol. 2. New York: McGraw-Hill, 2012:2542-8. [ISBN: 978-0-07-174887-2]">Dienstag 2012a</a>; <a href="./references#CD007003-bbs2-0034" title="DienstagJL . Chapter 306: Chronic hepatitis. In: LongoDL , FauciAS , KasperDL , HauserSL , JamesonJL , LoscalzoJ , editors(s). Harrison's Principles of Internal Medicine. 18th edition. Vol. 2. New York: McGraw-Hill, 2012:2578-84. [ISBN: 978-0-07-174887-2]">Dienstag 2012b</a>). The global prevalence of HCV infection is estimated to be 1%, affecting over 70 million people worldwide and continues to have significant morbidity and death. Genotypes 1 and 3 were the most common cause of infections accounting for 44% and 25%, respectively. The prevalence of infection varies in different regions of the world. The top six countries with the highest burden are China (9.795 million), Pakistan (7.172 million), India (6.245 million), Egypt (5.625 million), Russia (4.748 million) and the USA (2.936 million) (<a href="./references#CD007003-bbs2-0068" title="Polaris Observatory HCV Collaborators. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. The Lancet. Gastroenterology &amp; Hepatology2017;2(3):161-76. [MEDLINE: 28404132]">Polaris Observatory HCV Collaborators 2017</a>) because of their higher populations. The 69th World Health Assembly by WHO approved a global strategy of a "90% reduction in new cases, 65% reduction in deaths, and treatment of 80% of eligible chronic HCV patients" (<a href="./references#CD007003-bbs2-0080" title="World Health Organization (‎2016)‎. Global health sector strategy on viral hepatitis 2016-2021. Towards ending viral hepatitis. https://apps.who.int/iris/handle/10665/246177 (accessed 18 February 2023).">WHO 2016</a>). </p> <p>Males are more affected than females (2.1:1.1) probably because of behavioural risk factors and hormonal influences (<a href="./references#CD007003-bbs2-0033" title="DienstagJL . Chapter 203: Acute viral hepatitis. In: LongoDL , FauciAS , KasperDL , HauserSL , JamesonJL , LoscalzoJ , editors(s). Harrison's Principles of Internal Medicine. 18th edition. Vol. 2. New York: McGraw-Hill, 2012:2542-8. [ISBN: 978-0-07-174887-2]">Dienstag 2012a</a>; <a href="./references#CD007003-bbs2-0034" title="DienstagJL . Chapter 306: Chronic hepatitis. In: LongoDL , FauciAS , KasperDL , HauserSL , JamesonJL , LoscalzoJ , editors(s). Harrison's Principles of Internal Medicine. 18th edition. Vol. 2. New York: McGraw-Hill, 2012:2578-84. [ISBN: 978-0-07-174887-2]">Dienstag 2012b</a>). HCV is known to be prevalent (<a href="./references#CD007003-bbs2-0023" title="BergmanS , AccorttN , TurnerA , GlazeJ . Hepatitis C infection is acquired pre-ESRD. American Journal of Kidney Diseases2005;45(4):684-9. [MEDLINE: 15806471]">Bergman 2005</a>) ranging from 8% to 20% in CKD patients on dialysis (<a href="./references#CD007003-bbs2-0036" title="FabriziF , DulaiG , DixitV , BunnapradistS , MartinP . Meta-analysis: interferon for the treatment of chronic hepatitis C in dialysis patients. Alimentary Pharmacology &amp; Therapeutics2003;18(11-12):1071-81. [MEDLINE: 14653826]">Fabrizi 2003</a>) with a wide variation of 1.9% in the USA compared to 59% in Egypt (<a href="./references#CD007003-bbs2-0049" title="HassanAA , KhalilR . Hepatitis C in dialysis patients in Egypt: relationship to dialysis duration, blood transfusion, and liver disease. Saudi Journal of Kidney Diseases &amp; Transplantation2000;11(1):72-3. [MEDLINE: 18209303]">Hassan 2000</a>; <a href="./references#CD007003-bbs2-0070" title="RahnavardiM , Hosseini MoghaddamSM , AlavianSM . Hepatitis C in hemodialysis patients: current global magnitude, natural history, diagnostic difficulties, and preventive measures. American Journal of Nephrology2008;28(4):628-40. [MEDLINE: 18285684]">Rahnavardi 2008</a>). The DOPPS study reported a prevalence of 9.9% in dialysis compared to 3% in the general population with regional variation (<a href="./references#CD007003-bbs2-0055" title="JadoulM , BieberBA , MartinP , AkibaT , NwankwoC , ArduinoJM , et al. Prevalence, incidence, and risk factors for hepatitis C virus infection in hemodialysis patients. Kidney International2019;95(4):939-47. [MEDLINE: 30904068]">Jadoul 2019</a>). <a href="./references#CD007003-bbs2-0029" title="ChandraM , KhajaMN , HussainMM , PoduriCD , FareesN , HabeebMA , et al. Prevalence of hepatitis B and hepatitis C viral infections in Indian patients with chronic renal failure. Intervirology2004;47(6):374-6. [MEDLINE: 15564751]">Chandra 2004</a> conducted a study in 256 Indian patients with CKD and with a history of either a kidney transplant or haemodialysis (HD) and found that the prevalence was 46%. The implicated routes of transmission of HCV infection in the dialysis population include blood transfusions, cross‐contamination from supplies and surfaces within the dialysis unit, and direct contact with infected patients (<a href="./references#CD007003-bbs2-0024" title="Bravo ZuñigaJI , Loza MunárrizC , López‐AlcaldeJ . Isolation as a strategy for controlling the transmission of hepatitis C virus (HCV) infection in haemodialysis units. Cochrane Database of Systematic Reviews2016, Issue 8. Art. No: CD006420. [DOI: 10.1002/14651858.CD006420.pub2]">Bravo 2016</a>). Several studies have shown that HCV infection adversely affects survival in patients with CKD stage 5 (<a href="./references#CD007003-bbs2-0037" title="FabriziF , MartinP , DixitV , BunnapradistS , DulaiG . Meta-analysis: effect of hepatitis C virus infection on mortality in dialysis. Alimentary Pharmacology &amp; Therapeutics2004;20(11-12):1271-7. [MEDLINE: 15606388]">Fabrizi 2004</a>). A 2019 meta‐analysis found that in the dialysis population, HCV infection was associated with an adjusted all‐cause death risk of 1.26 (95% CI 1.18 to 1.34), an adjusted risk of liver‐disease associated death of 5.05 (95% CI 2.53 to 10.0), and cardiovascular death risk of 1.18 (95% CI 1.09 to 1.29) (<a href="./references#CD007003-bbs2-0042" title="FabriziF , DixitV , MessaP . Hepatitis C virus and mortality among patients on dialysis: A systematic review and meta-analysis. Clinics &amp; Research in Hepatology &amp; Gastroenterology2019;43(3):244-54. [MEDLINE: 30910601]">Fabrizi 2019</a>). The DOPPS study also found that HCV‐infected dialysis patients had a higher risk of death, hospitalisation, anaemia‐related complications, and worse quality of life (QoL) scores (<a href="./references#CD007003-bbs2-0045" title="GoodkinDA , BieberD , JadoulM , MartinP , KandaE , PisoniRL . Mortality, hospitalization, and quality of life among patients with hepatitis C infection on hemodialysis. Clinical Journal of The American Society of Nephrology: CJASN2017;12(2):287-97. [MEDLINE: 27908905]">Goodkin 2017</a>).  </p> <p>HCV infection is an independent risk factor for death in dialysis patients and adversely affects patient and graft survival after kidney transplantation (<a href="./references#CD007003-bbs2-0041" title="FabriziF , MartinP , DixitV , MessaP . Meta-analysis of observational studies: hepatitis C and survival after renal transplant. Journal of Viral Hepatitis2014;21(5):314-24. [MEDLINE: 24716634]">Fabrizi 2014</a>; <a href="./references#CD007003-bbs2-0065" title="NakayamaE , AkibaT , MarumoF , SatoC . Prognosis of anti-hepatitis C virus antibody-positive patients on regular hemodialysis therapy. Journal of the American Society of Nephrology2000;11(10):1896-902. [MEDLINE: 11004221]">Nakayama 2000</a>; <a href="./references#CD007003-bbs2-0071" title="RostamiZ , NourbalaMH , AlavianSM , BieraghdarF , JahaniY , EinollahiB . The impact of Hepatitis C virus infection on kidney transplantation outcomes: A systematic review of 18 observational studies: The impact of HCV on renal transplantation. Hepatitis Monthly2011;11(4):247-54. [MEDLINE: 22087151]">Rostami 2011</a>), is associated with the development of new‐onset diabetes mellitus (DM) (<a href="./references#CD007003-bbs2-0038" title="FabriziF , MartinP , DixitV , BunnapradistS , KanwalF , DulaiG . Post-transplant diabetes mellitus and HCV seropositive status after renal transplantation: meta-analysis of clinical studies. American Journal of Transplantation2005;5(10):2433-40. [MEDLINE: 16162192]">Fabrizi 2005</a>), de novo (<a href="./references#CD007003-bbs2-0032" title="CruzadoJM , CarreraM , TorrasJ , GrinyóJM . Hepatitis C virus infection and de novo glomerular lesions in renal allografts. American Journal of Transplantation2001;1(2):171-8. [MEDLINE: 12099366]">Cruzado 2001</a>) and recurrent (<a href="./references#CD007003-bbs2-0048" title="HammoudH , HaemJ , LaurentB , AlamartineE , DiabN , DefilippisJP , et al. Glomerular disease during HCV infection in renal transplantation. Nephrology Dialysis Transplantation1996;11 Suppl 4:54-5. [MEDLINE: 8918756]">Hammoud 1996</a>) glomerulonephritis, and post‐transplant lymphoproliferative disorder (<a href="./references#CD007003-bbs2-0027" title="BurraP , BudaA , LiviU , RigottiP , ZanusG , CalabreseF , et al. Occurrence of post-transplant lymphoproliferative disorders among over thousand adult recipients: any role for hepatitis C infection?European Journal of Gastroenterology &amp; Hepatology2006;18(10):1065-70. [MEDLINE: 16957512]">Burra 2006</a>). Observational studies have shown that sustained virological response (SVR), defined as the absence of detectable HCV RNA in the blood 12 to 24 weeks after the end of treatment, is associated with improved outcomes. A 2015 meta‐analysis found that the hazard ratio of death in patients achieving SVR was 0.50 (95% confidence interval (CI) 0.37 to 0.67) in the general population, 0.26 (95% CI 0.18 to 0.74) in those with cirrhosis, and 0.21 (95% CI 0.10 to 0.45) in those with HIV co‐infection (<a href="./references#CD007003-bbs2-0076" title="SimmonsB , SaleemJ , HeathK , CookeGS , HillA . Long-term treatment outcomes of patients infected with hepatitis C virus: a systematic review and meta-analysis of the survival benefit of achieving a sustained virological response. Clinical Infectious Diseases2015;61(5):730-40. [MEDLINE: 25987643]">Simmons 2015</a>). Large cohort studies have reported a reduction in death in patients being treated with direct‐acting antivirals (<a href="./references#CD007003-bbs2-0028" title="CarratF , FontaineH , DorivalC , SimonyM , DialloA , HezodeC , et al. Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study. Lancet2019;393(10179):1453-64. [MEDLINE: 30765123]">Carrat 2019</a>; <a href="./references#CD007003-bbs2-0057" title="KalidindiY , JungJ , FeldmanR , Riley T 3rd. Association of direct-acting antiviral treatment with mortality among Medicare beneficiaries with hepatitis C. JAMA Network Open2020;3(7):e2011055. [MEDLINE: 32692371]">Kalidindi 2020</a>). Other reported benefits associated with achieving SVR based on observational studies include a reduction in the development of liver‐related complications, including hepatocellular carcinoma and liver‐related death (<a href="./references#CD007003-bbs2-0064" title="NahonP , BourcierV , LayeseR , AudureauE , CagnotC , MarcellinP , et al. Eradication of hepatitis C virus infection in patients with cirrhosis reduces risk of liver and non-liver complications [Erratum in: Gastroenterology. 2021 Jul;161(1):377; PMID: 30817897]. Gastroenterology2017;152(1):142-56. [MEDLINE: 27641509]">Nahon 2017</a>), insulin resistance (<a href="./references#CD007003-bbs2-0018" title="AdinolfiLE , NevolaR , GuerreraB , D'AlterioG , MarroneA , GiordanoM , et al. Hepatitis C virus clearance by direct-acting antiviral treatments and impact on insulin resistance in chronic hepatitis C patients. Journal of Gastroenterology &amp; Hepatology2018;33(7):1379-82. [MEDLINE: 29228501]">Adinolfi 2018</a>), and DM risk (<a href="./references#CD007003-bbs2-0020" title="AraseY , SuzukiF , SuzukiY , AkutaN , KobayashiM , KawamuraY , et al. Sustained virological response reduces incidence of onset of type 2 diabetes in chronic hepatitis C. Hepatology2009;49(3):739-44. [MEDLINE: 19127513]">Arase 2009</a>). Based on this evidence, the American Association for the Study of Liver Diseases/Infectious Diseases Society of America (AASLD/IDSA) guidelines recommend treatment with antivirals for all patients with acute or chronic HCV infection, except for those with a short life expectancy that cannot be remedied by HCV therapy, liver transplantation, or another directed therapy (<a href="./references#CD007003-bbs2-0017" title="GhanyMG , MorganTR , AASLD/IDSA HCV Guidance Panel. Hepatitis C Guidance 2019 Update: American Association for the Study of Liver Diseases–Infectious Diseases Society of America recommendations for testing, managing, and treating hepatitis C virus infection. Hepatology2020;71(2):686-721. [DOI: https://doi.org/10.1002/hep.31060]">AASLD/IDSA HCV Guidance Panel 2020</a>). However, data that demonstrates that SVR at 12 weeks is associated with a reduction in death in CKD is lacking and those with advanced liver fibrosis or cirrhosis at the time of treatment are at risk of decompensation and hepatocellular carcinoma irrespective of SVR. Based on the evidence extrapolated from the general population and the favourable risk‐benefit profile of newer antivirals, the 2018 KDIGO guidelines recommend that all HCV‐positive CKD patients be evaluated for antiviral treatment. HCV‐infected kidney transplant candidates may be considered for antiviral treatment before or after transplantation. In advanced CKD, interferons are poorly tolerated, and ribavirin is associated with adverse events. Hence, interferon‐free therapy is recommended by KDIGO. Direct‐acting antiviral‐based regimen is preferred with a choice of drugs to be based on HCV genotype (and subtype), viral load, prior treatment, drug–drug interactions, glomerular filtration rate (GFR), degree of hepatic fibrosis, candidacy for a liver transplant, and co‐morbidities (<a href="./references#CD007003-bbs2-0058" title="Kidney Disease: Improving Global Outcomes (KDIGO) Hepatitis C Work Group. KDIGO 2018 Clinical Practice Guideline for the Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C in Chronic Kidney Disease. Kidney International Supplements2018;8(3):91-165. [MEDLINE: 30675443]">KDIGO 2018</a>). </p> </section> <section id="CD007003-sec-0011"> <h3 class="title" id="CD007003-sec-0011">Description of the intervention</h3> <p>The preferred antiviral therapy for HCV currently is a combination of direct‐acting antivirals. The HCV genome encodes for a polyprotein which requires cleaving by a host or virus‐coded proteases which are nonstructural proteins. Direct‐acting antivirals belong to three classes: NS3/4 protease inhibitors drug name ending with “previr”, NS5B nucleoside and nonnucleoside polymerase inhibitors drug name ending in “buvir” and NS5A inhibitors drug name ending in “asvir” (<a href="./references#CD007003-bbs2-0035" title="DienstagJL . Chapter 341: Chronic hepatitis. In: LoscalzoJ , FauciKD , HauserS , LongoD , JamesonJL , editors(s). Harrison's Principles of Internal Medicine. 21st edition. New York, NY: McGraw-Hill Education, 2022:2591-616. [ISBN: 9781264268504]">Dienstag 2022</a>). Grazoprevir, asunaprevir, simeprevir and paritaprevir inhibit NS3/4A, while elbasvir, daclatasvir, ledipasvir, velpatasvir and ombitasvir inhibit NS5A. Sofosbuvir and dasabuvir are NS5B inhibitors (<a href="./references#CD007003-bbs2-0056" title="JakobsenJC , NielsenEE , FeinbergJ , KatakamKK , FobianK , HauserG , et al. Direct-acting antivirals for chronic hepatitis C. Cochrane Database of Systematic Reviews2017, Issue 9. Art. No: CD012143. [DOI: 10.1002/14651858.CD012143.pub2]">Jakobsen 2017</a>; <a href="./references#CD007003-bbs2-0069" title="PoordadF , DieterichD . Treating hepatitis C: current standard of care and emerging direct-acting antiviral agents. Journal of Viral Hepatitis2012;19(7):449-64. [MEDLINE: 22676357]">Poordad 2012</a>). The preferred drug combination varies based on the genotype of the HCV virus, CKD stage and availability (<a href="./references#CD007003-bbs2-0058" title="Kidney Disease: Improving Global Outcomes (KDIGO) Hepatitis C Work Group. KDIGO 2018 Clinical Practice Guideline for the Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C in Chronic Kidney Disease. Kidney International Supplements2018;8(3):91-165. [MEDLINE: 30675443]">KDIGO 2018</a>). Telaprevir, a protease inhibitor, induces and requires CYP3A4 for elimination and cannot be used with other drugs which induce or are eliminated by this enzyme. Certain combinations such as glecaprevir‐pibrentasvir, sofosbuvir‐daclatasvir and sofosbuvir‐velpatasvir are pangenotypic (<a href="./references#CD007003-bbs2-0084" title="ZorattiMJ , SiddiquaA , MorassutRE , ZeraatkarD , ChouR , vanHoltenJ , et al. Pangenotypic direct acting antivirals for the treatment of chronic hepatitis C virus infection: a systematic literature review and meta-analysis. EClinicalMedicine2020;18:100237. [MEDLINE: 31922124]">Zoratti 2020</a>). Grazoprevir‐elbasvir combination is recommended in advanced CKD (<a href="./references#CD007003-bbs2-0026" title="BruchfeldA , RothD , MartinP , NelsonDR , PolS , LondonoMC , et al. Elbasvir plus grazoprevir in patients with hepatitis C virus infection and stage 4-5 chronic kidney disease: clinical, virological, and health-related quality-of-life outcomes from a phase 3, multicentre, randomised, double-blind, placebo-controlled trial. The Lancet. Gastroenterology &amp; Hepatology2017;2(8):585-94. [MEDLINE: 28576451]">Bruchfeld 2017</a>) in HCV genotypes 1 and 4. Both these are metabolised by the enzyme cytochrome P450 subfamily 3A (CYP3A) and concurrent administration of drugs which induce CYP3A such as rifampicin and phenytoin is to be avoided. Grazoprevir is a substrate for organic ion transporter B1 (OATB1) and concurrent administration of drugs which inhibit this protein, such as enalapril, angiotensin receptor blockers, statins and digoxin, are to be avoided. Other drugs recommended are paritaprevir‐ritonavir‐ombitasvir with or without dasabuvir, simeprevir and daclatasvir. Glecaprevir‐pibrentasvir combination can be used for all HCV genotypes (<a href="./references#CD007003-bbs2-0043" title="GaneE , LawitzE , PugatchD , PapatheodoridisG , BräuN , BrownA , et al. Glecaprevir and pibrentasvir in patients with HCV and severe renal impairment. New England Journal of Medicine2017;377(15):1448-55. [MEDLINE: 29020583]">Gane 2017</a>; <a href="./references#CD007003-bbs2-0059" title="LawitzE , GaneE , CohenE , VierlingJ , AgarwalK , HassaneinT , et al. Efficacy and safety of ombitasvir/paritaprevir/ritonavir in patients with hepatitis C virus genotype 1 or 4 infection and advanced kidney disease. KI Reports2019;4(2):257-66. [MEDLINE: 30775622]">Lawitz 2019</a>) with some reports of sofosbuvir‐ledipasvir or daclatasvir‐simeprevir, especially after kidney transplantation. Sofosbuvir can cause severe bradycardia if given with amiodarone and has drug‐drug interactions with p‐glycoprotein inducers like rifampin and proton‐pump inhibitors and decrease their concentrations. Protease inhibitors have drug‐drug interactions with CYP3A4 inducers. Daclatasvir levels are reduced by CYP3A inducers and inhibitors. Daclatasvir inhibits p‐glycoprotein OATP1B1, OATP1B3, breast cancer resistance protein and levels of drugs which are substrates for these proteins are increased. Elbasvir and grazoprevir can cause elevation of aminotransferases and are both metabolized through CYP3A. They both have multiple drug‐drug interactions and cannot be used with CYP3A inducers and CYP3A, OATP1B1 inhibitors can cause an increase in elbasvir‐grazoprevir concentrations. Glecaprevir‐pibrentasvir is avoided in decompensated cirrhosis (<a href="./references#CD007003-bbs2-0035" title="DienstagJL . Chapter 341: Chronic hepatitis. In: LoscalzoJ , FauciKD , HauserS , LongoD , JamesonJL , editors(s). Harrison's Principles of Internal Medicine. 21st edition. New York, NY: McGraw-Hill Education, 2022:2591-616. [ISBN: 9781264268504]">Dienstag 2022</a>). The recommended duration of therapy is usually 12 weeks, and common adverse events include fatigue, malaise, nausea, diarrhoea, vomiting and headache (<a href="./references#CD007003-bbs2-0050" title="HayesKN , BurkardT , WeilerS , TadrousM , BurdenAM . Global adverse events reported for direct-acting antiviral therapies for the treatment of hepatitis C: an analysis of the World Health Organization VigiBase. European Journal of Gastroenterology &amp; Hepatology2021;33(1S Suppl 1):e1017-21. [MEDLINE: 33883523]">Hayes 2021</a>). In severe kidney impairment, including those on HD, recommended medications are combinations are elbasvir‐grazoprevir for genotypes 1 and 4, glecaprevir‐pibrentasvir for all genotypes without dose adjustment, and those containing sofosbuvir (<a href="./references#CD007003-bbs2-0035" title="DienstagJL . Chapter 341: Chronic hepatitis. In: LoscalzoJ , FauciKD , HauserS , LongoD , JamesonJL , editors(s). Harrison's Principles of Internal Medicine. 21st edition. New York, NY: McGraw-Hill Education, 2022:2591-616. [ISBN: 9781264268504]">Dienstag 2022</a>). </p> <p>Interferons are proteins produced by nucleated cells available as recombinant standard or pegylated (PEG) forms. Standard interferons alpha‐2a and alpha‐2b are short‐acting, metabolised in the kidney, with doses being 1.5 to 3 million units subcutaneously (SC) 3 times/week for up to one year and no dose adjustment for kidney failure (<a href="./references#CD007003-bbs2-0082" title="WillsRJ . Clinical pharmacokinetics of interferons. Clinical Pharmacokinetics1990;19(5):390-9. [MEDLINE: 1702693]">Wills 1990</a>). PEG interferons alpha‐2a and alpha‐2b are conjugates of interferons with polyethylene glycol, with differing molecular weights, smaller alpha‐2b requires differential dosing 1.0 to 1.5 µg/kg/week, larger alpha‐2a uniform dosing 135 to 180 µg/week both once weekly up to 48 weeks. Pegylation protects from degradation, renal clearance and maintains stable concentrations, but increases toxicity on dialysis (<a href="./references#CD007003-bbs2-0021" title="AyazC , CelenMK , YuceUN , GeyikMF . Efficacy and safety of pegylated-interferon alpha-2a in hemodialysis patients with chronic hepatitis C. World Journal of Gastroenterology2008;14(2):255-9. [MEDLINE: 18186564]">Ayaz 2008</a>; <a href="./references#CD007003-bbs2-0033" title="DienstagJL . Chapter 203: Acute viral hepatitis. In: LongoDL , FauciAS , KasperDL , HauserSL , JamesonJL , LoscalzoJ , editors(s). Harrison's Principles of Internal Medicine. 18th edition. Vol. 2. New York: McGraw-Hill, 2012:2542-8. [ISBN: 978-0-07-174887-2]">Dienstag 2012a</a>; <a href="./references#CD007003-bbs2-0034" title="DienstagJL . Chapter 306: Chronic hepatitis. In: LongoDL , FauciAS , KasperDL , HauserSL , JamesonJL , LoscalzoJ , editors(s). Harrison's Principles of Internal Medicine. 18th edition. Vol. 2. New York: McGraw-Hill, 2012:2578-84. [ISBN: 978-0-07-174887-2]">Dienstag 2012b</a>). </p> <p>Adverse events of interferons include flu‐like symptoms, marrow suppression, emotional lability, autoimmune reactions, alopecia, rash, diarrhoea, tingling, and numbness of extremities with most being reversible but contraindicated in pregnancy (<a href="./references#CD007003-bbs2-0033" title="DienstagJL . Chapter 203: Acute viral hepatitis. In: LongoDL , FauciAS , KasperDL , HauserSL , JamesonJL , LoscalzoJ , editors(s). Harrison's Principles of Internal Medicine. 18th edition. Vol. 2. New York: McGraw-Hill, 2012:2542-8. [ISBN: 978-0-07-174887-2]">Dienstag 2012a</a>; <a href="./references#CD007003-bbs2-0034" title="DienstagJL . Chapter 306: Chronic hepatitis. In: LongoDL , FauciAS , KasperDL , HauserSL , JamesonJL , LoscalzoJ , editors(s). Harrison's Principles of Internal Medicine. 18th edition. Vol. 2. New York: McGraw-Hill, 2012:2578-84. [ISBN: 978-0-07-174887-2]">Dienstag 2012b</a>; <a href="./references#CD007003-bbs2-0066" title="NeumannAU , LamNP , DahariH , GretchDR , WileyTE , LaydenTJ , et al. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science1998;282(5386):103-7. [MEDLINE: 9756471]">Neumann 1998</a>; <a href="./references#CD007003-bbs2-0079" title="VialT , DescotesJ . Clinical toxicity of the interferons. Drug Safety1994;10(2):115-50. [MEDLINE: 7516663]">Vial 1994</a>), increased kidney allograft rejection (<a href="./references#CD007003-bbs2-0061" title="MagnoneM , HolleyJL , ShapiroR , ScantleburyV , McCauleyJ , JordanM , et al. Interferon-alpha-induced acute renal allograft rejection. Transplantation1995;59(7):1068-70. [MEDLINE: 7709447]">Magone 1995</a>), and drug‐drug interactions with telbivudine (<a href="./references#CD007003-bbs2-0083" title="ZhangXS , JinR , ZhangSB , TaoML . Clinical features of adverse reactions associated with telbivudine. World Journal of Gastroenterology2008;14(22):3549-53. [MEDLINE: 18567085]">Zhang 2008</a>) and theophylline (<a href="./references#CD007003-bbs2-0081" title="WilliamsSJ , Baird-LambertJA , FarrellGC . Inhibition of theophylline metabolism by interferon. Lancet1987;2(8565):939-41. [MEDLINE: 2444839]">Williams 1987</a>). </p> <p>Ribavirin is a nucleoside analogue used with interferons, with a dose of 800 to 1200 mg/day, reduced in kidney failure (<a href="./references#CD007003-bbs2-0022" title="BadenLR , DolinR . Antiviral chemotherapy excluding antiretroviral drugs. In: LongoDL , FauciAS , KasperDL , HauserSL , JamesonJL , LoscalzoJ , editors(s). Harrison's Principles of Internal Medicine. 18th edition. Vol. 1. New York: McGraw-Hill, 2012:1447. [ISBN: 978-0-07-163244-7]">Baden 2012</a>; <a href="./references#CD007003-bbs2-0025" title="BruchfeldA , StahleL , AnderssonJ , SchvarczR . Ribavirin treatment in dialysis patients with chronic hepatitis C virus infection--a pilot study. Journal of Viral Hepatitis2001;8(4):287–92. [MEDLINE: 11454181]">Bruchfeld 2001</a>). Adverse events are haemolytic anaemia, teratogenicity, and interactions with abacavir, lamivudine, zidovudine, interferon alpha‐2b (<a href="./references#CD007003-bbs2-0078" title="United States Pharmacopeial Convention. USP D1. Volume 1, Drug Information for the Health Care Professional. Greenwood Village, CO: Thomson/MICROMEDEX, 2006.">USP 2006</a>), azathioprine (<a href="./references#CD007003-bbs2-0030" title="ChaparroM , Trapero-MaruganM , Moreno-OteroR , GisbertJP . Azathioprine plus ribavirin treatment and pancytopenia. Alimentary Pharmacology &amp; Therapeutics2009;30(9):962-3. [MEDLINE: 19807727]">Chaparro 2009</a>), and didanosine (<a href="./references#CD007003-bbs2-0063" title="MorenoA , QueredaC , MorenoL , Perez-EliasMJ , MurielA , CasadoJL , et al. High rate of didanosine-related mitochondrial toxicity in HIV/HCV-coinfected patients receiving ribavirin. Antiviral Therapy2004;9(1):133-8. [MEDLINE: 15040545]">Moreno 2004</a>). </p> </section> <section id="CD007003-sec-0012"> <h3 class="title" id="CD007003-sec-0012">How the intervention might work</h3> <p>Direct‐acting antivirals target specific nonstructural proteins of HCV causing disruption of viral replication and infection. Direct‐acting antivirals are classified by their mechanism of action and therapeutic target into four classes i.e. nonstructural proteins 3/4A (NS3/4A) protease inhibitors which cleave the HCV polyprotein into structural and nonstructural proteins, NS5B nucleoside/non‐nucleoside polymerase inhibitors (NPIs/NNPIs) which inhibit the RNA‐dependent RNA polymerase required in viral RNA synthesis, and NS5A inhibitors which inhibit a membrane‐associated phosphoprotein required for HVC RNA replication (<a href="./references#CD007003-bbs2-0069" title="PoordadF , DieterichD . Treating hepatitis C: current standard of care and emerging direct-acting antiviral agents. Journal of Viral Hepatitis2012;19(7):449-64. [MEDLINE: 22676357]">Poordad 2012</a>). </p> <p>Interferons bind cell receptors, inhibit viral replication and cell proliferation, enhance macrophage phagocytic activity, natural killer cell and leukocyte antibody‐dependant cellular cytotoxicity, and cellular enzymes (<a href="./references#CD007003-bbs2-0053" title="HouglumJE . Interferon: mechanisms of action and clinical value. Clinical Pharmacy1983;2(1):20-8. [MEDLINE: 6192965]">Houglum 1983</a>) by stimulation of JAK‐STAT signal transduction of antiviral genes (<a href="./references#CD007003-bbs2-0033" title="DienstagJL . Chapter 203: Acute viral hepatitis. In: LongoDL , FauciAS , KasperDL , HauserSL , JamesonJL , LoscalzoJ , editors(s). Harrison's Principles of Internal Medicine. 18th edition. Vol. 2. New York: McGraw-Hill, 2012:2542-8. [ISBN: 978-0-07-174887-2]">Dienstag 2012a</a>; <a href="./references#CD007003-bbs2-0034" title="DienstagJL . Chapter 306: Chronic hepatitis. In: LongoDL , FauciAS , KasperDL , HauserSL , JamesonJL , LoscalzoJ , editors(s). Harrison's Principles of Internal Medicine. 18th edition. Vol. 2. New York: McGraw-Hill, 2012:2578-84. [ISBN: 978-0-07-174887-2]">Dienstag 2012b</a>). Ribavirin inhibits host inosine monophosphate dehydrogenase, reduces guanine nucleosides and viral replication, and induces virological mutational catastrophe and interferon‐stimulated gene expression (<a href="./references#CD007003-bbs2-0033" title="DienstagJL . Chapter 203: Acute viral hepatitis. In: LongoDL , FauciAS , KasperDL , HauserSL , JamesonJL , LoscalzoJ , editors(s). Harrison's Principles of Internal Medicine. 18th edition. Vol. 2. New York: McGraw-Hill, 2012:2542-8. [ISBN: 978-0-07-174887-2]">Dienstag 2012a</a>; <a href="./references#CD007003-bbs2-0034" title="DienstagJL . Chapter 306: Chronic hepatitis. In: LongoDL , FauciAS , KasperDL , HauserSL , JamesonJL , LoscalzoJ , editors(s). Harrison's Principles of Internal Medicine. 18th edition. Vol. 2. New York: McGraw-Hill, 2012:2578-84. [ISBN: 978-0-07-174887-2]">Dienstag 2012b</a>; <a href="./references#CD007003-bbs2-0077" title="ThomasE , FeldJJ , LiQ , HuZ , FriedMW , LiangTJ . Ribavirin potentiates interferon action by augmenting interferon-stimulated gene induction in hepatitis C virus cell culture models. Hepatology2011;53(1):32-41. [MEDLINE: 21254160]">Thomas 2011</a>). </p> </section> <section id="CD007003-sec-0013"> <h3 class="title" id="CD007003-sec-0013">Why it is important to do this review</h3> <p>Most studies on interventions in this area are of uncontrolled design, having small numbers of patients. Previous systematic reviews have included both controlled and uncontrolled studies. Previously, in non‐CKD patients, PEG interferon with ribavirin was preferred (<a href="./references#CD007003-bbs2-0033" title="DienstagJL . Chapter 203: Acute viral hepatitis. In: LongoDL , FauciAS , KasperDL , HauserSL , JamesonJL , LoscalzoJ , editors(s). Harrison's Principles of Internal Medicine. 18th edition. Vol. 2. New York: McGraw-Hill, 2012:2542-8. [ISBN: 978-0-07-174887-2]">Dienstag 2012a</a>; <a href="./references#CD007003-bbs2-0034" title="DienstagJL . Chapter 306: Chronic hepatitis. In: LongoDL , FauciAS , KasperDL , HauserSL , JamesonJL , LoscalzoJ , editors(s). Harrison's Principles of Internal Medicine. 18th edition. Vol. 2. New York: McGraw-Hill, 2012:2578-84. [ISBN: 978-0-07-174887-2]">Dienstag 2012b</a>). Considering the reduced clearance and toxicity of these drugs in CKD on dialysis, and the present preferred use of direct‐acting antivirals due to their reported safety and efficacy (<a href="./references#CD007003-bbs2-0054" title="IliescuEL , Mercan-StanciuA , TomaL . Safety and efficacy of direct-acting antivirals for chronic hepatitis C in patients with chronic kidney disease. BMC Nephrology2020;21(1):21. [MEDLINE: 31948406]">Iliescu 2020</a>), we updated this review to collate evidence for these and other interventions. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD007003-sec-0014" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD007003-sec-0014"></div> <p>We aimed to look at the benefits and harms of various interventions for HCV infection in CKD patients on HD or peritoneal dialysis (PD), specifically on death, disease relapse, response to treatment, treatment discontinuation, time to recovery, QoL, cost‐effectiveness, adverse events, and other outcomes. We aimed to study comparisons of available interventions with a placebo or control group, combinations of interventions with a placebo or control group, interventions with each other singly and in combination, and available standard interventions with newer treatment modalities. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD007003-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD007003-sec-0015"></div> <section id="CD007003-sec-0016"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD007003-sec-0017"> <h4 class="title">Types of studies</h4> <p>All randomised controlled trials (RCTs) and quasi‐RCTs (RCTs in which allocation to treatment was obtained by alternation, use of alternate medical records, date of birth or other predictable methods) looking at interventions for HCV infection in CKD patients on HD or PD were considered. The first period of randomised cross‐over studies was also considered. There were no language restrictions. </p> </section> <section id="CD007003-sec-0018"> <h4 class="title">Types of participants</h4> <section id="CD007003-sec-0019"> <h5 class="title">Inclusion criteria</h5> <p> <ul id="CD007003-list-0001"> <li> <p>Studies on patients with CKD stage 5 as diagnosed by National Kidney Foundation criteria on HD or PD with HCV infection (<a href="./references#CD007003-bbs2-0067" title="National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. American Journal of Kidney Diseases2002;39(2 Suppl 1):S1-266. [MEDLINE: 11904577]">NKF‐K/DOQI 2002</a>) </p> </li> <li> <p>HCV infection was established based on either a positive anti‐HCV antibody or detectable HCV RNA (i.e. &gt; 50 IU/mL). </p> </li> </ul> </p> </section> <section id="CD007003-sec-0020"> <h5 class="title">Exclusion criteria</h5> <p> <ul id="CD007003-list-0002"> <li> <p>Studies which included patients with HIV/HBsAg co‐infection</p> </li> <li> <p>Studies which included patients with HCV‐related manifestations (e.g. cryoglobulinaemia, arthritis, thyroid disease) other than liver disease </p> </li> <li> <p>Studies which analysed HCV as non‐A non‐B hepatitis.</p> </li> </ul> </p> </section> </section> <section id="CD007003-sec-0021"> <h4 class="title">Types of interventions</h4> <p> <ul id="CD007003-list-0003"> <li> <p>No treatment or placebo versus interferon therapy</p> </li> <li> <p>No treatment or placebo versus PEG interferon</p> </li> <li> <p>No treatment or placebo versus ribavirin</p> </li> <li> <p>No treatment or placebo versus interferon plus ribavirin</p> </li> <li> <p>No treatment or placebo versus PEG interferon plus ribavirin</p> </li> <li> <p>Interferon versus PEG interferon therapy</p> </li> <li> <p>Interferon versus ribavirin</p> </li> <li> <p>PEG interferon versus ribavirin</p> </li> <li> <p>Interferon monotherapy versus ribavirin plus PEG interferon</p> </li> <li> <p>PEG interferon monotherapy versus ribavirin plus interferon</p> </li> <li> <p>Interferon versus other newer treatment modalities</p> </li> <li> <p>PEG interferon versus other newer treatment modalities</p> </li> <li> <p>PEG interferon plus ribavirin versus other newer treatment modalities</p> </li> <li> <p>Interferons versus other antivirals</p> </li> <li> <p>Comparison of two antivirals other than interferons</p> </li> <li> <p>Antivirals other than interferons versus placebo to no treatment</p> </li> </ul> </p> </section> <section id="CD007003-sec-0022"> <h4 class="title">Types of outcome measures</h4> <section id="CD007003-sec-0023"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD007003-list-0004"> <li> <p>Death at maximum follow‐up of individual studies</p> </li> <li> <p>Relapse of disease: the reappearance of HCV RNA in patients who were HCV RNA negative at the end of treatment. </p> </li> </ul> </p> </section> <section id="CD007003-sec-0024"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD007003-list-0005"> <li> <p>End‐of‐treatment response: HCV RNA undetectable at the end of treatment</p> </li> <li> <p>SVR: HCV RNA undetectable 24 weeks after stopping treatment</p> </li> <li> <p>Time to recovery</p> </li> <li> <p>Treatment discontinuation</p> </li> <li> <p>Number and type of adverse events</p> </li> <li> <p>Cost‐effectiveness</p> </li> <li> <p>QoL issues</p> </li> <li> <p>Other outcomes, e.g. cardiovascular (myocardial infarction).</p> </li> </ul> </p> </section> </section> </section> <section id="CD007003-sec-0025"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD007003-sec-0026"> <h4 class="title">Electronic searches</h4> <p>We searched the <a href="http://kidneyandtransplant.cochrane.org/cochrane-kidney-and-transplant-specialised-register" target="_blank">Cochrane Kidney and Transplant Register of Studies</a> to 22 February 2023 through contact with the Information Specialist using search terms relevant to this review. The Register contains studies identified from the following sources: </p> <p> <ol id="CD007003-list-0006"> <li> <p>Monthly searches of the Cochrane Central Register of Controlled Trials (CENTRAL)</p> </li> <li> <p>Weekly searches of MEDLINE OVID SP</p> </li> <li> <p>Searches of kidney and transplant journals and the proceedings and abstracts from major kidney and transplant conferences </p> </li> <li> <p>Searching the current year of EMBASE OVID SP</p> </li> <li> <p>Weekly current awareness alerts for selected kidney and transplant journals</p> </li> <li> <p>Searches of the International Clinical Trials Register Portal (ICTRP) and ClinicalTrials.gov.</p> </li> </ol> </p> <p>Studies contained in the Register are identified through searches of CENTRAL, MEDLINE, and EMBASE based on the scope of Cochrane Kidney and Transplant. Details of search strategies, as well as a list of hand‐searched journals, conference proceedings and current awareness alerts, are available on the Cochrane Kidney and Transplant website under <a href="http://kidneyandtransplant.cochrane.org/cochrane-kidney-and-transplant-specialised-register" target="_blank">CKT Register of Studies</a>. </p> <p>See <a href="./appendices#CD007003-sec-0102">Appendix 1</a> for search terms used in strategies for this review. </p> </section> <section id="CD007003-sec-0027"> <h4 class="title">Searching other resources</h4> <p> <ul id="CD007003-list-0007"> <li> <p>Reference lists of clinical practice guidelines, review articles and relevant studies.</p> </li> <li> <p>Information about unpublished data, incomplete studies or availability of other RCTs was sought through electronic mail from the contact authors of RCTs. </p> </li> </ul> </p> </section> </section> <section id="CD007003-sec-0028"> <h3 class="title" id="CD007003-sec-0028">Data collection and analysis</h3> <section id="CD007003-sec-0029"> <h4 class="title">Selection of studies</h4> <p>The search strategy described was used to obtain titles and abstracts of studies that were relevant to the review. The titles and abstracts were screened independently by three authors, who discarded studies that were not applicable. However, studies and reviews that included relevant data or information on studies were retained initially. Three authors independently assessed and retrieved abstracts and, if necessary the full text of these studies to determine which studies satisfied the inclusion criteria. Disagreements were resolved in consultation with a fourth author. Attempts were made to identify duplicate publications based on author names, study location, setting, date, duration, number of participants, baseline data and details of interventions. </p> </section> <section id="CD007003-sec-0030"> <h4 class="title">Data extraction and management</h4> <p>Data extraction was carried out independently using standard pre‐structured data extraction forms. Studies reported in a non‐English language were translated before assessment with one study in Spanish requiring translation. Where more than one publication of a study exists, reports were grouped together using clinical trial registry entries and the most recent or most complete data set was used.  Authors independently applied the inclusion criteria, assessed study quality and extracted data. Disagreements were resolved by consensus or with a third author. </p> <p>The following information was obtained.</p> <p> <ul id="CD007003-list-0008"> <li> <p>Publication type and source, including the language of publication, year of publication, way of retrieval of the report </p> </li> <li> <p>Sources of support</p> </li> <li> <p>Study design, including method of generation and concealment of allocation, and type of control intervention </p> </li> <li> <p>Setting including country and level of care</p> </li> <li> <p>Patients: age, sex, CKD status along with hepatitis C infection, co‐morbidities, co‐intervention</p> </li> <li> <p>Intervention, criteria for choosing patients, chronic disease stage, timing of initiation of therapy, kidney transplantation status, number of withdrawals and dropouts/groups, modalities and duration of treatment </p> </li> <li> <p>Outcome measures included death, relapse and recovery as assessed by the end‐of‐treatment response and SVR </p> </li> <li> <p>Analysis, including whether analysis was done according to the intention‐to‐treat principle </p> </li> <li> <p>Results, including averages and variations of individual outcome assessments and different comparisons, test statistics and P values for comparisons within and between groups. </p> </li> </ul> </p> </section> <section id="CD007003-sec-0031"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>The following items were independently assessed by two authors using the risk of bias assessment tool (<a href="./references#CD007003-bbs2-0052" title="HigginsJP , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , et al. Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). Cochrane, 2022. Available from www.training.cochrane.org/handbook.">Higgins 2022</a>) (see <a href="./appendices#CD007003-sec-0103">Appendix 2</a>). </p> <p> <ul id="CD007003-list-0009"> <li> <p>Was there adequate sequence generation (selection bias)?</p> </li> <li> <p>Was allocation adequately concealed (selection bias)?</p> </li> <li> <p>Was knowledge of the allocated interventions adequately prevented during the study?</p> <ul id="CD007003-list-0010"> <li> <p>Participants and personnel (performance bias)</p> </li> <li> <p>Outcome assessors (detection bias)</p> </li> </ul> </li> <li> <p>Were incomplete outcome data adequately addressed (attrition bias)?</p> </li> <li> <p>Are reports of the study free of suggestion of selective outcome reporting (reporting bias)? </p> </li> <li> <p>Was the study apparently free of other problems that could put it at risk of bias?</p> </li> </ul> </p> </section> <section id="CD007003-sec-0032"> <h4 class="title">Measures of treatment effect</h4> <p>For dichotomous outcomes (e.g. death, remission or no remission), results were expressed as risk ratio (RR) with 95% CI. Data were pooled using the random‐effects model. None of the outcomes measured had continuous scales of measurement. Adverse events were tabulated and assessed with descriptive techniques, and the analysis was done for the number of patients having adverse events. Where data were available, serious adverse events were analysed separately. </p> </section> <section id="CD007003-sec-0033"> <h4 class="title">Unit of analysis issues</h4> <p>The search did not find any cluster RCTs, cross‐over studies or studies with multiple interventions. This review included studies of parallel design comparing two interventions, two doses of the same intervention and an intervention versus a control or placebo group. One RCT crossed over the placebo group to the intervention arm at end of the treatment; hence analysis was only done for the end‐of‐treatment response. </p> </section> <section id="CD007003-sec-0034"> <h4 class="title">Dealing with missing data</h4> <p>Studies were assessed for data with intention‐to‐treat principle and implication of missing outcome data discussed. </p> </section> <section id="CD007003-sec-0035"> <h4 class="title">Assessment of heterogeneity</h4> <p>We first assessed the heterogeneity by visual inspection of the forest plot. We then quantified statistical heterogeneity using the I² statistic, which describes the percentage of total variation across studies that is due to heterogeneity rather than sampling error (<a href="./references#CD007003-bbs2-0051" title="HigginsJP , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta-analyses. BMJ2003;327(7414):557-60. [MEDLINE: 12958120]">Higgins 2003</a>). A guide to the interpretation of I² values was as follows. </p> <p> <ul id="CD007003-list-0011"> <li> <p>0% to 40%: might not be important</p> </li> <li> <p>30% to 60%: may represent moderate heterogeneity</p> </li> <li> <p>50% to 90%: may represent substantial heterogeneity</p> </li> <li> <p>75% to 100%: considerable heterogeneity.</p> </li> </ul> </p> <p>The importance of the observed value of I² depends on the magnitude and direction of treatment effects and the strength of evidence for heterogeneity e.g. P value from the Chi² test or a CI for I² (<a href="./references#CD007003-bbs2-0052" title="HigginsJP , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , et al. Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). Cochrane, 2022. Available from www.training.cochrane.org/handbook.">Higgins 2022</a>). </p> </section> <section id="CD007003-sec-0036"> <h4 class="title">Assessment of reporting biases</h4> <p>Reporting bias was planned to be assessed using funnel plots with plotting of effect estimates against study size where data permitted. There were insufficient studies to assess reporting biases. </p> </section> <section id="CD007003-sec-0037"> <h4 class="title">Data synthesis</h4> <p>Data were pooled using the random‐effects model, but the fixed‐effect model was also analysed to ensure the robustness of the model chosen and susceptibility to outliers. </p> </section> <section id="CD007003-sec-0038"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>Subgroup analysis was planned for studies comparing different preparations of the same intervention or different doses of medications. Heterogeneity amongst participants could be related to age and kidney pathology, duration of disease, viral load, genotype, population and genetic differences. Heterogeneity in treatments could be related to prior agents used and the agent dose and duration of therapy. Heterogeneity in outcomes could be due to varying follow‐ups. There were too few studies to undertake meaningful subgroup analyses. </p> </section> <section id="CD007003-sec-0039"> <h4 class="title">Sensitivity analysis</h4> <p>Sensitivity analysis was planned by removing studies available in abstract form only, according to language, risk of bias, studies where smaller doses of the study drug were used, and where the drug was used for a longer duration. There were no large, long or unpublished studies. However, this was not undertaken due to the small number of studies available. </p> </section> <section id="CD007003-sec-0040"> <h4 class="title">Summary of findings and assessment of the certainty of the evidence</h4> <p>We have presented the main results of the review in Summary of Findings (SOF) tables. These tables present key information concerning the quality of the evidence, the magnitude of the effects of the interventions examined, and the sum of the available data for the main outcomes (<a href="./references#CD007003-bbs2-0073" title="SchünemannHJ , HigginsJP , VistGE , GlasziouP , AklEA , SkoetzN , et al. Chapter 14: Completing ‘Summary of findings’ tables and grading the certainty of the evidence. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). Cochrane, 2022. www.training.cochrane.org/handbook.">Schunemann 2022a</a>). The SOF tables also include an overall grading of the evidence related to each of the main outcomes using the GRADE (Grades of Recommendation, Assessment, Development and Evaluation) approach (<a href="./references#CD007003-bbs2-0046" title="GuyattGH , OxmanAD , VistGE , KunzR , Falck-YtterY , Alonso-CoelloP , et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ2008;336(7650):924-6. [MEDLINE: 18436948]">GRADE 2008</a>; <a href="./references#CD007003-bbs2-0047" title="GuyattG , OxmanAD , AklEA , KunzR , VistG , BrozekJ , et al. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. Journal of Clinical Epidemiology2011;64(4):383-94. [MEDLINE: 21195583]">GRADE 2011</a>). The GRADE approach defines the quality of a body of evidence as the extent to which one can be confident that an estimate of effect or association is close to the true quantity of specific interest. The quality of a body of evidence involves consideration of within‐trial risk of bias (methodological quality), directness of evidence, heterogeneity, precision of effect estimates and risk of publication bias (<a href="./references#CD007003-bbs2-0074" title="SchünemannHJ , VistGE , HigginsJP , SantessoN , DeeksJJ , GlasziouP , et al. Chapter 15: Interpreting results and drawing conclusions. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). Cochrane, 2022. Available from www.training.cochrane.org/handbook.">Schunemann 2022b</a>). We presented the following outcomes in the SOF tables. </p> <p> <ul id="CD007003-list-0012"> <li> <p>Death</p> </li> <li> <p>Relapse of disease</p> </li> <li> <p>End‐of‐treatment response</p> </li> <li> <p>SVR</p> </li> <li> <p>Treatment discontinuation</p> </li> <li> <p>Adverse events/serious adverse events.</p> </li> </ul> </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD007003-sec-0041" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD007003-sec-0041"></div> <section id="CD007003-sec-0042"> <h3 class="title">Description of studies</h3> <section id="CD007003-sec-0043"> <h4 class="title">Results of the search</h4> <p>In our 2015 review, 322 records were identified. After screening titles and abstracts, 34 reports underwent full‐text review. Ten studies (17 reports) were included, and six studies (eight reports) were excluded. In addition, three studies (nine reports) were completed prior to publication; however, no results were available. </p> <p>For this 2023 update, we last searched the Cochrane Kidney and Transplant Register of Studies on 22 February 2023 and identified nine reports. One new study (eight reports) was included. One study was recently completed and will be assessed in a future update (<a href="./references#CD007003-bbs2-0016" title="MuzammilM , TahirM , UllahN , ArifMM , RasheeqT , AtherMM . Comparison of efficacy of daily sofosbuvir and declatasvir with alternate day sofosbuvir and declatasvir in hepatitis C patients on hemodialysis in Pakistani population. Pakistan Journal of Medical &amp; Health Sciences2022;16(8):264-6. [CENTRAL: CN-02468336] [DOI: 10.53350/pjmhs22168264]">Muzammil 2022</a>). We also reassessed and reclassified seven studies. Three studies (nine reports) were moved from awaiting classification to included studies, and four excluded studies were deleted as they were not randomised. </p> <p>A total of 13 studies were included (34 reports, 997 randomised participants), two studies were excluded, and there is one study awaiting classification (<a href="#CD007003-fig-0001">Figure 1</a>). </p> <div class="figure" id="CD007003-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="PRISMA flow diagram including previous review and update" data-id="CD007003-fig-0001" src="/cdsr/doi/10.1002/14651858.CD007003.pub3/media/CDSR/CD007003/image_n/nCD007003-FIG-01.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>PRISMA flow diagram including previous review and update</p> </div> </div> </div> </section> <section id="CD007003-sec-0044"> <h4 class="title">Included studies</h4> <p>Thirteen studies (997 randomised participants) met our inclusion criteria (<a href="./references#CD007003-bbs2-0001" title="AlfurayhO , ChaabanA , PallA , Al MutawaN , EllisM , Al MeshariK , et al. Long-term follow up of haemodialysis (HD) patients with chronic hepatitis C (HCV) infection - favorable outcome with a-interferon (IFN) followed by kidney transplantation [abstract no: M221]. Nephrology Dialysis Transplantation2002;17(Suppl 1):110. [CENTRAL: CN-00509051] AlfurayhO , ChaabanA , PallA , EllisM , ChaudryT , AlmeshariK . Randomised controlled trial of interferon-alpha (IFNalpha) in patients with chronic hepatitis C (HCV) on haemodialysis (HD) [abstract]. Nephrology Dialysis Transplantation2000;15(9):A106. [CENTRAL: CN-00497910] AlfurayhOI , ChaabanAM , PallAA , EllisME , AlmeshariK , Al QuaizMN , et al. IFN-alpha for chronic hepatitis C infection (HCV) in haemodialysis (HD) patients - a prospective, randomised, controlled study [abstract]. Journal of the American Society of Nephrology2000;11(Sept):255A. [CENTRAL: CN-00517117] ">Alfurayh 2000</a>; <a href="./references#CD007003-bbs2-0002" title="CampistolJM , CasellasJ , CuevasX , LatorreB , MartínezJ , ModolJ , et al. Efficacy and tolerability of a-2b interferon in the treatment of virus C chronic hepatitis in an hemodialysis population [abstract no: 309] [Eficacia y tolerancia del interferon a-2b en el tratamiento de la hepatitis cronica por virus C (VHC) en la población en hemodialisis (HD)]. Nefrología1996;16(Suppl 1):80. [CENTRAL: CN-00400461] ">Campistol 1996</a>; <a href="./references#CD007003-bbs2-0003" title="CampistolJM , EsforzadoN , MartinezJ , RoselloL , VecianaL , ModolJ , et al. Efficacy and tolerance of interferon-alpha(2b) in the treatment of chronic hepatitis C virus infection in haemodialysis patients. Pre- and post-renal transplantation assessment. Nephrology Dialysis Transplantation1999;14(11):2704-9. [MEDLINE: 10534516]">Campistol 1999a</a>; <a href="./references#CD007003-bbs2-0004" title="ArduinoJM , ZhangB , JacksonB , RothD , BruchfeldA , khawajaS , et al. Impact of grazoprevir plus elbasvir on health-related quality of life in patients with hepatitis C virus genotype 1 infection and chronic kidney disease stages 4 and 5 [abstract no: TH-PO667]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):242A. BarrE , RothD , BruchfeldA , MartinP , NelsonDR , SilvaM , et al. Elbasvir (EBR)/grazoprevir (GZR) treatment of hepatitis C virus (HCV) infection in patients with chronic kidney disease stage 4/5: final results of the C-SURFER phase 3 study [abstract]. Journal of Gastroenterology &amp; Hepatology2016;31(Suppl 2):65-6. [EMBASE: 612983742]BruchfeldA , RothD , MartinP , NelsonD , StanislasP , LondonoMC , et al. Elbasvir/Grazoprevir (EBR/GZR) treatment of hepatitis C Virus (HCV) infection in patients with chronic kidney disease (CKD) stage 4/5: clinical, virological, and health-related quality of life outcomes in the C-SURFER study [abstract]. Swiss Medical Weekly2016;146(Suppl 221):23S. [EMBASE: 626845823]BruchfeldA , RothD , MartinP , NelsonDR , PolS , LondonoMC , et al. Elbasvir plus grazoprevir in patients with hepatitis C virus infection and stage 4-5 chronic kidney disease: clinical, virological, and health-related quality-of-life outcomes from a phase 3, multicentre, randomised, double-blind, placebo-controlled trial. The Lancet. Gastroenterology &amp; Hepatology2017;2(8):585-94. [MEDLINE: 28576451]BruchfeldA , RothD , NelsonD , LiapakisAM , SilvaM , MonsourH , et al. C-surfer: Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and chronic kidney disease [abstract no: FP267]. Nephrology Dialysis Transplantation2015;30(Suppl 3):iii156. [EMBASE: 72206687]RothD , BruchfeldA , MartinP , NelsonDR , SilvaM , MonsourH , et al. Grazoprevir(GZR)/elbasvir (EBR) treatment of hepatitis C virus (HCV) infection in patients with chronic kidney disease stage 4/5:final results of the C -SURFER phase 3 study [abstract no: SA-PO1100]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):B5. RothD , NelsonD , BruchfeldA , LiapakisA , SilvaM , MonsourHJ , et al. C-SURFER: grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and chronic kidney disease [abstract no: LP02]. Journal of Hepatology2015;62(Suppl 2):S263-4. [EMBASE: 71936662]RothD , NelsonDR , BruchfeldA , LiapakisA , SilvaM , MonsourH , et al. Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination phase 3 study [Erratum in: Lancet. 2015 Nov 7;386(10006):1824; PMID: 26843312]. Lancet2015;386(10003):1537-45. [MEDLINE: 26456905]">C‐SURFER 2015</a>; <a href="./references#CD007003-bbs2-0005" title="FernandezJL , RendoP , delPinoN , Nephrologists' Group for the Study of HCV Infection, ViolaL . A double-blind controlled trial of recombinant interferon alfa in hemodialysis patients with chronic hepatitis C [abstract]. Hepatology1995;22(4 (Pt 2)):116A. [CENTRAL: CN-00220972] FernandezJL , RendoP , delPinoN , Nephrologists' Group for the Study of HCV, ViolaL , CusumanoA . A controlled trial of interferon alfa 2b in hemodialysis patients with chronic hepatitis C [abstract no: A0989]. Journal of the American Society of Nephrology1996;7(9):1446. [CENTRAL: CN-00445323] FernandezJL , RendoP , delPinoN , ViolaL . A double-blind controlled trial of recombinant interferon-alpha 2b in haemodialysis patients with chronic hepatitis C virus infection and abnormal aminotransferase levels. Nephrologists' Group for the Study of HCV infection. Journal of Viral Hepatitis1997;4(2):113-9. [MEDLINE: 9097267]">Fernandez 1997</a>; <a href="./references#CD007003-bbs2-0006" title="LiuCH , HuangCF , LiuCJ , DaiCY , LiangCC , HuangJF , et al. Peginterferon alfa-2a with or without low dose ribavirin for hemodialysis patients with hepatitis C virus genotype 2 infection: a randomized trial [abstract no: 1851]. Hepatology2013;58(4 Suppl 1):1096A. [EMBASE: 71237851]LiuCH , HuangCF , LiuCJ , DaiCY , LiangCC , HuangJF , et al. Pegylated interferon-alpha2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 1 receiving hemodialysis: a randomized trial. Annals of Internal Medicine2013;159(11):729-38. [MEDLINE: 24297189]LiuCH , LiangCC , SuTH , HungPH , TsaiHB , LiuCJ , et al. Peginterferon alfa-2a plus low dose ribavirin versus peginterferon alfa-2a monotherapy for dialysis patients with hepatitis C virus genotype 1 infection: a randomized trial [abstract no: 1722]. Hepatology2012;56(4 Suppl 1):993A. [EMBASE: 70943304]LiuCH , LiuCJ , HuangCF , LinJW , DaiCY , LiangCC , et al. Peginterferon alfa-2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 2 receiving haemodialysis: a randomised trial. Gut2015;64(2):303-11. [MEDLINE: 24747867]">HELPER 2013</a>; <a href="./references#CD007003-bbs2-0007" title="Peck-RadosavljevicM , BoletisJ , BesisikF , Lucia FerrazM , AlricL , SamuelD , et al. Low-dose peginterferon alfa-2A (40KD) (PEGASYS®) to treat hepatitis C infected end-stage renal disease patients undergoing haemodialysis: final study results [abstract no: 999]. Journal of Hepatology2008;48(Suppl 2):S374. [CENTRAL: CN-00653069] Peck-RadosavljevicM , BoletisJ , BesisikF , Lucia FerrazM , AlricL , SamuelD , et al. Low-dose peginterferon alfa-2a is safe and produces a sustained virologic response in patients with chronic hepatitis C and end-stage renal disease. Clinical Gastroenterology &amp; Hepatology2011;9(3):242-8. [MEDLINE: 21056689]Peck-RadosavljevicM , BoletisJ , BesisikF , Lucia FerrazM , AlricL , SamuelD , et al. Use of low-dose peginterferon alfa-2a (40 kD) (Pegasys) to treat hepatitis C infected end-stage renal disease patients undergoing haemodialysis: interim results from a randomised study [abstract no: 628]. Journal of Hepatology2007;46(Suppl 1):S237-8. [CENTRAL: CN-00716095] ">HELPS 2011</a>; <a href="./references#CD007003-bbs2-0008" title="HuraibS , IqbalA , TanimuD , AbdullahA . Sustained virological and histological response with pretransplant interferon therapy in renal transplant patients with chronic viral hepatitis C. American Journal of Nephrology2001;21(6):435-40. [MEDLINE: 11799259]">Huraib 2001</a>; <a href="./references#CD007003-bbs2-0009" title="LiuCH , LiangCC , LinJW , ChenSI , TsaiHB , ChangCS , et al. Pegylated interferon alpha-2a versus standard interferon alpha-2a for treatment-naive dialysis patients with chronic hepatitis C: a randomised study. Gut2008;57(4):525-30. [MEDLINE: 17881538]">Liu 2008a</a>; <a href="./references#CD007003-bbs2-0010" title="LuxonBA , MuirAJ , HeneghanMA . Safety and tolerability of pegylated interferon with or without low dose ribavirin for treatment of hepatitis C in hemodialysis patients [abstract no: 1281]. Hepatology2005;42(4 Suppl 1):703-4A. [CENTRAL: CN-00581669] ">Luxon 2005</a>; <a href="./references#CD007003-bbs2-0011" title="RussoMW , GhalibR , SigalS , JoshiV . Randomized trial of pegylated interferon alpha-2b monotherapy in haemodialysis patients with chronic hepatitis C. Nephrology Dialysis Transplantation2006;21(2):437-43. [MEDLINE: 16234288]RussoMW , GhalibR , SigalSH , JoshiV , DetwilerR , AndreoniK , et al. A multi-center randomized trial of pegylated interferon alfa-2B monotherapy (PEG-INTRON) in patients with chronic hepatitis C and end stage kidney disease on dialysis [abstract no: 540]. Hepatology2004;40(4 Suppl 1):399A. [CENTRAL: CN-00507218] ">Russo 2006</a>; <a href="./references#CD007003-bbs2-0012" title="BasuP , ShahN , SirikiR , RahamanM , FarhatS . Telaprevir with adjusted dose of ribavirin in naive CHC-G1: efficacy and treatment in CHC in hemodialysis population target C trial: a placebo randomized control clinical trial [abstract no: 513]. American Journal of Gastroenterology2013;108(Suppl 1):S152. [EMBASE: 71220810]BasuP , SirikiR , ShahNJ , FarhatS , MittimaniK , AtluriS , et al. Telaprevir with adjusted dose of ribavirin in naive CHC-G1: Efficacy and treatment in CHC in hemodialysis population. Target C trial-A placebo randomized control clinical trial [abstract no: 517]. Gastroenterology2013;144(5 Suppl 1):S950. [EMBASE: 71119328]BasuPP , ShahNJ , Ashfique, FarhatS , SirikiR . Telaprevir with adjusted dose of ribavirin in naive CHC-G1: efficacy and treatment in CHC in hemodialysis population. Target C trial-a placebo randomized control clinical trial [abstract no: P196]. Surgical Endoscopy2014;28(1 Suppl):S362. [EMBASE: 71480241]BasuPP , ShahNJ , SirikiR , RahamanM . Telaprevir with adjusted dose of ribavirin in Naive CHC-G1: Efficacy and treatment in CHC in hemodialysis population. TARGET C Trial-a placebo randomized control clinical trial [abstract no: P-298]. Liver Transplantation2014;20(Suppl 1):S244. [EMBASE: 71562627]BasuPP , SinkiR , ShahNJ , FarhatS , MittimaniK , AtluriS , et al. Telaprevir with adjusted dose of ribavirin in naive CHC-G1: efficacy and treatment in CHC in hemodialysis population. TARGET C (RCT) [abstract no: 67]. Journal of Hepatology2013;58(Suppl 1):S30-1. [EMBASE: 71054340]">TARGET C 2013</a>; <a href="./references#CD007003-bbs2-0013" title="TuglularS , Karadayi h, KarakullukcuF , ErmanM , YukselS , CelikM , et al. Preliminary results of interferon compared to interferon combined with ribavirin in the treatment of chronic HCV in patients on chronic hemodialysis [abstract no: A2147]. Journal of the American Society of Nephrology2001;12(Program &amp; Abstracts):416-7A. [CENTRAL: CN-00543899] ">Tuglular 2001</a>). </p> <p>See <a href="./references#CD007003-sec-0114" title="">Characteristics of included studies</a>. </p> <section id="CD007003-sec-0045"> <h5 class="title">Design</h5> <p> <ul id="CD007003-list-0013"> <li> <p>All 13 studies were RCTs, eight were published in full (<a href="./references#CD007003-bbs2-0003" title="CampistolJM , EsforzadoN , MartinezJ , RoselloL , VecianaL , ModolJ , et al. Efficacy and tolerance of interferon-alpha(2b) in the treatment of chronic hepatitis C virus infection in haemodialysis patients. Pre- and post-renal transplantation assessment. Nephrology Dialysis Transplantation1999;14(11):2704-9. [MEDLINE: 10534516]">Campistol 1999a</a>; <a href="./references#CD007003-bbs2-0005" title="FernandezJL , RendoP , delPinoN , Nephrologists' Group for the Study of HCV Infection, ViolaL . A double-blind controlled trial of recombinant interferon alfa in hemodialysis patients with chronic hepatitis C [abstract]. Hepatology1995;22(4 (Pt 2)):116A. [CENTRAL: CN-00220972] FernandezJL , RendoP , delPinoN , Nephrologists' Group for the Study of HCV, ViolaL , CusumanoA . A controlled trial of interferon alfa 2b in hemodialysis patients with chronic hepatitis C [abstract no: A0989]. Journal of the American Society of Nephrology1996;7(9):1446. [CENTRAL: CN-00445323] FernandezJL , RendoP , delPinoN , ViolaL . A double-blind controlled trial of recombinant interferon-alpha 2b in haemodialysis patients with chronic hepatitis C virus infection and abnormal aminotransferase levels. Nephrologists' Group for the Study of HCV infection. Journal of Viral Hepatitis1997;4(2):113-9. [MEDLINE: 9097267]">Fernandez 1997</a>; <a href="./references#CD007003-bbs2-0008" title="HuraibS , IqbalA , TanimuD , AbdullahA . Sustained virological and histological response with pretransplant interferon therapy in renal transplant patients with chronic viral hepatitis C. American Journal of Nephrology2001;21(6):435-40. [MEDLINE: 11799259]">Huraib 2001</a>; <a href="./references#CD007003-bbs2-0009" title="LiuCH , LiangCC , LinJW , ChenSI , TsaiHB , ChangCS , et al. Pegylated interferon alpha-2a versus standard interferon alpha-2a for treatment-naive dialysis patients with chronic hepatitis C: a randomised study. Gut2008;57(4):525-30. [MEDLINE: 17881538]">Liu 2008a</a>; <a href="./references#CD007003-bbs2-0007" title="Peck-RadosavljevicM , BoletisJ , BesisikF , Lucia FerrazM , AlricL , SamuelD , et al. Low-dose peginterferon alfa-2A (40KD) (PEGASYS®) to treat hepatitis C infected end-stage renal disease patients undergoing haemodialysis: final study results [abstract no: 999]. Journal of Hepatology2008;48(Suppl 2):S374. [CENTRAL: CN-00653069] Peck-RadosavljevicM , BoletisJ , BesisikF , Lucia FerrazM , AlricL , SamuelD , et al. Low-dose peginterferon alfa-2a is safe and produces a sustained virologic response in patients with chronic hepatitis C and end-stage renal disease. Clinical Gastroenterology &amp; Hepatology2011;9(3):242-8. [MEDLINE: 21056689]Peck-RadosavljevicM , BoletisJ , BesisikF , Lucia FerrazM , AlricL , SamuelD , et al. Use of low-dose peginterferon alfa-2a (40 kD) (Pegasys) to treat hepatitis C infected end-stage renal disease patients undergoing haemodialysis: interim results from a randomised study [abstract no: 628]. Journal of Hepatology2007;46(Suppl 1):S237-8. [CENTRAL: CN-00716095] ">HELPS 2011</a>; <a href="./references#CD007003-bbs2-0011" title="RussoMW , GhalibR , SigalS , JoshiV . Randomized trial of pegylated interferon alpha-2b monotherapy in haemodialysis patients with chronic hepatitis C. Nephrology Dialysis Transplantation2006;21(2):437-43. [MEDLINE: 16234288]RussoMW , GhalibR , SigalSH , JoshiV , DetwilerR , AndreoniK , et al. A multi-center randomized trial of pegylated interferon alfa-2B monotherapy (PEG-INTRON) in patients with chronic hepatitis C and end stage kidney disease on dialysis [abstract no: 540]. Hepatology2004;40(4 Suppl 1):399A. [CENTRAL: CN-00507218] ">Russo 2006</a>; <a href="./references#CD007003-bbs2-0004" title="ArduinoJM , ZhangB , JacksonB , RothD , BruchfeldA , khawajaS , et al. Impact of grazoprevir plus elbasvir on health-related quality of life in patients with hepatitis C virus genotype 1 infection and chronic kidney disease stages 4 and 5 [abstract no: TH-PO667]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):242A. BarrE , RothD , BruchfeldA , MartinP , NelsonDR , SilvaM , et al. Elbasvir (EBR)/grazoprevir (GZR) treatment of hepatitis C virus (HCV) infection in patients with chronic kidney disease stage 4/5: final results of the C-SURFER phase 3 study [abstract]. Journal of Gastroenterology &amp; Hepatology2016;31(Suppl 2):65-6. [EMBASE: 612983742]BruchfeldA , RothD , MartinP , NelsonD , StanislasP , LondonoMC , et al. Elbasvir/Grazoprevir (EBR/GZR) treatment of hepatitis C Virus (HCV) infection in patients with chronic kidney disease (CKD) stage 4/5: clinical, virological, and health-related quality of life outcomes in the C-SURFER study [abstract]. Swiss Medical Weekly2016;146(Suppl 221):23S. [EMBASE: 626845823]BruchfeldA , RothD , MartinP , NelsonDR , PolS , LondonoMC , et al. Elbasvir plus grazoprevir in patients with hepatitis C virus infection and stage 4-5 chronic kidney disease: clinical, virological, and health-related quality-of-life outcomes from a phase 3, multicentre, randomised, double-blind, placebo-controlled trial. The Lancet. Gastroenterology &amp; Hepatology2017;2(8):585-94. [MEDLINE: 28576451]BruchfeldA , RothD , NelsonD , LiapakisAM , SilvaM , MonsourH , et al. C-surfer: Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and chronic kidney disease [abstract no: FP267]. Nephrology Dialysis Transplantation2015;30(Suppl 3):iii156. [EMBASE: 72206687]RothD , BruchfeldA , MartinP , NelsonDR , SilvaM , MonsourH , et al. Grazoprevir(GZR)/elbasvir (EBR) treatment of hepatitis C virus (HCV) infection in patients with chronic kidney disease stage 4/5:final results of the C -SURFER phase 3 study [abstract no: SA-PO1100]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):B5. RothD , NelsonD , BruchfeldA , LiapakisA , SilvaM , MonsourHJ , et al. C-SURFER: grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and chronic kidney disease [abstract no: LP02]. Journal of Hepatology2015;62(Suppl 2):S263-4. [EMBASE: 71936662]RothD , NelsonDR , BruchfeldA , LiapakisA , SilvaM , MonsourH , et al. Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination phase 3 study [Erratum in: Lancet. 2015 Nov 7;386(10006):1824; PMID: 26843312]. Lancet2015;386(10003):1537-45. [MEDLINE: 26456905]">C‐SURFER 2015</a>; <a href="./references#CD007003-bbs2-0006" title="LiuCH , HuangCF , LiuCJ , DaiCY , LiangCC , HuangJF , et al. Peginterferon alfa-2a with or without low dose ribavirin for hemodialysis patients with hepatitis C virus genotype 2 infection: a randomized trial [abstract no: 1851]. Hepatology2013;58(4 Suppl 1):1096A. [EMBASE: 71237851]LiuCH , HuangCF , LiuCJ , DaiCY , LiangCC , HuangJF , et al. Pegylated interferon-alpha2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 1 receiving hemodialysis: a randomized trial. Annals of Internal Medicine2013;159(11):729-38. [MEDLINE: 24297189]LiuCH , LiangCC , SuTH , HungPH , TsaiHB , LiuCJ , et al. Peginterferon alfa-2a plus low dose ribavirin versus peginterferon alfa-2a monotherapy for dialysis patients with hepatitis C virus genotype 1 infection: a randomized trial [abstract no: 1722]. Hepatology2012;56(4 Suppl 1):993A. [EMBASE: 70943304]LiuCH , LiuCJ , HuangCF , LinJW , DaiCY , LiangCC , et al. Peginterferon alfa-2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 2 receiving haemodialysis: a randomised trial. Gut2015;64(2):303-11. [MEDLINE: 24747867]">HELPER 2013</a>) and five were conference abstracts (<a href="./references#CD007003-bbs2-0001" title="AlfurayhO , ChaabanA , PallA , Al MutawaN , EllisM , Al MeshariK , et al. Long-term follow up of haemodialysis (HD) patients with chronic hepatitis C (HCV) infection - favorable outcome with a-interferon (IFN) followed by kidney transplantation [abstract no: M221]. Nephrology Dialysis Transplantation2002;17(Suppl 1):110. [CENTRAL: CN-00509051] AlfurayhO , ChaabanA , PallA , EllisM , ChaudryT , AlmeshariK . Randomised controlled trial of interferon-alpha (IFNalpha) in patients with chronic hepatitis C (HCV) on haemodialysis (HD) [abstract]. Nephrology Dialysis Transplantation2000;15(9):A106. [CENTRAL: CN-00497910] AlfurayhOI , ChaabanAM , PallAA , EllisME , AlmeshariK , Al QuaizMN , et al. IFN-alpha for chronic hepatitis C infection (HCV) in haemodialysis (HD) patients - a prospective, randomised, controlled study [abstract]. Journal of the American Society of Nephrology2000;11(Sept):255A. [CENTRAL: CN-00517117] ">Alfurayh 2000</a>; <a href="./references#CD007003-bbs2-0002" title="CampistolJM , CasellasJ , CuevasX , LatorreB , MartínezJ , ModolJ , et al. Efficacy and tolerability of a-2b interferon in the treatment of virus C chronic hepatitis in an hemodialysis population [abstract no: 309] [Eficacia y tolerancia del interferon a-2b en el tratamiento de la hepatitis cronica por virus C (VHC) en la población en hemodialisis (HD)]. Nefrología1996;16(Suppl 1):80. [CENTRAL: CN-00400461] ">Campistol 1996</a>; <a href="./references#CD007003-bbs2-0010" title="LuxonBA , MuirAJ , HeneghanMA . Safety and tolerability of pegylated interferon with or without low dose ribavirin for treatment of hepatitis C in hemodialysis patients [abstract no: 1281]. Hepatology2005;42(4 Suppl 1):703-4A. [CENTRAL: CN-00581669] ">Luxon 2005</a>; <a href="./references#CD007003-bbs2-0013" title="TuglularS , Karadayi h, KarakullukcuF , ErmanM , YukselS , CelikM , et al. Preliminary results of interferon compared to interferon combined with ribavirin in the treatment of chronic HCV in patients on chronic hemodialysis [abstract no: A2147]. Journal of the American Society of Nephrology2001;12(Program &amp; Abstracts):416-7A. [CENTRAL: CN-00543899] ">Tuglular 2001</a>; <a href="./references#CD007003-bbs2-0012" title="BasuP , ShahN , SirikiR , RahamanM , FarhatS . Telaprevir with adjusted dose of ribavirin in naive CHC-G1: efficacy and treatment in CHC in hemodialysis population target C trial: a placebo randomized control clinical trial [abstract no: 513]. American Journal of Gastroenterology2013;108(Suppl 1):S152. [EMBASE: 71220810]BasuP , SirikiR , ShahNJ , FarhatS , MittimaniK , AtluriS , et al. Telaprevir with adjusted dose of ribavirin in naive CHC-G1: Efficacy and treatment in CHC in hemodialysis population. Target C trial-A placebo randomized control clinical trial [abstract no: 517]. Gastroenterology2013;144(5 Suppl 1):S950. [EMBASE: 71119328]BasuPP , ShahNJ , Ashfique, FarhatS , SirikiR . Telaprevir with adjusted dose of ribavirin in naive CHC-G1: efficacy and treatment in CHC in hemodialysis population. Target C trial-a placebo randomized control clinical trial [abstract no: P196]. Surgical Endoscopy2014;28(1 Suppl):S362. [EMBASE: 71480241]BasuPP , ShahNJ , SirikiR , RahamanM . Telaprevir with adjusted dose of ribavirin in Naive CHC-G1: Efficacy and treatment in CHC in hemodialysis population. TARGET C Trial-a placebo randomized control clinical trial [abstract no: P-298]. Liver Transplantation2014;20(Suppl 1):S244. [EMBASE: 71562627]BasuPP , SinkiR , ShahNJ , FarhatS , MittimaniK , AtluriS , et al. Telaprevir with adjusted dose of ribavirin in naive CHC-G1: efficacy and treatment in CHC in hemodialysis population. TARGET C (RCT) [abstract no: 67]. Journal of Hepatology2013;58(Suppl 1):S30-1. [EMBASE: 71054340]">TARGET C 2013</a>). </p> </li> <li> <p>Language: one study was in Spanish (<a href="./references#CD007003-bbs2-0002" title="CampistolJM , CasellasJ , CuevasX , LatorreB , MartínezJ , ModolJ , et al. Efficacy and tolerability of a-2b interferon in the treatment of virus C chronic hepatitis in an hemodialysis population [abstract no: 309] [Eficacia y tolerancia del interferon a-2b en el tratamiento de la hepatitis cronica por virus C (VHC) en la población en hemodialisis (HD)]. Nefrología1996;16(Suppl 1):80. [CENTRAL: CN-00400461] ">Campistol 1996</a>). </p> </li> <li> <p>Sample size: 11 studies had less than 100 participants (range 10 to 81) (<a href="./references#CD007003-bbs2-0001" title="AlfurayhO , ChaabanA , PallA , Al MutawaN , EllisM , Al MeshariK , et al. Long-term follow up of haemodialysis (HD) patients with chronic hepatitis C (HCV) infection - favorable outcome with a-interferon (IFN) followed by kidney transplantation [abstract no: M221]. Nephrology Dialysis Transplantation2002;17(Suppl 1):110. [CENTRAL: CN-00509051] AlfurayhO , ChaabanA , PallA , EllisM , ChaudryT , AlmeshariK . Randomised controlled trial of interferon-alpha (IFNalpha) in patients with chronic hepatitis C (HCV) on haemodialysis (HD) [abstract]. Nephrology Dialysis Transplantation2000;15(9):A106. [CENTRAL: CN-00497910] AlfurayhOI , ChaabanAM , PallAA , EllisME , AlmeshariK , Al QuaizMN , et al. IFN-alpha for chronic hepatitis C infection (HCV) in haemodialysis (HD) patients - a prospective, randomised, controlled study [abstract]. Journal of the American Society of Nephrology2000;11(Sept):255A. [CENTRAL: CN-00517117] ">Alfurayh 2000</a>; <a href="./references#CD007003-bbs2-0002" title="CampistolJM , CasellasJ , CuevasX , LatorreB , MartínezJ , ModolJ , et al. Efficacy and tolerability of a-2b interferon in the treatment of virus C chronic hepatitis in an hemodialysis population [abstract no: 309] [Eficacia y tolerancia del interferon a-2b en el tratamiento de la hepatitis cronica por virus C (VHC) en la población en hemodialisis (HD)]. Nefrología1996;16(Suppl 1):80. [CENTRAL: CN-00400461] ">Campistol 1996</a>; <a href="./references#CD007003-bbs2-0003" title="CampistolJM , EsforzadoN , MartinezJ , RoselloL , VecianaL , ModolJ , et al. Efficacy and tolerance of interferon-alpha(2b) in the treatment of chronic hepatitis C virus infection in haemodialysis patients. Pre- and post-renal transplantation assessment. Nephrology Dialysis Transplantation1999;14(11):2704-9. [MEDLINE: 10534516]">Campistol 1999a</a>; <a href="./references#CD007003-bbs2-0005" title="FernandezJL , RendoP , delPinoN , Nephrologists' Group for the Study of HCV Infection, ViolaL . A double-blind controlled trial of recombinant interferon alfa in hemodialysis patients with chronic hepatitis C [abstract]. Hepatology1995;22(4 (Pt 2)):116A. [CENTRAL: CN-00220972] FernandezJL , RendoP , delPinoN , Nephrologists' Group for the Study of HCV, ViolaL , CusumanoA . A controlled trial of interferon alfa 2b in hemodialysis patients with chronic hepatitis C [abstract no: A0989]. Journal of the American Society of Nephrology1996;7(9):1446. [CENTRAL: CN-00445323] FernandezJL , RendoP , delPinoN , ViolaL . A double-blind controlled trial of recombinant interferon-alpha 2b in haemodialysis patients with chronic hepatitis C virus infection and abnormal aminotransferase levels. Nephrologists' Group for the Study of HCV infection. Journal of Viral Hepatitis1997;4(2):113-9. [MEDLINE: 9097267]">Fernandez 1997</a>; <a href="./references#CD007003-bbs2-0007" title="Peck-RadosavljevicM , BoletisJ , BesisikF , Lucia FerrazM , AlricL , SamuelD , et al. Low-dose peginterferon alfa-2A (40KD) (PEGASYS®) to treat hepatitis C infected end-stage renal disease patients undergoing haemodialysis: final study results [abstract no: 999]. Journal of Hepatology2008;48(Suppl 2):S374. [CENTRAL: CN-00653069] Peck-RadosavljevicM , BoletisJ , BesisikF , Lucia FerrazM , AlricL , SamuelD , et al. Low-dose peginterferon alfa-2a is safe and produces a sustained virologic response in patients with chronic hepatitis C and end-stage renal disease. Clinical Gastroenterology &amp; Hepatology2011;9(3):242-8. [MEDLINE: 21056689]Peck-RadosavljevicM , BoletisJ , BesisikF , Lucia FerrazM , AlricL , SamuelD , et al. Use of low-dose peginterferon alfa-2a (40 kD) (Pegasys) to treat hepatitis C infected end-stage renal disease patients undergoing haemodialysis: interim results from a randomised study [abstract no: 628]. Journal of Hepatology2007;46(Suppl 1):S237-8. [CENTRAL: CN-00716095] ">HELPS 2011</a>; <a href="./references#CD007003-bbs2-0008" title="HuraibS , IqbalA , TanimuD , AbdullahA . Sustained virological and histological response with pretransplant interferon therapy in renal transplant patients with chronic viral hepatitis C. American Journal of Nephrology2001;21(6):435-40. [MEDLINE: 11799259]">Huraib 2001</a>; <a href="./references#CD007003-bbs2-0009" title="LiuCH , LiangCC , LinJW , ChenSI , TsaiHB , ChangCS , et al. Pegylated interferon alpha-2a versus standard interferon alpha-2a for treatment-naive dialysis patients with chronic hepatitis C: a randomised study. Gut2008;57(4):525-30. [MEDLINE: 17881538]">Liu 2008a</a>; <a href="./references#CD007003-bbs2-0010" title="LuxonBA , MuirAJ , HeneghanMA . Safety and tolerability of pegylated interferon with or without low dose ribavirin for treatment of hepatitis C in hemodialysis patients [abstract no: 1281]. Hepatology2005;42(4 Suppl 1):703-4A. [CENTRAL: CN-00581669] ">Luxon 2005</a>; <a href="./references#CD007003-bbs2-0011" title="RussoMW , GhalibR , SigalS , JoshiV . Randomized trial of pegylated interferon alpha-2b monotherapy in haemodialysis patients with chronic hepatitis C. Nephrology Dialysis Transplantation2006;21(2):437-43. [MEDLINE: 16234288]RussoMW , GhalibR , SigalSH , JoshiV , DetwilerR , AndreoniK , et al. A multi-center randomized trial of pegylated interferon alfa-2B monotherapy (PEG-INTRON) in patients with chronic hepatitis C and end stage kidney disease on dialysis [abstract no: 540]. Hepatology2004;40(4 Suppl 1):399A. [CENTRAL: CN-00507218] ">Russo 2006</a>; <a href="./references#CD007003-bbs2-0012" title="BasuP , ShahN , SirikiR , RahamanM , FarhatS . Telaprevir with adjusted dose of ribavirin in naive CHC-G1: efficacy and treatment in CHC in hemodialysis population target C trial: a placebo randomized control clinical trial [abstract no: 513]. American Journal of Gastroenterology2013;108(Suppl 1):S152. [EMBASE: 71220810]BasuP , SirikiR , ShahNJ , FarhatS , MittimaniK , AtluriS , et al. Telaprevir with adjusted dose of ribavirin in naive CHC-G1: Efficacy and treatment in CHC in hemodialysis population. Target C trial-A placebo randomized control clinical trial [abstract no: 517]. Gastroenterology2013;144(5 Suppl 1):S950. [EMBASE: 71119328]BasuPP , ShahNJ , Ashfique, FarhatS , SirikiR . Telaprevir with adjusted dose of ribavirin in naive CHC-G1: efficacy and treatment in CHC in hemodialysis population. Target C trial-a placebo randomized control clinical trial [abstract no: P196]. Surgical Endoscopy2014;28(1 Suppl):S362. [EMBASE: 71480241]BasuPP , ShahNJ , SirikiR , RahamanM . Telaprevir with adjusted dose of ribavirin in Naive CHC-G1: Efficacy and treatment in CHC in hemodialysis population. TARGET C Trial-a placebo randomized control clinical trial [abstract no: P-298]. Liver Transplantation2014;20(Suppl 1):S244. [EMBASE: 71562627]BasuPP , SinkiR , ShahNJ , FarhatS , MittimaniK , AtluriS , et al. Telaprevir with adjusted dose of ribavirin in naive CHC-G1: efficacy and treatment in CHC in hemodialysis population. TARGET C (RCT) [abstract no: 67]. Journal of Hepatology2013;58(Suppl 1):S30-1. [EMBASE: 71054340]">TARGET C 2013</a>; <a href="./references#CD007003-bbs2-0013" title="TuglularS , Karadayi h, KarakullukcuF , ErmanM , YukselS , CelikM , et al. Preliminary results of interferon compared to interferon combined with ribavirin in the treatment of chronic HCV in patients on chronic hemodialysis [abstract no: A2147]. Journal of the American Society of Nephrology2001;12(Program &amp; Abstracts):416-7A. [CENTRAL: CN-00543899] ">Tuglular 2001</a>), and <a href="./references#CD007003-bbs2-0004" title="ArduinoJM , ZhangB , JacksonB , RothD , BruchfeldA , khawajaS , et al. Impact of grazoprevir plus elbasvir on health-related quality of life in patients with hepatitis C virus genotype 1 infection and chronic kidney disease stages 4 and 5 [abstract no: TH-PO667]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):242A. BarrE , RothD , BruchfeldA , MartinP , NelsonDR , SilvaM , et al. Elbasvir (EBR)/grazoprevir (GZR) treatment of hepatitis C virus (HCV) infection in patients with chronic kidney disease stage 4/5: final results of the C-SURFER phase 3 study [abstract]. Journal of Gastroenterology &amp; Hepatology2016;31(Suppl 2):65-6. [EMBASE: 612983742]BruchfeldA , RothD , MartinP , NelsonD , StanislasP , LondonoMC , et al. Elbasvir/Grazoprevir (EBR/GZR) treatment of hepatitis C Virus (HCV) infection in patients with chronic kidney disease (CKD) stage 4/5: clinical, virological, and health-related quality of life outcomes in the C-SURFER study [abstract]. Swiss Medical Weekly2016;146(Suppl 221):23S. [EMBASE: 626845823]BruchfeldA , RothD , MartinP , NelsonDR , PolS , LondonoMC , et al. Elbasvir plus grazoprevir in patients with hepatitis C virus infection and stage 4-5 chronic kidney disease: clinical, virological, and health-related quality-of-life outcomes from a phase 3, multicentre, randomised, double-blind, placebo-controlled trial. The Lancet. Gastroenterology &amp; Hepatology2017;2(8):585-94. [MEDLINE: 28576451]BruchfeldA , RothD , NelsonD , LiapakisAM , SilvaM , MonsourH , et al. C-surfer: Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and chronic kidney disease [abstract no: FP267]. Nephrology Dialysis Transplantation2015;30(Suppl 3):iii156. [EMBASE: 72206687]RothD , BruchfeldA , MartinP , NelsonDR , SilvaM , MonsourH , et al. Grazoprevir(GZR)/elbasvir (EBR) treatment of hepatitis C virus (HCV) infection in patients with chronic kidney disease stage 4/5:final results of the C -SURFER phase 3 study [abstract no: SA-PO1100]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):B5. RothD , NelsonD , BruchfeldA , LiapakisA , SilvaM , MonsourHJ , et al. C-SURFER: grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and chronic kidney disease [abstract no: LP02]. Journal of Hepatology2015;62(Suppl 2):S263-4. [EMBASE: 71936662]RothD , NelsonDR , BruchfeldA , LiapakisA , SilvaM , MonsourH , et al. Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination phase 3 study [Erratum in: Lancet. 2015 Nov 7;386(10006):1824; PMID: 26843312]. Lancet2015;386(10003):1537-45. [MEDLINE: 26456905]">C‐SURFER 2015</a> and <a href="./references#CD007003-bbs2-0006" title="LiuCH , HuangCF , LiuCJ , DaiCY , LiangCC , HuangJF , et al. Peginterferon alfa-2a with or without low dose ribavirin for hemodialysis patients with hepatitis C virus genotype 2 infection: a randomized trial [abstract no: 1851]. Hepatology2013;58(4 Suppl 1):1096A. [EMBASE: 71237851]LiuCH , HuangCF , LiuCJ , DaiCY , LiangCC , HuangJF , et al. Pegylated interferon-alpha2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 1 receiving hemodialysis: a randomized trial. Annals of Internal Medicine2013;159(11):729-38. [MEDLINE: 24297189]LiuCH , LiangCC , SuTH , HungPH , TsaiHB , LiuCJ , et al. Peginterferon alfa-2a plus low dose ribavirin versus peginterferon alfa-2a monotherapy for dialysis patients with hepatitis C virus genotype 1 infection: a randomized trial [abstract no: 1722]. Hepatology2012;56(4 Suppl 1):993A. [EMBASE: 70943304]LiuCH , LiuCJ , HuangCF , LinJW , DaiCY , LiangCC , et al. Peginterferon alfa-2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 2 receiving haemodialysis: a randomised trial. Gut2015;64(2):303-11. [MEDLINE: 24747867]">HELPER 2013</a> randomised 224 and 377 participants, respectively. </p> </li> <li> <p>Setting: all studies included outpatients; nine were multicentre (2 to 68 sites) (<a href="./references#CD007003-bbs2-0002" title="CampistolJM , CasellasJ , CuevasX , LatorreB , MartínezJ , ModolJ , et al. Efficacy and tolerability of a-2b interferon in the treatment of virus C chronic hepatitis in an hemodialysis population [abstract no: 309] [Eficacia y tolerancia del interferon a-2b en el tratamiento de la hepatitis cronica por virus C (VHC) en la población en hemodialisis (HD)]. Nefrología1996;16(Suppl 1):80. [CENTRAL: CN-00400461] ">Campistol 1996</a>; <a href="./references#CD007003-bbs2-0003" title="CampistolJM , EsforzadoN , MartinezJ , RoselloL , VecianaL , ModolJ , et al. Efficacy and tolerance of interferon-alpha(2b) in the treatment of chronic hepatitis C virus infection in haemodialysis patients. Pre- and post-renal transplantation assessment. Nephrology Dialysis Transplantation1999;14(11):2704-9. [MEDLINE: 10534516]">Campistol 1999a</a>; <a href="./references#CD007003-bbs2-0004" title="ArduinoJM , ZhangB , JacksonB , RothD , BruchfeldA , khawajaS , et al. Impact of grazoprevir plus elbasvir on health-related quality of life in patients with hepatitis C virus genotype 1 infection and chronic kidney disease stages 4 and 5 [abstract no: TH-PO667]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):242A. BarrE , RothD , BruchfeldA , MartinP , NelsonDR , SilvaM , et al. Elbasvir (EBR)/grazoprevir (GZR) treatment of hepatitis C virus (HCV) infection in patients with chronic kidney disease stage 4/5: final results of the C-SURFER phase 3 study [abstract]. Journal of Gastroenterology &amp; Hepatology2016;31(Suppl 2):65-6. [EMBASE: 612983742]BruchfeldA , RothD , MartinP , NelsonD , StanislasP , LondonoMC , et al. Elbasvir/Grazoprevir (EBR/GZR) treatment of hepatitis C Virus (HCV) infection in patients with chronic kidney disease (CKD) stage 4/5: clinical, virological, and health-related quality of life outcomes in the C-SURFER study [abstract]. Swiss Medical Weekly2016;146(Suppl 221):23S. [EMBASE: 626845823]BruchfeldA , RothD , MartinP , NelsonDR , PolS , LondonoMC , et al. Elbasvir plus grazoprevir in patients with hepatitis C virus infection and stage 4-5 chronic kidney disease: clinical, virological, and health-related quality-of-life outcomes from a phase 3, multicentre, randomised, double-blind, placebo-controlled trial. The Lancet. Gastroenterology &amp; Hepatology2017;2(8):585-94. [MEDLINE: 28576451]BruchfeldA , RothD , NelsonD , LiapakisAM , SilvaM , MonsourH , et al. C-surfer: Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and chronic kidney disease [abstract no: FP267]. Nephrology Dialysis Transplantation2015;30(Suppl 3):iii156. [EMBASE: 72206687]RothD , BruchfeldA , MartinP , NelsonDR , SilvaM , MonsourH , et al. Grazoprevir(GZR)/elbasvir (EBR) treatment of hepatitis C virus (HCV) infection in patients with chronic kidney disease stage 4/5:final results of the C -SURFER phase 3 study [abstract no: SA-PO1100]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):B5. RothD , NelsonD , BruchfeldA , LiapakisA , SilvaM , MonsourHJ , et al. C-SURFER: grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and chronic kidney disease [abstract no: LP02]. Journal of Hepatology2015;62(Suppl 2):S263-4. [EMBASE: 71936662]RothD , NelsonDR , BruchfeldA , LiapakisA , SilvaM , MonsourH , et al. Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination phase 3 study [Erratum in: Lancet. 2015 Nov 7;386(10006):1824; PMID: 26843312]. Lancet2015;386(10003):1537-45. [MEDLINE: 26456905]">C‐SURFER 2015</a>; <a href="./references#CD007003-bbs2-0006" title="LiuCH , HuangCF , LiuCJ , DaiCY , LiangCC , HuangJF , et al. Peginterferon alfa-2a with or without low dose ribavirin for hemodialysis patients with hepatitis C virus genotype 2 infection: a randomized trial [abstract no: 1851]. Hepatology2013;58(4 Suppl 1):1096A. [EMBASE: 71237851]LiuCH , HuangCF , LiuCJ , DaiCY , LiangCC , HuangJF , et al. Pegylated interferon-alpha2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 1 receiving hemodialysis: a randomized trial. Annals of Internal Medicine2013;159(11):729-38. [MEDLINE: 24297189]LiuCH , LiangCC , SuTH , HungPH , TsaiHB , LiuCJ , et al. Peginterferon alfa-2a plus low dose ribavirin versus peginterferon alfa-2a monotherapy for dialysis patients with hepatitis C virus genotype 1 infection: a randomized trial [abstract no: 1722]. Hepatology2012;56(4 Suppl 1):993A. [EMBASE: 70943304]LiuCH , LiuCJ , HuangCF , LinJW , DaiCY , LiangCC , et al. Peginterferon alfa-2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 2 receiving haemodialysis: a randomised trial. Gut2015;64(2):303-11. [MEDLINE: 24747867]">HELPER 2013</a>; <a href="./references#CD007003-bbs2-0009" title="LiuCH , LiangCC , LinJW , ChenSI , TsaiHB , ChangCS , et al. Pegylated interferon alpha-2a versus standard interferon alpha-2a for treatment-naive dialysis patients with chronic hepatitis C: a randomised study. Gut2008;57(4):525-30. [MEDLINE: 17881538]">Liu 2008a</a>; <a href="./references#CD007003-bbs2-0010" title="LuxonBA , MuirAJ , HeneghanMA . Safety and tolerability of pegylated interferon with or without low dose ribavirin for treatment of hepatitis C in hemodialysis patients [abstract no: 1281]. Hepatology2005;42(4 Suppl 1):703-4A. [CENTRAL: CN-00581669] ">Luxon 2005</a>; <a href="./references#CD007003-bbs2-0007" title="Peck-RadosavljevicM , BoletisJ , BesisikF , Lucia FerrazM , AlricL , SamuelD , et al. Low-dose peginterferon alfa-2A (40KD) (PEGASYS®) to treat hepatitis C infected end-stage renal disease patients undergoing haemodialysis: final study results [abstract no: 999]. Journal of Hepatology2008;48(Suppl 2):S374. [CENTRAL: CN-00653069] Peck-RadosavljevicM , BoletisJ , BesisikF , Lucia FerrazM , AlricL , SamuelD , et al. Low-dose peginterferon alfa-2a is safe and produces a sustained virologic response in patients with chronic hepatitis C and end-stage renal disease. Clinical Gastroenterology &amp; Hepatology2011;9(3):242-8. [MEDLINE: 21056689]Peck-RadosavljevicM , BoletisJ , BesisikF , Lucia FerrazM , AlricL , SamuelD , et al. Use of low-dose peginterferon alfa-2a (40 kD) (Pegasys) to treat hepatitis C infected end-stage renal disease patients undergoing haemodialysis: interim results from a randomised study [abstract no: 628]. Journal of Hepatology2007;46(Suppl 1):S237-8. [CENTRAL: CN-00716095] ">HELPS 2011</a>; <a href="./references#CD007003-bbs2-0011" title="RussoMW , GhalibR , SigalS , JoshiV . Randomized trial of pegylated interferon alpha-2b monotherapy in haemodialysis patients with chronic hepatitis C. Nephrology Dialysis Transplantation2006;21(2):437-43. [MEDLINE: 16234288]RussoMW , GhalibR , SigalSH , JoshiV , DetwilerR , AndreoniK , et al. A multi-center randomized trial of pegylated interferon alfa-2B monotherapy (PEG-INTRON) in patients with chronic hepatitis C and end stage kidney disease on dialysis [abstract no: 540]. Hepatology2004;40(4 Suppl 1):399A. [CENTRAL: CN-00507218] ">Russo 2006</a>; <a href="./references#CD007003-bbs2-0013" title="TuglularS , Karadayi h, KarakullukcuF , ErmanM , YukselS , CelikM , et al. Preliminary results of interferon compared to interferon combined with ribavirin in the treatment of chronic HCV in patients on chronic hemodialysis [abstract no: A2147]. Journal of the American Society of Nephrology2001;12(Program &amp; Abstracts):416-7A. [CENTRAL: CN-00543899] ">Tuglular 2001</a>) including two which were international (eight sites, 12 countries) (<a href="./references#CD007003-bbs2-0004" title="ArduinoJM , ZhangB , JacksonB , RothD , BruchfeldA , khawajaS , et al. Impact of grazoprevir plus elbasvir on health-related quality of life in patients with hepatitis C virus genotype 1 infection and chronic kidney disease stages 4 and 5 [abstract no: TH-PO667]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):242A. BarrE , RothD , BruchfeldA , MartinP , NelsonDR , SilvaM , et al. Elbasvir (EBR)/grazoprevir (GZR) treatment of hepatitis C virus (HCV) infection in patients with chronic kidney disease stage 4/5: final results of the C-SURFER phase 3 study [abstract]. Journal of Gastroenterology &amp; Hepatology2016;31(Suppl 2):65-6. [EMBASE: 612983742]BruchfeldA , RothD , MartinP , NelsonD , StanislasP , LondonoMC , et al. Elbasvir/Grazoprevir (EBR/GZR) treatment of hepatitis C Virus (HCV) infection in patients with chronic kidney disease (CKD) stage 4/5: clinical, virological, and health-related quality of life outcomes in the C-SURFER study [abstract]. Swiss Medical Weekly2016;146(Suppl 221):23S. [EMBASE: 626845823]BruchfeldA , RothD , MartinP , NelsonDR , PolS , LondonoMC , et al. Elbasvir plus grazoprevir in patients with hepatitis C virus infection and stage 4-5 chronic kidney disease: clinical, virological, and health-related quality-of-life outcomes from a phase 3, multicentre, randomised, double-blind, placebo-controlled trial. The Lancet. Gastroenterology &amp; Hepatology2017;2(8):585-94. [MEDLINE: 28576451]BruchfeldA , RothD , NelsonD , LiapakisAM , SilvaM , MonsourH , et al. C-surfer: Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and chronic kidney disease [abstract no: FP267]. Nephrology Dialysis Transplantation2015;30(Suppl 3):iii156. [EMBASE: 72206687]RothD , BruchfeldA , MartinP , NelsonDR , SilvaM , MonsourH , et al. Grazoprevir(GZR)/elbasvir (EBR) treatment of hepatitis C virus (HCV) infection in patients with chronic kidney disease stage 4/5:final results of the C -SURFER phase 3 study [abstract no: SA-PO1100]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):B5. RothD , NelsonD , BruchfeldA , LiapakisA , SilvaM , MonsourHJ , et al. C-SURFER: grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and chronic kidney disease [abstract no: LP02]. Journal of Hepatology2015;62(Suppl 2):S263-4. [EMBASE: 71936662]RothD , NelsonDR , BruchfeldA , LiapakisA , SilvaM , MonsourH , et al. Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination phase 3 study [Erratum in: Lancet. 2015 Nov 7;386(10006):1824; PMID: 26843312]. Lancet2015;386(10003):1537-45. [MEDLINE: 26456905]">C‐SURFER 2015</a>; <a href="./references#CD007003-bbs2-0007" title="Peck-RadosavljevicM , BoletisJ , BesisikF , Lucia FerrazM , AlricL , SamuelD , et al. Low-dose peginterferon alfa-2A (40KD) (PEGASYS®) to treat hepatitis C infected end-stage renal disease patients undergoing haemodialysis: final study results [abstract no: 999]. Journal of Hepatology2008;48(Suppl 2):S374. [CENTRAL: CN-00653069] Peck-RadosavljevicM , BoletisJ , BesisikF , Lucia FerrazM , AlricL , SamuelD , et al. Low-dose peginterferon alfa-2a is safe and produces a sustained virologic response in patients with chronic hepatitis C and end-stage renal disease. Clinical Gastroenterology &amp; Hepatology2011;9(3):242-8. [MEDLINE: 21056689]Peck-RadosavljevicM , BoletisJ , BesisikF , Lucia FerrazM , AlricL , SamuelD , et al. Use of low-dose peginterferon alfa-2a (40 kD) (Pegasys) to treat hepatitis C infected end-stage renal disease patients undergoing haemodialysis: interim results from a randomised study [abstract no: 628]. Journal of Hepatology2007;46(Suppl 1):S237-8. [CENTRAL: CN-00716095] ">HELPS 2011</a>). </p> </li> <li> <p>Participants: CKD patients on HD, positive for anti‐HCV antibody or HCV RNA were included in all studies. There were no studies in patients on PD. All recruited adults (age range 16 to 65) of both genders. HCV genotyping was done in 10 studies (<a href="./references#CD007003-bbs2-0003" title="CampistolJM , EsforzadoN , MartinezJ , RoselloL , VecianaL , ModolJ , et al. Efficacy and tolerance of interferon-alpha(2b) in the treatment of chronic hepatitis C virus infection in haemodialysis patients. Pre- and post-renal transplantation assessment. Nephrology Dialysis Transplantation1999;14(11):2704-9. [MEDLINE: 10534516]">Campistol 1999a</a>; <a href="./references#CD007003-bbs2-0004" title="ArduinoJM , ZhangB , JacksonB , RothD , BruchfeldA , khawajaS , et al. Impact of grazoprevir plus elbasvir on health-related quality of life in patients with hepatitis C virus genotype 1 infection and chronic kidney disease stages 4 and 5 [abstract no: TH-PO667]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):242A. BarrE , RothD , BruchfeldA , MartinP , NelsonDR , SilvaM , et al. Elbasvir (EBR)/grazoprevir (GZR) treatment of hepatitis C virus (HCV) infection in patients with chronic kidney disease stage 4/5: final results of the C-SURFER phase 3 study [abstract]. Journal of Gastroenterology &amp; Hepatology2016;31(Suppl 2):65-6. [EMBASE: 612983742]BruchfeldA , RothD , MartinP , NelsonD , StanislasP , LondonoMC , et al. Elbasvir/Grazoprevir (EBR/GZR) treatment of hepatitis C Virus (HCV) infection in patients with chronic kidney disease (CKD) stage 4/5: clinical, virological, and health-related quality of life outcomes in the C-SURFER study [abstract]. Swiss Medical Weekly2016;146(Suppl 221):23S. [EMBASE: 626845823]BruchfeldA , RothD , MartinP , NelsonDR , PolS , LondonoMC , et al. Elbasvir plus grazoprevir in patients with hepatitis C virus infection and stage 4-5 chronic kidney disease: clinical, virological, and health-related quality-of-life outcomes from a phase 3, multicentre, randomised, double-blind, placebo-controlled trial. The Lancet. Gastroenterology &amp; Hepatology2017;2(8):585-94. [MEDLINE: 28576451]BruchfeldA , RothD , NelsonD , LiapakisAM , SilvaM , MonsourH , et al. C-surfer: Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and chronic kidney disease [abstract no: FP267]. Nephrology Dialysis Transplantation2015;30(Suppl 3):iii156. [EMBASE: 72206687]RothD , BruchfeldA , MartinP , NelsonDR , SilvaM , MonsourH , et al. Grazoprevir(GZR)/elbasvir (EBR) treatment of hepatitis C virus (HCV) infection in patients with chronic kidney disease stage 4/5:final results of the C -SURFER phase 3 study [abstract no: SA-PO1100]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):B5. RothD , NelsonD , BruchfeldA , LiapakisA , SilvaM , MonsourHJ , et al. C-SURFER: grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and chronic kidney disease [abstract no: LP02]. Journal of Hepatology2015;62(Suppl 2):S263-4. [EMBASE: 71936662]RothD , NelsonDR , BruchfeldA , LiapakisA , SilvaM , MonsourH , et al. Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination phase 3 study [Erratum in: Lancet. 2015 Nov 7;386(10006):1824; PMID: 26843312]. Lancet2015;386(10003):1537-45. [MEDLINE: 26456905]">C‐SURFER 2015</a>; <a href="./references#CD007003-bbs2-0005" title="FernandezJL , RendoP , delPinoN , Nephrologists' Group for the Study of HCV Infection, ViolaL . A double-blind controlled trial of recombinant interferon alfa in hemodialysis patients with chronic hepatitis C [abstract]. Hepatology1995;22(4 (Pt 2)):116A. [CENTRAL: CN-00220972] FernandezJL , RendoP , delPinoN , Nephrologists' Group for the Study of HCV, ViolaL , CusumanoA . A controlled trial of interferon alfa 2b in hemodialysis patients with chronic hepatitis C [abstract no: A0989]. Journal of the American Society of Nephrology1996;7(9):1446. [CENTRAL: CN-00445323] FernandezJL , RendoP , delPinoN , ViolaL . A double-blind controlled trial of recombinant interferon-alpha 2b in haemodialysis patients with chronic hepatitis C virus infection and abnormal aminotransferase levels. Nephrologists' Group for the Study of HCV infection. Journal of Viral Hepatitis1997;4(2):113-9. [MEDLINE: 9097267]">Fernandez 1997</a>; <a href="./references#CD007003-bbs2-0006" title="LiuCH , HuangCF , LiuCJ , DaiCY , LiangCC , HuangJF , et al. Peginterferon alfa-2a with or without low dose ribavirin for hemodialysis patients with hepatitis C virus genotype 2 infection: a randomized trial [abstract no: 1851]. Hepatology2013;58(4 Suppl 1):1096A. [EMBASE: 71237851]LiuCH , HuangCF , LiuCJ , DaiCY , LiangCC , HuangJF , et al. Pegylated interferon-alpha2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 1 receiving hemodialysis: a randomized trial. Annals of Internal Medicine2013;159(11):729-38. [MEDLINE: 24297189]LiuCH , LiangCC , SuTH , HungPH , TsaiHB , LiuCJ , et al. Peginterferon alfa-2a plus low dose ribavirin versus peginterferon alfa-2a monotherapy for dialysis patients with hepatitis C virus genotype 1 infection: a randomized trial [abstract no: 1722]. Hepatology2012;56(4 Suppl 1):993A. [EMBASE: 70943304]LiuCH , LiuCJ , HuangCF , LinJW , DaiCY , LiangCC , et al. Peginterferon alfa-2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 2 receiving haemodialysis: a randomised trial. Gut2015;64(2):303-11. [MEDLINE: 24747867]">HELPER 2013</a>; <a href="./references#CD007003-bbs2-0007" title="Peck-RadosavljevicM , BoletisJ , BesisikF , Lucia FerrazM , AlricL , SamuelD , et al. Low-dose peginterferon alfa-2A (40KD) (PEGASYS®) to treat hepatitis C infected end-stage renal disease patients undergoing haemodialysis: final study results [abstract no: 999]. Journal of Hepatology2008;48(Suppl 2):S374. [CENTRAL: CN-00653069] Peck-RadosavljevicM , BoletisJ , BesisikF , Lucia FerrazM , AlricL , SamuelD , et al. Low-dose peginterferon alfa-2a is safe and produces a sustained virologic response in patients with chronic hepatitis C and end-stage renal disease. Clinical Gastroenterology &amp; Hepatology2011;9(3):242-8. [MEDLINE: 21056689]Peck-RadosavljevicM , BoletisJ , BesisikF , Lucia FerrazM , AlricL , SamuelD , et al. Use of low-dose peginterferon alfa-2a (40 kD) (Pegasys) to treat hepatitis C infected end-stage renal disease patients undergoing haemodialysis: interim results from a randomised study [abstract no: 628]. Journal of Hepatology2007;46(Suppl 1):S237-8. [CENTRAL: CN-00716095] ">HELPS 2011</a>; <a href="./references#CD007003-bbs2-0008" title="HuraibS , IqbalA , TanimuD , AbdullahA . Sustained virological and histological response with pretransplant interferon therapy in renal transplant patients with chronic viral hepatitis C. American Journal of Nephrology2001;21(6):435-40. [MEDLINE: 11799259]">Huraib 2001</a>; <a href="./references#CD007003-bbs2-0009" title="LiuCH , LiangCC , LinJW , ChenSI , TsaiHB , ChangCS , et al. Pegylated interferon alpha-2a versus standard interferon alpha-2a for treatment-naive dialysis patients with chronic hepatitis C: a randomised study. Gut2008;57(4):525-30. [MEDLINE: 17881538]">Liu 2008a</a>; <a href="./references#CD007003-bbs2-0010" title="LuxonBA , MuirAJ , HeneghanMA . Safety and tolerability of pegylated interferon with or without low dose ribavirin for treatment of hepatitis C in hemodialysis patients [abstract no: 1281]. Hepatology2005;42(4 Suppl 1):703-4A. [CENTRAL: CN-00581669] ">Luxon 2005</a>; <a href="./references#CD007003-bbs2-0011" title="RussoMW , GhalibR , SigalS , JoshiV . Randomized trial of pegylated interferon alpha-2b monotherapy in haemodialysis patients with chronic hepatitis C. Nephrology Dialysis Transplantation2006;21(2):437-43. [MEDLINE: 16234288]RussoMW , GhalibR , SigalSH , JoshiV , DetwilerR , AndreoniK , et al. A multi-center randomized trial of pegylated interferon alfa-2B monotherapy (PEG-INTRON) in patients with chronic hepatitis C and end stage kidney disease on dialysis [abstract no: 540]. Hepatology2004;40(4 Suppl 1):399A. [CENTRAL: CN-00507218] ">Russo 2006</a>; <a href="./references#CD007003-bbs2-0012" title="BasuP , ShahN , SirikiR , RahamanM , FarhatS . Telaprevir with adjusted dose of ribavirin in naive CHC-G1: efficacy and treatment in CHC in hemodialysis population target C trial: a placebo randomized control clinical trial [abstract no: 513]. American Journal of Gastroenterology2013;108(Suppl 1):S152. [EMBASE: 71220810]BasuP , SirikiR , ShahNJ , FarhatS , MittimaniK , AtluriS , et al. Telaprevir with adjusted dose of ribavirin in naive CHC-G1: Efficacy and treatment in CHC in hemodialysis population. Target C trial-A placebo randomized control clinical trial [abstract no: 517]. Gastroenterology2013;144(5 Suppl 1):S950. [EMBASE: 71119328]BasuPP , ShahNJ , Ashfique, FarhatS , SirikiR . Telaprevir with adjusted dose of ribavirin in naive CHC-G1: efficacy and treatment in CHC in hemodialysis population. Target C trial-a placebo randomized control clinical trial [abstract no: P196]. Surgical Endoscopy2014;28(1 Suppl):S362. [EMBASE: 71480241]BasuPP , ShahNJ , SirikiR , RahamanM . Telaprevir with adjusted dose of ribavirin in Naive CHC-G1: Efficacy and treatment in CHC in hemodialysis population. TARGET C Trial-a placebo randomized control clinical trial [abstract no: P-298]. Liver Transplantation2014;20(Suppl 1):S244. [EMBASE: 71562627]BasuPP , SinkiR , ShahNJ , FarhatS , MittimaniK , AtluriS , et al. Telaprevir with adjusted dose of ribavirin in naive CHC-G1: efficacy and treatment in CHC in hemodialysis population. TARGET C (RCT) [abstract no: 67]. Journal of Hepatology2013;58(Suppl 1):S30-1. [EMBASE: 71054340]">TARGET C 2013</a>) and <a href="./references#CD007003-bbs2-0006" title="LiuCH , HuangCF , LiuCJ , DaiCY , LiangCC , HuangJF , et al. Peginterferon alfa-2a with or without low dose ribavirin for hemodialysis patients with hepatitis C virus genotype 2 infection: a randomized trial [abstract no: 1851]. Hepatology2013;58(4 Suppl 1):1096A. [EMBASE: 71237851]LiuCH , HuangCF , LiuCJ , DaiCY , LiangCC , HuangJF , et al. Pegylated interferon-alpha2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 1 receiving hemodialysis: a randomized trial. Annals of Internal Medicine2013;159(11):729-38. [MEDLINE: 24297189]LiuCH , LiangCC , SuTH , HungPH , TsaiHB , LiuCJ , et al. Peginterferon alfa-2a plus low dose ribavirin versus peginterferon alfa-2a monotherapy for dialysis patients with hepatitis C virus genotype 1 infection: a randomized trial [abstract no: 1722]. Hepatology2012;56(4 Suppl 1):993A. [EMBASE: 70943304]LiuCH , LiuCJ , HuangCF , LinJW , DaiCY , LiangCC , et al. Peginterferon alfa-2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 2 receiving haemodialysis: a randomised trial. Gut2015;64(2):303-11. [MEDLINE: 24747867]">HELPER 2013</a> and <a href="./references#CD007003-bbs2-0007" title="Peck-RadosavljevicM , BoletisJ , BesisikF , Lucia FerrazM , AlricL , SamuelD , et al. Low-dose peginterferon alfa-2A (40KD) (PEGASYS®) to treat hepatitis C infected end-stage renal disease patients undergoing haemodialysis: final study results [abstract no: 999]. Journal of Hepatology2008;48(Suppl 2):S374. [CENTRAL: CN-00653069] Peck-RadosavljevicM , BoletisJ , BesisikF , Lucia FerrazM , AlricL , SamuelD , et al. Low-dose peginterferon alfa-2a is safe and produces a sustained virologic response in patients with chronic hepatitis C and end-stage renal disease. Clinical Gastroenterology &amp; Hepatology2011;9(3):242-8. [MEDLINE: 21056689]Peck-RadosavljevicM , BoletisJ , BesisikF , Lucia FerrazM , AlricL , SamuelD , et al. Use of low-dose peginterferon alfa-2a (40 kD) (Pegasys) to treat hepatitis C infected end-stage renal disease patients undergoing haemodialysis: interim results from a randomised study [abstract no: 628]. Journal of Hepatology2007;46(Suppl 1):S237-8. [CENTRAL: CN-00716095] ">HELPS 2011</a> were stratified and analysed (but not in the others due to small numbers). <a href="./references#CD007003-bbs2-0004" title="ArduinoJM , ZhangB , JacksonB , RothD , BruchfeldA , khawajaS , et al. Impact of grazoprevir plus elbasvir on health-related quality of life in patients with hepatitis C virus genotype 1 infection and chronic kidney disease stages 4 and 5 [abstract no: TH-PO667]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):242A. BarrE , RothD , BruchfeldA , MartinP , NelsonDR , SilvaM , et al. Elbasvir (EBR)/grazoprevir (GZR) treatment of hepatitis C virus (HCV) infection in patients with chronic kidney disease stage 4/5: final results of the C-SURFER phase 3 study [abstract]. Journal of Gastroenterology &amp; Hepatology2016;31(Suppl 2):65-6. [EMBASE: 612983742]BruchfeldA , RothD , MartinP , NelsonD , StanislasP , LondonoMC , et al. Elbasvir/Grazoprevir (EBR/GZR) treatment of hepatitis C Virus (HCV) infection in patients with chronic kidney disease (CKD) stage 4/5: clinical, virological, and health-related quality of life outcomes in the C-SURFER study [abstract]. Swiss Medical Weekly2016;146(Suppl 221):23S. [EMBASE: 626845823]BruchfeldA , RothD , MartinP , NelsonDR , PolS , LondonoMC , et al. Elbasvir plus grazoprevir in patients with hepatitis C virus infection and stage 4-5 chronic kidney disease: clinical, virological, and health-related quality-of-life outcomes from a phase 3, multicentre, randomised, double-blind, placebo-controlled trial. The Lancet. Gastroenterology &amp; Hepatology2017;2(8):585-94. [MEDLINE: 28576451]BruchfeldA , RothD , NelsonD , LiapakisAM , SilvaM , MonsourH , et al. C-surfer: Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and chronic kidney disease [abstract no: FP267]. Nephrology Dialysis Transplantation2015;30(Suppl 3):iii156. [EMBASE: 72206687]RothD , BruchfeldA , MartinP , NelsonDR , SilvaM , MonsourH , et al. Grazoprevir(GZR)/elbasvir (EBR) treatment of hepatitis C virus (HCV) infection in patients with chronic kidney disease stage 4/5:final results of the C -SURFER phase 3 study [abstract no: SA-PO1100]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):B5. RothD , NelsonD , BruchfeldA , LiapakisA , SilvaM , MonsourHJ , et al. C-SURFER: grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and chronic kidney disease [abstract no: LP02]. Journal of Hepatology2015;62(Suppl 2):S263-4. [EMBASE: 71936662]RothD , NelsonDR , BruchfeldA , LiapakisA , SilvaM , MonsourH , et al. Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination phase 3 study [Erratum in: Lancet. 2015 Nov 7;386(10006):1824; PMID: 26843312]. Lancet2015;386(10003):1537-45. [MEDLINE: 26456905]">C‐SURFER 2015</a> and <a href="./references#CD007003-bbs2-0012" title="BasuP , ShahN , SirikiR , RahamanM , FarhatS . Telaprevir with adjusted dose of ribavirin in naive CHC-G1: efficacy and treatment in CHC in hemodialysis population target C trial: a placebo randomized control clinical trial [abstract no: 513]. American Journal of Gastroenterology2013;108(Suppl 1):S152. [EMBASE: 71220810]BasuP , SirikiR , ShahNJ , FarhatS , MittimaniK , AtluriS , et al. Telaprevir with adjusted dose of ribavirin in naive CHC-G1: Efficacy and treatment in CHC in hemodialysis population. Target C trial-A placebo randomized control clinical trial [abstract no: 517]. Gastroenterology2013;144(5 Suppl 1):S950. [EMBASE: 71119328]BasuPP , ShahNJ , Ashfique, FarhatS , SirikiR . Telaprevir with adjusted dose of ribavirin in naive CHC-G1: efficacy and treatment in CHC in hemodialysis population. Target C trial-a placebo randomized control clinical trial [abstract no: P196]. Surgical Endoscopy2014;28(1 Suppl):S362. [EMBASE: 71480241]BasuPP , ShahNJ , SirikiR , RahamanM . Telaprevir with adjusted dose of ribavirin in Naive CHC-G1: Efficacy and treatment in CHC in hemodialysis population. TARGET C Trial-a placebo randomized control clinical trial [abstract no: P-298]. Liver Transplantation2014;20(Suppl 1):S244. [EMBASE: 71562627]BasuPP , SinkiR , ShahNJ , FarhatS , MittimaniK , AtluriS , et al. Telaprevir with adjusted dose of ribavirin in naive CHC-G1: efficacy and treatment in CHC in hemodialysis population. TARGET C (RCT) [abstract no: 67]. Journal of Hepatology2013;58(Suppl 1):S30-1. [EMBASE: 71054340]">TARGET C 2013</a> included HCV genotype 1 alone and <a href="./references#CD007003-bbs2-0006" title="LiuCH , HuangCF , LiuCJ , DaiCY , LiangCC , HuangJF , et al. Peginterferon alfa-2a with or without low dose ribavirin for hemodialysis patients with hepatitis C virus genotype 2 infection: a randomized trial [abstract no: 1851]. Hepatology2013;58(4 Suppl 1):1096A. [EMBASE: 71237851]LiuCH , HuangCF , LiuCJ , DaiCY , LiangCC , HuangJF , et al. Pegylated interferon-alpha2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 1 receiving hemodialysis: a randomized trial. Annals of Internal Medicine2013;159(11):729-38. [MEDLINE: 24297189]LiuCH , LiangCC , SuTH , HungPH , TsaiHB , LiuCJ , et al. Peginterferon alfa-2a plus low dose ribavirin versus peginterferon alfa-2a monotherapy for dialysis patients with hepatitis C virus genotype 1 infection: a randomized trial [abstract no: 1722]. Hepatology2012;56(4 Suppl 1):993A. [EMBASE: 70943304]LiuCH , LiuCJ , HuangCF , LinJW , DaiCY , LiangCC , et al. Peginterferon alfa-2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 2 receiving haemodialysis: a randomised trial. Gut2015;64(2):303-11. [MEDLINE: 24747867]">HELPER 2013</a> stratified according to HCV genotypes 1 and 2. Follow‐up post‐kidney transplant was available in two studies (<a href="./references#CD007003-bbs2-0003" title="CampistolJM , EsforzadoN , MartinezJ , RoselloL , VecianaL , ModolJ , et al. Efficacy and tolerance of interferon-alpha(2b) in the treatment of chronic hepatitis C virus infection in haemodialysis patients. Pre- and post-renal transplantation assessment. Nephrology Dialysis Transplantation1999;14(11):2704-9. [MEDLINE: 10534516]">Campistol 1999a</a>; <a href="./references#CD007003-bbs2-0008" title="HuraibS , IqbalA , TanimuD , AbdullahA . Sustained virological and histological response with pretransplant interferon therapy in renal transplant patients with chronic viral hepatitis C. American Journal of Nephrology2001;21(6):435-40. [MEDLINE: 11799259]">Huraib 2001</a>). </p> </li> </ul> </p> </section> <section id="CD007003-sec-0046"> <h5 class="title">Interventions</h5> <p> <ul id="CD007003-list-0014"> <li> <p>Standard recombinant interferon versus placebo or control: five studies (<a href="./references#CD007003-bbs2-0001" title="AlfurayhO , ChaabanA , PallA , Al MutawaN , EllisM , Al MeshariK , et al. Long-term follow up of haemodialysis (HD) patients with chronic hepatitis C (HCV) infection - favorable outcome with a-interferon (IFN) followed by kidney transplantation [abstract no: M221]. Nephrology Dialysis Transplantation2002;17(Suppl 1):110. [CENTRAL: CN-00509051] AlfurayhO , ChaabanA , PallA , EllisM , ChaudryT , AlmeshariK . Randomised controlled trial of interferon-alpha (IFNalpha) in patients with chronic hepatitis C (HCV) on haemodialysis (HD) [abstract]. Nephrology Dialysis Transplantation2000;15(9):A106. [CENTRAL: CN-00497910] AlfurayhOI , ChaabanAM , PallAA , EllisME , AlmeshariK , Al QuaizMN , et al. IFN-alpha for chronic hepatitis C infection (HCV) in haemodialysis (HD) patients - a prospective, randomised, controlled study [abstract]. Journal of the American Society of Nephrology2000;11(Sept):255A. [CENTRAL: CN-00517117] ">Alfurayh 2000</a>; <a href="./references#CD007003-bbs2-0002" title="CampistolJM , CasellasJ , CuevasX , LatorreB , MartínezJ , ModolJ , et al. Efficacy and tolerability of a-2b interferon in the treatment of virus C chronic hepatitis in an hemodialysis population [abstract no: 309] [Eficacia y tolerancia del interferon a-2b en el tratamiento de la hepatitis cronica por virus C (VHC) en la población en hemodialisis (HD)]. Nefrología1996;16(Suppl 1):80. [CENTRAL: CN-00400461] ">Campistol 1996</a>; <a href="./references#CD007003-bbs2-0003" title="CampistolJM , EsforzadoN , MartinezJ , RoselloL , VecianaL , ModolJ , et al. Efficacy and tolerance of interferon-alpha(2b) in the treatment of chronic hepatitis C virus infection in haemodialysis patients. Pre- and post-renal transplantation assessment. Nephrology Dialysis Transplantation1999;14(11):2704-9. [MEDLINE: 10534516]">Campistol 1999a</a>; <a href="./references#CD007003-bbs2-0005" title="FernandezJL , RendoP , delPinoN , Nephrologists' Group for the Study of HCV Infection, ViolaL . A double-blind controlled trial of recombinant interferon alfa in hemodialysis patients with chronic hepatitis C [abstract]. Hepatology1995;22(4 (Pt 2)):116A. [CENTRAL: CN-00220972] FernandezJL , RendoP , delPinoN , Nephrologists' Group for the Study of HCV, ViolaL , CusumanoA . A controlled trial of interferon alfa 2b in hemodialysis patients with chronic hepatitis C [abstract no: A0989]. Journal of the American Society of Nephrology1996;7(9):1446. [CENTRAL: CN-00445323] FernandezJL , RendoP , delPinoN , ViolaL . A double-blind controlled trial of recombinant interferon-alpha 2b in haemodialysis patients with chronic hepatitis C virus infection and abnormal aminotransferase levels. Nephrologists' Group for the Study of HCV infection. Journal of Viral Hepatitis1997;4(2):113-9. [MEDLINE: 9097267]">Fernandez 1997</a>; <a href="./references#CD007003-bbs2-0008" title="HuraibS , IqbalA , TanimuD , AbdullahA . Sustained virological and histological response with pretransplant interferon therapy in renal transplant patients with chronic viral hepatitis C. American Journal of Nephrology2001;21(6):435-40. [MEDLINE: 11799259]">Huraib 2001</a>) </p> <ul id="CD007003-list-0015"> <li> <p>Dose of interferon (SC) was 1.5 to 3 million units, 3 times/week given for 6 to 12 months; 1.5 million units in <a href="./references#CD007003-bbs2-0005" title="FernandezJL , RendoP , delPinoN , Nephrologists' Group for the Study of HCV Infection, ViolaL . A double-blind controlled trial of recombinant interferon alfa in hemodialysis patients with chronic hepatitis C [abstract]. Hepatology1995;22(4 (Pt 2)):116A. [CENTRAL: CN-00220972] FernandezJL , RendoP , delPinoN , Nephrologists' Group for the Study of HCV, ViolaL , CusumanoA . A controlled trial of interferon alfa 2b in hemodialysis patients with chronic hepatitis C [abstract no: A0989]. Journal of the American Society of Nephrology1996;7(9):1446. [CENTRAL: CN-00445323] FernandezJL , RendoP , delPinoN , ViolaL . A double-blind controlled trial of recombinant interferon-alpha 2b in haemodialysis patients with chronic hepatitis C virus infection and abnormal aminotransferase levels. Nephrologists' Group for the Study of HCV infection. Journal of Viral Hepatitis1997;4(2):113-9. [MEDLINE: 9097267]">Fernandez 1997</a> and for 12 months in <a href="./references#CD007003-bbs2-0001" title="AlfurayhO , ChaabanA , PallA , Al MutawaN , EllisM , Al MeshariK , et al. Long-term follow up of haemodialysis (HD) patients with chronic hepatitis C (HCV) infection - favorable outcome with a-interferon (IFN) followed by kidney transplantation [abstract no: M221]. Nephrology Dialysis Transplantation2002;17(Suppl 1):110. [CENTRAL: CN-00509051] AlfurayhO , ChaabanA , PallA , EllisM , ChaudryT , AlmeshariK . Randomised controlled trial of interferon-alpha (IFNalpha) in patients with chronic hepatitis C (HCV) on haemodialysis (HD) [abstract]. Nephrology Dialysis Transplantation2000;15(9):A106. [CENTRAL: CN-00497910] AlfurayhOI , ChaabanAM , PallAA , EllisME , AlmeshariK , Al QuaizMN , et al. IFN-alpha for chronic hepatitis C infection (HCV) in haemodialysis (HD) patients - a prospective, randomised, controlled study [abstract]. Journal of the American Society of Nephrology2000;11(Sept):255A. [CENTRAL: CN-00517117] ">Alfurayh 2000</a> and <a href="./references#CD007003-bbs2-0008" title="HuraibS , IqbalA , TanimuD , AbdullahA . Sustained virological and histological response with pretransplant interferon therapy in renal transplant patients with chronic viral hepatitis C. American Journal of Nephrology2001;21(6):435-40. [MEDLINE: 11799259]">Huraib 2001</a>. </p> </li> </ul> </li> <li> <p>Standard recombinant interferon versus PEG interferon: one study (<a href="./references#CD007003-bbs2-0009" title="LiuCH , LiangCC , LinJW , ChenSI , TsaiHB , ChangCS , et al. Pegylated interferon alpha-2a versus standard interferon alpha-2a for treatment-naive dialysis patients with chronic hepatitis C: a randomised study. Gut2008;57(4):525-30. [MEDLINE: 17881538]">Liu 2008a</a>) </p> <ul id="CD007003-list-0016"> <li> <p>Standard interferon (SC) was given 3 million units 3 times/week and PEG interferon 135 µg once/week for six months. </p> </li> </ul> </li> <li> <p>High versus low dose PEG interferon: two studies (<a href="./references#CD007003-bbs2-0007" title="Peck-RadosavljevicM , BoletisJ , BesisikF , Lucia FerrazM , AlricL , SamuelD , et al. Low-dose peginterferon alfa-2A (40KD) (PEGASYS®) to treat hepatitis C infected end-stage renal disease patients undergoing haemodialysis: final study results [abstract no: 999]. Journal of Hepatology2008;48(Suppl 2):S374. [CENTRAL: CN-00653069] Peck-RadosavljevicM , BoletisJ , BesisikF , Lucia FerrazM , AlricL , SamuelD , et al. Low-dose peginterferon alfa-2a is safe and produces a sustained virologic response in patients with chronic hepatitis C and end-stage renal disease. Clinical Gastroenterology &amp; Hepatology2011;9(3):242-8. [MEDLINE: 21056689]Peck-RadosavljevicM , BoletisJ , BesisikF , Lucia FerrazM , AlricL , SamuelD , et al. Use of low-dose peginterferon alfa-2a (40 kD) (Pegasys) to treat hepatitis C infected end-stage renal disease patients undergoing haemodialysis: interim results from a randomised study [abstract no: 628]. Journal of Hepatology2007;46(Suppl 1):S237-8. [CENTRAL: CN-00716095] ">HELPS 2011</a>; <a href="./references#CD007003-bbs2-0011" title="RussoMW , GhalibR , SigalS , JoshiV . Randomized trial of pegylated interferon alpha-2b monotherapy in haemodialysis patients with chronic hepatitis C. Nephrology Dialysis Transplantation2006;21(2):437-43. [MEDLINE: 16234288]RussoMW , GhalibR , SigalSH , JoshiV , DetwilerR , AndreoniK , et al. A multi-center randomized trial of pegylated interferon alfa-2B monotherapy (PEG-INTRON) in patients with chronic hepatitis C and end stage kidney disease on dialysis [abstract no: 540]. Hepatology2004;40(4 Suppl 1):399A. [CENTRAL: CN-00507218] ">Russo 2006</a>) </p> <ul id="CD007003-list-0017"> <li> <p>The doses used were 135 µg/week (SC) versus 90 µg/week (SC) of alpha‐2a preparation in (<a href="./references#CD007003-bbs2-0007" title="Peck-RadosavljevicM , BoletisJ , BesisikF , Lucia FerrazM , AlricL , SamuelD , et al. Low-dose peginterferon alfa-2A (40KD) (PEGASYS®) to treat hepatitis C infected end-stage renal disease patients undergoing haemodialysis: final study results [abstract no: 999]. Journal of Hepatology2008;48(Suppl 2):S374. [CENTRAL: CN-00653069] Peck-RadosavljevicM , BoletisJ , BesisikF , Lucia FerrazM , AlricL , SamuelD , et al. Low-dose peginterferon alfa-2a is safe and produces a sustained virologic response in patients with chronic hepatitis C and end-stage renal disease. Clinical Gastroenterology &amp; Hepatology2011;9(3):242-8. [MEDLINE: 21056689]Peck-RadosavljevicM , BoletisJ , BesisikF , Lucia FerrazM , AlricL , SamuelD , et al. Use of low-dose peginterferon alfa-2a (40 kD) (Pegasys) to treat hepatitis C infected end-stage renal disease patients undergoing haemodialysis: interim results from a randomised study [abstract no: 628]. Journal of Hepatology2007;46(Suppl 1):S237-8. [CENTRAL: CN-00716095] ">HELPS 2011</a>) and 1.0 µg/kg/week versus 0.5 µg/kg/week of alpha‐2b preparation in (<a href="./references#CD007003-bbs2-0011" title="RussoMW , GhalibR , SigalS , JoshiV . Randomized trial of pegylated interferon alpha-2b monotherapy in haemodialysis patients with chronic hepatitis C. Nephrology Dialysis Transplantation2006;21(2):437-43. [MEDLINE: 16234288]RussoMW , GhalibR , SigalSH , JoshiV , DetwilerR , AndreoniK , et al. A multi-center randomized trial of pegylated interferon alfa-2B monotherapy (PEG-INTRON) in patients with chronic hepatitis C and end stage kidney disease on dialysis [abstract no: 540]. Hepatology2004;40(4 Suppl 1):399A. [CENTRAL: CN-00507218] ">Russo 2006</a>), for 48 weeks in both </p> </li> </ul> </li> <li> <p>Standard (<a href="./references#CD007003-bbs2-0013" title="TuglularS , Karadayi h, KarakullukcuF , ErmanM , YukselS , CelikM , et al. Preliminary results of interferon compared to interferon combined with ribavirin in the treatment of chronic HCV in patients on chronic hemodialysis [abstract no: A2147]. Journal of the American Society of Nephrology2001;12(Program &amp; Abstracts):416-7A. [CENTRAL: CN-00543899] ">Tuglular 2001</a>) or PEG interferon (<a href="./references#CD007003-bbs2-0010" title="LuxonBA , MuirAJ , HeneghanMA . Safety and tolerability of pegylated interferon with or without low dose ribavirin for treatment of hepatitis C in hemodialysis patients [abstract no: 1281]. Hepatology2005;42(4 Suppl 1):703-4A. [CENTRAL: CN-00581669] ">Luxon 2005</a>, <a href="./references#CD007003-bbs2-0006" title="LiuCH , HuangCF , LiuCJ , DaiCY , LiangCC , HuangJF , et al. Peginterferon alfa-2a with or without low dose ribavirin for hemodialysis patients with hepatitis C virus genotype 2 infection: a randomized trial [abstract no: 1851]. Hepatology2013;58(4 Suppl 1):1096A. [EMBASE: 71237851]LiuCH , HuangCF , LiuCJ , DaiCY , LiangCC , HuangJF , et al. Pegylated interferon-alpha2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 1 receiving hemodialysis: a randomized trial. Annals of Internal Medicine2013;159(11):729-38. [MEDLINE: 24297189]LiuCH , LiangCC , SuTH , HungPH , TsaiHB , LiuCJ , et al. Peginterferon alfa-2a plus low dose ribavirin versus peginterferon alfa-2a monotherapy for dialysis patients with hepatitis C virus genotype 1 infection: a randomized trial [abstract no: 1722]. Hepatology2012;56(4 Suppl 1):993A. [EMBASE: 70943304]LiuCH , LiuCJ , HuangCF , LinJW , DaiCY , LiangCC , et al. Peginterferon alfa-2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 2 receiving haemodialysis: a randomised trial. Gut2015;64(2):303-11. [MEDLINE: 24747867]">HELPER 2013</a>) alone or in combination with ribavirin </p> <ul id="CD007003-list-0018"> <li> <p>Standard interferon dose was 3 million units, 3 times/week and PEG interferon alpha‐2b 1 µg/kg/week, alpha‐2a 135 µg/week </p> </li> <li> <p>Ribavirin dose was 200 mg/week increasing to 2 or 3 times/week as tolerated in <a href="./references#CD007003-bbs2-0010" title="LuxonBA , MuirAJ , HeneghanMA . Safety and tolerability of pegylated interferon with or without low dose ribavirin for treatment of hepatitis C in hemodialysis patients [abstract no: 1281]. Hepatology2005;42(4 Suppl 1):703-4A. [CENTRAL: CN-00581669] ">Luxon 2005</a>, 400 mg/day reducing to 200 mg/day as per tolerance in <a href="./references#CD007003-bbs2-0013" title="TuglularS , Karadayi h, KarakullukcuF , ErmanM , YukselS , CelikM , et al. Preliminary results of interferon compared to interferon combined with ribavirin in the treatment of chronic HCV in patients on chronic hemodialysis [abstract no: A2147]. Journal of the American Society of Nephrology2001;12(Program &amp; Abstracts):416-7A. [CENTRAL: CN-00543899] ">Tuglular 2001</a> and 200 mg/day in <a href="./references#CD007003-bbs2-0006" title="LiuCH , HuangCF , LiuCJ , DaiCY , LiangCC , HuangJF , et al. Peginterferon alfa-2a with or without low dose ribavirin for hemodialysis patients with hepatitis C virus genotype 2 infection: a randomized trial [abstract no: 1851]. Hepatology2013;58(4 Suppl 1):1096A. [EMBASE: 71237851]LiuCH , HuangCF , LiuCJ , DaiCY , LiangCC , HuangJF , et al. Pegylated interferon-alpha2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 1 receiving hemodialysis: a randomized trial. Annals of Internal Medicine2013;159(11):729-38. [MEDLINE: 24297189]LiuCH , LiangCC , SuTH , HungPH , TsaiHB , LiuCJ , et al. Peginterferon alfa-2a plus low dose ribavirin versus peginterferon alfa-2a monotherapy for dialysis patients with hepatitis C virus genotype 1 infection: a randomized trial [abstract no: 1722]. Hepatology2012;56(4 Suppl 1):993A. [EMBASE: 70943304]LiuCH , LiuCJ , HuangCF , LinJW , DaiCY , LiangCC , et al. Peginterferon alfa-2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 2 receiving haemodialysis: a randomised trial. Gut2015;64(2):303-11. [MEDLINE: 24747867]">HELPER 2013</a>. </p> </li> </ul> </li> <li> <p>Direct‐acting antivirals</p> <ul id="CD007003-list-0019"> <li> <p>Grazoprevir 100 mg and elbasvir 50 mg both once/day (<a href="./references#CD007003-bbs2-0004" title="ArduinoJM , ZhangB , JacksonB , RothD , BruchfeldA , khawajaS , et al. Impact of grazoprevir plus elbasvir on health-related quality of life in patients with hepatitis C virus genotype 1 infection and chronic kidney disease stages 4 and 5 [abstract no: TH-PO667]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):242A. BarrE , RothD , BruchfeldA , MartinP , NelsonDR , SilvaM , et al. Elbasvir (EBR)/grazoprevir (GZR) treatment of hepatitis C virus (HCV) infection in patients with chronic kidney disease stage 4/5: final results of the C-SURFER phase 3 study [abstract]. Journal of Gastroenterology &amp; Hepatology2016;31(Suppl 2):65-6. [EMBASE: 612983742]BruchfeldA , RothD , MartinP , NelsonD , StanislasP , LondonoMC , et al. Elbasvir/Grazoprevir (EBR/GZR) treatment of hepatitis C Virus (HCV) infection in patients with chronic kidney disease (CKD) stage 4/5: clinical, virological, and health-related quality of life outcomes in the C-SURFER study [abstract]. Swiss Medical Weekly2016;146(Suppl 221):23S. [EMBASE: 626845823]BruchfeldA , RothD , MartinP , NelsonDR , PolS , LondonoMC , et al. Elbasvir plus grazoprevir in patients with hepatitis C virus infection and stage 4-5 chronic kidney disease: clinical, virological, and health-related quality-of-life outcomes from a phase 3, multicentre, randomised, double-blind, placebo-controlled trial. The Lancet. Gastroenterology &amp; Hepatology2017;2(8):585-94. [MEDLINE: 28576451]BruchfeldA , RothD , NelsonD , LiapakisAM , SilvaM , MonsourH , et al. C-surfer: Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and chronic kidney disease [abstract no: FP267]. Nephrology Dialysis Transplantation2015;30(Suppl 3):iii156. [EMBASE: 72206687]RothD , BruchfeldA , MartinP , NelsonDR , SilvaM , MonsourH , et al. Grazoprevir(GZR)/elbasvir (EBR) treatment of hepatitis C virus (HCV) infection in patients with chronic kidney disease stage 4/5:final results of the C -SURFER phase 3 study [abstract no: SA-PO1100]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):B5. RothD , NelsonD , BruchfeldA , LiapakisA , SilvaM , MonsourHJ , et al. C-SURFER: grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and chronic kidney disease [abstract no: LP02]. Journal of Hepatology2015;62(Suppl 2):S263-4. [EMBASE: 71936662]RothD , NelsonDR , BruchfeldA , LiapakisA , SilvaM , MonsourH , et al. Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination phase 3 study [Erratum in: Lancet. 2015 Nov 7;386(10006):1824; PMID: 26843312]. Lancet2015;386(10003):1537-45. [MEDLINE: 26456905]">C‐SURFER 2015</a>) </p> </li> <li> <p>Telaprevir 4500 mg/day for 3 days, PEG interferon alpha‐2a 135 µg once/week and ribavirin 400 mg (<a href="./references#CD007003-bbs2-0012" title="BasuP , ShahN , SirikiR , RahamanM , FarhatS . Telaprevir with adjusted dose of ribavirin in naive CHC-G1: efficacy and treatment in CHC in hemodialysis population target C trial: a placebo randomized control clinical trial [abstract no: 513]. American Journal of Gastroenterology2013;108(Suppl 1):S152. [EMBASE: 71220810]BasuP , SirikiR , ShahNJ , FarhatS , MittimaniK , AtluriS , et al. Telaprevir with adjusted dose of ribavirin in naive CHC-G1: Efficacy and treatment in CHC in hemodialysis population. Target C trial-A placebo randomized control clinical trial [abstract no: 517]. Gastroenterology2013;144(5 Suppl 1):S950. [EMBASE: 71119328]BasuPP , ShahNJ , Ashfique, FarhatS , SirikiR . Telaprevir with adjusted dose of ribavirin in naive CHC-G1: efficacy and treatment in CHC in hemodialysis population. Target C trial-a placebo randomized control clinical trial [abstract no: P196]. Surgical Endoscopy2014;28(1 Suppl):S362. [EMBASE: 71480241]BasuPP , ShahNJ , SirikiR , RahamanM . Telaprevir with adjusted dose of ribavirin in Naive CHC-G1: Efficacy and treatment in CHC in hemodialysis population. TARGET C Trial-a placebo randomized control clinical trial [abstract no: P-298]. Liver Transplantation2014;20(Suppl 1):S244. [EMBASE: 71562627]BasuPP , SinkiR , ShahNJ , FarhatS , MittimaniK , AtluriS , et al. Telaprevir with adjusted dose of ribavirin in naive CHC-G1: efficacy and treatment in CHC in hemodialysis population. TARGET C (RCT) [abstract no: 67]. Journal of Hepatology2013;58(Suppl 1):S30-1. [EMBASE: 71054340]">TARGET C 2013</a>) for 24 and 48 weeks. </p> </li> </ul> </li> </ul> </p> </section> <section id="CD007003-sec-0047"> <h5 class="title">Outcomes</h5> <p> <ul id="CD007003-list-0020"> <li> <p>Relapse: data were not clear in <a href="./references#CD007003-bbs2-0001" title="AlfurayhO , ChaabanA , PallA , Al MutawaN , EllisM , Al MeshariK , et al. Long-term follow up of haemodialysis (HD) patients with chronic hepatitis C (HCV) infection - favorable outcome with a-interferon (IFN) followed by kidney transplantation [abstract no: M221]. Nephrology Dialysis Transplantation2002;17(Suppl 1):110. [CENTRAL: CN-00509051] AlfurayhO , ChaabanA , PallA , EllisM , ChaudryT , AlmeshariK . Randomised controlled trial of interferon-alpha (IFNalpha) in patients with chronic hepatitis C (HCV) on haemodialysis (HD) [abstract]. Nephrology Dialysis Transplantation2000;15(9):A106. [CENTRAL: CN-00497910] AlfurayhOI , ChaabanAM , PallAA , EllisME , AlmeshariK , Al QuaizMN , et al. IFN-alpha for chronic hepatitis C infection (HCV) in haemodialysis (HD) patients - a prospective, randomised, controlled study [abstract]. Journal of the American Society of Nephrology2000;11(Sept):255A. [CENTRAL: CN-00517117] ">Alfurayh 2000</a> and only available in four studies (<a href="./references#CD007003-bbs2-0003" title="CampistolJM , EsforzadoN , MartinezJ , RoselloL , VecianaL , ModolJ , et al. Efficacy and tolerance of interferon-alpha(2b) in the treatment of chronic hepatitis C virus infection in haemodialysis patients. Pre- and post-renal transplantation assessment. Nephrology Dialysis Transplantation1999;14(11):2704-9. [MEDLINE: 10534516]">Campistol 1999a</a>; <a href="./references#CD007003-bbs2-0006" title="LiuCH , HuangCF , LiuCJ , DaiCY , LiangCC , HuangJF , et al. Peginterferon alfa-2a with or without low dose ribavirin for hemodialysis patients with hepatitis C virus genotype 2 infection: a randomized trial [abstract no: 1851]. Hepatology2013;58(4 Suppl 1):1096A. [EMBASE: 71237851]LiuCH , HuangCF , LiuCJ , DaiCY , LiangCC , HuangJF , et al. Pegylated interferon-alpha2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 1 receiving hemodialysis: a randomized trial. Annals of Internal Medicine2013;159(11):729-38. [MEDLINE: 24297189]LiuCH , LiangCC , SuTH , HungPH , TsaiHB , LiuCJ , et al. Peginterferon alfa-2a plus low dose ribavirin versus peginterferon alfa-2a monotherapy for dialysis patients with hepatitis C virus genotype 1 infection: a randomized trial [abstract no: 1722]. Hepatology2012;56(4 Suppl 1):993A. [EMBASE: 70943304]LiuCH , LiuCJ , HuangCF , LinJW , DaiCY , LiangCC , et al. Peginterferon alfa-2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 2 receiving haemodialysis: a randomised trial. Gut2015;64(2):303-11. [MEDLINE: 24747867]">HELPER 2013</a>; <a href="./references#CD007003-bbs2-0007" title="Peck-RadosavljevicM , BoletisJ , BesisikF , Lucia FerrazM , AlricL , SamuelD , et al. Low-dose peginterferon alfa-2A (40KD) (PEGASYS®) to treat hepatitis C infected end-stage renal disease patients undergoing haemodialysis: final study results [abstract no: 999]. Journal of Hepatology2008;48(Suppl 2):S374. [CENTRAL: CN-00653069] Peck-RadosavljevicM , BoletisJ , BesisikF , Lucia FerrazM , AlricL , SamuelD , et al. Low-dose peginterferon alfa-2a is safe and produces a sustained virologic response in patients with chronic hepatitis C and end-stage renal disease. Clinical Gastroenterology &amp; Hepatology2011;9(3):242-8. [MEDLINE: 21056689]Peck-RadosavljevicM , BoletisJ , BesisikF , Lucia FerrazM , AlricL , SamuelD , et al. Use of low-dose peginterferon alfa-2a (40 kD) (Pegasys) to treat hepatitis C infected end-stage renal disease patients undergoing haemodialysis: interim results from a randomised study [abstract no: 628]. Journal of Hepatology2007;46(Suppl 1):S237-8. [CENTRAL: CN-00716095] ">HELPS 2011</a>; <a href="./references#CD007003-bbs2-0009" title="LiuCH , LiangCC , LinJW , ChenSI , TsaiHB , ChangCS , et al. Pegylated interferon alpha-2a versus standard interferon alpha-2a for treatment-naive dialysis patients with chronic hepatitis C: a randomised study. Gut2008;57(4):525-30. [MEDLINE: 17881538]">Liu 2008a</a>) </p> </li> <li> <p>Death data were available in eight studies (<a href="./references#CD007003-bbs2-0001" title="AlfurayhO , ChaabanA , PallA , Al MutawaN , EllisM , Al MeshariK , et al. Long-term follow up of haemodialysis (HD) patients with chronic hepatitis C (HCV) infection - favorable outcome with a-interferon (IFN) followed by kidney transplantation [abstract no: M221]. Nephrology Dialysis Transplantation2002;17(Suppl 1):110. [CENTRAL: CN-00509051] AlfurayhO , ChaabanA , PallA , EllisM , ChaudryT , AlmeshariK . Randomised controlled trial of interferon-alpha (IFNalpha) in patients with chronic hepatitis C (HCV) on haemodialysis (HD) [abstract]. Nephrology Dialysis Transplantation2000;15(9):A106. [CENTRAL: CN-00497910] AlfurayhOI , ChaabanAM , PallAA , EllisME , AlmeshariK , Al QuaizMN , et al. IFN-alpha for chronic hepatitis C infection (HCV) in haemodialysis (HD) patients - a prospective, randomised, controlled study [abstract]. Journal of the American Society of Nephrology2000;11(Sept):255A. [CENTRAL: CN-00517117] ">Alfurayh 2000</a>; <a href="./references#CD007003-bbs2-0002" title="CampistolJM , CasellasJ , CuevasX , LatorreB , MartínezJ , ModolJ , et al. Efficacy and tolerability of a-2b interferon in the treatment of virus C chronic hepatitis in an hemodialysis population [abstract no: 309] [Eficacia y tolerancia del interferon a-2b en el tratamiento de la hepatitis cronica por virus C (VHC) en la población en hemodialisis (HD)]. Nefrología1996;16(Suppl 1):80. [CENTRAL: CN-00400461] ">Campistol 1996</a>; <a href="./references#CD007003-bbs2-0003" title="CampistolJM , EsforzadoN , MartinezJ , RoselloL , VecianaL , ModolJ , et al. Efficacy and tolerance of interferon-alpha(2b) in the treatment of chronic hepatitis C virus infection in haemodialysis patients. Pre- and post-renal transplantation assessment. Nephrology Dialysis Transplantation1999;14(11):2704-9. [MEDLINE: 10534516]">Campistol 1999a</a>; <a href="./references#CD007003-bbs2-0005" title="FernandezJL , RendoP , delPinoN , Nephrologists' Group for the Study of HCV Infection, ViolaL . A double-blind controlled trial of recombinant interferon alfa in hemodialysis patients with chronic hepatitis C [abstract]. Hepatology1995;22(4 (Pt 2)):116A. [CENTRAL: CN-00220972] FernandezJL , RendoP , delPinoN , Nephrologists' Group for the Study of HCV, ViolaL , CusumanoA . A controlled trial of interferon alfa 2b in hemodialysis patients with chronic hepatitis C [abstract no: A0989]. Journal of the American Society of Nephrology1996;7(9):1446. [CENTRAL: CN-00445323] FernandezJL , RendoP , delPinoN , ViolaL . A double-blind controlled trial of recombinant interferon-alpha 2b in haemodialysis patients with chronic hepatitis C virus infection and abnormal aminotransferase levels. Nephrologists' Group for the Study of HCV infection. Journal of Viral Hepatitis1997;4(2):113-9. [MEDLINE: 9097267]">Fernandez 1997</a>; <a href="./references#CD007003-bbs2-0007" title="Peck-RadosavljevicM , BoletisJ , BesisikF , Lucia FerrazM , AlricL , SamuelD , et al. Low-dose peginterferon alfa-2A (40KD) (PEGASYS®) to treat hepatitis C infected end-stage renal disease patients undergoing haemodialysis: final study results [abstract no: 999]. Journal of Hepatology2008;48(Suppl 2):S374. [CENTRAL: CN-00653069] Peck-RadosavljevicM , BoletisJ , BesisikF , Lucia FerrazM , AlricL , SamuelD , et al. Low-dose peginterferon alfa-2a is safe and produces a sustained virologic response in patients with chronic hepatitis C and end-stage renal disease. Clinical Gastroenterology &amp; Hepatology2011;9(3):242-8. [MEDLINE: 21056689]Peck-RadosavljevicM , BoletisJ , BesisikF , Lucia FerrazM , AlricL , SamuelD , et al. Use of low-dose peginterferon alfa-2a (40 kD) (Pegasys) to treat hepatitis C infected end-stage renal disease patients undergoing haemodialysis: interim results from a randomised study [abstract no: 628]. Journal of Hepatology2007;46(Suppl 1):S237-8. [CENTRAL: CN-00716095] ">HELPS 2011</a>; <a href="./references#CD007003-bbs2-0008" title="HuraibS , IqbalA , TanimuD , AbdullahA . Sustained virological and histological response with pretransplant interferon therapy in renal transplant patients with chronic viral hepatitis C. American Journal of Nephrology2001;21(6):435-40. [MEDLINE: 11799259]">Huraib 2001</a>; <a href="./references#CD007003-bbs2-0009" title="LiuCH , LiangCC , LinJW , ChenSI , TsaiHB , ChangCS , et al. Pegylated interferon alpha-2a versus standard interferon alpha-2a for treatment-naive dialysis patients with chronic hepatitis C: a randomised study. Gut2008;57(4):525-30. [MEDLINE: 17881538]">Liu 2008a</a>; <a href="./references#CD007003-bbs2-0011" title="RussoMW , GhalibR , SigalS , JoshiV . Randomized trial of pegylated interferon alpha-2b monotherapy in haemodialysis patients with chronic hepatitis C. Nephrology Dialysis Transplantation2006;21(2):437-43. [MEDLINE: 16234288]RussoMW , GhalibR , SigalSH , JoshiV , DetwilerR , AndreoniK , et al. A multi-center randomized trial of pegylated interferon alfa-2B monotherapy (PEG-INTRON) in patients with chronic hepatitis C and end stage kidney disease on dialysis [abstract no: 540]. Hepatology2004;40(4 Suppl 1):399A. [CENTRAL: CN-00507218] ">Russo 2006</a>) </p> </li> <li> <p>End‐of‐treatment response was available in 10 studies (<a href="./references#CD007003-bbs2-0001" title="AlfurayhO , ChaabanA , PallA , Al MutawaN , EllisM , Al MeshariK , et al. Long-term follow up of haemodialysis (HD) patients with chronic hepatitis C (HCV) infection - favorable outcome with a-interferon (IFN) followed by kidney transplantation [abstract no: M221]. Nephrology Dialysis Transplantation2002;17(Suppl 1):110. [CENTRAL: CN-00509051] AlfurayhO , ChaabanA , PallA , EllisM , ChaudryT , AlmeshariK . Randomised controlled trial of interferon-alpha (IFNalpha) in patients with chronic hepatitis C (HCV) on haemodialysis (HD) [abstract]. Nephrology Dialysis Transplantation2000;15(9):A106. [CENTRAL: CN-00497910] AlfurayhOI , ChaabanAM , PallAA , EllisME , AlmeshariK , Al QuaizMN , et al. IFN-alpha for chronic hepatitis C infection (HCV) in haemodialysis (HD) patients - a prospective, randomised, controlled study [abstract]. Journal of the American Society of Nephrology2000;11(Sept):255A. [CENTRAL: CN-00517117] ">Alfurayh 2000</a>; <a href="./references#CD007003-bbs2-0002" title="CampistolJM , CasellasJ , CuevasX , LatorreB , MartínezJ , ModolJ , et al. Efficacy and tolerability of a-2b interferon in the treatment of virus C chronic hepatitis in an hemodialysis population [abstract no: 309] [Eficacia y tolerancia del interferon a-2b en el tratamiento de la hepatitis cronica por virus C (VHC) en la población en hemodialisis (HD)]. Nefrología1996;16(Suppl 1):80. [CENTRAL: CN-00400461] ">Campistol 1996</a>; <a href="./references#CD007003-bbs2-0003" title="CampistolJM , EsforzadoN , MartinezJ , RoselloL , VecianaL , ModolJ , et al. Efficacy and tolerance of interferon-alpha(2b) in the treatment of chronic hepatitis C virus infection in haemodialysis patients. Pre- and post-renal transplantation assessment. Nephrology Dialysis Transplantation1999;14(11):2704-9. [MEDLINE: 10534516]">Campistol 1999a</a>; <a href="./references#CD007003-bbs2-0004" title="ArduinoJM , ZhangB , JacksonB , RothD , BruchfeldA , khawajaS , et al. Impact of grazoprevir plus elbasvir on health-related quality of life in patients with hepatitis C virus genotype 1 infection and chronic kidney disease stages 4 and 5 [abstract no: TH-PO667]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):242A. BarrE , RothD , BruchfeldA , MartinP , NelsonDR , SilvaM , et al. Elbasvir (EBR)/grazoprevir (GZR) treatment of hepatitis C virus (HCV) infection in patients with chronic kidney disease stage 4/5: final results of the C-SURFER phase 3 study [abstract]. Journal of Gastroenterology &amp; Hepatology2016;31(Suppl 2):65-6. [EMBASE: 612983742]BruchfeldA , RothD , MartinP , NelsonD , StanislasP , LondonoMC , et al. Elbasvir/Grazoprevir (EBR/GZR) treatment of hepatitis C Virus (HCV) infection in patients with chronic kidney disease (CKD) stage 4/5: clinical, virological, and health-related quality of life outcomes in the C-SURFER study [abstract]. Swiss Medical Weekly2016;146(Suppl 221):23S. [EMBASE: 626845823]BruchfeldA , RothD , MartinP , NelsonDR , PolS , LondonoMC , et al. Elbasvir plus grazoprevir in patients with hepatitis C virus infection and stage 4-5 chronic kidney disease: clinical, virological, and health-related quality-of-life outcomes from a phase 3, multicentre, randomised, double-blind, placebo-controlled trial. The Lancet. Gastroenterology &amp; Hepatology2017;2(8):585-94. [MEDLINE: 28576451]BruchfeldA , RothD , NelsonD , LiapakisAM , SilvaM , MonsourH , et al. C-surfer: Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and chronic kidney disease [abstract no: FP267]. Nephrology Dialysis Transplantation2015;30(Suppl 3):iii156. [EMBASE: 72206687]RothD , BruchfeldA , MartinP , NelsonDR , SilvaM , MonsourH , et al. Grazoprevir(GZR)/elbasvir (EBR) treatment of hepatitis C virus (HCV) infection in patients with chronic kidney disease stage 4/5:final results of the C -SURFER phase 3 study [abstract no: SA-PO1100]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):B5. RothD , NelsonD , BruchfeldA , LiapakisA , SilvaM , MonsourHJ , et al. C-SURFER: grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and chronic kidney disease [abstract no: LP02]. Journal of Hepatology2015;62(Suppl 2):S263-4. [EMBASE: 71936662]RothD , NelsonDR , BruchfeldA , LiapakisA , SilvaM , MonsourH , et al. Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination phase 3 study [Erratum in: Lancet. 2015 Nov 7;386(10006):1824; PMID: 26843312]. Lancet2015;386(10003):1537-45. [MEDLINE: 26456905]">C‐SURFER 2015</a>; <a href="./references#CD007003-bbs2-0005" title="FernandezJL , RendoP , delPinoN , Nephrologists' Group for the Study of HCV Infection, ViolaL . A double-blind controlled trial of recombinant interferon alfa in hemodialysis patients with chronic hepatitis C [abstract]. Hepatology1995;22(4 (Pt 2)):116A. [CENTRAL: CN-00220972] FernandezJL , RendoP , delPinoN , Nephrologists' Group for the Study of HCV, ViolaL , CusumanoA . A controlled trial of interferon alfa 2b in hemodialysis patients with chronic hepatitis C [abstract no: A0989]. Journal of the American Society of Nephrology1996;7(9):1446. [CENTRAL: CN-00445323] FernandezJL , RendoP , delPinoN , ViolaL . A double-blind controlled trial of recombinant interferon-alpha 2b in haemodialysis patients with chronic hepatitis C virus infection and abnormal aminotransferase levels. Nephrologists' Group for the Study of HCV infection. Journal of Viral Hepatitis1997;4(2):113-9. [MEDLINE: 9097267]">Fernandez 1997</a>; <a href="./references#CD007003-bbs2-0006" title="LiuCH , HuangCF , LiuCJ , DaiCY , LiangCC , HuangJF , et al. Peginterferon alfa-2a with or without low dose ribavirin for hemodialysis patients with hepatitis C virus genotype 2 infection: a randomized trial [abstract no: 1851]. Hepatology2013;58(4 Suppl 1):1096A. [EMBASE: 71237851]LiuCH , HuangCF , LiuCJ , DaiCY , LiangCC , HuangJF , et al. Pegylated interferon-alpha2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 1 receiving hemodialysis: a randomized trial. Annals of Internal Medicine2013;159(11):729-38. [MEDLINE: 24297189]LiuCH , LiangCC , SuTH , HungPH , TsaiHB , LiuCJ , et al. Peginterferon alfa-2a plus low dose ribavirin versus peginterferon alfa-2a monotherapy for dialysis patients with hepatitis C virus genotype 1 infection: a randomized trial [abstract no: 1722]. Hepatology2012;56(4 Suppl 1):993A. [EMBASE: 70943304]LiuCH , LiuCJ , HuangCF , LinJW , DaiCY , LiangCC , et al. Peginterferon alfa-2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 2 receiving haemodialysis: a randomised trial. Gut2015;64(2):303-11. [MEDLINE: 24747867]">HELPER 2013</a>; <a href="./references#CD007003-bbs2-0007" title="Peck-RadosavljevicM , BoletisJ , BesisikF , Lucia FerrazM , AlricL , SamuelD , et al. Low-dose peginterferon alfa-2A (40KD) (PEGASYS®) to treat hepatitis C infected end-stage renal disease patients undergoing haemodialysis: final study results [abstract no: 999]. Journal of Hepatology2008;48(Suppl 2):S374. [CENTRAL: CN-00653069] Peck-RadosavljevicM , BoletisJ , BesisikF , Lucia FerrazM , AlricL , SamuelD , et al. Low-dose peginterferon alfa-2a is safe and produces a sustained virologic response in patients with chronic hepatitis C and end-stage renal disease. Clinical Gastroenterology &amp; Hepatology2011;9(3):242-8. [MEDLINE: 21056689]Peck-RadosavljevicM , BoletisJ , BesisikF , Lucia FerrazM , AlricL , SamuelD , et al. Use of low-dose peginterferon alfa-2a (40 kD) (Pegasys) to treat hepatitis C infected end-stage renal disease patients undergoing haemodialysis: interim results from a randomised study [abstract no: 628]. Journal of Hepatology2007;46(Suppl 1):S237-8. [CENTRAL: CN-00716095] ">HELPS 2011</a>; <a href="./references#CD007003-bbs2-0008" title="HuraibS , IqbalA , TanimuD , AbdullahA . Sustained virological and histological response with pretransplant interferon therapy in renal transplant patients with chronic viral hepatitis C. American Journal of Nephrology2001;21(6):435-40. [MEDLINE: 11799259]">Huraib 2001</a>; <a href="./references#CD007003-bbs2-0011" title="RussoMW , GhalibR , SigalS , JoshiV . Randomized trial of pegylated interferon alpha-2b monotherapy in haemodialysis patients with chronic hepatitis C. Nephrology Dialysis Transplantation2006;21(2):437-43. [MEDLINE: 16234288]RussoMW , GhalibR , SigalSH , JoshiV , DetwilerR , AndreoniK , et al. A multi-center randomized trial of pegylated interferon alfa-2B monotherapy (PEG-INTRON) in patients with chronic hepatitis C and end stage kidney disease on dialysis [abstract no: 540]. Hepatology2004;40(4 Suppl 1):399A. [CENTRAL: CN-00507218] ">Russo 2006</a>; <a href="./references#CD007003-bbs2-0012" title="BasuP , ShahN , SirikiR , RahamanM , FarhatS . Telaprevir with adjusted dose of ribavirin in naive CHC-G1: efficacy and treatment in CHC in hemodialysis population target C trial: a placebo randomized control clinical trial [abstract no: 513]. American Journal of Gastroenterology2013;108(Suppl 1):S152. [EMBASE: 71220810]BasuP , SirikiR , ShahNJ , FarhatS , MittimaniK , AtluriS , et al. Telaprevir with adjusted dose of ribavirin in naive CHC-G1: Efficacy and treatment in CHC in hemodialysis population. Target C trial-A placebo randomized control clinical trial [abstract no: 517]. Gastroenterology2013;144(5 Suppl 1):S950. [EMBASE: 71119328]BasuPP , ShahNJ , Ashfique, FarhatS , SirikiR . Telaprevir with adjusted dose of ribavirin in naive CHC-G1: efficacy and treatment in CHC in hemodialysis population. Target C trial-a placebo randomized control clinical trial [abstract no: P196]. Surgical Endoscopy2014;28(1 Suppl):S362. [EMBASE: 71480241]BasuPP , ShahNJ , SirikiR , RahamanM . Telaprevir with adjusted dose of ribavirin in Naive CHC-G1: Efficacy and treatment in CHC in hemodialysis population. TARGET C Trial-a placebo randomized control clinical trial [abstract no: P-298]. Liver Transplantation2014;20(Suppl 1):S244. [EMBASE: 71562627]BasuPP , SinkiR , ShahNJ , FarhatS , MittimaniK , AtluriS , et al. Telaprevir with adjusted dose of ribavirin in naive CHC-G1: efficacy and treatment in CHC in hemodialysis population. TARGET C (RCT) [abstract no: 67]. Journal of Hepatology2013;58(Suppl 1):S30-1. [EMBASE: 71054340]">TARGET C 2013</a>) </p> </li> <li> <p>Adverse events data were available in nine studies (<a href="./references#CD007003-bbs2-0001" title="AlfurayhO , ChaabanA , PallA , Al MutawaN , EllisM , Al MeshariK , et al. Long-term follow up of haemodialysis (HD) patients with chronic hepatitis C (HCV) infection - favorable outcome with a-interferon (IFN) followed by kidney transplantation [abstract no: M221]. Nephrology Dialysis Transplantation2002;17(Suppl 1):110. [CENTRAL: CN-00509051] AlfurayhO , ChaabanA , PallA , EllisM , ChaudryT , AlmeshariK . Randomised controlled trial of interferon-alpha (IFNalpha) in patients with chronic hepatitis C (HCV) on haemodialysis (HD) [abstract]. Nephrology Dialysis Transplantation2000;15(9):A106. [CENTRAL: CN-00497910] AlfurayhOI , ChaabanAM , PallAA , EllisME , AlmeshariK , Al QuaizMN , et al. IFN-alpha for chronic hepatitis C infection (HCV) in haemodialysis (HD) patients - a prospective, randomised, controlled study [abstract]. Journal of the American Society of Nephrology2000;11(Sept):255A. [CENTRAL: CN-00517117] ">Alfurayh 2000</a>; <a href="./references#CD007003-bbs2-0002" title="CampistolJM , CasellasJ , CuevasX , LatorreB , MartínezJ , ModolJ , et al. Efficacy and tolerability of a-2b interferon in the treatment of virus C chronic hepatitis in an hemodialysis population [abstract no: 309] [Eficacia y tolerancia del interferon a-2b en el tratamiento de la hepatitis cronica por virus C (VHC) en la población en hemodialisis (HD)]. Nefrología1996;16(Suppl 1):80. [CENTRAL: CN-00400461] ">Campistol 1996</a>; <a href="./references#CD007003-bbs2-0003" title="CampistolJM , EsforzadoN , MartinezJ , RoselloL , VecianaL , ModolJ , et al. Efficacy and tolerance of interferon-alpha(2b) in the treatment of chronic hepatitis C virus infection in haemodialysis patients. Pre- and post-renal transplantation assessment. Nephrology Dialysis Transplantation1999;14(11):2704-9. [MEDLINE: 10534516]">Campistol 1999a</a>; <a href="./references#CD007003-bbs2-0005" title="FernandezJL , RendoP , delPinoN , Nephrologists' Group for the Study of HCV Infection, ViolaL . A double-blind controlled trial of recombinant interferon alfa in hemodialysis patients with chronic hepatitis C [abstract]. Hepatology1995;22(4 (Pt 2)):116A. [CENTRAL: CN-00220972] FernandezJL , RendoP , delPinoN , Nephrologists' Group for the Study of HCV, ViolaL , CusumanoA . A controlled trial of interferon alfa 2b in hemodialysis patients with chronic hepatitis C [abstract no: A0989]. Journal of the American Society of Nephrology1996;7(9):1446. [CENTRAL: CN-00445323] FernandezJL , RendoP , delPinoN , ViolaL . A double-blind controlled trial of recombinant interferon-alpha 2b in haemodialysis patients with chronic hepatitis C virus infection and abnormal aminotransferase levels. Nephrologists' Group for the Study of HCV infection. Journal of Viral Hepatitis1997;4(2):113-9. [MEDLINE: 9097267]">Fernandez 1997</a>; <a href="./references#CD007003-bbs2-0006" title="LiuCH , HuangCF , LiuCJ , DaiCY , LiangCC , HuangJF , et al. Peginterferon alfa-2a with or without low dose ribavirin for hemodialysis patients with hepatitis C virus genotype 2 infection: a randomized trial [abstract no: 1851]. Hepatology2013;58(4 Suppl 1):1096A. [EMBASE: 71237851]LiuCH , HuangCF , LiuCJ , DaiCY , LiangCC , HuangJF , et al. Pegylated interferon-alpha2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 1 receiving hemodialysis: a randomized trial. Annals of Internal Medicine2013;159(11):729-38. [MEDLINE: 24297189]LiuCH , LiangCC , SuTH , HungPH , TsaiHB , LiuCJ , et al. Peginterferon alfa-2a plus low dose ribavirin versus peginterferon alfa-2a monotherapy for dialysis patients with hepatitis C virus genotype 1 infection: a randomized trial [abstract no: 1722]. Hepatology2012;56(4 Suppl 1):993A. [EMBASE: 70943304]LiuCH , LiuCJ , HuangCF , LinJW , DaiCY , LiangCC , et al. Peginterferon alfa-2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 2 receiving haemodialysis: a randomised trial. Gut2015;64(2):303-11. [MEDLINE: 24747867]">HELPER 2013</a>; <a href="./references#CD007003-bbs2-0007" title="Peck-RadosavljevicM , BoletisJ , BesisikF , Lucia FerrazM , AlricL , SamuelD , et al. Low-dose peginterferon alfa-2A (40KD) (PEGASYS®) to treat hepatitis C infected end-stage renal disease patients undergoing haemodialysis: final study results [abstract no: 999]. Journal of Hepatology2008;48(Suppl 2):S374. [CENTRAL: CN-00653069] Peck-RadosavljevicM , BoletisJ , BesisikF , Lucia FerrazM , AlricL , SamuelD , et al. Low-dose peginterferon alfa-2a is safe and produces a sustained virologic response in patients with chronic hepatitis C and end-stage renal disease. Clinical Gastroenterology &amp; Hepatology2011;9(3):242-8. [MEDLINE: 21056689]Peck-RadosavljevicM , BoletisJ , BesisikF , Lucia FerrazM , AlricL , SamuelD , et al. Use of low-dose peginterferon alfa-2a (40 kD) (Pegasys) to treat hepatitis C infected end-stage renal disease patients undergoing haemodialysis: interim results from a randomised study [abstract no: 628]. Journal of Hepatology2007;46(Suppl 1):S237-8. [CENTRAL: CN-00716095] ">HELPS 2011</a>; <a href="./references#CD007003-bbs2-0008" title="HuraibS , IqbalA , TanimuD , AbdullahA . Sustained virological and histological response with pretransplant interferon therapy in renal transplant patients with chronic viral hepatitis C. American Journal of Nephrology2001;21(6):435-40. [MEDLINE: 11799259]">Huraib 2001</a>; <a href="./references#CD007003-bbs2-0009" title="LiuCH , LiangCC , LinJW , ChenSI , TsaiHB , ChangCS , et al. Pegylated interferon alpha-2a versus standard interferon alpha-2a for treatment-naive dialysis patients with chronic hepatitis C: a randomised study. Gut2008;57(4):525-30. [MEDLINE: 17881538]">Liu 2008a</a>; <a href="./references#CD007003-bbs2-0011" title="RussoMW , GhalibR , SigalS , JoshiV . Randomized trial of pegylated interferon alpha-2b monotherapy in haemodialysis patients with chronic hepatitis C. Nephrology Dialysis Transplantation2006;21(2):437-43. [MEDLINE: 16234288]RussoMW , GhalibR , SigalSH , JoshiV , DetwilerR , AndreoniK , et al. A multi-center randomized trial of pegylated interferon alfa-2B monotherapy (PEG-INTRON) in patients with chronic hepatitis C and end stage kidney disease on dialysis [abstract no: 540]. Hepatology2004;40(4 Suppl 1):399A. [CENTRAL: CN-00507218] ">Russo 2006</a>) </p> </li> <li> <p>Treatment discontinuation was available in nine studies (<a href="./references#CD007003-bbs2-0002" title="CampistolJM , CasellasJ , CuevasX , LatorreB , MartínezJ , ModolJ , et al. Efficacy and tolerability of a-2b interferon in the treatment of virus C chronic hepatitis in an hemodialysis population [abstract no: 309] [Eficacia y tolerancia del interferon a-2b en el tratamiento de la hepatitis cronica por virus C (VHC) en la población en hemodialisis (HD)]. Nefrología1996;16(Suppl 1):80. [CENTRAL: CN-00400461] ">Campistol 1996</a>; <a href="./references#CD007003-bbs2-0003" title="CampistolJM , EsforzadoN , MartinezJ , RoselloL , VecianaL , ModolJ , et al. Efficacy and tolerance of interferon-alpha(2b) in the treatment of chronic hepatitis C virus infection in haemodialysis patients. Pre- and post-renal transplantation assessment. Nephrology Dialysis Transplantation1999;14(11):2704-9. [MEDLINE: 10534516]">Campistol 1999a</a>; <a href="./references#CD007003-bbs2-0005" title="FernandezJL , RendoP , delPinoN , Nephrologists' Group for the Study of HCV Infection, ViolaL . A double-blind controlled trial of recombinant interferon alfa in hemodialysis patients with chronic hepatitis C [abstract]. Hepatology1995;22(4 (Pt 2)):116A. [CENTRAL: CN-00220972] FernandezJL , RendoP , delPinoN , Nephrologists' Group for the Study of HCV, ViolaL , CusumanoA . A controlled trial of interferon alfa 2b in hemodialysis patients with chronic hepatitis C [abstract no: A0989]. Journal of the American Society of Nephrology1996;7(9):1446. [CENTRAL: CN-00445323] FernandezJL , RendoP , delPinoN , ViolaL . A double-blind controlled trial of recombinant interferon-alpha 2b in haemodialysis patients with chronic hepatitis C virus infection and abnormal aminotransferase levels. Nephrologists' Group for the Study of HCV infection. Journal of Viral Hepatitis1997;4(2):113-9. [MEDLINE: 9097267]">Fernandez 1997</a>; <a href="./references#CD007003-bbs2-0006" title="LiuCH , HuangCF , LiuCJ , DaiCY , LiangCC , HuangJF , et al. Peginterferon alfa-2a with or without low dose ribavirin for hemodialysis patients with hepatitis C virus genotype 2 infection: a randomized trial [abstract no: 1851]. Hepatology2013;58(4 Suppl 1):1096A. [EMBASE: 71237851]LiuCH , HuangCF , LiuCJ , DaiCY , LiangCC , HuangJF , et al. Pegylated interferon-alpha2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 1 receiving hemodialysis: a randomized trial. Annals of Internal Medicine2013;159(11):729-38. [MEDLINE: 24297189]LiuCH , LiangCC , SuTH , HungPH , TsaiHB , LiuCJ , et al. Peginterferon alfa-2a plus low dose ribavirin versus peginterferon alfa-2a monotherapy for dialysis patients with hepatitis C virus genotype 1 infection: a randomized trial [abstract no: 1722]. Hepatology2012;56(4 Suppl 1):993A. [EMBASE: 70943304]LiuCH , LiuCJ , HuangCF , LinJW , DaiCY , LiangCC , et al. Peginterferon alfa-2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 2 receiving haemodialysis: a randomised trial. Gut2015;64(2):303-11. [MEDLINE: 24747867]">HELPER 2013</a>; <a href="./references#CD007003-bbs2-0007" title="Peck-RadosavljevicM , BoletisJ , BesisikF , Lucia FerrazM , AlricL , SamuelD , et al. Low-dose peginterferon alfa-2A (40KD) (PEGASYS®) to treat hepatitis C infected end-stage renal disease patients undergoing haemodialysis: final study results [abstract no: 999]. Journal of Hepatology2008;48(Suppl 2):S374. [CENTRAL: CN-00653069] Peck-RadosavljevicM , BoletisJ , BesisikF , Lucia FerrazM , AlricL , SamuelD , et al. Low-dose peginterferon alfa-2a is safe and produces a sustained virologic response in patients with chronic hepatitis C and end-stage renal disease. Clinical Gastroenterology &amp; Hepatology2011;9(3):242-8. [MEDLINE: 21056689]Peck-RadosavljevicM , BoletisJ , BesisikF , Lucia FerrazM , AlricL , SamuelD , et al. Use of low-dose peginterferon alfa-2a (40 kD) (Pegasys) to treat hepatitis C infected end-stage renal disease patients undergoing haemodialysis: interim results from a randomised study [abstract no: 628]. Journal of Hepatology2007;46(Suppl 1):S237-8. [CENTRAL: CN-00716095] ">HELPS 2011</a>; <a href="./references#CD007003-bbs2-0008" title="HuraibS , IqbalA , TanimuD , AbdullahA . Sustained virological and histological response with pretransplant interferon therapy in renal transplant patients with chronic viral hepatitis C. American Journal of Nephrology2001;21(6):435-40. [MEDLINE: 11799259]">Huraib 2001</a>; <a href="./references#CD007003-bbs2-0009" title="LiuCH , LiangCC , LinJW , ChenSI , TsaiHB , ChangCS , et al. Pegylated interferon alpha-2a versus standard interferon alpha-2a for treatment-naive dialysis patients with chronic hepatitis C: a randomised study. Gut2008;57(4):525-30. [MEDLINE: 17881538]">Liu 2008a</a>; <a href="./references#CD007003-bbs2-0011" title="RussoMW , GhalibR , SigalS , JoshiV . Randomized trial of pegylated interferon alpha-2b monotherapy in haemodialysis patients with chronic hepatitis C. Nephrology Dialysis Transplantation2006;21(2):437-43. [MEDLINE: 16234288]RussoMW , GhalibR , SigalSH , JoshiV , DetwilerR , AndreoniK , et al. A multi-center randomized trial of pegylated interferon alfa-2B monotherapy (PEG-INTRON) in patients with chronic hepatitis C and end stage kidney disease on dialysis [abstract no: 540]. Hepatology2004;40(4 Suppl 1):399A. [CENTRAL: CN-00507218] ">Russo 2006</a>; <a href="./references#CD007003-bbs2-0013" title="TuglularS , Karadayi h, KarakullukcuF , ErmanM , YukselS , CelikM , et al. Preliminary results of interferon compared to interferon combined with ribavirin in the treatment of chronic HCV in patients on chronic hemodialysis [abstract no: A2147]. Journal of the American Society of Nephrology2001;12(Program &amp; Abstracts):416-7A. [CENTRAL: CN-00543899] ">Tuglular 2001</a>) </p> </li> <li> <p>Data on SVR was available in nine studies (<a href="./references#CD007003-bbs2-0001" title="AlfurayhO , ChaabanA , PallA , Al MutawaN , EllisM , Al MeshariK , et al. Long-term follow up of haemodialysis (HD) patients with chronic hepatitis C (HCV) infection - favorable outcome with a-interferon (IFN) followed by kidney transplantation [abstract no: M221]. Nephrology Dialysis Transplantation2002;17(Suppl 1):110. [CENTRAL: CN-00509051] AlfurayhO , ChaabanA , PallA , EllisM , ChaudryT , AlmeshariK . Randomised controlled trial of interferon-alpha (IFNalpha) in patients with chronic hepatitis C (HCV) on haemodialysis (HD) [abstract]. Nephrology Dialysis Transplantation2000;15(9):A106. [CENTRAL: CN-00497910] AlfurayhOI , ChaabanAM , PallAA , EllisME , AlmeshariK , Al QuaizMN , et al. IFN-alpha for chronic hepatitis C infection (HCV) in haemodialysis (HD) patients - a prospective, randomised, controlled study [abstract]. Journal of the American Society of Nephrology2000;11(Sept):255A. [CENTRAL: CN-00517117] ">Alfurayh 2000</a>; <a href="./references#CD007003-bbs2-0003" title="CampistolJM , EsforzadoN , MartinezJ , RoselloL , VecianaL , ModolJ , et al. Efficacy and tolerance of interferon-alpha(2b) in the treatment of chronic hepatitis C virus infection in haemodialysis patients. Pre- and post-renal transplantation assessment. Nephrology Dialysis Transplantation1999;14(11):2704-9. [MEDLINE: 10534516]">Campistol 1999a</a>; <a href="./references#CD007003-bbs2-0005" title="FernandezJL , RendoP , delPinoN , Nephrologists' Group for the Study of HCV Infection, ViolaL . A double-blind controlled trial of recombinant interferon alfa in hemodialysis patients with chronic hepatitis C [abstract]. Hepatology1995;22(4 (Pt 2)):116A. [CENTRAL: CN-00220972] FernandezJL , RendoP , delPinoN , Nephrologists' Group for the Study of HCV, ViolaL , CusumanoA . A controlled trial of interferon alfa 2b in hemodialysis patients with chronic hepatitis C [abstract no: A0989]. Journal of the American Society of Nephrology1996;7(9):1446. [CENTRAL: CN-00445323] FernandezJL , RendoP , delPinoN , ViolaL . A double-blind controlled trial of recombinant interferon-alpha 2b in haemodialysis patients with chronic hepatitis C virus infection and abnormal aminotransferase levels. Nephrologists' Group for the Study of HCV infection. Journal of Viral Hepatitis1997;4(2):113-9. [MEDLINE: 9097267]">Fernandez 1997</a>; <a href="./references#CD007003-bbs2-0006" title="LiuCH , HuangCF , LiuCJ , DaiCY , LiangCC , HuangJF , et al. Peginterferon alfa-2a with or without low dose ribavirin for hemodialysis patients with hepatitis C virus genotype 2 infection: a randomized trial [abstract no: 1851]. Hepatology2013;58(4 Suppl 1):1096A. [EMBASE: 71237851]LiuCH , HuangCF , LiuCJ , DaiCY , LiangCC , HuangJF , et al. Pegylated interferon-alpha2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 1 receiving hemodialysis: a randomized trial. Annals of Internal Medicine2013;159(11):729-38. [MEDLINE: 24297189]LiuCH , LiangCC , SuTH , HungPH , TsaiHB , LiuCJ , et al. Peginterferon alfa-2a plus low dose ribavirin versus peginterferon alfa-2a monotherapy for dialysis patients with hepatitis C virus genotype 1 infection: a randomized trial [abstract no: 1722]. Hepatology2012;56(4 Suppl 1):993A. [EMBASE: 70943304]LiuCH , LiuCJ , HuangCF , LinJW , DaiCY , LiangCC , et al. Peginterferon alfa-2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 2 receiving haemodialysis: a randomised trial. Gut2015;64(2):303-11. [MEDLINE: 24747867]">HELPER 2013</a>; <a href="./references#CD007003-bbs2-0007" title="Peck-RadosavljevicM , BoletisJ , BesisikF , Lucia FerrazM , AlricL , SamuelD , et al. Low-dose peginterferon alfa-2A (40KD) (PEGASYS®) to treat hepatitis C infected end-stage renal disease patients undergoing haemodialysis: final study results [abstract no: 999]. Journal of Hepatology2008;48(Suppl 2):S374. [CENTRAL: CN-00653069] Peck-RadosavljevicM , BoletisJ , BesisikF , Lucia FerrazM , AlricL , SamuelD , et al. Low-dose peginterferon alfa-2a is safe and produces a sustained virologic response in patients with chronic hepatitis C and end-stage renal disease. Clinical Gastroenterology &amp; Hepatology2011;9(3):242-8. [MEDLINE: 21056689]Peck-RadosavljevicM , BoletisJ , BesisikF , Lucia FerrazM , AlricL , SamuelD , et al. Use of low-dose peginterferon alfa-2a (40 kD) (Pegasys) to treat hepatitis C infected end-stage renal disease patients undergoing haemodialysis: interim results from a randomised study [abstract no: 628]. Journal of Hepatology2007;46(Suppl 1):S237-8. [CENTRAL: CN-00716095] ">HELPS 2011</a>; <a href="./references#CD007003-bbs2-0008" title="HuraibS , IqbalA , TanimuD , AbdullahA . Sustained virological and histological response with pretransplant interferon therapy in renal transplant patients with chronic viral hepatitis C. American Journal of Nephrology2001;21(6):435-40. [MEDLINE: 11799259]">Huraib 2001</a>; <a href="./references#CD007003-bbs2-0009" title="LiuCH , LiangCC , LinJW , ChenSI , TsaiHB , ChangCS , et al. Pegylated interferon alpha-2a versus standard interferon alpha-2a for treatment-naive dialysis patients with chronic hepatitis C: a randomised study. Gut2008;57(4):525-30. [MEDLINE: 17881538]">Liu 2008a</a>; <a href="./references#CD007003-bbs2-0011" title="RussoMW , GhalibR , SigalS , JoshiV . Randomized trial of pegylated interferon alpha-2b monotherapy in haemodialysis patients with chronic hepatitis C. Nephrology Dialysis Transplantation2006;21(2):437-43. [MEDLINE: 16234288]RussoMW , GhalibR , SigalSH , JoshiV , DetwilerR , AndreoniK , et al. A multi-center randomized trial of pegylated interferon alfa-2B monotherapy (PEG-INTRON) in patients with chronic hepatitis C and end stage kidney disease on dialysis [abstract no: 540]. Hepatology2004;40(4 Suppl 1):399A. [CENTRAL: CN-00507218] ">Russo 2006</a>; <a href="./references#CD007003-bbs2-0012" title="BasuP , ShahN , SirikiR , RahamanM , FarhatS . Telaprevir with adjusted dose of ribavirin in naive CHC-G1: efficacy and treatment in CHC in hemodialysis population target C trial: a placebo randomized control clinical trial [abstract no: 513]. American Journal of Gastroenterology2013;108(Suppl 1):S152. [EMBASE: 71220810]BasuP , SirikiR , ShahNJ , FarhatS , MittimaniK , AtluriS , et al. Telaprevir with adjusted dose of ribavirin in naive CHC-G1: Efficacy and treatment in CHC in hemodialysis population. Target C trial-A placebo randomized control clinical trial [abstract no: 517]. Gastroenterology2013;144(5 Suppl 1):S950. [EMBASE: 71119328]BasuPP , ShahNJ , Ashfique, FarhatS , SirikiR . Telaprevir with adjusted dose of ribavirin in naive CHC-G1: efficacy and treatment in CHC in hemodialysis population. Target C trial-a placebo randomized control clinical trial [abstract no: P196]. Surgical Endoscopy2014;28(1 Suppl):S362. [EMBASE: 71480241]BasuPP , ShahNJ , SirikiR , RahamanM . Telaprevir with adjusted dose of ribavirin in Naive CHC-G1: Efficacy and treatment in CHC in hemodialysis population. TARGET C Trial-a placebo randomized control clinical trial [abstract no: P-298]. Liver Transplantation2014;20(Suppl 1):S244. [EMBASE: 71562627]BasuPP , SinkiR , ShahNJ , FarhatS , MittimaniK , AtluriS , et al. Telaprevir with adjusted dose of ribavirin in naive CHC-G1: efficacy and treatment in CHC in hemodialysis population. TARGET C (RCT) [abstract no: 67]. Journal of Hepatology2013;58(Suppl 1):S30-1. [EMBASE: 71054340]">TARGET C 2013</a>) </p> <ul id="CD007003-list-0021"> <li> <p><a href="./references#CD007003-bbs2-0004" title="ArduinoJM , ZhangB , JacksonB , RothD , BruchfeldA , khawajaS , et al. Impact of grazoprevir plus elbasvir on health-related quality of life in patients with hepatitis C virus genotype 1 infection and chronic kidney disease stages 4 and 5 [abstract no: TH-PO667]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):242A. BarrE , RothD , BruchfeldA , MartinP , NelsonDR , SilvaM , et al. Elbasvir (EBR)/grazoprevir (GZR) treatment of hepatitis C virus (HCV) infection in patients with chronic kidney disease stage 4/5: final results of the C-SURFER phase 3 study [abstract]. Journal of Gastroenterology &amp; Hepatology2016;31(Suppl 2):65-6. [EMBASE: 612983742]BruchfeldA , RothD , MartinP , NelsonD , StanislasP , LondonoMC , et al. Elbasvir/Grazoprevir (EBR/GZR) treatment of hepatitis C Virus (HCV) infection in patients with chronic kidney disease (CKD) stage 4/5: clinical, virological, and health-related quality of life outcomes in the C-SURFER study [abstract]. Swiss Medical Weekly2016;146(Suppl 221):23S. [EMBASE: 626845823]BruchfeldA , RothD , MartinP , NelsonDR , PolS , LondonoMC , et al. Elbasvir plus grazoprevir in patients with hepatitis C virus infection and stage 4-5 chronic kidney disease: clinical, virological, and health-related quality-of-life outcomes from a phase 3, multicentre, randomised, double-blind, placebo-controlled trial. The Lancet. Gastroenterology &amp; Hepatology2017;2(8):585-94. [MEDLINE: 28576451]BruchfeldA , RothD , NelsonD , LiapakisAM , SilvaM , MonsourH , et al. C-surfer: Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and chronic kidney disease [abstract no: FP267]. Nephrology Dialysis Transplantation2015;30(Suppl 3):iii156. [EMBASE: 72206687]RothD , BruchfeldA , MartinP , NelsonDR , SilvaM , MonsourH , et al. Grazoprevir(GZR)/elbasvir (EBR) treatment of hepatitis C virus (HCV) infection in patients with chronic kidney disease stage 4/5:final results of the C -SURFER phase 3 study [abstract no: SA-PO1100]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):B5. RothD , NelsonD , BruchfeldA , LiapakisA , SilvaM , MonsourHJ , et al. C-SURFER: grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and chronic kidney disease [abstract no: LP02]. Journal of Hepatology2015;62(Suppl 2):S263-4. [EMBASE: 71936662]RothD , NelsonDR , BruchfeldA , LiapakisA , SilvaM , MonsourH , et al. Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination phase 3 study [Erratum in: Lancet. 2015 Nov 7;386(10006):1824; PMID: 26843312]. Lancet2015;386(10003):1537-45. [MEDLINE: 26456905]">C‐SURFER 2015</a> used an outcomes' definition of SVR12 i.e. SVR 12 weeks after treatment </p> </li> </ul> </li> <li> <p>Time to recovery, cost‐effectiveness, QoL and other outcome data were not available</p> </li> <li> <p>Outcomes data were not complete for those recruited in two studies (<a href="./references#CD007003-bbs2-0001" title="AlfurayhO , ChaabanA , PallA , Al MutawaN , EllisM , Al MeshariK , et al. Long-term follow up of haemodialysis (HD) patients with chronic hepatitis C (HCV) infection - favorable outcome with a-interferon (IFN) followed by kidney transplantation [abstract no: M221]. Nephrology Dialysis Transplantation2002;17(Suppl 1):110. [CENTRAL: CN-00509051] AlfurayhO , ChaabanA , PallA , EllisM , ChaudryT , AlmeshariK . Randomised controlled trial of interferon-alpha (IFNalpha) in patients with chronic hepatitis C (HCV) on haemodialysis (HD) [abstract]. Nephrology Dialysis Transplantation2000;15(9):A106. [CENTRAL: CN-00497910] AlfurayhOI , ChaabanAM , PallAA , EllisME , AlmeshariK , Al QuaizMN , et al. IFN-alpha for chronic hepatitis C infection (HCV) in haemodialysis (HD) patients - a prospective, randomised, controlled study [abstract]. Journal of the American Society of Nephrology2000;11(Sept):255A. [CENTRAL: CN-00517117] ">Alfurayh 2000</a>; <a href="./references#CD007003-bbs2-0008" title="HuraibS , IqbalA , TanimuD , AbdullahA . Sustained virological and histological response with pretransplant interferon therapy in renal transplant patients with chronic viral hepatitis C. American Journal of Nephrology2001;21(6):435-40. [MEDLINE: 11799259]">Huraib 2001</a>) </p> </li> <li> <p>Data on outcomes were combined and reported together for both groups in <a href="./references#CD007003-bbs2-0010" title="LuxonBA , MuirAJ , HeneghanMA . Safety and tolerability of pegylated interferon with or without low dose ribavirin for treatment of hepatitis C in hemodialysis patients [abstract no: 1281]. Hepatology2005;42(4 Suppl 1):703-4A. [CENTRAL: CN-00581669] ">Luxon 2005</a> </p> </li> <li> <p>Data on outcomes were not complete in <a href="./references#CD007003-bbs2-0012" title="BasuP , ShahN , SirikiR , RahamanM , FarhatS . Telaprevir with adjusted dose of ribavirin in naive CHC-G1: efficacy and treatment in CHC in hemodialysis population target C trial: a placebo randomized control clinical trial [abstract no: 513]. American Journal of Gastroenterology2013;108(Suppl 1):S152. [EMBASE: 71220810]BasuP , SirikiR , ShahNJ , FarhatS , MittimaniK , AtluriS , et al. Telaprevir with adjusted dose of ribavirin in naive CHC-G1: Efficacy and treatment in CHC in hemodialysis population. Target C trial-A placebo randomized control clinical trial [abstract no: 517]. Gastroenterology2013;144(5 Suppl 1):S950. [EMBASE: 71119328]BasuPP , ShahNJ , Ashfique, FarhatS , SirikiR . Telaprevir with adjusted dose of ribavirin in naive CHC-G1: efficacy and treatment in CHC in hemodialysis population. Target C trial-a placebo randomized control clinical trial [abstract no: P196]. Surgical Endoscopy2014;28(1 Suppl):S362. [EMBASE: 71480241]BasuPP , ShahNJ , SirikiR , RahamanM . Telaprevir with adjusted dose of ribavirin in Naive CHC-G1: Efficacy and treatment in CHC in hemodialysis population. TARGET C Trial-a placebo randomized control clinical trial [abstract no: P-298]. Liver Transplantation2014;20(Suppl 1):S244. [EMBASE: 71562627]BasuPP , SinkiR , ShahNJ , FarhatS , MittimaniK , AtluriS , et al. Telaprevir with adjusted dose of ribavirin in naive CHC-G1: efficacy and treatment in CHC in hemodialysis population. TARGET C (RCT) [abstract no: 67]. Journal of Hepatology2013;58(Suppl 1):S30-1. [EMBASE: 71054340]">TARGET C 2013</a>. </p> </li> </ul> </p> </section> </section> <section id="CD007003-sec-0048"> <h4 class="title">Excluded studies</h4> <p>Hepatitis C was not specifically mentioned in two studies (reported as non‐A non‐B hepatitis) (<a href="./references#CD007003-bbs2-0014" title="EllisME , AlfurayhO , HalimMA , SieckJO , AliMA , BernvilSS , et al. Chronic non-A, non-B hepatitis complicated by end-stage renal failure treated with recombinant interferon alpha. Journal of Hepatology1993;18(2):210-6. [MEDLINE: 8409337]">Ellis 1993</a>; <a href="./references#CD007003-bbs2-0015" title="SimonN . Prevention of non-A, non-B hepatitis in haemodialysis patients by hepatitis B immunoglobulin. Lancet1984;2(8410):1047. [MEDLINE: 6149434]">Simon 1984</a>). </p> <p>See <a href="./references#CD007003-sec-0115" title="">Characteristics of excluded studies</a>. </p> </section> </section> <section id="CD007003-sec-0049"> <h3 class="title">Risk of bias in included studies</h3> <p>Overall, there was a low risk of bias in seven studies (<a href="./references#CD007003-bbs2-0003" title="CampistolJM , EsforzadoN , MartinezJ , RoselloL , VecianaL , ModolJ , et al. Efficacy and tolerance of interferon-alpha(2b) in the treatment of chronic hepatitis C virus infection in haemodialysis patients. Pre- and post-renal transplantation assessment. Nephrology Dialysis Transplantation1999;14(11):2704-9. [MEDLINE: 10534516]">Campistol 1999a</a>; <a href="./references#CD007003-bbs2-0004" title="ArduinoJM , ZhangB , JacksonB , RothD , BruchfeldA , khawajaS , et al. Impact of grazoprevir plus elbasvir on health-related quality of life in patients with hepatitis C virus genotype 1 infection and chronic kidney disease stages 4 and 5 [abstract no: TH-PO667]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):242A. BarrE , RothD , BruchfeldA , MartinP , NelsonDR , SilvaM , et al. Elbasvir (EBR)/grazoprevir (GZR) treatment of hepatitis C virus (HCV) infection in patients with chronic kidney disease stage 4/5: final results of the C-SURFER phase 3 study [abstract]. Journal of Gastroenterology &amp; Hepatology2016;31(Suppl 2):65-6. [EMBASE: 612983742]BruchfeldA , RothD , MartinP , NelsonD , StanislasP , LondonoMC , et al. Elbasvir/Grazoprevir (EBR/GZR) treatment of hepatitis C Virus (HCV) infection in patients with chronic kidney disease (CKD) stage 4/5: clinical, virological, and health-related quality of life outcomes in the C-SURFER study [abstract]. Swiss Medical Weekly2016;146(Suppl 221):23S. [EMBASE: 626845823]BruchfeldA , RothD , MartinP , NelsonDR , PolS , LondonoMC , et al. Elbasvir plus grazoprevir in patients with hepatitis C virus infection and stage 4-5 chronic kidney disease: clinical, virological, and health-related quality-of-life outcomes from a phase 3, multicentre, randomised, double-blind, placebo-controlled trial. The Lancet. Gastroenterology &amp; Hepatology2017;2(8):585-94. [MEDLINE: 28576451]BruchfeldA , RothD , NelsonD , LiapakisAM , SilvaM , MonsourH , et al. C-surfer: Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and chronic kidney disease [abstract no: FP267]. Nephrology Dialysis Transplantation2015;30(Suppl 3):iii156. [EMBASE: 72206687]RothD , BruchfeldA , MartinP , NelsonDR , SilvaM , MonsourH , et al. Grazoprevir(GZR)/elbasvir (EBR) treatment of hepatitis C virus (HCV) infection in patients with chronic kidney disease stage 4/5:final results of the C -SURFER phase 3 study [abstract no: SA-PO1100]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):B5. RothD , NelsonD , BruchfeldA , LiapakisA , SilvaM , MonsourHJ , et al. C-SURFER: grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and chronic kidney disease [abstract no: LP02]. Journal of Hepatology2015;62(Suppl 2):S263-4. [EMBASE: 71936662]RothD , NelsonDR , BruchfeldA , LiapakisA , SilvaM , MonsourH , et al. Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination phase 3 study [Erratum in: Lancet. 2015 Nov 7;386(10006):1824; PMID: 26843312]. Lancet2015;386(10003):1537-45. [MEDLINE: 26456905]">C‐SURFER 2015</a>; <a href="./references#CD007003-bbs2-0005" title="FernandezJL , RendoP , delPinoN , Nephrologists' Group for the Study of HCV Infection, ViolaL . A double-blind controlled trial of recombinant interferon alfa in hemodialysis patients with chronic hepatitis C [abstract]. Hepatology1995;22(4 (Pt 2)):116A. [CENTRAL: CN-00220972] FernandezJL , RendoP , delPinoN , Nephrologists' Group for the Study of HCV, ViolaL , CusumanoA . A controlled trial of interferon alfa 2b in hemodialysis patients with chronic hepatitis C [abstract no: A0989]. Journal of the American Society of Nephrology1996;7(9):1446. [CENTRAL: CN-00445323] FernandezJL , RendoP , delPinoN , ViolaL . A double-blind controlled trial of recombinant interferon-alpha 2b in haemodialysis patients with chronic hepatitis C virus infection and abnormal aminotransferase levels. Nephrologists' Group for the Study of HCV infection. Journal of Viral Hepatitis1997;4(2):113-9. [MEDLINE: 9097267]">Fernandez 1997</a>; <a href="./references#CD007003-bbs2-0006" title="LiuCH , HuangCF , LiuCJ , DaiCY , LiangCC , HuangJF , et al. Peginterferon alfa-2a with or without low dose ribavirin for hemodialysis patients with hepatitis C virus genotype 2 infection: a randomized trial [abstract no: 1851]. Hepatology2013;58(4 Suppl 1):1096A. [EMBASE: 71237851]LiuCH , HuangCF , LiuCJ , DaiCY , LiangCC , HuangJF , et al. Pegylated interferon-alpha2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 1 receiving hemodialysis: a randomized trial. Annals of Internal Medicine2013;159(11):729-38. [MEDLINE: 24297189]LiuCH , LiangCC , SuTH , HungPH , TsaiHB , LiuCJ , et al. Peginterferon alfa-2a plus low dose ribavirin versus peginterferon alfa-2a monotherapy for dialysis patients with hepatitis C virus genotype 1 infection: a randomized trial [abstract no: 1722]. Hepatology2012;56(4 Suppl 1):993A. [EMBASE: 70943304]LiuCH , LiuCJ , HuangCF , LinJW , DaiCY , LiangCC , et al. Peginterferon alfa-2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 2 receiving haemodialysis: a randomised trial. Gut2015;64(2):303-11. [MEDLINE: 24747867]">HELPER 2013</a>; <a href="./references#CD007003-bbs2-0009" title="LiuCH , LiangCC , LinJW , ChenSI , TsaiHB , ChangCS , et al. Pegylated interferon alpha-2a versus standard interferon alpha-2a for treatment-naive dialysis patients with chronic hepatitis C: a randomised study. Gut2008;57(4):525-30. [MEDLINE: 17881538]">Liu 2008a</a>; <a href="./references#CD007003-bbs2-0007" title="Peck-RadosavljevicM , BoletisJ , BesisikF , Lucia FerrazM , AlricL , SamuelD , et al. Low-dose peginterferon alfa-2A (40KD) (PEGASYS®) to treat hepatitis C infected end-stage renal disease patients undergoing haemodialysis: final study results [abstract no: 999]. Journal of Hepatology2008;48(Suppl 2):S374. [CENTRAL: CN-00653069] Peck-RadosavljevicM , BoletisJ , BesisikF , Lucia FerrazM , AlricL , SamuelD , et al. Low-dose peginterferon alfa-2a is safe and produces a sustained virologic response in patients with chronic hepatitis C and end-stage renal disease. Clinical Gastroenterology &amp; Hepatology2011;9(3):242-8. [MEDLINE: 21056689]Peck-RadosavljevicM , BoletisJ , BesisikF , Lucia FerrazM , AlricL , SamuelD , et al. Use of low-dose peginterferon alfa-2a (40 kD) (Pegasys) to treat hepatitis C infected end-stage renal disease patients undergoing haemodialysis: interim results from a randomised study [abstract no: 628]. Journal of Hepatology2007;46(Suppl 1):S237-8. [CENTRAL: CN-00716095] ">HELPS 2011</a>; <a href="./references#CD007003-bbs2-0011" title="RussoMW , GhalibR , SigalS , JoshiV . Randomized trial of pegylated interferon alpha-2b monotherapy in haemodialysis patients with chronic hepatitis C. Nephrology Dialysis Transplantation2006;21(2):437-43. [MEDLINE: 16234288]RussoMW , GhalibR , SigalSH , JoshiV , DetwilerR , AndreoniK , et al. A multi-center randomized trial of pegylated interferon alfa-2B monotherapy (PEG-INTRON) in patients with chronic hepatitis C and end stage kidney disease on dialysis [abstract no: 540]. Hepatology2004;40(4 Suppl 1):399A. [CENTRAL: CN-00507218] ">Russo 2006</a>), unclear in four studies (<a href="./references#CD007003-bbs2-0001" title="AlfurayhO , ChaabanA , PallA , Al MutawaN , EllisM , Al MeshariK , et al. Long-term follow up of haemodialysis (HD) patients with chronic hepatitis C (HCV) infection - favorable outcome with a-interferon (IFN) followed by kidney transplantation [abstract no: M221]. Nephrology Dialysis Transplantation2002;17(Suppl 1):110. [CENTRAL: CN-00509051] AlfurayhO , ChaabanA , PallA , EllisM , ChaudryT , AlmeshariK . Randomised controlled trial of interferon-alpha (IFNalpha) in patients with chronic hepatitis C (HCV) on haemodialysis (HD) [abstract]. Nephrology Dialysis Transplantation2000;15(9):A106. [CENTRAL: CN-00497910] AlfurayhOI , ChaabanAM , PallAA , EllisME , AlmeshariK , Al QuaizMN , et al. IFN-alpha for chronic hepatitis C infection (HCV) in haemodialysis (HD) patients - a prospective, randomised, controlled study [abstract]. Journal of the American Society of Nephrology2000;11(Sept):255A. [CENTRAL: CN-00517117] ">Alfurayh 2000</a>; <a href="./references#CD007003-bbs2-0010" title="LuxonBA , MuirAJ , HeneghanMA . Safety and tolerability of pegylated interferon with or without low dose ribavirin for treatment of hepatitis C in hemodialysis patients [abstract no: 1281]. Hepatology2005;42(4 Suppl 1):703-4A. [CENTRAL: CN-00581669] ">Luxon 2005</a>; <a href="./references#CD007003-bbs2-0012" title="BasuP , ShahN , SirikiR , RahamanM , FarhatS . Telaprevir with adjusted dose of ribavirin in naive CHC-G1: efficacy and treatment in CHC in hemodialysis population target C trial: a placebo randomized control clinical trial [abstract no: 513]. American Journal of Gastroenterology2013;108(Suppl 1):S152. [EMBASE: 71220810]BasuP , SirikiR , ShahNJ , FarhatS , MittimaniK , AtluriS , et al. Telaprevir with adjusted dose of ribavirin in naive CHC-G1: Efficacy and treatment in CHC in hemodialysis population. Target C trial-A placebo randomized control clinical trial [abstract no: 517]. Gastroenterology2013;144(5 Suppl 1):S950. [EMBASE: 71119328]BasuPP , ShahNJ , Ashfique, FarhatS , SirikiR . Telaprevir with adjusted dose of ribavirin in naive CHC-G1: efficacy and treatment in CHC in hemodialysis population. Target C trial-a placebo randomized control clinical trial [abstract no: P196]. Surgical Endoscopy2014;28(1 Suppl):S362. [EMBASE: 71480241]BasuPP , ShahNJ , SirikiR , RahamanM . Telaprevir with adjusted dose of ribavirin in Naive CHC-G1: Efficacy and treatment in CHC in hemodialysis population. TARGET C Trial-a placebo randomized control clinical trial [abstract no: P-298]. Liver Transplantation2014;20(Suppl 1):S244. [EMBASE: 71562627]BasuPP , SinkiR , ShahNJ , FarhatS , MittimaniK , AtluriS , et al. Telaprevir with adjusted dose of ribavirin in naive CHC-G1: efficacy and treatment in CHC in hemodialysis population. TARGET C (RCT) [abstract no: 67]. Journal of Hepatology2013;58(Suppl 1):S30-1. [EMBASE: 71054340]">TARGET C 2013</a>; <a href="./references#CD007003-bbs2-0013" title="TuglularS , Karadayi h, KarakullukcuF , ErmanM , YukselS , CelikM , et al. Preliminary results of interferon compared to interferon combined with ribavirin in the treatment of chronic HCV in patients on chronic hemodialysis [abstract no: A2147]. Journal of the American Society of Nephrology2001;12(Program &amp; Abstracts):416-7A. [CENTRAL: CN-00543899] ">Tuglular 2001</a>), low to unclear in <a href="./references#CD007003-bbs2-0008" title="HuraibS , IqbalA , TanimuD , AbdullahA . Sustained virological and histological response with pretransplant interferon therapy in renal transplant patients with chronic viral hepatitis C. American Journal of Nephrology2001;21(6):435-40. [MEDLINE: 11799259]">Huraib 2001</a>, and high in <a href="./references#CD007003-bbs2-0002" title="CampistolJM , CasellasJ , CuevasX , LatorreB , MartínezJ , ModolJ , et al. Efficacy and tolerability of a-2b interferon in the treatment of virus C chronic hepatitis in an hemodialysis population [abstract no: 309] [Eficacia y tolerancia del interferon a-2b en el tratamiento de la hepatitis cronica por virus C (VHC) en la población en hemodialisis (HD)]. Nefrología1996;16(Suppl 1):80. [CENTRAL: CN-00400461] ">Campistol 1996</a>  </p> <p>See <a href="#CD007003-fig-0002">Figure 2</a> and <a href="#CD007003-fig-0003">Figure 3</a>. </p> <div class="figure" id="CD007003-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies" data-id="CD007003-fig-0002" src="/cdsr/doi/10.1002/14651858.CD007003.pub3/media/CDSR/CD007003/image_n/nCD007003-FIG-02.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies </p> </div> </div> </div> <div class="figure" id="CD007003-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study" data-id="CD007003-fig-0003" src="/cdsr/doi/10.1002/14651858.CD007003.pub3/media/CDSR/CD007003/image_n/nCD007003-FIG-03.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study </p> </div> </div> </div> <section id="CD007003-sec-0050"> <h4 class="title">Allocation</h4> <section id="CD007003-sec-0051"> <h5 class="title">Random sequence generation</h5> <p>Random sequence generation was judged to be at low risk of bias in five studies (<a href="./references#CD007003-bbs2-0004" title="ArduinoJM , ZhangB , JacksonB , RothD , BruchfeldA , khawajaS , et al. Impact of grazoprevir plus elbasvir on health-related quality of life in patients with hepatitis C virus genotype 1 infection and chronic kidney disease stages 4 and 5 [abstract no: TH-PO667]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):242A. BarrE , RothD , BruchfeldA , MartinP , NelsonDR , SilvaM , et al. Elbasvir (EBR)/grazoprevir (GZR) treatment of hepatitis C virus (HCV) infection in patients with chronic kidney disease stage 4/5: final results of the C-SURFER phase 3 study [abstract]. Journal of Gastroenterology &amp; Hepatology2016;31(Suppl 2):65-6. [EMBASE: 612983742]BruchfeldA , RothD , MartinP , NelsonD , StanislasP , LondonoMC , et al. Elbasvir/Grazoprevir (EBR/GZR) treatment of hepatitis C Virus (HCV) infection in patients with chronic kidney disease (CKD) stage 4/5: clinical, virological, and health-related quality of life outcomes in the C-SURFER study [abstract]. Swiss Medical Weekly2016;146(Suppl 221):23S. [EMBASE: 626845823]BruchfeldA , RothD , MartinP , NelsonDR , PolS , LondonoMC , et al. Elbasvir plus grazoprevir in patients with hepatitis C virus infection and stage 4-5 chronic kidney disease: clinical, virological, and health-related quality-of-life outcomes from a phase 3, multicentre, randomised, double-blind, placebo-controlled trial. The Lancet. Gastroenterology &amp; Hepatology2017;2(8):585-94. [MEDLINE: 28576451]BruchfeldA , RothD , NelsonD , LiapakisAM , SilvaM , MonsourH , et al. C-surfer: Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and chronic kidney disease [abstract no: FP267]. Nephrology Dialysis Transplantation2015;30(Suppl 3):iii156. [EMBASE: 72206687]RothD , BruchfeldA , MartinP , NelsonDR , SilvaM , MonsourH , et al. Grazoprevir(GZR)/elbasvir (EBR) treatment of hepatitis C virus (HCV) infection in patients with chronic kidney disease stage 4/5:final results of the C -SURFER phase 3 study [abstract no: SA-PO1100]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):B5. RothD , NelsonD , BruchfeldA , LiapakisA , SilvaM , MonsourHJ , et al. C-SURFER: grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and chronic kidney disease [abstract no: LP02]. Journal of Hepatology2015;62(Suppl 2):S263-4. [EMBASE: 71936662]RothD , NelsonDR , BruchfeldA , LiapakisA , SilvaM , MonsourH , et al. Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination phase 3 study [Erratum in: Lancet. 2015 Nov 7;386(10006):1824; PMID: 26843312]. Lancet2015;386(10003):1537-45. [MEDLINE: 26456905]">C‐SURFER 2015</a>; <a href="./references#CD007003-bbs2-0006" title="LiuCH , HuangCF , LiuCJ , DaiCY , LiangCC , HuangJF , et al. Peginterferon alfa-2a with or without low dose ribavirin for hemodialysis patients with hepatitis C virus genotype 2 infection: a randomized trial [abstract no: 1851]. Hepatology2013;58(4 Suppl 1):1096A. [EMBASE: 71237851]LiuCH , HuangCF , LiuCJ , DaiCY , LiangCC , HuangJF , et al. Pegylated interferon-alpha2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 1 receiving hemodialysis: a randomized trial. Annals of Internal Medicine2013;159(11):729-38. [MEDLINE: 24297189]LiuCH , LiangCC , SuTH , HungPH , TsaiHB , LiuCJ , et al. Peginterferon alfa-2a plus low dose ribavirin versus peginterferon alfa-2a monotherapy for dialysis patients with hepatitis C virus genotype 1 infection: a randomized trial [abstract no: 1722]. Hepatology2012;56(4 Suppl 1):993A. [EMBASE: 70943304]LiuCH , LiuCJ , HuangCF , LinJW , DaiCY , LiangCC , et al. Peginterferon alfa-2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 2 receiving haemodialysis: a randomised trial. Gut2015;64(2):303-11. [MEDLINE: 24747867]">HELPER 2013</a>; <a href="./references#CD007003-bbs2-0007" title="Peck-RadosavljevicM , BoletisJ , BesisikF , Lucia FerrazM , AlricL , SamuelD , et al. Low-dose peginterferon alfa-2A (40KD) (PEGASYS®) to treat hepatitis C infected end-stage renal disease patients undergoing haemodialysis: final study results [abstract no: 999]. Journal of Hepatology2008;48(Suppl 2):S374. [CENTRAL: CN-00653069] Peck-RadosavljevicM , BoletisJ , BesisikF , Lucia FerrazM , AlricL , SamuelD , et al. Low-dose peginterferon alfa-2a is safe and produces a sustained virologic response in patients with chronic hepatitis C and end-stage renal disease. Clinical Gastroenterology &amp; Hepatology2011;9(3):242-8. [MEDLINE: 21056689]Peck-RadosavljevicM , BoletisJ , BesisikF , Lucia FerrazM , AlricL , SamuelD , et al. Use of low-dose peginterferon alfa-2a (40 kD) (Pegasys) to treat hepatitis C infected end-stage renal disease patients undergoing haemodialysis: interim results from a randomised study [abstract no: 628]. Journal of Hepatology2007;46(Suppl 1):S237-8. [CENTRAL: CN-00716095] ">HELPS 2011</a>; <a href="./references#CD007003-bbs2-0009" title="LiuCH , LiangCC , LinJW , ChenSI , TsaiHB , ChangCS , et al. Pegylated interferon alpha-2a versus standard interferon alpha-2a for treatment-naive dialysis patients with chronic hepatitis C: a randomised study. Gut2008;57(4):525-30. [MEDLINE: 17881538]">Liu 2008a</a>; <a href="./references#CD007003-bbs2-0011" title="RussoMW , GhalibR , SigalS , JoshiV . Randomized trial of pegylated interferon alpha-2b monotherapy in haemodialysis patients with chronic hepatitis C. Nephrology Dialysis Transplantation2006;21(2):437-43. [MEDLINE: 16234288]RussoMW , GhalibR , SigalSH , JoshiV , DetwilerR , AndreoniK , et al. A multi-center randomized trial of pegylated interferon alfa-2B monotherapy (PEG-INTRON) in patients with chronic hepatitis C and end stage kidney disease on dialysis [abstract no: 540]. Hepatology2004;40(4 Suppl 1):399A. [CENTRAL: CN-00507218] ">Russo 2006</a>); randomisation was done by computer‐generated table or permuted block in four studies (<a href="./references#CD007003-bbs2-0006" title="LiuCH , HuangCF , LiuCJ , DaiCY , LiangCC , HuangJF , et al. Peginterferon alfa-2a with or without low dose ribavirin for hemodialysis patients with hepatitis C virus genotype 2 infection: a randomized trial [abstract no: 1851]. Hepatology2013;58(4 Suppl 1):1096A. [EMBASE: 71237851]LiuCH , HuangCF , LiuCJ , DaiCY , LiangCC , HuangJF , et al. Pegylated interferon-alpha2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 1 receiving hemodialysis: a randomized trial. Annals of Internal Medicine2013;159(11):729-38. [MEDLINE: 24297189]LiuCH , LiangCC , SuTH , HungPH , TsaiHB , LiuCJ , et al. Peginterferon alfa-2a plus low dose ribavirin versus peginterferon alfa-2a monotherapy for dialysis patients with hepatitis C virus genotype 1 infection: a randomized trial [abstract no: 1722]. Hepatology2012;56(4 Suppl 1):993A. [EMBASE: 70943304]LiuCH , LiuCJ , HuangCF , LinJW , DaiCY , LiangCC , et al. Peginterferon alfa-2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 2 receiving haemodialysis: a randomised trial. Gut2015;64(2):303-11. [MEDLINE: 24747867]">HELPER 2013</a>; <a href="./references#CD007003-bbs2-0007" title="Peck-RadosavljevicM , BoletisJ , BesisikF , Lucia FerrazM , AlricL , SamuelD , et al. Low-dose peginterferon alfa-2A (40KD) (PEGASYS®) to treat hepatitis C infected end-stage renal disease patients undergoing haemodialysis: final study results [abstract no: 999]. Journal of Hepatology2008;48(Suppl 2):S374. [CENTRAL: CN-00653069] Peck-RadosavljevicM , BoletisJ , BesisikF , Lucia FerrazM , AlricL , SamuelD , et al. Low-dose peginterferon alfa-2a is safe and produces a sustained virologic response in patients with chronic hepatitis C and end-stage renal disease. Clinical Gastroenterology &amp; Hepatology2011;9(3):242-8. [MEDLINE: 21056689]Peck-RadosavljevicM , BoletisJ , BesisikF , Lucia FerrazM , AlricL , SamuelD , et al. Use of low-dose peginterferon alfa-2a (40 kD) (Pegasys) to treat hepatitis C infected end-stage renal disease patients undergoing haemodialysis: interim results from a randomised study [abstract no: 628]. Journal of Hepatology2007;46(Suppl 1):S237-8. [CENTRAL: CN-00716095] ">HELPS 2011</a>; <a href="./references#CD007003-bbs2-0009" title="LiuCH , LiangCC , LinJW , ChenSI , TsaiHB , ChangCS , et al. Pegylated interferon alpha-2a versus standard interferon alpha-2a for treatment-naive dialysis patients with chronic hepatitis C: a randomised study. Gut2008;57(4):525-30. [MEDLINE: 17881538]">Liu 2008a</a>; <a href="./references#CD007003-bbs2-0011" title="RussoMW , GhalibR , SigalS , JoshiV . Randomized trial of pegylated interferon alpha-2b monotherapy in haemodialysis patients with chronic hepatitis C. Nephrology Dialysis Transplantation2006;21(2):437-43. [MEDLINE: 16234288]RussoMW , GhalibR , SigalSH , JoshiV , DetwilerR , AndreoniK , et al. A multi-center randomized trial of pegylated interferon alfa-2B monotherapy (PEG-INTRON) in patients with chronic hepatitis C and end stage kidney disease on dialysis [abstract no: 540]. Hepatology2004;40(4 Suppl 1):399A. [CENTRAL: CN-00507218] ">Russo 2006</a>), and centralised in three (<a href="./references#CD007003-bbs2-0004" title="ArduinoJM , ZhangB , JacksonB , RothD , BruchfeldA , khawajaS , et al. Impact of grazoprevir plus elbasvir on health-related quality of life in patients with hepatitis C virus genotype 1 infection and chronic kidney disease stages 4 and 5 [abstract no: TH-PO667]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):242A. BarrE , RothD , BruchfeldA , MartinP , NelsonDR , SilvaM , et al. Elbasvir (EBR)/grazoprevir (GZR) treatment of hepatitis C virus (HCV) infection in patients with chronic kidney disease stage 4/5: final results of the C-SURFER phase 3 study [abstract]. Journal of Gastroenterology &amp; Hepatology2016;31(Suppl 2):65-6. [EMBASE: 612983742]BruchfeldA , RothD , MartinP , NelsonD , StanislasP , LondonoMC , et al. Elbasvir/Grazoprevir (EBR/GZR) treatment of hepatitis C Virus (HCV) infection in patients with chronic kidney disease (CKD) stage 4/5: clinical, virological, and health-related quality of life outcomes in the C-SURFER study [abstract]. Swiss Medical Weekly2016;146(Suppl 221):23S. [EMBASE: 626845823]BruchfeldA , RothD , MartinP , NelsonDR , PolS , LondonoMC , et al. Elbasvir plus grazoprevir in patients with hepatitis C virus infection and stage 4-5 chronic kidney disease: clinical, virological, and health-related quality-of-life outcomes from a phase 3, multicentre, randomised, double-blind, placebo-controlled trial. The Lancet. Gastroenterology &amp; Hepatology2017;2(8):585-94. [MEDLINE: 28576451]BruchfeldA , RothD , NelsonD , LiapakisAM , SilvaM , MonsourH , et al. C-surfer: Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and chronic kidney disease [abstract no: FP267]. Nephrology Dialysis Transplantation2015;30(Suppl 3):iii156. [EMBASE: 72206687]RothD , BruchfeldA , MartinP , NelsonDR , SilvaM , MonsourH , et al. Grazoprevir(GZR)/elbasvir (EBR) treatment of hepatitis C virus (HCV) infection in patients with chronic kidney disease stage 4/5:final results of the C -SURFER phase 3 study [abstract no: SA-PO1100]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):B5. RothD , NelsonD , BruchfeldA , LiapakisA , SilvaM , MonsourHJ , et al. C-SURFER: grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and chronic kidney disease [abstract no: LP02]. Journal of Hepatology2015;62(Suppl 2):S263-4. [EMBASE: 71936662]RothD , NelsonDR , BruchfeldA , LiapakisA , SilvaM , MonsourH , et al. Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination phase 3 study [Erratum in: Lancet. 2015 Nov 7;386(10006):1824; PMID: 26843312]. Lancet2015;386(10003):1537-45. [MEDLINE: 26456905]">C‐SURFER 2015</a>; <a href="./references#CD007003-bbs2-0007" title="Peck-RadosavljevicM , BoletisJ , BesisikF , Lucia FerrazM , AlricL , SamuelD , et al. Low-dose peginterferon alfa-2A (40KD) (PEGASYS®) to treat hepatitis C infected end-stage renal disease patients undergoing haemodialysis: final study results [abstract no: 999]. Journal of Hepatology2008;48(Suppl 2):S374. [CENTRAL: CN-00653069] Peck-RadosavljevicM , BoletisJ , BesisikF , Lucia FerrazM , AlricL , SamuelD , et al. Low-dose peginterferon alfa-2a is safe and produces a sustained virologic response in patients with chronic hepatitis C and end-stage renal disease. Clinical Gastroenterology &amp; Hepatology2011;9(3):242-8. [MEDLINE: 21056689]Peck-RadosavljevicM , BoletisJ , BesisikF , Lucia FerrazM , AlricL , SamuelD , et al. Use of low-dose peginterferon alfa-2a (40 kD) (Pegasys) to treat hepatitis C infected end-stage renal disease patients undergoing haemodialysis: interim results from a randomised study [abstract no: 628]. Journal of Hepatology2007;46(Suppl 1):S237-8. [CENTRAL: CN-00716095] ">HELPS 2011</a>; <a href="./references#CD007003-bbs2-0011" title="RussoMW , GhalibR , SigalS , JoshiV . Randomized trial of pegylated interferon alpha-2b monotherapy in haemodialysis patients with chronic hepatitis C. Nephrology Dialysis Transplantation2006;21(2):437-43. [MEDLINE: 16234288]RussoMW , GhalibR , SigalSH , JoshiV , DetwilerR , AndreoniK , et al. A multi-center randomized trial of pegylated interferon alfa-2B monotherapy (PEG-INTRON) in patients with chronic hepatitis C and end stage kidney disease on dialysis [abstract no: 540]. Hepatology2004;40(4 Suppl 1):399A. [CENTRAL: CN-00507218] ">Russo 2006</a>). The remaining eight studies were judged to have an unclear risk of bias (<a href="./references#CD007003-bbs2-0001" title="AlfurayhO , ChaabanA , PallA , Al MutawaN , EllisM , Al MeshariK , et al. Long-term follow up of haemodialysis (HD) patients with chronic hepatitis C (HCV) infection - favorable outcome with a-interferon (IFN) followed by kidney transplantation [abstract no: M221]. Nephrology Dialysis Transplantation2002;17(Suppl 1):110. [CENTRAL: CN-00509051] AlfurayhO , ChaabanA , PallA , EllisM , ChaudryT , AlmeshariK . Randomised controlled trial of interferon-alpha (IFNalpha) in patients with chronic hepatitis C (HCV) on haemodialysis (HD) [abstract]. Nephrology Dialysis Transplantation2000;15(9):A106. [CENTRAL: CN-00497910] AlfurayhOI , ChaabanAM , PallAA , EllisME , AlmeshariK , Al QuaizMN , et al. IFN-alpha for chronic hepatitis C infection (HCV) in haemodialysis (HD) patients - a prospective, randomised, controlled study [abstract]. Journal of the American Society of Nephrology2000;11(Sept):255A. [CENTRAL: CN-00517117] ">Alfurayh 2000</a>; <a href="./references#CD007003-bbs2-0002" title="CampistolJM , CasellasJ , CuevasX , LatorreB , MartínezJ , ModolJ , et al. Efficacy and tolerability of a-2b interferon in the treatment of virus C chronic hepatitis in an hemodialysis population [abstract no: 309] [Eficacia y tolerancia del interferon a-2b en el tratamiento de la hepatitis cronica por virus C (VHC) en la población en hemodialisis (HD)]. Nefrología1996;16(Suppl 1):80. [CENTRAL: CN-00400461] ">Campistol 1996</a>; <a href="./references#CD007003-bbs2-0003" title="CampistolJM , EsforzadoN , MartinezJ , RoselloL , VecianaL , ModolJ , et al. Efficacy and tolerance of interferon-alpha(2b) in the treatment of chronic hepatitis C virus infection in haemodialysis patients. Pre- and post-renal transplantation assessment. Nephrology Dialysis Transplantation1999;14(11):2704-9. [MEDLINE: 10534516]">Campistol 1999a</a>; <a href="./references#CD007003-bbs2-0005" title="FernandezJL , RendoP , delPinoN , Nephrologists' Group for the Study of HCV Infection, ViolaL . A double-blind controlled trial of recombinant interferon alfa in hemodialysis patients with chronic hepatitis C [abstract]. Hepatology1995;22(4 (Pt 2)):116A. [CENTRAL: CN-00220972] FernandezJL , RendoP , delPinoN , Nephrologists' Group for the Study of HCV, ViolaL , CusumanoA . A controlled trial of interferon alfa 2b in hemodialysis patients with chronic hepatitis C [abstract no: A0989]. Journal of the American Society of Nephrology1996;7(9):1446. [CENTRAL: CN-00445323] FernandezJL , RendoP , delPinoN , ViolaL . A double-blind controlled trial of recombinant interferon-alpha 2b in haemodialysis patients with chronic hepatitis C virus infection and abnormal aminotransferase levels. Nephrologists' Group for the Study of HCV infection. Journal of Viral Hepatitis1997;4(2):113-9. [MEDLINE: 9097267]">Fernandez 1997</a>; <a href="./references#CD007003-bbs2-0008" title="HuraibS , IqbalA , TanimuD , AbdullahA . Sustained virological and histological response with pretransplant interferon therapy in renal transplant patients with chronic viral hepatitis C. American Journal of Nephrology2001;21(6):435-40. [MEDLINE: 11799259]">Huraib 2001</a>; <a href="./references#CD007003-bbs2-0010" title="LuxonBA , MuirAJ , HeneghanMA . Safety and tolerability of pegylated interferon with or without low dose ribavirin for treatment of hepatitis C in hemodialysis patients [abstract no: 1281]. Hepatology2005;42(4 Suppl 1):703-4A. [CENTRAL: CN-00581669] ">Luxon 2005</a>; <a href="./references#CD007003-bbs2-0012" title="BasuP , ShahN , SirikiR , RahamanM , FarhatS . Telaprevir with adjusted dose of ribavirin in naive CHC-G1: efficacy and treatment in CHC in hemodialysis population target C trial: a placebo randomized control clinical trial [abstract no: 513]. American Journal of Gastroenterology2013;108(Suppl 1):S152. [EMBASE: 71220810]BasuP , SirikiR , ShahNJ , FarhatS , MittimaniK , AtluriS , et al. Telaprevir with adjusted dose of ribavirin in naive CHC-G1: Efficacy and treatment in CHC in hemodialysis population. Target C trial-A placebo randomized control clinical trial [abstract no: 517]. Gastroenterology2013;144(5 Suppl 1):S950. [EMBASE: 71119328]BasuPP , ShahNJ , Ashfique, FarhatS , SirikiR . Telaprevir with adjusted dose of ribavirin in naive CHC-G1: efficacy and treatment in CHC in hemodialysis population. Target C trial-a placebo randomized control clinical trial [abstract no: P196]. Surgical Endoscopy2014;28(1 Suppl):S362. [EMBASE: 71480241]BasuPP , ShahNJ , SirikiR , RahamanM . Telaprevir with adjusted dose of ribavirin in Naive CHC-G1: Efficacy and treatment in CHC in hemodialysis population. TARGET C Trial-a placebo randomized control clinical trial [abstract no: P-298]. Liver Transplantation2014;20(Suppl 1):S244. [EMBASE: 71562627]BasuPP , SinkiR , ShahNJ , FarhatS , MittimaniK , AtluriS , et al. Telaprevir with adjusted dose of ribavirin in naive CHC-G1: efficacy and treatment in CHC in hemodialysis population. TARGET C (RCT) [abstract no: 67]. Journal of Hepatology2013;58(Suppl 1):S30-1. [EMBASE: 71054340]">TARGET C 2013</a>; <a href="./references#CD007003-bbs2-0013" title="TuglularS , Karadayi h, KarakullukcuF , ErmanM , YukselS , CelikM , et al. Preliminary results of interferon compared to interferon combined with ribavirin in the treatment of chronic HCV in patients on chronic hemodialysis [abstract no: A2147]. Journal of the American Society of Nephrology2001;12(Program &amp; Abstracts):416-7A. [CENTRAL: CN-00543899] ">Tuglular 2001</a>). </p> </section> <section id="CD007003-sec-0052"> <h5 class="title">Allocation concealment</h5> <p>Allocation concealment was judged to be at high risk of bias in two studies (<a href="./references#CD007003-bbs2-0002" title="CampistolJM , CasellasJ , CuevasX , LatorreB , MartínezJ , ModolJ , et al. Efficacy and tolerability of a-2b interferon in the treatment of virus C chronic hepatitis in an hemodialysis population [abstract no: 309] [Eficacia y tolerancia del interferon a-2b en el tratamiento de la hepatitis cronica por virus C (VHC) en la población en hemodialisis (HD)]. Nefrología1996;16(Suppl 1):80. [CENTRAL: CN-00400461] ">Campistol 1996</a>; <a href="./references#CD007003-bbs2-0003" title="CampistolJM , EsforzadoN , MartinezJ , RoselloL , VecianaL , ModolJ , et al. Efficacy and tolerance of interferon-alpha(2b) in the treatment of chronic hepatitis C virus infection in haemodialysis patients. Pre- and post-renal transplantation assessment. Nephrology Dialysis Transplantation1999;14(11):2704-9. [MEDLINE: 10534516]">Campistol 1999a</a>), low in four studies (<a href="./references#CD007003-bbs2-0004" title="ArduinoJM , ZhangB , JacksonB , RothD , BruchfeldA , khawajaS , et al. Impact of grazoprevir plus elbasvir on health-related quality of life in patients with hepatitis C virus genotype 1 infection and chronic kidney disease stages 4 and 5 [abstract no: TH-PO667]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):242A. BarrE , RothD , BruchfeldA , MartinP , NelsonDR , SilvaM , et al. Elbasvir (EBR)/grazoprevir (GZR) treatment of hepatitis C virus (HCV) infection in patients with chronic kidney disease stage 4/5: final results of the C-SURFER phase 3 study [abstract]. Journal of Gastroenterology &amp; Hepatology2016;31(Suppl 2):65-6. [EMBASE: 612983742]BruchfeldA , RothD , MartinP , NelsonD , StanislasP , LondonoMC , et al. Elbasvir/Grazoprevir (EBR/GZR) treatment of hepatitis C Virus (HCV) infection in patients with chronic kidney disease (CKD) stage 4/5: clinical, virological, and health-related quality of life outcomes in the C-SURFER study [abstract]. Swiss Medical Weekly2016;146(Suppl 221):23S. [EMBASE: 626845823]BruchfeldA , RothD , MartinP , NelsonDR , PolS , LondonoMC , et al. Elbasvir plus grazoprevir in patients with hepatitis C virus infection and stage 4-5 chronic kidney disease: clinical, virological, and health-related quality-of-life outcomes from a phase 3, multicentre, randomised, double-blind, placebo-controlled trial. The Lancet. Gastroenterology &amp; Hepatology2017;2(8):585-94. [MEDLINE: 28576451]BruchfeldA , RothD , NelsonD , LiapakisAM , SilvaM , MonsourH , et al. C-surfer: Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and chronic kidney disease [abstract no: FP267]. Nephrology Dialysis Transplantation2015;30(Suppl 3):iii156. [EMBASE: 72206687]RothD , BruchfeldA , MartinP , NelsonDR , SilvaM , MonsourH , et al. Grazoprevir(GZR)/elbasvir (EBR) treatment of hepatitis C virus (HCV) infection in patients with chronic kidney disease stage 4/5:final results of the C -SURFER phase 3 study [abstract no: SA-PO1100]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):B5. RothD , NelsonD , BruchfeldA , LiapakisA , SilvaM , MonsourHJ , et al. C-SURFER: grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and chronic kidney disease [abstract no: LP02]. Journal of Hepatology2015;62(Suppl 2):S263-4. [EMBASE: 71936662]RothD , NelsonDR , BruchfeldA , LiapakisA , SilvaM , MonsourH , et al. Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination phase 3 study [Erratum in: Lancet. 2015 Nov 7;386(10006):1824; PMID: 26843312]. Lancet2015;386(10003):1537-45. [MEDLINE: 26456905]">C‐SURFER 2015</a>; <a href="./references#CD007003-bbs2-0007" title="Peck-RadosavljevicM , BoletisJ , BesisikF , Lucia FerrazM , AlricL , SamuelD , et al. Low-dose peginterferon alfa-2A (40KD) (PEGASYS®) to treat hepatitis C infected end-stage renal disease patients undergoing haemodialysis: final study results [abstract no: 999]. Journal of Hepatology2008;48(Suppl 2):S374. [CENTRAL: CN-00653069] Peck-RadosavljevicM , BoletisJ , BesisikF , Lucia FerrazM , AlricL , SamuelD , et al. Low-dose peginterferon alfa-2a is safe and produces a sustained virologic response in patients with chronic hepatitis C and end-stage renal disease. Clinical Gastroenterology &amp; Hepatology2011;9(3):242-8. [MEDLINE: 21056689]Peck-RadosavljevicM , BoletisJ , BesisikF , Lucia FerrazM , AlricL , SamuelD , et al. Use of low-dose peginterferon alfa-2a (40 kD) (Pegasys) to treat hepatitis C infected end-stage renal disease patients undergoing haemodialysis: interim results from a randomised study [abstract no: 628]. Journal of Hepatology2007;46(Suppl 1):S237-8. [CENTRAL: CN-00716095] ">HELPS 2011</a>; <a href="./references#CD007003-bbs2-0006" title="LiuCH , HuangCF , LiuCJ , DaiCY , LiangCC , HuangJF , et al. Peginterferon alfa-2a with or without low dose ribavirin for hemodialysis patients with hepatitis C virus genotype 2 infection: a randomized trial [abstract no: 1851]. Hepatology2013;58(4 Suppl 1):1096A. [EMBASE: 71237851]LiuCH , HuangCF , LiuCJ , DaiCY , LiangCC , HuangJF , et al. Pegylated interferon-alpha2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 1 receiving hemodialysis: a randomized trial. Annals of Internal Medicine2013;159(11):729-38. [MEDLINE: 24297189]LiuCH , LiangCC , SuTH , HungPH , TsaiHB , LiuCJ , et al. Peginterferon alfa-2a plus low dose ribavirin versus peginterferon alfa-2a monotherapy for dialysis patients with hepatitis C virus genotype 1 infection: a randomized trial [abstract no: 1722]. Hepatology2012;56(4 Suppl 1):993A. [EMBASE: 70943304]LiuCH , LiuCJ , HuangCF , LinJW , DaiCY , LiangCC , et al. Peginterferon alfa-2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 2 receiving haemodialysis: a randomised trial. Gut2015;64(2):303-11. [MEDLINE: 24747867]">HELPER 2013</a>; <a href="./references#CD007003-bbs2-0011" title="RussoMW , GhalibR , SigalS , JoshiV . Randomized trial of pegylated interferon alpha-2b monotherapy in haemodialysis patients with chronic hepatitis C. Nephrology Dialysis Transplantation2006;21(2):437-43. [MEDLINE: 16234288]RussoMW , GhalibR , SigalSH , JoshiV , DetwilerR , AndreoniK , et al. A multi-center randomized trial of pegylated interferon alfa-2B monotherapy (PEG-INTRON) in patients with chronic hepatitis C and end stage kidney disease on dialysis [abstract no: 540]. Hepatology2004;40(4 Suppl 1):399A. [CENTRAL: CN-00507218] ">Russo 2006</a>), and unclear in the remaining seven studies (<a href="./references#CD007003-bbs2-0001" title="AlfurayhO , ChaabanA , PallA , Al MutawaN , EllisM , Al MeshariK , et al. Long-term follow up of haemodialysis (HD) patients with chronic hepatitis C (HCV) infection - favorable outcome with a-interferon (IFN) followed by kidney transplantation [abstract no: M221]. Nephrology Dialysis Transplantation2002;17(Suppl 1):110. [CENTRAL: CN-00509051] AlfurayhO , ChaabanA , PallA , EllisM , ChaudryT , AlmeshariK . Randomised controlled trial of interferon-alpha (IFNalpha) in patients with chronic hepatitis C (HCV) on haemodialysis (HD) [abstract]. Nephrology Dialysis Transplantation2000;15(9):A106. [CENTRAL: CN-00497910] AlfurayhOI , ChaabanAM , PallAA , EllisME , AlmeshariK , Al QuaizMN , et al. IFN-alpha for chronic hepatitis C infection (HCV) in haemodialysis (HD) patients - a prospective, randomised, controlled study [abstract]. Journal of the American Society of Nephrology2000;11(Sept):255A. [CENTRAL: CN-00517117] ">Alfurayh 2000</a>; <a href="./references#CD007003-bbs2-0005" title="FernandezJL , RendoP , delPinoN , Nephrologists' Group for the Study of HCV Infection, ViolaL . A double-blind controlled trial of recombinant interferon alfa in hemodialysis patients with chronic hepatitis C [abstract]. Hepatology1995;22(4 (Pt 2)):116A. [CENTRAL: CN-00220972] FernandezJL , RendoP , delPinoN , Nephrologists' Group for the Study of HCV, ViolaL , CusumanoA . A controlled trial of interferon alfa 2b in hemodialysis patients with chronic hepatitis C [abstract no: A0989]. Journal of the American Society of Nephrology1996;7(9):1446. [CENTRAL: CN-00445323] FernandezJL , RendoP , delPinoN , ViolaL . A double-blind controlled trial of recombinant interferon-alpha 2b in haemodialysis patients with chronic hepatitis C virus infection and abnormal aminotransferase levels. Nephrologists' Group for the Study of HCV infection. Journal of Viral Hepatitis1997;4(2):113-9. [MEDLINE: 9097267]">Fernandez 1997</a>; <a href="./references#CD007003-bbs2-0008" title="HuraibS , IqbalA , TanimuD , AbdullahA . Sustained virological and histological response with pretransplant interferon therapy in renal transplant patients with chronic viral hepatitis C. American Journal of Nephrology2001;21(6):435-40. [MEDLINE: 11799259]">Huraib 2001</a>; <a href="./references#CD007003-bbs2-0009" title="LiuCH , LiangCC , LinJW , ChenSI , TsaiHB , ChangCS , et al. Pegylated interferon alpha-2a versus standard interferon alpha-2a for treatment-naive dialysis patients with chronic hepatitis C: a randomised study. Gut2008;57(4):525-30. [MEDLINE: 17881538]">Liu 2008a</a>; <a href="./references#CD007003-bbs2-0010" title="LuxonBA , MuirAJ , HeneghanMA . Safety and tolerability of pegylated interferon with or without low dose ribavirin for treatment of hepatitis C in hemodialysis patients [abstract no: 1281]. Hepatology2005;42(4 Suppl 1):703-4A. [CENTRAL: CN-00581669] ">Luxon 2005</a>; <a href="./references#CD007003-bbs2-0012" title="BasuP , ShahN , SirikiR , RahamanM , FarhatS . Telaprevir with adjusted dose of ribavirin in naive CHC-G1: efficacy and treatment in CHC in hemodialysis population target C trial: a placebo randomized control clinical trial [abstract no: 513]. American Journal of Gastroenterology2013;108(Suppl 1):S152. [EMBASE: 71220810]BasuP , SirikiR , ShahNJ , FarhatS , MittimaniK , AtluriS , et al. Telaprevir with adjusted dose of ribavirin in naive CHC-G1: Efficacy and treatment in CHC in hemodialysis population. Target C trial-A placebo randomized control clinical trial [abstract no: 517]. Gastroenterology2013;144(5 Suppl 1):S950. [EMBASE: 71119328]BasuPP , ShahNJ , Ashfique, FarhatS , SirikiR . Telaprevir with adjusted dose of ribavirin in naive CHC-G1: efficacy and treatment in CHC in hemodialysis population. Target C trial-a placebo randomized control clinical trial [abstract no: P196]. Surgical Endoscopy2014;28(1 Suppl):S362. [EMBASE: 71480241]BasuPP , ShahNJ , SirikiR , RahamanM . Telaprevir with adjusted dose of ribavirin in Naive CHC-G1: Efficacy and treatment in CHC in hemodialysis population. TARGET C Trial-a placebo randomized control clinical trial [abstract no: P-298]. Liver Transplantation2014;20(Suppl 1):S244. [EMBASE: 71562627]BasuPP , SinkiR , ShahNJ , FarhatS , MittimaniK , AtluriS , et al. Telaprevir with adjusted dose of ribavirin in naive CHC-G1: efficacy and treatment in CHC in hemodialysis population. TARGET C (RCT) [abstract no: 67]. Journal of Hepatology2013;58(Suppl 1):S30-1. [EMBASE: 71054340]">TARGET C 2013</a>; <a href="./references#CD007003-bbs2-0013" title="TuglularS , Karadayi h, KarakullukcuF , ErmanM , YukselS , CelikM , et al. Preliminary results of interferon compared to interferon combined with ribavirin in the treatment of chronic HCV in patients on chronic hemodialysis [abstract no: A2147]. Journal of the American Society of Nephrology2001;12(Program &amp; Abstracts):416-7A. [CENTRAL: CN-00543899] ">Tuglular 2001</a>). </p> </section> </section> <section id="CD007003-sec-0053"> <h4 class="title">Blinding</h4> <section id="CD007003-sec-0054"> <h5 class="title">Performance bias</h5> <p>Five studies were open‐label and were judged to be at high risk of bias (<a href="./references#CD007003-bbs2-0002" title="CampistolJM , CasellasJ , CuevasX , LatorreB , MartínezJ , ModolJ , et al. Efficacy and tolerability of a-2b interferon in the treatment of virus C chronic hepatitis in an hemodialysis population [abstract no: 309] [Eficacia y tolerancia del interferon a-2b en el tratamiento de la hepatitis cronica por virus C (VHC) en la población en hemodialisis (HD)]. Nefrología1996;16(Suppl 1):80. [CENTRAL: CN-00400461] ">Campistol 1996</a>; <a href="./references#CD007003-bbs2-0003" title="CampistolJM , EsforzadoN , MartinezJ , RoselloL , VecianaL , ModolJ , et al. Efficacy and tolerance of interferon-alpha(2b) in the treatment of chronic hepatitis C virus infection in haemodialysis patients. Pre- and post-renal transplantation assessment. Nephrology Dialysis Transplantation1999;14(11):2704-9. [MEDLINE: 10534516]">Campistol 1999a</a>; <a href="./references#CD007003-bbs2-0006" title="LiuCH , HuangCF , LiuCJ , DaiCY , LiangCC , HuangJF , et al. Peginterferon alfa-2a with or without low dose ribavirin for hemodialysis patients with hepatitis C virus genotype 2 infection: a randomized trial [abstract no: 1851]. Hepatology2013;58(4 Suppl 1):1096A. [EMBASE: 71237851]LiuCH , HuangCF , LiuCJ , DaiCY , LiangCC , HuangJF , et al. Pegylated interferon-alpha2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 1 receiving hemodialysis: a randomized trial. Annals of Internal Medicine2013;159(11):729-38. [MEDLINE: 24297189]LiuCH , LiangCC , SuTH , HungPH , TsaiHB , LiuCJ , et al. Peginterferon alfa-2a plus low dose ribavirin versus peginterferon alfa-2a monotherapy for dialysis patients with hepatitis C virus genotype 1 infection: a randomized trial [abstract no: 1722]. Hepatology2012;56(4 Suppl 1):993A. [EMBASE: 70943304]LiuCH , LiuCJ , HuangCF , LinJW , DaiCY , LiangCC , et al. Peginterferon alfa-2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 2 receiving haemodialysis: a randomised trial. Gut2015;64(2):303-11. [MEDLINE: 24747867]">HELPER 2013</a>; <a href="./references#CD007003-bbs2-0007" title="Peck-RadosavljevicM , BoletisJ , BesisikF , Lucia FerrazM , AlricL , SamuelD , et al. Low-dose peginterferon alfa-2A (40KD) (PEGASYS®) to treat hepatitis C infected end-stage renal disease patients undergoing haemodialysis: final study results [abstract no: 999]. Journal of Hepatology2008;48(Suppl 2):S374. [CENTRAL: CN-00653069] Peck-RadosavljevicM , BoletisJ , BesisikF , Lucia FerrazM , AlricL , SamuelD , et al. Low-dose peginterferon alfa-2a is safe and produces a sustained virologic response in patients with chronic hepatitis C and end-stage renal disease. Clinical Gastroenterology &amp; Hepatology2011;9(3):242-8. [MEDLINE: 21056689]Peck-RadosavljevicM , BoletisJ , BesisikF , Lucia FerrazM , AlricL , SamuelD , et al. Use of low-dose peginterferon alfa-2a (40 kD) (Pegasys) to treat hepatitis C infected end-stage renal disease patients undergoing haemodialysis: interim results from a randomised study [abstract no: 628]. Journal of Hepatology2007;46(Suppl 1):S237-8. [CENTRAL: CN-00716095] ">HELPS 2011</a>; <a href="./references#CD007003-bbs2-0011" title="RussoMW , GhalibR , SigalS , JoshiV . Randomized trial of pegylated interferon alpha-2b monotherapy in haemodialysis patients with chronic hepatitis C. Nephrology Dialysis Transplantation2006;21(2):437-43. [MEDLINE: 16234288]RussoMW , GhalibR , SigalSH , JoshiV , DetwilerR , AndreoniK , et al. A multi-center randomized trial of pegylated interferon alfa-2B monotherapy (PEG-INTRON) in patients with chronic hepatitis C and end stage kidney disease on dialysis [abstract no: 540]. Hepatology2004;40(4 Suppl 1):399A. [CENTRAL: CN-00507218] ">Russo 2006</a>). Three studies were judged to be at low risk of bias (<a href="./references#CD007003-bbs2-0004" title="ArduinoJM , ZhangB , JacksonB , RothD , BruchfeldA , khawajaS , et al. Impact of grazoprevir plus elbasvir on health-related quality of life in patients with hepatitis C virus genotype 1 infection and chronic kidney disease stages 4 and 5 [abstract no: TH-PO667]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):242A. BarrE , RothD , BruchfeldA , MartinP , NelsonDR , SilvaM , et al. Elbasvir (EBR)/grazoprevir (GZR) treatment of hepatitis C virus (HCV) infection in patients with chronic kidney disease stage 4/5: final results of the C-SURFER phase 3 study [abstract]. Journal of Gastroenterology &amp; Hepatology2016;31(Suppl 2):65-6. [EMBASE: 612983742]BruchfeldA , RothD , MartinP , NelsonD , StanislasP , LondonoMC , et al. Elbasvir/Grazoprevir (EBR/GZR) treatment of hepatitis C Virus (HCV) infection in patients with chronic kidney disease (CKD) stage 4/5: clinical, virological, and health-related quality of life outcomes in the C-SURFER study [abstract]. Swiss Medical Weekly2016;146(Suppl 221):23S. [EMBASE: 626845823]BruchfeldA , RothD , MartinP , NelsonDR , PolS , LondonoMC , et al. Elbasvir plus grazoprevir in patients with hepatitis C virus infection and stage 4-5 chronic kidney disease: clinical, virological, and health-related quality-of-life outcomes from a phase 3, multicentre, randomised, double-blind, placebo-controlled trial. The Lancet. Gastroenterology &amp; Hepatology2017;2(8):585-94. [MEDLINE: 28576451]BruchfeldA , RothD , NelsonD , LiapakisAM , SilvaM , MonsourH , et al. C-surfer: Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and chronic kidney disease [abstract no: FP267]. Nephrology Dialysis Transplantation2015;30(Suppl 3):iii156. [EMBASE: 72206687]RothD , BruchfeldA , MartinP , NelsonDR , SilvaM , MonsourH , et al. Grazoprevir(GZR)/elbasvir (EBR) treatment of hepatitis C virus (HCV) infection in patients with chronic kidney disease stage 4/5:final results of the C -SURFER phase 3 study [abstract no: SA-PO1100]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):B5. RothD , NelsonD , BruchfeldA , LiapakisA , SilvaM , MonsourHJ , et al. C-SURFER: grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and chronic kidney disease [abstract no: LP02]. Journal of Hepatology2015;62(Suppl 2):S263-4. [EMBASE: 71936662]RothD , NelsonDR , BruchfeldA , LiapakisA , SilvaM , MonsourH , et al. Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination phase 3 study [Erratum in: Lancet. 2015 Nov 7;386(10006):1824; PMID: 26843312]. Lancet2015;386(10003):1537-45. [MEDLINE: 26456905]">C‐SURFER 2015</a>; <a href="./references#CD007003-bbs2-0005" title="FernandezJL , RendoP , delPinoN , Nephrologists' Group for the Study of HCV Infection, ViolaL . A double-blind controlled trial of recombinant interferon alfa in hemodialysis patients with chronic hepatitis C [abstract]. Hepatology1995;22(4 (Pt 2)):116A. [CENTRAL: CN-00220972] FernandezJL , RendoP , delPinoN , Nephrologists' Group for the Study of HCV, ViolaL , CusumanoA . A controlled trial of interferon alfa 2b in hemodialysis patients with chronic hepatitis C [abstract no: A0989]. Journal of the American Society of Nephrology1996;7(9):1446. [CENTRAL: CN-00445323] FernandezJL , RendoP , delPinoN , ViolaL . A double-blind controlled trial of recombinant interferon-alpha 2b in haemodialysis patients with chronic hepatitis C virus infection and abnormal aminotransferase levels. Nephrologists' Group for the Study of HCV infection. Journal of Viral Hepatitis1997;4(2):113-9. [MEDLINE: 9097267]">Fernandez 1997</a>; <a href="./references#CD007003-bbs2-0008" title="HuraibS , IqbalA , TanimuD , AbdullahA . Sustained virological and histological response with pretransplant interferon therapy in renal transplant patients with chronic viral hepatitis C. American Journal of Nephrology2001;21(6):435-40. [MEDLINE: 11799259]">Huraib 2001</a>), and the remaining five studies were judged to have an unclear risk of bias (<a href="./references#CD007003-bbs2-0001" title="AlfurayhO , ChaabanA , PallA , Al MutawaN , EllisM , Al MeshariK , et al. Long-term follow up of haemodialysis (HD) patients with chronic hepatitis C (HCV) infection - favorable outcome with a-interferon (IFN) followed by kidney transplantation [abstract no: M221]. Nephrology Dialysis Transplantation2002;17(Suppl 1):110. [CENTRAL: CN-00509051] AlfurayhO , ChaabanA , PallA , EllisM , ChaudryT , AlmeshariK . Randomised controlled trial of interferon-alpha (IFNalpha) in patients with chronic hepatitis C (HCV) on haemodialysis (HD) [abstract]. Nephrology Dialysis Transplantation2000;15(9):A106. [CENTRAL: CN-00497910] AlfurayhOI , ChaabanAM , PallAA , EllisME , AlmeshariK , Al QuaizMN , et al. IFN-alpha for chronic hepatitis C infection (HCV) in haemodialysis (HD) patients - a prospective, randomised, controlled study [abstract]. Journal of the American Society of Nephrology2000;11(Sept):255A. [CENTRAL: CN-00517117] ">Alfurayh 2000</a>; <a href="./references#CD007003-bbs2-0009" title="LiuCH , LiangCC , LinJW , ChenSI , TsaiHB , ChangCS , et al. Pegylated interferon alpha-2a versus standard interferon alpha-2a for treatment-naive dialysis patients with chronic hepatitis C: a randomised study. Gut2008;57(4):525-30. [MEDLINE: 17881538]">Liu 2008a</a>; <a href="./references#CD007003-bbs2-0010" title="LuxonBA , MuirAJ , HeneghanMA . Safety and tolerability of pegylated interferon with or without low dose ribavirin for treatment of hepatitis C in hemodialysis patients [abstract no: 1281]. Hepatology2005;42(4 Suppl 1):703-4A. [CENTRAL: CN-00581669] ">Luxon 2005</a>; <a href="./references#CD007003-bbs2-0012" title="BasuP , ShahN , SirikiR , RahamanM , FarhatS . Telaprevir with adjusted dose of ribavirin in naive CHC-G1: efficacy and treatment in CHC in hemodialysis population target C trial: a placebo randomized control clinical trial [abstract no: 513]. American Journal of Gastroenterology2013;108(Suppl 1):S152. [EMBASE: 71220810]BasuP , SirikiR , ShahNJ , FarhatS , MittimaniK , AtluriS , et al. Telaprevir with adjusted dose of ribavirin in naive CHC-G1: Efficacy and treatment in CHC in hemodialysis population. Target C trial-A placebo randomized control clinical trial [abstract no: 517]. Gastroenterology2013;144(5 Suppl 1):S950. [EMBASE: 71119328]BasuPP , ShahNJ , Ashfique, FarhatS , SirikiR . Telaprevir with adjusted dose of ribavirin in naive CHC-G1: efficacy and treatment in CHC in hemodialysis population. Target C trial-a placebo randomized control clinical trial [abstract no: P196]. Surgical Endoscopy2014;28(1 Suppl):S362. [EMBASE: 71480241]BasuPP , ShahNJ , SirikiR , RahamanM . Telaprevir with adjusted dose of ribavirin in Naive CHC-G1: Efficacy and treatment in CHC in hemodialysis population. TARGET C Trial-a placebo randomized control clinical trial [abstract no: P-298]. Liver Transplantation2014;20(Suppl 1):S244. [EMBASE: 71562627]BasuPP , SinkiR , ShahNJ , FarhatS , MittimaniK , AtluriS , et al. Telaprevir with adjusted dose of ribavirin in naive CHC-G1: efficacy and treatment in CHC in hemodialysis population. TARGET C (RCT) [abstract no: 67]. Journal of Hepatology2013;58(Suppl 1):S30-1. [EMBASE: 71054340]">TARGET C 2013</a>; <a href="./references#CD007003-bbs2-0013" title="TuglularS , Karadayi h, KarakullukcuF , ErmanM , YukselS , CelikM , et al. Preliminary results of interferon compared to interferon combined with ribavirin in the treatment of chronic HCV in patients on chronic hemodialysis [abstract no: A2147]. Journal of the American Society of Nephrology2001;12(Program &amp; Abstracts):416-7A. [CENTRAL: CN-00543899] ">Tuglular 2001</a>). </p> </section> <section id="CD007003-sec-0055"> <h5 class="title">Detection bias</h5> <p>Detection bias was judged as low in seven studies as the outcomes assessed were laboratory‐based (i.e. absence or presence of HCV RNA) (<a href="./references#CD007003-bbs2-0002" title="CampistolJM , CasellasJ , CuevasX , LatorreB , MartínezJ , ModolJ , et al. Efficacy and tolerability of a-2b interferon in the treatment of virus C chronic hepatitis in an hemodialysis population [abstract no: 309] [Eficacia y tolerancia del interferon a-2b en el tratamiento de la hepatitis cronica por virus C (VHC) en la población en hemodialisis (HD)]. Nefrología1996;16(Suppl 1):80. [CENTRAL: CN-00400461] ">Campistol 1996</a>; <a href="./references#CD007003-bbs2-0003" title="CampistolJM , EsforzadoN , MartinezJ , RoselloL , VecianaL , ModolJ , et al. Efficacy and tolerance of interferon-alpha(2b) in the treatment of chronic hepatitis C virus infection in haemodialysis patients. Pre- and post-renal transplantation assessment. Nephrology Dialysis Transplantation1999;14(11):2704-9. [MEDLINE: 10534516]">Campistol 1999a</a>; <a href="./references#CD007003-bbs2-0005" title="FernandezJL , RendoP , delPinoN , Nephrologists' Group for the Study of HCV Infection, ViolaL . A double-blind controlled trial of recombinant interferon alfa in hemodialysis patients with chronic hepatitis C [abstract]. Hepatology1995;22(4 (Pt 2)):116A. [CENTRAL: CN-00220972] FernandezJL , RendoP , delPinoN , Nephrologists' Group for the Study of HCV, ViolaL , CusumanoA . A controlled trial of interferon alfa 2b in hemodialysis patients with chronic hepatitis C [abstract no: A0989]. Journal of the American Society of Nephrology1996;7(9):1446. [CENTRAL: CN-00445323] FernandezJL , RendoP , delPinoN , ViolaL . A double-blind controlled trial of recombinant interferon-alpha 2b in haemodialysis patients with chronic hepatitis C virus infection and abnormal aminotransferase levels. Nephrologists' Group for the Study of HCV infection. Journal of Viral Hepatitis1997;4(2):113-9. [MEDLINE: 9097267]">Fernandez 1997</a>; <a href="./references#CD007003-bbs2-0007" title="Peck-RadosavljevicM , BoletisJ , BesisikF , Lucia FerrazM , AlricL , SamuelD , et al. Low-dose peginterferon alfa-2A (40KD) (PEGASYS®) to treat hepatitis C infected end-stage renal disease patients undergoing haemodialysis: final study results [abstract no: 999]. Journal of Hepatology2008;48(Suppl 2):S374. [CENTRAL: CN-00653069] Peck-RadosavljevicM , BoletisJ , BesisikF , Lucia FerrazM , AlricL , SamuelD , et al. Low-dose peginterferon alfa-2a is safe and produces a sustained virologic response in patients with chronic hepatitis C and end-stage renal disease. Clinical Gastroenterology &amp; Hepatology2011;9(3):242-8. [MEDLINE: 21056689]Peck-RadosavljevicM , BoletisJ , BesisikF , Lucia FerrazM , AlricL , SamuelD , et al. Use of low-dose peginterferon alfa-2a (40 kD) (Pegasys) to treat hepatitis C infected end-stage renal disease patients undergoing haemodialysis: interim results from a randomised study [abstract no: 628]. Journal of Hepatology2007;46(Suppl 1):S237-8. [CENTRAL: CN-00716095] ">HELPS 2011</a>; <a href="./references#CD007003-bbs2-0008" title="HuraibS , IqbalA , TanimuD , AbdullahA . Sustained virological and histological response with pretransplant interferon therapy in renal transplant patients with chronic viral hepatitis C. American Journal of Nephrology2001;21(6):435-40. [MEDLINE: 11799259]">Huraib 2001</a>; <a href="./references#CD007003-bbs2-0009" title="LiuCH , LiangCC , LinJW , ChenSI , TsaiHB , ChangCS , et al. Pegylated interferon alpha-2a versus standard interferon alpha-2a for treatment-naive dialysis patients with chronic hepatitis C: a randomised study. Gut2008;57(4):525-30. [MEDLINE: 17881538]">Liu 2008a</a>; <a href="./references#CD007003-bbs2-0011" title="RussoMW , GhalibR , SigalS , JoshiV . Randomized trial of pegylated interferon alpha-2b monotherapy in haemodialysis patients with chronic hepatitis C. Nephrology Dialysis Transplantation2006;21(2):437-43. [MEDLINE: 16234288]RussoMW , GhalibR , SigalSH , JoshiV , DetwilerR , AndreoniK , et al. A multi-center randomized trial of pegylated interferon alfa-2B monotherapy (PEG-INTRON) in patients with chronic hepatitis C and end stage kidney disease on dialysis [abstract no: 540]. Hepatology2004;40(4 Suppl 1):399A. [CENTRAL: CN-00507218] ">Russo 2006</a>). One study unmasked the placebo group after week 16 (<a href="./references#CD007003-bbs2-0004" title="ArduinoJM , ZhangB , JacksonB , RothD , BruchfeldA , khawajaS , et al. Impact of grazoprevir plus elbasvir on health-related quality of life in patients with hepatitis C virus genotype 1 infection and chronic kidney disease stages 4 and 5 [abstract no: TH-PO667]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):242A. BarrE , RothD , BruchfeldA , MartinP , NelsonDR , SilvaM , et al. Elbasvir (EBR)/grazoprevir (GZR) treatment of hepatitis C virus (HCV) infection in patients with chronic kidney disease stage 4/5: final results of the C-SURFER phase 3 study [abstract]. Journal of Gastroenterology &amp; Hepatology2016;31(Suppl 2):65-6. [EMBASE: 612983742]BruchfeldA , RothD , MartinP , NelsonD , StanislasP , LondonoMC , et al. Elbasvir/Grazoprevir (EBR/GZR) treatment of hepatitis C Virus (HCV) infection in patients with chronic kidney disease (CKD) stage 4/5: clinical, virological, and health-related quality of life outcomes in the C-SURFER study [abstract]. Swiss Medical Weekly2016;146(Suppl 221):23S. [EMBASE: 626845823]BruchfeldA , RothD , MartinP , NelsonDR , PolS , LondonoMC , et al. Elbasvir plus grazoprevir in patients with hepatitis C virus infection and stage 4-5 chronic kidney disease: clinical, virological, and health-related quality-of-life outcomes from a phase 3, multicentre, randomised, double-blind, placebo-controlled trial. The Lancet. Gastroenterology &amp; Hepatology2017;2(8):585-94. [MEDLINE: 28576451]BruchfeldA , RothD , NelsonD , LiapakisAM , SilvaM , MonsourH , et al. C-surfer: Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and chronic kidney disease [abstract no: FP267]. Nephrology Dialysis Transplantation2015;30(Suppl 3):iii156. [EMBASE: 72206687]RothD , BruchfeldA , MartinP , NelsonDR , SilvaM , MonsourH , et al. Grazoprevir(GZR)/elbasvir (EBR) treatment of hepatitis C virus (HCV) infection in patients with chronic kidney disease stage 4/5:final results of the C -SURFER phase 3 study [abstract no: SA-PO1100]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):B5. RothD , NelsonD , BruchfeldA , LiapakisA , SilvaM , MonsourHJ , et al. C-SURFER: grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and chronic kidney disease [abstract no: LP02]. Journal of Hepatology2015;62(Suppl 2):S263-4. [EMBASE: 71936662]RothD , NelsonDR , BruchfeldA , LiapakisA , SilvaM , MonsourH , et al. Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination phase 3 study [Erratum in: Lancet. 2015 Nov 7;386(10006):1824; PMID: 26843312]. Lancet2015;386(10003):1537-45. [MEDLINE: 26456905]">C‐SURFER 2015</a>) which might influence the assessment of outcomes such as treatment discontinuation and some adverse events and was judged to be at high risk of bias. The remaining five studies were judged to have an unclear risk of bias (<a href="./references#CD007003-bbs2-0001" title="AlfurayhO , ChaabanA , PallA , Al MutawaN , EllisM , Al MeshariK , et al. Long-term follow up of haemodialysis (HD) patients with chronic hepatitis C (HCV) infection - favorable outcome with a-interferon (IFN) followed by kidney transplantation [abstract no: M221]. Nephrology Dialysis Transplantation2002;17(Suppl 1):110. [CENTRAL: CN-00509051] AlfurayhO , ChaabanA , PallA , EllisM , ChaudryT , AlmeshariK . Randomised controlled trial of interferon-alpha (IFNalpha) in patients with chronic hepatitis C (HCV) on haemodialysis (HD) [abstract]. Nephrology Dialysis Transplantation2000;15(9):A106. [CENTRAL: CN-00497910] AlfurayhOI , ChaabanAM , PallAA , EllisME , AlmeshariK , Al QuaizMN , et al. IFN-alpha for chronic hepatitis C infection (HCV) in haemodialysis (HD) patients - a prospective, randomised, controlled study [abstract]. Journal of the American Society of Nephrology2000;11(Sept):255A. [CENTRAL: CN-00517117] ">Alfurayh 2000</a>; <a href="./references#CD007003-bbs2-0006" title="LiuCH , HuangCF , LiuCJ , DaiCY , LiangCC , HuangJF , et al. Peginterferon alfa-2a with or without low dose ribavirin for hemodialysis patients with hepatitis C virus genotype 2 infection: a randomized trial [abstract no: 1851]. Hepatology2013;58(4 Suppl 1):1096A. [EMBASE: 71237851]LiuCH , HuangCF , LiuCJ , DaiCY , LiangCC , HuangJF , et al. Pegylated interferon-alpha2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 1 receiving hemodialysis: a randomized trial. Annals of Internal Medicine2013;159(11):729-38. [MEDLINE: 24297189]LiuCH , LiangCC , SuTH , HungPH , TsaiHB , LiuCJ , et al. Peginterferon alfa-2a plus low dose ribavirin versus peginterferon alfa-2a monotherapy for dialysis patients with hepatitis C virus genotype 1 infection: a randomized trial [abstract no: 1722]. Hepatology2012;56(4 Suppl 1):993A. [EMBASE: 70943304]LiuCH , LiuCJ , HuangCF , LinJW , DaiCY , LiangCC , et al. Peginterferon alfa-2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 2 receiving haemodialysis: a randomised trial. Gut2015;64(2):303-11. [MEDLINE: 24747867]">HELPER 2013</a>; <a href="./references#CD007003-bbs2-0010" title="LuxonBA , MuirAJ , HeneghanMA . Safety and tolerability of pegylated interferon with or without low dose ribavirin for treatment of hepatitis C in hemodialysis patients [abstract no: 1281]. Hepatology2005;42(4 Suppl 1):703-4A. [CENTRAL: CN-00581669] ">Luxon 2005</a>; <a href="./references#CD007003-bbs2-0012" title="BasuP , ShahN , SirikiR , RahamanM , FarhatS . Telaprevir with adjusted dose of ribavirin in naive CHC-G1: efficacy and treatment in CHC in hemodialysis population target C trial: a placebo randomized control clinical trial [abstract no: 513]. American Journal of Gastroenterology2013;108(Suppl 1):S152. [EMBASE: 71220810]BasuP , SirikiR , ShahNJ , FarhatS , MittimaniK , AtluriS , et al. Telaprevir with adjusted dose of ribavirin in naive CHC-G1: Efficacy and treatment in CHC in hemodialysis population. Target C trial-A placebo randomized control clinical trial [abstract no: 517]. Gastroenterology2013;144(5 Suppl 1):S950. [EMBASE: 71119328]BasuPP , ShahNJ , Ashfique, FarhatS , SirikiR . Telaprevir with adjusted dose of ribavirin in naive CHC-G1: efficacy and treatment in CHC in hemodialysis population. Target C trial-a placebo randomized control clinical trial [abstract no: P196]. Surgical Endoscopy2014;28(1 Suppl):S362. [EMBASE: 71480241]BasuPP , ShahNJ , SirikiR , RahamanM . Telaprevir with adjusted dose of ribavirin in Naive CHC-G1: Efficacy and treatment in CHC in hemodialysis population. TARGET C Trial-a placebo randomized control clinical trial [abstract no: P-298]. Liver Transplantation2014;20(Suppl 1):S244. [EMBASE: 71562627]BasuPP , SinkiR , ShahNJ , FarhatS , MittimaniK , AtluriS , et al. Telaprevir with adjusted dose of ribavirin in naive CHC-G1: efficacy and treatment in CHC in hemodialysis population. TARGET C (RCT) [abstract no: 67]. Journal of Hepatology2013;58(Suppl 1):S30-1. [EMBASE: 71054340]">TARGET C 2013</a>; <a href="./references#CD007003-bbs2-0013" title="TuglularS , Karadayi h, KarakullukcuF , ErmanM , YukselS , CelikM , et al. Preliminary results of interferon compared to interferon combined with ribavirin in the treatment of chronic HCV in patients on chronic hemodialysis [abstract no: A2147]. Journal of the American Society of Nephrology2001;12(Program &amp; Abstracts):416-7A. [CENTRAL: CN-00543899] ">Tuglular 2001</a>). </p> </section> </section> <section id="CD007003-sec-0056"> <h4 class="title">Incomplete outcome data</h4> <p>Two studies were judged to be at high risk of attrition bias (<a href="./references#CD007003-bbs2-0001" title="AlfurayhO , ChaabanA , PallA , Al MutawaN , EllisM , Al MeshariK , et al. Long-term follow up of haemodialysis (HD) patients with chronic hepatitis C (HCV) infection - favorable outcome with a-interferon (IFN) followed by kidney transplantation [abstract no: M221]. Nephrology Dialysis Transplantation2002;17(Suppl 1):110. [CENTRAL: CN-00509051] AlfurayhO , ChaabanA , PallA , EllisM , ChaudryT , AlmeshariK . Randomised controlled trial of interferon-alpha (IFNalpha) in patients with chronic hepatitis C (HCV) on haemodialysis (HD) [abstract]. Nephrology Dialysis Transplantation2000;15(9):A106. [CENTRAL: CN-00497910] AlfurayhOI , ChaabanAM , PallAA , EllisME , AlmeshariK , Al QuaizMN , et al. IFN-alpha for chronic hepatitis C infection (HCV) in haemodialysis (HD) patients - a prospective, randomised, controlled study [abstract]. Journal of the American Society of Nephrology2000;11(Sept):255A. [CENTRAL: CN-00517117] ">Alfurayh 2000</a>; <a href="./references#CD007003-bbs2-0008" title="HuraibS , IqbalA , TanimuD , AbdullahA . Sustained virological and histological response with pretransplant interferon therapy in renal transplant patients with chronic viral hepatitis C. American Journal of Nephrology2001;21(6):435-40. [MEDLINE: 11799259]">Huraib 2001</a>). Nine studies reported intention‐to‐treat analysis and were judged to be at low risk of attrition bias (<a href="./references#CD007003-bbs2-0002" title="CampistolJM , CasellasJ , CuevasX , LatorreB , MartínezJ , ModolJ , et al. Efficacy and tolerability of a-2b interferon in the treatment of virus C chronic hepatitis in an hemodialysis population [abstract no: 309] [Eficacia y tolerancia del interferon a-2b en el tratamiento de la hepatitis cronica por virus C (VHC) en la población en hemodialisis (HD)]. Nefrología1996;16(Suppl 1):80. [CENTRAL: CN-00400461] ">Campistol 1996</a>; <a href="./references#CD007003-bbs2-0003" title="CampistolJM , EsforzadoN , MartinezJ , RoselloL , VecianaL , ModolJ , et al. Efficacy and tolerance of interferon-alpha(2b) in the treatment of chronic hepatitis C virus infection in haemodialysis patients. Pre- and post-renal transplantation assessment. Nephrology Dialysis Transplantation1999;14(11):2704-9. [MEDLINE: 10534516]">Campistol 1999a</a>; <a href="./references#CD007003-bbs2-0004" title="ArduinoJM , ZhangB , JacksonB , RothD , BruchfeldA , khawajaS , et al. Impact of grazoprevir plus elbasvir on health-related quality of life in patients with hepatitis C virus genotype 1 infection and chronic kidney disease stages 4 and 5 [abstract no: TH-PO667]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):242A. BarrE , RothD , BruchfeldA , MartinP , NelsonDR , SilvaM , et al. Elbasvir (EBR)/grazoprevir (GZR) treatment of hepatitis C virus (HCV) infection in patients with chronic kidney disease stage 4/5: final results of the C-SURFER phase 3 study [abstract]. Journal of Gastroenterology &amp; Hepatology2016;31(Suppl 2):65-6. [EMBASE: 612983742]BruchfeldA , RothD , MartinP , NelsonD , StanislasP , LondonoMC , et al. Elbasvir/Grazoprevir (EBR/GZR) treatment of hepatitis C Virus (HCV) infection in patients with chronic kidney disease (CKD) stage 4/5: clinical, virological, and health-related quality of life outcomes in the C-SURFER study [abstract]. Swiss Medical Weekly2016;146(Suppl 221):23S. [EMBASE: 626845823]BruchfeldA , RothD , MartinP , NelsonDR , PolS , LondonoMC , et al. Elbasvir plus grazoprevir in patients with hepatitis C virus infection and stage 4-5 chronic kidney disease: clinical, virological, and health-related quality-of-life outcomes from a phase 3, multicentre, randomised, double-blind, placebo-controlled trial. The Lancet. Gastroenterology &amp; Hepatology2017;2(8):585-94. [MEDLINE: 28576451]BruchfeldA , RothD , NelsonD , LiapakisAM , SilvaM , MonsourH , et al. C-surfer: Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and chronic kidney disease [abstract no: FP267]. Nephrology Dialysis Transplantation2015;30(Suppl 3):iii156. [EMBASE: 72206687]RothD , BruchfeldA , MartinP , NelsonDR , SilvaM , MonsourH , et al. Grazoprevir(GZR)/elbasvir (EBR) treatment of hepatitis C virus (HCV) infection in patients with chronic kidney disease stage 4/5:final results of the C -SURFER phase 3 study [abstract no: SA-PO1100]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):B5. RothD , NelsonD , BruchfeldA , LiapakisA , SilvaM , MonsourHJ , et al. C-SURFER: grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and chronic kidney disease [abstract no: LP02]. Journal of Hepatology2015;62(Suppl 2):S263-4. [EMBASE: 71936662]RothD , NelsonDR , BruchfeldA , LiapakisA , SilvaM , MonsourH , et al. Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination phase 3 study [Erratum in: Lancet. 2015 Nov 7;386(10006):1824; PMID: 26843312]. Lancet2015;386(10003):1537-45. [MEDLINE: 26456905]">C‐SURFER 2015</a>; <a href="./references#CD007003-bbs2-0005" title="FernandezJL , RendoP , delPinoN , Nephrologists' Group for the Study of HCV Infection, ViolaL . A double-blind controlled trial of recombinant interferon alfa in hemodialysis patients with chronic hepatitis C [abstract]. Hepatology1995;22(4 (Pt 2)):116A. [CENTRAL: CN-00220972] FernandezJL , RendoP , delPinoN , Nephrologists' Group for the Study of HCV, ViolaL , CusumanoA . A controlled trial of interferon alfa 2b in hemodialysis patients with chronic hepatitis C [abstract no: A0989]. Journal of the American Society of Nephrology1996;7(9):1446. [CENTRAL: CN-00445323] FernandezJL , RendoP , delPinoN , ViolaL . A double-blind controlled trial of recombinant interferon-alpha 2b in haemodialysis patients with chronic hepatitis C virus infection and abnormal aminotransferase levels. Nephrologists' Group for the Study of HCV infection. Journal of Viral Hepatitis1997;4(2):113-9. [MEDLINE: 9097267]">Fernandez 1997</a>; <a href="./references#CD007003-bbs2-0006" title="LiuCH , HuangCF , LiuCJ , DaiCY , LiangCC , HuangJF , et al. Peginterferon alfa-2a with or without low dose ribavirin for hemodialysis patients with hepatitis C virus genotype 2 infection: a randomized trial [abstract no: 1851]. Hepatology2013;58(4 Suppl 1):1096A. [EMBASE: 71237851]LiuCH , HuangCF , LiuCJ , DaiCY , LiangCC , HuangJF , et al. Pegylated interferon-alpha2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 1 receiving hemodialysis: a randomized trial. Annals of Internal Medicine2013;159(11):729-38. [MEDLINE: 24297189]LiuCH , LiangCC , SuTH , HungPH , TsaiHB , LiuCJ , et al. Peginterferon alfa-2a plus low dose ribavirin versus peginterferon alfa-2a monotherapy for dialysis patients with hepatitis C virus genotype 1 infection: a randomized trial [abstract no: 1722]. Hepatology2012;56(4 Suppl 1):993A. [EMBASE: 70943304]LiuCH , LiuCJ , HuangCF , LinJW , DaiCY , LiangCC , et al. Peginterferon alfa-2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 2 receiving haemodialysis: a randomised trial. Gut2015;64(2):303-11. [MEDLINE: 24747867]">HELPER 2013</a>; <a href="./references#CD007003-bbs2-0007" title="Peck-RadosavljevicM , BoletisJ , BesisikF , Lucia FerrazM , AlricL , SamuelD , et al. Low-dose peginterferon alfa-2A (40KD) (PEGASYS®) to treat hepatitis C infected end-stage renal disease patients undergoing haemodialysis: final study results [abstract no: 999]. Journal of Hepatology2008;48(Suppl 2):S374. [CENTRAL: CN-00653069] Peck-RadosavljevicM , BoletisJ , BesisikF , Lucia FerrazM , AlricL , SamuelD , et al. Low-dose peginterferon alfa-2a is safe and produces a sustained virologic response in patients with chronic hepatitis C and end-stage renal disease. Clinical Gastroenterology &amp; Hepatology2011;9(3):242-8. [MEDLINE: 21056689]Peck-RadosavljevicM , BoletisJ , BesisikF , Lucia FerrazM , AlricL , SamuelD , et al. Use of low-dose peginterferon alfa-2a (40 kD) (Pegasys) to treat hepatitis C infected end-stage renal disease patients undergoing haemodialysis: interim results from a randomised study [abstract no: 628]. Journal of Hepatology2007;46(Suppl 1):S237-8. [CENTRAL: CN-00716095] ">HELPS 2011</a>; <a href="./references#CD007003-bbs2-0009" title="LiuCH , LiangCC , LinJW , ChenSI , TsaiHB , ChangCS , et al. Pegylated interferon alpha-2a versus standard interferon alpha-2a for treatment-naive dialysis patients with chronic hepatitis C: a randomised study. Gut2008;57(4):525-30. [MEDLINE: 17881538]">Liu 2008a</a>; <a href="./references#CD007003-bbs2-0011" title="RussoMW , GhalibR , SigalS , JoshiV . Randomized trial of pegylated interferon alpha-2b monotherapy in haemodialysis patients with chronic hepatitis C. Nephrology Dialysis Transplantation2006;21(2):437-43. [MEDLINE: 16234288]RussoMW , GhalibR , SigalSH , JoshiV , DetwilerR , AndreoniK , et al. A multi-center randomized trial of pegylated interferon alfa-2B monotherapy (PEG-INTRON) in patients with chronic hepatitis C and end stage kidney disease on dialysis [abstract no: 540]. Hepatology2004;40(4 Suppl 1):399A. [CENTRAL: CN-00507218] ">Russo 2006</a>; <a href="./references#CD007003-bbs2-0012" title="BasuP , ShahN , SirikiR , RahamanM , FarhatS . Telaprevir with adjusted dose of ribavirin in naive CHC-G1: efficacy and treatment in CHC in hemodialysis population target C trial: a placebo randomized control clinical trial [abstract no: 513]. American Journal of Gastroenterology2013;108(Suppl 1):S152. [EMBASE: 71220810]BasuP , SirikiR , ShahNJ , FarhatS , MittimaniK , AtluriS , et al. Telaprevir with adjusted dose of ribavirin in naive CHC-G1: Efficacy and treatment in CHC in hemodialysis population. Target C trial-A placebo randomized control clinical trial [abstract no: 517]. Gastroenterology2013;144(5 Suppl 1):S950. [EMBASE: 71119328]BasuPP , ShahNJ , Ashfique, FarhatS , SirikiR . Telaprevir with adjusted dose of ribavirin in naive CHC-G1: efficacy and treatment in CHC in hemodialysis population. Target C trial-a placebo randomized control clinical trial [abstract no: P196]. Surgical Endoscopy2014;28(1 Suppl):S362. [EMBASE: 71480241]BasuPP , ShahNJ , SirikiR , RahamanM . Telaprevir with adjusted dose of ribavirin in Naive CHC-G1: Efficacy and treatment in CHC in hemodialysis population. TARGET C Trial-a placebo randomized control clinical trial [abstract no: P-298]. Liver Transplantation2014;20(Suppl 1):S244. [EMBASE: 71562627]BasuPP , SinkiR , ShahNJ , FarhatS , MittimaniK , AtluriS , et al. Telaprevir with adjusted dose of ribavirin in naive CHC-G1: efficacy and treatment in CHC in hemodialysis population. TARGET C (RCT) [abstract no: 67]. Journal of Hepatology2013;58(Suppl 1):S30-1. [EMBASE: 71054340]">TARGET C 2013</a>). The remaining two studies were judged to have an unclear risk of attrition bias (<a href="./references#CD007003-bbs2-0010" title="LuxonBA , MuirAJ , HeneghanMA . Safety and tolerability of pegylated interferon with or without low dose ribavirin for treatment of hepatitis C in hemodialysis patients [abstract no: 1281]. Hepatology2005;42(4 Suppl 1):703-4A. [CENTRAL: CN-00581669] ">Luxon 2005</a>; <a href="./references#CD007003-bbs2-0013" title="TuglularS , Karadayi h, KarakullukcuF , ErmanM , YukselS , CelikM , et al. Preliminary results of interferon compared to interferon combined with ribavirin in the treatment of chronic HCV in patients on chronic hemodialysis [abstract no: A2147]. Journal of the American Society of Nephrology2001;12(Program &amp; Abstracts):416-7A. [CENTRAL: CN-00543899] ">Tuglular 2001</a>) </p> </section> <section id="CD007003-sec-0057"> <h4 class="title">Selective reporting</h4> <p>Four studies were available only as conference abstracts (<a href="./references#CD007003-bbs2-0001" title="AlfurayhO , ChaabanA , PallA , Al MutawaN , EllisM , Al MeshariK , et al. Long-term follow up of haemodialysis (HD) patients with chronic hepatitis C (HCV) infection - favorable outcome with a-interferon (IFN) followed by kidney transplantation [abstract no: M221]. Nephrology Dialysis Transplantation2002;17(Suppl 1):110. [CENTRAL: CN-00509051] AlfurayhO , ChaabanA , PallA , EllisM , ChaudryT , AlmeshariK . Randomised controlled trial of interferon-alpha (IFNalpha) in patients with chronic hepatitis C (HCV) on haemodialysis (HD) [abstract]. Nephrology Dialysis Transplantation2000;15(9):A106. [CENTRAL: CN-00497910] AlfurayhOI , ChaabanAM , PallAA , EllisME , AlmeshariK , Al QuaizMN , et al. IFN-alpha for chronic hepatitis C infection (HCV) in haemodialysis (HD) patients - a prospective, randomised, controlled study [abstract]. Journal of the American Society of Nephrology2000;11(Sept):255A. [CENTRAL: CN-00517117] ">Alfurayh 2000</a>; <a href="./references#CD007003-bbs2-0002" title="CampistolJM , CasellasJ , CuevasX , LatorreB , MartínezJ , ModolJ , et al. Efficacy and tolerability of a-2b interferon in the treatment of virus C chronic hepatitis in an hemodialysis population [abstract no: 309] [Eficacia y tolerancia del interferon a-2b en el tratamiento de la hepatitis cronica por virus C (VHC) en la población en hemodialisis (HD)]. Nefrología1996;16(Suppl 1):80. [CENTRAL: CN-00400461] ">Campistol 1996</a>; <a href="./references#CD007003-bbs2-0010" title="LuxonBA , MuirAJ , HeneghanMA . Safety and tolerability of pegylated interferon with or without low dose ribavirin for treatment of hepatitis C in hemodialysis patients [abstract no: 1281]. Hepatology2005;42(4 Suppl 1):703-4A. [CENTRAL: CN-00581669] ">Luxon 2005</a>; <a href="./references#CD007003-bbs2-0013" title="TuglularS , Karadayi h, KarakullukcuF , ErmanM , YukselS , CelikM , et al. Preliminary results of interferon compared to interferon combined with ribavirin in the treatment of chronic HCV in patients on chronic hemodialysis [abstract no: A2147]. Journal of the American Society of Nephrology2001;12(Program &amp; Abstracts):416-7A. [CENTRAL: CN-00543899] ">Tuglular 2001</a>) and were judged to be at high risk of reporting bias because the number of participants mentioned differed for each outcome (<a href="./references#CD007003-bbs2-0001" title="AlfurayhO , ChaabanA , PallA , Al MutawaN , EllisM , Al MeshariK , et al. Long-term follow up of haemodialysis (HD) patients with chronic hepatitis C (HCV) infection - favorable outcome with a-interferon (IFN) followed by kidney transplantation [abstract no: M221]. Nephrology Dialysis Transplantation2002;17(Suppl 1):110. [CENTRAL: CN-00509051] AlfurayhO , ChaabanA , PallA , EllisM , ChaudryT , AlmeshariK . Randomised controlled trial of interferon-alpha (IFNalpha) in patients with chronic hepatitis C (HCV) on haemodialysis (HD) [abstract]. Nephrology Dialysis Transplantation2000;15(9):A106. [CENTRAL: CN-00497910] AlfurayhOI , ChaabanAM , PallAA , EllisME , AlmeshariK , Al QuaizMN , et al. IFN-alpha for chronic hepatitis C infection (HCV) in haemodialysis (HD) patients - a prospective, randomised, controlled study [abstract]. Journal of the American Society of Nephrology2000;11(Sept):255A. [CENTRAL: CN-00517117] ">Alfurayh 2000</a>); the follow‐up was only six months (<a href="./references#CD007003-bbs2-0002" title="CampistolJM , CasellasJ , CuevasX , LatorreB , MartínezJ , ModolJ , et al. Efficacy and tolerability of a-2b interferon in the treatment of virus C chronic hepatitis in an hemodialysis population [abstract no: 309] [Eficacia y tolerancia del interferon a-2b en el tratamiento de la hepatitis cronica por virus C (VHC) en la población en hemodialisis (HD)]. Nefrología1996;16(Suppl 1):80. [CENTRAL: CN-00400461] ">Campistol 1996</a>); there was no follow‐up (<a href="./references#CD007003-bbs2-0013" title="TuglularS , Karadayi h, KarakullukcuF , ErmanM , YukselS , CelikM , et al. Preliminary results of interferon compared to interferon combined with ribavirin in the treatment of chronic HCV in patients on chronic hemodialysis [abstract no: A2147]. Journal of the American Society of Nephrology2001;12(Program &amp; Abstracts):416-7A. [CENTRAL: CN-00543899] ">Tuglular 2001</a>); or there was pooled reporting of results (<a href="./references#CD007003-bbs2-0010" title="LuxonBA , MuirAJ , HeneghanMA . Safety and tolerability of pegylated interferon with or without low dose ribavirin for treatment of hepatitis C in hemodialysis patients [abstract no: 1281]. Hepatology2005;42(4 Suppl 1):703-4A. [CENTRAL: CN-00581669] ">Luxon 2005</a>). The remaining nine studies were judged to be at low risk of bias (<a href="./references#CD007003-bbs2-0003" title="CampistolJM , EsforzadoN , MartinezJ , RoselloL , VecianaL , ModolJ , et al. Efficacy and tolerance of interferon-alpha(2b) in the treatment of chronic hepatitis C virus infection in haemodialysis patients. Pre- and post-renal transplantation assessment. Nephrology Dialysis Transplantation1999;14(11):2704-9. [MEDLINE: 10534516]">Campistol 1999a</a>; <a href="./references#CD007003-bbs2-0004" title="ArduinoJM , ZhangB , JacksonB , RothD , BruchfeldA , khawajaS , et al. Impact of grazoprevir plus elbasvir on health-related quality of life in patients with hepatitis C virus genotype 1 infection and chronic kidney disease stages 4 and 5 [abstract no: TH-PO667]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):242A. BarrE , RothD , BruchfeldA , MartinP , NelsonDR , SilvaM , et al. Elbasvir (EBR)/grazoprevir (GZR) treatment of hepatitis C virus (HCV) infection in patients with chronic kidney disease stage 4/5: final results of the C-SURFER phase 3 study [abstract]. Journal of Gastroenterology &amp; Hepatology2016;31(Suppl 2):65-6. [EMBASE: 612983742]BruchfeldA , RothD , MartinP , NelsonD , StanislasP , LondonoMC , et al. Elbasvir/Grazoprevir (EBR/GZR) treatment of hepatitis C Virus (HCV) infection in patients with chronic kidney disease (CKD) stage 4/5: clinical, virological, and health-related quality of life outcomes in the C-SURFER study [abstract]. Swiss Medical Weekly2016;146(Suppl 221):23S. [EMBASE: 626845823]BruchfeldA , RothD , MartinP , NelsonDR , PolS , LondonoMC , et al. Elbasvir plus grazoprevir in patients with hepatitis C virus infection and stage 4-5 chronic kidney disease: clinical, virological, and health-related quality-of-life outcomes from a phase 3, multicentre, randomised, double-blind, placebo-controlled trial. The Lancet. Gastroenterology &amp; Hepatology2017;2(8):585-94. [MEDLINE: 28576451]BruchfeldA , RothD , NelsonD , LiapakisAM , SilvaM , MonsourH , et al. C-surfer: Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and chronic kidney disease [abstract no: FP267]. Nephrology Dialysis Transplantation2015;30(Suppl 3):iii156. [EMBASE: 72206687]RothD , BruchfeldA , MartinP , NelsonDR , SilvaM , MonsourH , et al. Grazoprevir(GZR)/elbasvir (EBR) treatment of hepatitis C virus (HCV) infection in patients with chronic kidney disease stage 4/5:final results of the C -SURFER phase 3 study [abstract no: SA-PO1100]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):B5. RothD , NelsonD , BruchfeldA , LiapakisA , SilvaM , MonsourHJ , et al. C-SURFER: grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and chronic kidney disease [abstract no: LP02]. Journal of Hepatology2015;62(Suppl 2):S263-4. [EMBASE: 71936662]RothD , NelsonDR , BruchfeldA , LiapakisA , SilvaM , MonsourH , et al. Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination phase 3 study [Erratum in: Lancet. 2015 Nov 7;386(10006):1824; PMID: 26843312]. Lancet2015;386(10003):1537-45. [MEDLINE: 26456905]">C‐SURFER 2015</a>; <a href="./references#CD007003-bbs2-0005" title="FernandezJL , RendoP , delPinoN , Nephrologists' Group for the Study of HCV Infection, ViolaL . A double-blind controlled trial of recombinant interferon alfa in hemodialysis patients with chronic hepatitis C [abstract]. Hepatology1995;22(4 (Pt 2)):116A. [CENTRAL: CN-00220972] FernandezJL , RendoP , delPinoN , Nephrologists' Group for the Study of HCV, ViolaL , CusumanoA . A controlled trial of interferon alfa 2b in hemodialysis patients with chronic hepatitis C [abstract no: A0989]. Journal of the American Society of Nephrology1996;7(9):1446. [CENTRAL: CN-00445323] FernandezJL , RendoP , delPinoN , ViolaL . A double-blind controlled trial of recombinant interferon-alpha 2b in haemodialysis patients with chronic hepatitis C virus infection and abnormal aminotransferase levels. Nephrologists' Group for the Study of HCV infection. Journal of Viral Hepatitis1997;4(2):113-9. [MEDLINE: 9097267]">Fernandez 1997</a>; <a href="./references#CD007003-bbs2-0006" title="LiuCH , HuangCF , LiuCJ , DaiCY , LiangCC , HuangJF , et al. Peginterferon alfa-2a with or without low dose ribavirin for hemodialysis patients with hepatitis C virus genotype 2 infection: a randomized trial [abstract no: 1851]. Hepatology2013;58(4 Suppl 1):1096A. [EMBASE: 71237851]LiuCH , HuangCF , LiuCJ , DaiCY , LiangCC , HuangJF , et al. Pegylated interferon-alpha2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 1 receiving hemodialysis: a randomized trial. Annals of Internal Medicine2013;159(11):729-38. [MEDLINE: 24297189]LiuCH , LiangCC , SuTH , HungPH , TsaiHB , LiuCJ , et al. Peginterferon alfa-2a plus low dose ribavirin versus peginterferon alfa-2a monotherapy for dialysis patients with hepatitis C virus genotype 1 infection: a randomized trial [abstract no: 1722]. Hepatology2012;56(4 Suppl 1):993A. [EMBASE: 70943304]LiuCH , LiuCJ , HuangCF , LinJW , DaiCY , LiangCC , et al. Peginterferon alfa-2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 2 receiving haemodialysis: a randomised trial. Gut2015;64(2):303-11. [MEDLINE: 24747867]">HELPER 2013</a>; <a href="./references#CD007003-bbs2-0007" title="Peck-RadosavljevicM , BoletisJ , BesisikF , Lucia FerrazM , AlricL , SamuelD , et al. Low-dose peginterferon alfa-2A (40KD) (PEGASYS®) to treat hepatitis C infected end-stage renal disease patients undergoing haemodialysis: final study results [abstract no: 999]. Journal of Hepatology2008;48(Suppl 2):S374. [CENTRAL: CN-00653069] Peck-RadosavljevicM , BoletisJ , BesisikF , Lucia FerrazM , AlricL , SamuelD , et al. Low-dose peginterferon alfa-2a is safe and produces a sustained virologic response in patients with chronic hepatitis C and end-stage renal disease. Clinical Gastroenterology &amp; Hepatology2011;9(3):242-8. [MEDLINE: 21056689]Peck-RadosavljevicM , BoletisJ , BesisikF , Lucia FerrazM , AlricL , SamuelD , et al. Use of low-dose peginterferon alfa-2a (40 kD) (Pegasys) to treat hepatitis C infected end-stage renal disease patients undergoing haemodialysis: interim results from a randomised study [abstract no: 628]. Journal of Hepatology2007;46(Suppl 1):S237-8. [CENTRAL: CN-00716095] ">HELPS 2011</a>; <a href="./references#CD007003-bbs2-0008" title="HuraibS , IqbalA , TanimuD , AbdullahA . Sustained virological and histological response with pretransplant interferon therapy in renal transplant patients with chronic viral hepatitis C. American Journal of Nephrology2001;21(6):435-40. [MEDLINE: 11799259]">Huraib 2001</a>; <a href="./references#CD007003-bbs2-0009" title="LiuCH , LiangCC , LinJW , ChenSI , TsaiHB , ChangCS , et al. Pegylated interferon alpha-2a versus standard interferon alpha-2a for treatment-naive dialysis patients with chronic hepatitis C: a randomised study. Gut2008;57(4):525-30. [MEDLINE: 17881538]">Liu 2008a</a>; <a href="./references#CD007003-bbs2-0011" title="RussoMW , GhalibR , SigalS , JoshiV . Randomized trial of pegylated interferon alpha-2b monotherapy in haemodialysis patients with chronic hepatitis C. Nephrology Dialysis Transplantation2006;21(2):437-43. [MEDLINE: 16234288]RussoMW , GhalibR , SigalSH , JoshiV , DetwilerR , AndreoniK , et al. A multi-center randomized trial of pegylated interferon alfa-2B monotherapy (PEG-INTRON) in patients with chronic hepatitis C and end stage kidney disease on dialysis [abstract no: 540]. Hepatology2004;40(4 Suppl 1):399A. [CENTRAL: CN-00507218] ">Russo 2006</a>; <a href="./references#CD007003-bbs2-0012" title="BasuP , ShahN , SirikiR , RahamanM , FarhatS . Telaprevir with adjusted dose of ribavirin in naive CHC-G1: efficacy and treatment in CHC in hemodialysis population target C trial: a placebo randomized control clinical trial [abstract no: 513]. American Journal of Gastroenterology2013;108(Suppl 1):S152. [EMBASE: 71220810]BasuP , SirikiR , ShahNJ , FarhatS , MittimaniK , AtluriS , et al. Telaprevir with adjusted dose of ribavirin in naive CHC-G1: Efficacy and treatment in CHC in hemodialysis population. Target C trial-A placebo randomized control clinical trial [abstract no: 517]. Gastroenterology2013;144(5 Suppl 1):S950. [EMBASE: 71119328]BasuPP , ShahNJ , Ashfique, FarhatS , SirikiR . Telaprevir with adjusted dose of ribavirin in naive CHC-G1: efficacy and treatment in CHC in hemodialysis population. Target C trial-a placebo randomized control clinical trial [abstract no: P196]. Surgical Endoscopy2014;28(1 Suppl):S362. [EMBASE: 71480241]BasuPP , ShahNJ , SirikiR , RahamanM . Telaprevir with adjusted dose of ribavirin in Naive CHC-G1: Efficacy and treatment in CHC in hemodialysis population. TARGET C Trial-a placebo randomized control clinical trial [abstract no: P-298]. Liver Transplantation2014;20(Suppl 1):S244. [EMBASE: 71562627]BasuPP , SinkiR , ShahNJ , FarhatS , MittimaniK , AtluriS , et al. Telaprevir with adjusted dose of ribavirin in naive CHC-G1: efficacy and treatment in CHC in hemodialysis population. TARGET C (RCT) [abstract no: 67]. Journal of Hepatology2013;58(Suppl 1):S30-1. [EMBASE: 71054340]">TARGET C 2013</a>). </p> </section> <section id="CD007003-sec-0058"> <h4 class="title">Other potential sources of bias</h4> <p>The potential for other biases was low in five studies (<a href="./references#CD007003-bbs2-0003" title="CampistolJM , EsforzadoN , MartinezJ , RoselloL , VecianaL , ModolJ , et al. Efficacy and tolerance of interferon-alpha(2b) in the treatment of chronic hepatitis C virus infection in haemodialysis patients. Pre- and post-renal transplantation assessment. Nephrology Dialysis Transplantation1999;14(11):2704-9. [MEDLINE: 10534516]">Campistol 1999a</a>; <a href="./references#CD007003-bbs2-0004" title="ArduinoJM , ZhangB , JacksonB , RothD , BruchfeldA , khawajaS , et al. Impact of grazoprevir plus elbasvir on health-related quality of life in patients with hepatitis C virus genotype 1 infection and chronic kidney disease stages 4 and 5 [abstract no: TH-PO667]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):242A. BarrE , RothD , BruchfeldA , MartinP , NelsonDR , SilvaM , et al. Elbasvir (EBR)/grazoprevir (GZR) treatment of hepatitis C virus (HCV) infection in patients with chronic kidney disease stage 4/5: final results of the C-SURFER phase 3 study [abstract]. Journal of Gastroenterology &amp; Hepatology2016;31(Suppl 2):65-6. [EMBASE: 612983742]BruchfeldA , RothD , MartinP , NelsonD , StanislasP , LondonoMC , et al. Elbasvir/Grazoprevir (EBR/GZR) treatment of hepatitis C Virus (HCV) infection in patients with chronic kidney disease (CKD) stage 4/5: clinical, virological, and health-related quality of life outcomes in the C-SURFER study [abstract]. Swiss Medical Weekly2016;146(Suppl 221):23S. [EMBASE: 626845823]BruchfeldA , RothD , MartinP , NelsonDR , PolS , LondonoMC , et al. Elbasvir plus grazoprevir in patients with hepatitis C virus infection and stage 4-5 chronic kidney disease: clinical, virological, and health-related quality-of-life outcomes from a phase 3, multicentre, randomised, double-blind, placebo-controlled trial. The Lancet. Gastroenterology &amp; Hepatology2017;2(8):585-94. [MEDLINE: 28576451]BruchfeldA , RothD , NelsonD , LiapakisAM , SilvaM , MonsourH , et al. C-surfer: Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and chronic kidney disease [abstract no: FP267]. Nephrology Dialysis Transplantation2015;30(Suppl 3):iii156. [EMBASE: 72206687]RothD , BruchfeldA , MartinP , NelsonDR , SilvaM , MonsourH , et al. Grazoprevir(GZR)/elbasvir (EBR) treatment of hepatitis C virus (HCV) infection in patients with chronic kidney disease stage 4/5:final results of the C -SURFER phase 3 study [abstract no: SA-PO1100]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):B5. RothD , NelsonD , BruchfeldA , LiapakisA , SilvaM , MonsourHJ , et al. C-SURFER: grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and chronic kidney disease [abstract no: LP02]. Journal of Hepatology2015;62(Suppl 2):S263-4. [EMBASE: 71936662]RothD , NelsonDR , BruchfeldA , LiapakisA , SilvaM , MonsourH , et al. Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination phase 3 study [Erratum in: Lancet. 2015 Nov 7;386(10006):1824; PMID: 26843312]. Lancet2015;386(10003):1537-45. [MEDLINE: 26456905]">C‐SURFER 2015</a>; <a href="./references#CD007003-bbs2-0005" title="FernandezJL , RendoP , delPinoN , Nephrologists' Group for the Study of HCV Infection, ViolaL . A double-blind controlled trial of recombinant interferon alfa in hemodialysis patients with chronic hepatitis C [abstract]. Hepatology1995;22(4 (Pt 2)):116A. [CENTRAL: CN-00220972] FernandezJL , RendoP , delPinoN , Nephrologists' Group for the Study of HCV, ViolaL , CusumanoA . A controlled trial of interferon alfa 2b in hemodialysis patients with chronic hepatitis C [abstract no: A0989]. Journal of the American Society of Nephrology1996;7(9):1446. [CENTRAL: CN-00445323] FernandezJL , RendoP , delPinoN , ViolaL . A double-blind controlled trial of recombinant interferon-alpha 2b in haemodialysis patients with chronic hepatitis C virus infection and abnormal aminotransferase levels. Nephrologists' Group for the Study of HCV infection. Journal of Viral Hepatitis1997;4(2):113-9. [MEDLINE: 9097267]">Fernandez 1997</a>; <a href="./references#CD007003-bbs2-0006" title="LiuCH , HuangCF , LiuCJ , DaiCY , LiangCC , HuangJF , et al. Peginterferon alfa-2a with or without low dose ribavirin for hemodialysis patients with hepatitis C virus genotype 2 infection: a randomized trial [abstract no: 1851]. Hepatology2013;58(4 Suppl 1):1096A. [EMBASE: 71237851]LiuCH , HuangCF , LiuCJ , DaiCY , LiangCC , HuangJF , et al. Pegylated interferon-alpha2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 1 receiving hemodialysis: a randomized trial. Annals of Internal Medicine2013;159(11):729-38. [MEDLINE: 24297189]LiuCH , LiangCC , SuTH , HungPH , TsaiHB , LiuCJ , et al. Peginterferon alfa-2a plus low dose ribavirin versus peginterferon alfa-2a monotherapy for dialysis patients with hepatitis C virus genotype 1 infection: a randomized trial [abstract no: 1722]. Hepatology2012;56(4 Suppl 1):993A. [EMBASE: 70943304]LiuCH , LiuCJ , HuangCF , LinJW , DaiCY , LiangCC , et al. Peginterferon alfa-2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 2 receiving haemodialysis: a randomised trial. Gut2015;64(2):303-11. [MEDLINE: 24747867]">HELPER 2013</a>; <a href="./references#CD007003-bbs2-0009" title="LiuCH , LiangCC , LinJW , ChenSI , TsaiHB , ChangCS , et al. Pegylated interferon alpha-2a versus standard interferon alpha-2a for treatment-naive dialysis patients with chronic hepatitis C: a randomised study. Gut2008;57(4):525-30. [MEDLINE: 17881538]">Liu 2008a</a>) and high in two (<a href="./references#CD007003-bbs2-0007" title="Peck-RadosavljevicM , BoletisJ , BesisikF , Lucia FerrazM , AlricL , SamuelD , et al. Low-dose peginterferon alfa-2A (40KD) (PEGASYS®) to treat hepatitis C infected end-stage renal disease patients undergoing haemodialysis: final study results [abstract no: 999]. Journal of Hepatology2008;48(Suppl 2):S374. [CENTRAL: CN-00653069] Peck-RadosavljevicM , BoletisJ , BesisikF , Lucia FerrazM , AlricL , SamuelD , et al. Low-dose peginterferon alfa-2a is safe and produces a sustained virologic response in patients with chronic hepatitis C and end-stage renal disease. Clinical Gastroenterology &amp; Hepatology2011;9(3):242-8. [MEDLINE: 21056689]Peck-RadosavljevicM , BoletisJ , BesisikF , Lucia FerrazM , AlricL , SamuelD , et al. Use of low-dose peginterferon alfa-2a (40 kD) (Pegasys) to treat hepatitis C infected end-stage renal disease patients undergoing haemodialysis: interim results from a randomised study [abstract no: 628]. Journal of Hepatology2007;46(Suppl 1):S237-8. [CENTRAL: CN-00716095] ">HELPS 2011</a> <a href="./references#CD007003-bbs2-0011" title="RussoMW , GhalibR , SigalS , JoshiV . Randomized trial of pegylated interferon alpha-2b monotherapy in haemodialysis patients with chronic hepatitis C. Nephrology Dialysis Transplantation2006;21(2):437-43. [MEDLINE: 16234288]RussoMW , GhalibR , SigalSH , JoshiV , DetwilerR , AndreoniK , et al. A multi-center randomized trial of pegylated interferon alfa-2B monotherapy (PEG-INTRON) in patients with chronic hepatitis C and end stage kidney disease on dialysis [abstract no: 540]. Hepatology2004;40(4 Suppl 1):399A. [CENTRAL: CN-00507218] ">Russo 2006</a>). <a href="./references#CD007003-bbs2-0007" title="Peck-RadosavljevicM , BoletisJ , BesisikF , Lucia FerrazM , AlricL , SamuelD , et al. Low-dose peginterferon alfa-2A (40KD) (PEGASYS®) to treat hepatitis C infected end-stage renal disease patients undergoing haemodialysis: final study results [abstract no: 999]. Journal of Hepatology2008;48(Suppl 2):S374. [CENTRAL: CN-00653069] Peck-RadosavljevicM , BoletisJ , BesisikF , Lucia FerrazM , AlricL , SamuelD , et al. Low-dose peginterferon alfa-2a is safe and produces a sustained virologic response in patients with chronic hepatitis C and end-stage renal disease. Clinical Gastroenterology &amp; Hepatology2011;9(3):242-8. [MEDLINE: 21056689]Peck-RadosavljevicM , BoletisJ , BesisikF , Lucia FerrazM , AlricL , SamuelD , et al. Use of low-dose peginterferon alfa-2a (40 kD) (Pegasys) to treat hepatitis C infected end-stage renal disease patients undergoing haemodialysis: interim results from a randomised study [abstract no: 628]. Journal of Hepatology2007;46(Suppl 1):S237-8. [CENTRAL: CN-00716095] ">HELPS 2011</a> and <a href="./references#CD007003-bbs2-0011" title="RussoMW , GhalibR , SigalS , JoshiV . Randomized trial of pegylated interferon alpha-2b monotherapy in haemodialysis patients with chronic hepatitis C. Nephrology Dialysis Transplantation2006;21(2):437-43. [MEDLINE: 16234288]RussoMW , GhalibR , SigalSH , JoshiV , DetwilerR , AndreoniK , et al. A multi-center randomized trial of pegylated interferon alfa-2B monotherapy (PEG-INTRON) in patients with chronic hepatitis C and end stage kidney disease on dialysis [abstract no: 540]. Hepatology2004;40(4 Suppl 1):399A. [CENTRAL: CN-00507218] ">Russo 2006</a> were industry‐funded, and <a href="./references#CD007003-bbs2-0011" title="RussoMW , GhalibR , SigalS , JoshiV . Randomized trial of pegylated interferon alpha-2b monotherapy in haemodialysis patients with chronic hepatitis C. Nephrology Dialysis Transplantation2006;21(2):437-43. [MEDLINE: 16234288]RussoMW , GhalibR , SigalSH , JoshiV , DetwilerR , AndreoniK , et al. A multi-center randomized trial of pegylated interferon alfa-2B monotherapy (PEG-INTRON) in patients with chronic hepatitis C and end stage kidney disease on dialysis [abstract no: 540]. Hepatology2004;40(4 Suppl 1):399A. [CENTRAL: CN-00507218] ">Russo 2006</a> was terminated early. The remaining six studies were judged to have an unclear risk of bias (<a href="./references#CD007003-bbs2-0001" title="AlfurayhO , ChaabanA , PallA , Al MutawaN , EllisM , Al MeshariK , et al. Long-term follow up of haemodialysis (HD) patients with chronic hepatitis C (HCV) infection - favorable outcome with a-interferon (IFN) followed by kidney transplantation [abstract no: M221]. Nephrology Dialysis Transplantation2002;17(Suppl 1):110. [CENTRAL: CN-00509051] AlfurayhO , ChaabanA , PallA , EllisM , ChaudryT , AlmeshariK . Randomised controlled trial of interferon-alpha (IFNalpha) in patients with chronic hepatitis C (HCV) on haemodialysis (HD) [abstract]. Nephrology Dialysis Transplantation2000;15(9):A106. [CENTRAL: CN-00497910] AlfurayhOI , ChaabanAM , PallAA , EllisME , AlmeshariK , Al QuaizMN , et al. IFN-alpha for chronic hepatitis C infection (HCV) in haemodialysis (HD) patients - a prospective, randomised, controlled study [abstract]. Journal of the American Society of Nephrology2000;11(Sept):255A. [CENTRAL: CN-00517117] ">Alfurayh 2000</a>; <a href="./references#CD007003-bbs2-0002" title="CampistolJM , CasellasJ , CuevasX , LatorreB , MartínezJ , ModolJ , et al. Efficacy and tolerability of a-2b interferon in the treatment of virus C chronic hepatitis in an hemodialysis population [abstract no: 309] [Eficacia y tolerancia del interferon a-2b en el tratamiento de la hepatitis cronica por virus C (VHC) en la población en hemodialisis (HD)]. Nefrología1996;16(Suppl 1):80. [CENTRAL: CN-00400461] ">Campistol 1996</a>; <a href="./references#CD007003-bbs2-0008" title="HuraibS , IqbalA , TanimuD , AbdullahA . Sustained virological and histological response with pretransplant interferon therapy in renal transplant patients with chronic viral hepatitis C. American Journal of Nephrology2001;21(6):435-40. [MEDLINE: 11799259]">Huraib 2001</a>; <a href="./references#CD007003-bbs2-0010" title="LuxonBA , MuirAJ , HeneghanMA . Safety and tolerability of pegylated interferon with or without low dose ribavirin for treatment of hepatitis C in hemodialysis patients [abstract no: 1281]. Hepatology2005;42(4 Suppl 1):703-4A. [CENTRAL: CN-00581669] ">Luxon 2005</a>; <a href="./references#CD007003-bbs2-0012" title="BasuP , ShahN , SirikiR , RahamanM , FarhatS . Telaprevir with adjusted dose of ribavirin in naive CHC-G1: efficacy and treatment in CHC in hemodialysis population target C trial: a placebo randomized control clinical trial [abstract no: 513]. American Journal of Gastroenterology2013;108(Suppl 1):S152. [EMBASE: 71220810]BasuP , SirikiR , ShahNJ , FarhatS , MittimaniK , AtluriS , et al. Telaprevir with adjusted dose of ribavirin in naive CHC-G1: Efficacy and treatment in CHC in hemodialysis population. Target C trial-A placebo randomized control clinical trial [abstract no: 517]. Gastroenterology2013;144(5 Suppl 1):S950. [EMBASE: 71119328]BasuPP , ShahNJ , Ashfique, FarhatS , SirikiR . Telaprevir with adjusted dose of ribavirin in naive CHC-G1: efficacy and treatment in CHC in hemodialysis population. Target C trial-a placebo randomized control clinical trial [abstract no: P196]. Surgical Endoscopy2014;28(1 Suppl):S362. [EMBASE: 71480241]BasuPP , ShahNJ , SirikiR , RahamanM . Telaprevir with adjusted dose of ribavirin in Naive CHC-G1: Efficacy and treatment in CHC in hemodialysis population. TARGET C Trial-a placebo randomized control clinical trial [abstract no: P-298]. Liver Transplantation2014;20(Suppl 1):S244. [EMBASE: 71562627]BasuPP , SinkiR , ShahNJ , FarhatS , MittimaniK , AtluriS , et al. Telaprevir with adjusted dose of ribavirin in naive CHC-G1: efficacy and treatment in CHC in hemodialysis population. TARGET C (RCT) [abstract no: 67]. Journal of Hepatology2013;58(Suppl 1):S30-1. [EMBASE: 71054340]">TARGET C 2013</a>; <a href="./references#CD007003-bbs2-0013" title="TuglularS , Karadayi h, KarakullukcuF , ErmanM , YukselS , CelikM , et al. Preliminary results of interferon compared to interferon combined with ribavirin in the treatment of chronic HCV in patients on chronic hemodialysis [abstract no: A2147]. Journal of the American Society of Nephrology2001;12(Program &amp; Abstracts):416-7A. [CENTRAL: CN-00543899] ">Tuglular 2001</a>). </p> </section> </section> <section id="CD007003-sec-0059"> <h3 class="title" id="CD007003-sec-0059">Effects of interventions</h3> <p>See: <a href="./full#CD007003-tbl-0001"><b>Summary of findings 1</b> Standard interferon versus placebo or control for haemodialysis patients with hepatitis C virus infection</a>; <a href="./full#CD007003-tbl-0002"><b>Summary of findings 2</b> Pegylated interferon alpha‐2a versus standard interferon for haemodialysis patients with hepatitis C virus infection</a>; <a href="./full#CD007003-tbl-0003"><b>Summary of findings 3</b> High versus low dose pegylated interferon alpha‐2a or alpha‐2b for haemodialysis patients with hepatitis C virus infection</a>; <a href="./full#CD007003-tbl-0004"><b>Summary of findings 4</b> Standard interferon plus ribavirin versus standard interferon alone for haemodialysis patients with hepatitis C virus infection</a>; <a href="./full#CD007003-tbl-0005"><b>Summary of findings 5</b> Pegylated interferon plus ribavirin versus pegylated interferon alone for haemodialysis patients with hepatitis C infection</a>; <a href="./full#CD007003-tbl-0006"><b>Summary of findings 6</b> Direct antivirals (grazoprevir and elbasvir) versus placebo for haemodialysis patients with hepatitis C infection</a>; <a href="./full#CD007003-tbl-0007"><b>Summary of findings 7</b> Pegylated interferon + ribavirin (24 weeks) + initial telepravir (12 weeks) versus pegylated interferon (48 weeks) + initial telepravir (12 weeks) + initial low dose ribavirin (12 + 36 weeks) for haemodialysis patients with hepatitis C infection</a> </p> <section id="CD007003-sec-0060"> <h4 class="title">Standard interferon versus placebo or control</h4> <p>See <a href="./full#CD007003-tbl-0001">summary of findings Table 1</a> </p> <p>Five studies compared standard recombinant interferon with placebo or control (<a href="./references#CD007003-bbs2-0001" title="AlfurayhO , ChaabanA , PallA , Al MutawaN , EllisM , Al MeshariK , et al. Long-term follow up of haemodialysis (HD) patients with chronic hepatitis C (HCV) infection - favorable outcome with a-interferon (IFN) followed by kidney transplantation [abstract no: M221]. Nephrology Dialysis Transplantation2002;17(Suppl 1):110. [CENTRAL: CN-00509051] AlfurayhO , ChaabanA , PallA , EllisM , ChaudryT , AlmeshariK . Randomised controlled trial of interferon-alpha (IFNalpha) in patients with chronic hepatitis C (HCV) on haemodialysis (HD) [abstract]. Nephrology Dialysis Transplantation2000;15(9):A106. [CENTRAL: CN-00497910] AlfurayhOI , ChaabanAM , PallAA , EllisME , AlmeshariK , Al QuaizMN , et al. IFN-alpha for chronic hepatitis C infection (HCV) in haemodialysis (HD) patients - a prospective, randomised, controlled study [abstract]. Journal of the American Society of Nephrology2000;11(Sept):255A. [CENTRAL: CN-00517117] ">Alfurayh 2000</a>; <a href="./references#CD007003-bbs2-0002" title="CampistolJM , CasellasJ , CuevasX , LatorreB , MartínezJ , ModolJ , et al. Efficacy and tolerability of a-2b interferon in the treatment of virus C chronic hepatitis in an hemodialysis population [abstract no: 309] [Eficacia y tolerancia del interferon a-2b en el tratamiento de la hepatitis cronica por virus C (VHC) en la población en hemodialisis (HD)]. Nefrología1996;16(Suppl 1):80. [CENTRAL: CN-00400461] ">Campistol 1996</a>; <a href="./references#CD007003-bbs2-0003" title="CampistolJM , EsforzadoN , MartinezJ , RoselloL , VecianaL , ModolJ , et al. Efficacy and tolerance of interferon-alpha(2b) in the treatment of chronic hepatitis C virus infection in haemodialysis patients. Pre- and post-renal transplantation assessment. Nephrology Dialysis Transplantation1999;14(11):2704-9. [MEDLINE: 10534516]">Campistol 1999a</a>; <a href="./references#CD007003-bbs2-0005" title="FernandezJL , RendoP , delPinoN , Nephrologists' Group for the Study of HCV Infection, ViolaL . A double-blind controlled trial of recombinant interferon alfa in hemodialysis patients with chronic hepatitis C [abstract]. Hepatology1995;22(4 (Pt 2)):116A. [CENTRAL: CN-00220972] FernandezJL , RendoP , delPinoN , Nephrologists' Group for the Study of HCV, ViolaL , CusumanoA . A controlled trial of interferon alfa 2b in hemodialysis patients with chronic hepatitis C [abstract no: A0989]. Journal of the American Society of Nephrology1996;7(9):1446. [CENTRAL: CN-00445323] FernandezJL , RendoP , delPinoN , ViolaL . A double-blind controlled trial of recombinant interferon-alpha 2b in haemodialysis patients with chronic hepatitis C virus infection and abnormal aminotransferase levels. Nephrologists' Group for the Study of HCV infection. Journal of Viral Hepatitis1997;4(2):113-9. [MEDLINE: 9097267]">Fernandez 1997</a>; <a href="./references#CD007003-bbs2-0008" title="HuraibS , IqbalA , TanimuD , AbdullahA . Sustained virological and histological response with pretransplant interferon therapy in renal transplant patients with chronic viral hepatitis C. American Journal of Nephrology2001;21(6):435-40. [MEDLINE: 11799259]">Huraib 2001</a>). Duration of treatment ranged from six months (<a href="./references#CD007003-bbs2-0003" title="CampistolJM , EsforzadoN , MartinezJ , RoselloL , VecianaL , ModolJ , et al. Efficacy and tolerance of interferon-alpha(2b) in the treatment of chronic hepatitis C virus infection in haemodialysis patients. Pre- and post-renal transplantation assessment. Nephrology Dialysis Transplantation1999;14(11):2704-9. [MEDLINE: 10534516]">Campistol 1999a</a>; <a href="./references#CD007003-bbs2-0005" title="FernandezJL , RendoP , delPinoN , Nephrologists' Group for the Study of HCV Infection, ViolaL . A double-blind controlled trial of recombinant interferon alfa in hemodialysis patients with chronic hepatitis C [abstract]. Hepatology1995;22(4 (Pt 2)):116A. [CENTRAL: CN-00220972] FernandezJL , RendoP , delPinoN , Nephrologists' Group for the Study of HCV, ViolaL , CusumanoA . A controlled trial of interferon alfa 2b in hemodialysis patients with chronic hepatitis C [abstract no: A0989]. Journal of the American Society of Nephrology1996;7(9):1446. [CENTRAL: CN-00445323] FernandezJL , RendoP , delPinoN , ViolaL . A double-blind controlled trial of recombinant interferon-alpha 2b in haemodialysis patients with chronic hepatitis C virus infection and abnormal aminotransferase levels. Nephrologists' Group for the Study of HCV infection. Journal of Viral Hepatitis1997;4(2):113-9. [MEDLINE: 9097267]">Fernandez 1997</a>) to one year (<a href="./references#CD007003-bbs2-0001" title="AlfurayhO , ChaabanA , PallA , Al MutawaN , EllisM , Al MeshariK , et al. Long-term follow up of haemodialysis (HD) patients with chronic hepatitis C (HCV) infection - favorable outcome with a-interferon (IFN) followed by kidney transplantation [abstract no: M221]. Nephrology Dialysis Transplantation2002;17(Suppl 1):110. [CENTRAL: CN-00509051] AlfurayhO , ChaabanA , PallA , EllisM , ChaudryT , AlmeshariK . Randomised controlled trial of interferon-alpha (IFNalpha) in patients with chronic hepatitis C (HCV) on haemodialysis (HD) [abstract]. Nephrology Dialysis Transplantation2000;15(9):A106. [CENTRAL: CN-00497910] AlfurayhOI , ChaabanAM , PallAA , EllisME , AlmeshariK , Al QuaizMN , et al. IFN-alpha for chronic hepatitis C infection (HCV) in haemodialysis (HD) patients - a prospective, randomised, controlled study [abstract]. Journal of the American Society of Nephrology2000;11(Sept):255A. [CENTRAL: CN-00517117] ">Alfurayh 2000</a>; <a href="./references#CD007003-bbs2-0008" title="HuraibS , IqbalA , TanimuD , AbdullahA . Sustained virological and histological response with pretransplant interferon therapy in renal transplant patients with chronic viral hepatitis C. American Journal of Nephrology2001;21(6):435-40. [MEDLINE: 11799259]">Huraib 2001</a>), while <a href="./references#CD007003-bbs2-0002" title="CampistolJM , CasellasJ , CuevasX , LatorreB , MartínezJ , ModolJ , et al. Efficacy and tolerability of a-2b interferon in the treatment of virus C chronic hepatitis in an hemodialysis population [abstract no: 309] [Eficacia y tolerancia del interferon a-2b en el tratamiento de la hepatitis cronica por virus C (VHC) en la población en hemodialisis (HD)]. Nefrología1996;16(Suppl 1):80. [CENTRAL: CN-00400461] ">Campistol 1996</a> did not report the duration of treatment. Follow‐up after treatment ranged from zero to 46 months. The dose of interferon used was 1.5 million units, 3 times/week (<a href="./references#CD007003-bbs2-0005" title="FernandezJL , RendoP , delPinoN , Nephrologists' Group for the Study of HCV Infection, ViolaL . A double-blind controlled trial of recombinant interferon alfa in hemodialysis patients with chronic hepatitis C [abstract]. Hepatology1995;22(4 (Pt 2)):116A. [CENTRAL: CN-00220972] FernandezJL , RendoP , delPinoN , Nephrologists' Group for the Study of HCV, ViolaL , CusumanoA . A controlled trial of interferon alfa 2b in hemodialysis patients with chronic hepatitis C [abstract no: A0989]. Journal of the American Society of Nephrology1996;7(9):1446. [CENTRAL: CN-00445323] FernandezJL , RendoP , delPinoN , ViolaL . A double-blind controlled trial of recombinant interferon-alpha 2b in haemodialysis patients with chronic hepatitis C virus infection and abnormal aminotransferase levels. Nephrologists' Group for the Study of HCV infection. Journal of Viral Hepatitis1997;4(2):113-9. [MEDLINE: 9097267]">Fernandez 1997</a>) and 3 million units, 3 times/week (<a href="./references#CD007003-bbs2-0001" title="AlfurayhO , ChaabanA , PallA , Al MutawaN , EllisM , Al MeshariK , et al. Long-term follow up of haemodialysis (HD) patients with chronic hepatitis C (HCV) infection - favorable outcome with a-interferon (IFN) followed by kidney transplantation [abstract no: M221]. Nephrology Dialysis Transplantation2002;17(Suppl 1):110. [CENTRAL: CN-00509051] AlfurayhO , ChaabanA , PallA , EllisM , ChaudryT , AlmeshariK . Randomised controlled trial of interferon-alpha (IFNalpha) in patients with chronic hepatitis C (HCV) on haemodialysis (HD) [abstract]. Nephrology Dialysis Transplantation2000;15(9):A106. [CENTRAL: CN-00497910] AlfurayhOI , ChaabanAM , PallAA , EllisME , AlmeshariK , Al QuaizMN , et al. IFN-alpha for chronic hepatitis C infection (HCV) in haemodialysis (HD) patients - a prospective, randomised, controlled study [abstract]. Journal of the American Society of Nephrology2000;11(Sept):255A. [CENTRAL: CN-00517117] ">Alfurayh 2000</a>; <a href="./references#CD007003-bbs2-0002" title="CampistolJM , CasellasJ , CuevasX , LatorreB , MartínezJ , ModolJ , et al. Efficacy and tolerability of a-2b interferon in the treatment of virus C chronic hepatitis in an hemodialysis population [abstract no: 309] [Eficacia y tolerancia del interferon a-2b en el tratamiento de la hepatitis cronica por virus C (VHC) en la población en hemodialisis (HD)]. Nefrología1996;16(Suppl 1):80. [CENTRAL: CN-00400461] ">Campistol 1996</a>; <a href="./references#CD007003-bbs2-0003" title="CampistolJM , EsforzadoN , MartinezJ , RoselloL , VecianaL , ModolJ , et al. Efficacy and tolerance of interferon-alpha(2b) in the treatment of chronic hepatitis C virus infection in haemodialysis patients. Pre- and post-renal transplantation assessment. Nephrology Dialysis Transplantation1999;14(11):2704-9. [MEDLINE: 10534516]">Campistol 1999a</a>; <a href="./references#CD007003-bbs2-0008" title="HuraibS , IqbalA , TanimuD , AbdullahA . Sustained virological and histological response with pretransplant interferon therapy in renal transplant patients with chronic viral hepatitis C. American Journal of Nephrology2001;21(6):435-40. [MEDLINE: 11799259]">Huraib 2001</a>). Post‐kidney transplant follow‐up was reported in three studies (<a href="./references#CD007003-bbs2-0001" title="AlfurayhO , ChaabanA , PallA , Al MutawaN , EllisM , Al MeshariK , et al. Long-term follow up of haemodialysis (HD) patients with chronic hepatitis C (HCV) infection - favorable outcome with a-interferon (IFN) followed by kidney transplantation [abstract no: M221]. Nephrology Dialysis Transplantation2002;17(Suppl 1):110. [CENTRAL: CN-00509051] AlfurayhO , ChaabanA , PallA , EllisM , ChaudryT , AlmeshariK . Randomised controlled trial of interferon-alpha (IFNalpha) in patients with chronic hepatitis C (HCV) on haemodialysis (HD) [abstract]. Nephrology Dialysis Transplantation2000;15(9):A106. [CENTRAL: CN-00497910] AlfurayhOI , ChaabanAM , PallAA , EllisME , AlmeshariK , Al QuaizMN , et al. IFN-alpha for chronic hepatitis C infection (HCV) in haemodialysis (HD) patients - a prospective, randomised, controlled study [abstract]. Journal of the American Society of Nephrology2000;11(Sept):255A. [CENTRAL: CN-00517117] ">Alfurayh 2000</a>; <a href="./references#CD007003-bbs2-0003" title="CampistolJM , EsforzadoN , MartinezJ , RoselloL , VecianaL , ModolJ , et al. Efficacy and tolerance of interferon-alpha(2b) in the treatment of chronic hepatitis C virus infection in haemodialysis patients. Pre- and post-renal transplantation assessment. Nephrology Dialysis Transplantation1999;14(11):2704-9. [MEDLINE: 10534516]">Campistol 1999a</a>; <a href="./references#CD007003-bbs2-0008" title="HuraibS , IqbalA , TanimuD , AbdullahA . Sustained virological and histological response with pretransplant interferon therapy in renal transplant patients with chronic viral hepatitis C. American Journal of Nephrology2001;21(6):435-40. [MEDLINE: 11799259]">Huraib 2001</a>) with <a href="./references#CD007003-bbs2-0008" title="HuraibS , IqbalA , TanimuD , AbdullahA . Sustained virological and histological response with pretransplant interferon therapy in renal transplant patients with chronic viral hepatitis C. American Journal of Nephrology2001;21(6):435-40. [MEDLINE: 11799259]">Huraib 2001</a> analysing only transplanted patients out of the total number randomised. Data on relapses was complete in <a href="./references#CD007003-bbs2-0003" title="CampistolJM , EsforzadoN , MartinezJ , RoselloL , VecianaL , ModolJ , et al. Efficacy and tolerance of interferon-alpha(2b) in the treatment of chronic hepatitis C virus infection in haemodialysis patients. Pre- and post-renal transplantation assessment. Nephrology Dialysis Transplantation1999;14(11):2704-9. [MEDLINE: 10534516]">Campistol 1999a</a>. </p> <section id="CD007003-sec-0061"> <h5 class="title">Death</h5> <p>Standard interferon may make little or no difference to death compared to placebo or control (<a href="./references#CD007003-fig-0004" title="">Analysis 1.1</a> (5 studies, 134 participants): RR 0.89, 95% CI 0.06 to 13.23; low certainty evidence). Only <a href="./references#CD007003-bbs2-0003" title="CampistolJM , EsforzadoN , MartinezJ , RoselloL , VecianaL , ModolJ , et al. Efficacy and tolerance of interferon-alpha(2b) in the treatment of chronic hepatitis C virus infection in haemodialysis patients. Pre- and post-renal transplantation assessment. Nephrology Dialysis Transplantation1999;14(11):2704-9. [MEDLINE: 10534516]">Campistol 1999a</a> reported one death in each group over 6 to 52 months of follow‐up. </p> </section> <section id="CD007003-sec-0062"> <h5 class="title">Relapse</h5> <p><a href="./references#CD007003-bbs2-0003" title="CampistolJM , EsforzadoN , MartinezJ , RoselloL , VecianaL , ModolJ , et al. Efficacy and tolerance of interferon-alpha(2b) in the treatment of chronic hepatitis C virus infection in haemodialysis patients. Pre- and post-renal transplantation assessment. Nephrology Dialysis Transplantation1999;14(11):2704-9. [MEDLINE: 10534516]">Campistol 1999a</a> reported six relapses in the 11 patients who initially responded to treatment (<a href="./references#CD007003-fig-0005" title="">Analysis 1.2</a>) up to 46 months after treatment. One patient in the control group 'responded' but relapsed by 46 months.  Two out of four responders (<a href="./references#CD007003-bbs2-0005" title="FernandezJL , RendoP , delPinoN , Nephrologists' Group for the Study of HCV Infection, ViolaL . A double-blind controlled trial of recombinant interferon alfa in hemodialysis patients with chronic hepatitis C [abstract]. Hepatology1995;22(4 (Pt 2)):116A. [CENTRAL: CN-00220972] FernandezJL , RendoP , delPinoN , Nephrologists' Group for the Study of HCV, ViolaL , CusumanoA . A controlled trial of interferon alfa 2b in hemodialysis patients with chronic hepatitis C [abstract no: A0989]. Journal of the American Society of Nephrology1996;7(9):1446. [CENTRAL: CN-00445323] FernandezJL , RendoP , delPinoN , ViolaL . A double-blind controlled trial of recombinant interferon-alpha 2b in haemodialysis patients with chronic hepatitis C virus infection and abnormal aminotransferase levels. Nephrologists' Group for the Study of HCV infection. Journal of Viral Hepatitis1997;4(2):113-9. [MEDLINE: 9097267]">Fernandez 1997</a>) and none out of four responders (<a href="./references#CD007003-bbs2-0008" title="HuraibS , IqbalA , TanimuD , AbdullahA . Sustained virological and histological response with pretransplant interferon therapy in renal transplant patients with chronic viral hepatitis C. American Journal of Nephrology2001;21(6):435-40. [MEDLINE: 11799259]">Huraib 2001</a>) in the standard interferon group relapsed. These studies could not be analysed due to the absence of response in the placebo or control groups. In one study there was no follow‐up after treatment (<a href="./references#CD007003-bbs2-0002" title="CampistolJM , CasellasJ , CuevasX , LatorreB , MartínezJ , ModolJ , et al. Efficacy and tolerability of a-2b interferon in the treatment of virus C chronic hepatitis in an hemodialysis population [abstract no: 309] [Eficacia y tolerancia del interferon a-2b en el tratamiento de la hepatitis cronica por virus C (VHC) en la población en hemodialisis (HD)]. Nefrología1996;16(Suppl 1):80. [CENTRAL: CN-00400461] ">Campistol 1996</a>), and data was not available in <a href="./references#CD007003-bbs2-0001" title="AlfurayhO , ChaabanA , PallA , Al MutawaN , EllisM , Al MeshariK , et al. Long-term follow up of haemodialysis (HD) patients with chronic hepatitis C (HCV) infection - favorable outcome with a-interferon (IFN) followed by kidney transplantation [abstract no: M221]. Nephrology Dialysis Transplantation2002;17(Suppl 1):110. [CENTRAL: CN-00509051] AlfurayhO , ChaabanA , PallA , EllisM , ChaudryT , AlmeshariK . Randomised controlled trial of interferon-alpha (IFNalpha) in patients with chronic hepatitis C (HCV) on haemodialysis (HD) [abstract]. Nephrology Dialysis Transplantation2000;15(9):A106. [CENTRAL: CN-00497910] AlfurayhOI , ChaabanAM , PallAA , EllisME , AlmeshariK , Al QuaizMN , et al. IFN-alpha for chronic hepatitis C infection (HCV) in haemodialysis (HD) patients - a prospective, randomised, controlled study [abstract]. Journal of the American Society of Nephrology2000;11(Sept):255A. [CENTRAL: CN-00517117] ">Alfurayh 2000</a>. </p> </section> <section id="CD007003-sec-0063"> <h5 class="title">End‐of‐treatment response</h5> <p>Standard interferon probably improves the end‐of‐treatment response compared to placebo or control (<a href="./references#CD007003-fig-0006" title="">Analysis 1.3</a> (5 studies, 132 participants): RR 8.62, 95% CI 3.03 to 24.55; I² = 0%; moderate certainty evidence). </p> </section> <section id="CD007003-sec-0064"> <h5 class="title">Sustained virological response</h5> <p>Standard interferon probably makes little or no difference to SVR compared to placebo or control (<a href="./references#CD007003-fig-0007" title="">Analysis 1.4</a> (4 studies, 98 participants): RR 3.25, 95% CI 0.81 to 13.07; I² = 53%; moderate certainty evidence). There was no follow‐up data available in <a href="./references#CD007003-bbs2-0002" title="CampistolJM , CasellasJ , CuevasX , LatorreB , MartínezJ , ModolJ , et al. Efficacy and tolerability of a-2b interferon in the treatment of virus C chronic hepatitis in an hemodialysis population [abstract no: 309] [Eficacia y tolerancia del interferon a-2b en el tratamiento de la hepatitis cronica por virus C (VHC) en la población en hemodialisis (HD)]. Nefrología1996;16(Suppl 1):80. [CENTRAL: CN-00400461] ">Campistol 1996</a>. </p> </section> <section id="CD007003-sec-0065"> <h5 class="title">Treatment discontinuation</h5> <p>Standard interferon probably makes little or no difference to the number of patients discontinuing treatment compared to placebo or control (<a href="./references#CD007003-fig-0008" title="">Analysis 1.5</a> (4 studies, 116 participants): RR 4.59, 95% CI 0.49 to 42.69; I² = 63%; moderate certainty evidence). </p> </section> <section id="CD007003-sec-0066"> <h5 class="title">Adverse events</h5> <p>Standard interferon probably makes little or no difference to the number of patients experiencing adverse events compared to placebo or control (<a href="./references#CD007003-fig-0009" title="">Analysis 1.6</a> (5 studies, 143 participants): RR 3.56, 95% CI 0.98 to 13.01; I² = 25%; moderate certainty evidence). Adverse events are reported in <a href="./appendices#CD007003-sec-0104">Appendix 3</a>. </p> </section> <section id="CD007003-sec-0067"> <h5 class="title">Other outcomes</h5> <p>There were no data reported for time to recovery, QoL, cost‐effectiveness and outcomes such as myocardial infarction. </p> </section> </section> <section id="CD007003-sec-0068"> <h4 class="title">Pegylated interferon versus standard interferon</h4> <p>See <a href="./full#CD007003-tbl-0002">summary of findings Table 2</a> </p> <p><a href="./references#CD007003-bbs2-0009" title="LiuCH , LiangCC , LinJW , ChenSI , TsaiHB , ChangCS , et al. Pegylated interferon alpha-2a versus standard interferon alpha-2a for treatment-naive dialysis patients with chronic hepatitis C: a randomised study. Gut2008;57(4):525-30. [MEDLINE: 17881538]">Liu 2008a</a> compared PEG interferon alpha‐2a and standard interferon alpha‐2a. The duration of treatment was 24 weeks with a follow‐up of 24 weeks after treatment. The dose of PEG interferon alpha‐2a was 135 µg once/week and for standard interferon 3 million units, 3 times/week with the doses reduced to 90 µg or 1.5 million units, respectively, or stopped in the event of adverse events. Dose modification was required in 3/25 in the PEG interferon group and in 5/25 in the standard interferon group. HCV genotype was tested but not stratified due to small numbers. Analysis was as per the intention‐to‐treat principle. </p> <section id="CD007003-sec-0069"> <h5 class="title">Death</h5> <p><a href="./references#CD007003-bbs2-0009" title="LiuCH , LiangCC , LinJW , ChenSI , TsaiHB , ChangCS , et al. Pegylated interferon alpha-2a versus standard interferon alpha-2a for treatment-naive dialysis patients with chronic hepatitis C: a randomised study. Gut2008;57(4):525-30. [MEDLINE: 17881538]">Liu 2008a</a> reported PEG interferon may make little or no difference to death compared to standard interferon (<a href="./references#CD007003-fig-0010" title="">Analysis 2.1</a> (1 study, 50 participants): RR 0.33, 95% CI 0.01 to 7.81; low certainty evidence). </p> </section> <section id="CD007003-sec-0070"> <h5 class="title">Relapse</h5> <p><a href="./references#CD007003-bbs2-0009" title="LiuCH , LiangCC , LinJW , ChenSI , TsaiHB , ChangCS , et al. Pegylated interferon alpha-2a versus standard interferon alpha-2a for treatment-naive dialysis patients with chronic hepatitis C: a randomised study. Gut2008;57(4):525-30. [MEDLINE: 17881538]">Liu 2008a</a> reported PEG interferon may make little or no difference to the number of relapses compared to standard interferon (<a href="./references#CD007003-fig-0011" title="">Analysis 2.2</a> (1 study, 50 participants, 38 having relapse): RR 0.72, 95% CI 0.41 to 1.25; low certainty evidence). </p> </section> <section id="CD007003-sec-0071"> <h5 class="title">End‐of‐treatment response</h5> <p><a href="./references#CD007003-bbs2-0009" title="LiuCH , LiangCC , LinJW , ChenSI , TsaiHB , ChangCS , et al. Pegylated interferon alpha-2a versus standard interferon alpha-2a for treatment-naive dialysis patients with chronic hepatitis C: a randomised study. Gut2008;57(4):525-30. [MEDLINE: 17881538]">Liu 2008a</a> reported PEG interferon may lead to more end‐of‐treatment response compared to standard interferon (<a href="./references#CD007003-fig-0012" title="">Analysis 2.3</a> (1 study, 50 participants): RR 1.53, 95% CI 1.09 to 2.15; low certainty evidence). </p> </section> <section id="CD007003-sec-0072"> <h5 class="title">Sustained virological response</h5> <p><a href="./references#CD007003-bbs2-0009" title="LiuCH , LiangCC , LinJW , ChenSI , TsaiHB , ChangCS , et al. Pegylated interferon alpha-2a versus standard interferon alpha-2a for treatment-naive dialysis patients with chronic hepatitis C: a randomised study. Gut2008;57(4):525-30. [MEDLINE: 17881538]">Liu 2008a</a> reported that PEG interferon may make little or no difference to the number of patients having SVR compared to standard interferon (<a href="./references#CD007003-fig-0013" title="">Analysis 2.4</a> (1 study, 50 participants): RR 2.40, 95% CI 0.99 to 5.81; low certainty evidence). </p> </section> <section id="CD007003-sec-0073"> <h5 class="title">Treatment discontinuation</h5> <p><a href="./references#CD007003-bbs2-0009" title="LiuCH , LiangCC , LinJW , ChenSI , TsaiHB , ChangCS , et al. Pegylated interferon alpha-2a versus standard interferon alpha-2a for treatment-naive dialysis patients with chronic hepatitis C: a randomised study. Gut2008;57(4):525-30. [MEDLINE: 17881538]">Liu 2008a</a> reported that PEG interferon may make little or no difference to the number of patients discontinuing treatment compared to standard interferon (<a href="./references#CD007003-fig-0014" title="">Analysis 2.5</a> (1 study, 50 participants): RR 0.11, 95% CI 0.01 to 1.96; low certainty evidence). </p> </section> <section id="CD007003-sec-0074"> <h5 class="title">Adverse events</h5> <p><a href="./references#CD007003-bbs2-0009" title="LiuCH , LiangCC , LinJW , ChenSI , TsaiHB , ChangCS , et al. Pegylated interferon alpha-2a versus standard interferon alpha-2a for treatment-naive dialysis patients with chronic hepatitis C: a randomised study. Gut2008;57(4):525-30. [MEDLINE: 17881538]">Liu 2008a</a> reported PEG interferon may make little or no difference to the number of patients having major adverse events requiring treatment withdrawal compared to standard interferon (<a href="./references#CD007003-fig-0015" title="">Analysis 2.6</a> (1 study, 50 participants): RR 0.11, 95% CI 0.01 to 1.96; low certainty evidence). Refer to <a href="./appendices#CD007003-sec-0104">Appendix 3</a> for the description of adverse events. </p> </section> <section id="CD007003-sec-0075"> <h5 class="title">Other outcomes</h5> <p>There were no data on time to recovery, QoL, cost‐effectiveness, and outcomes such as myocardial infarction. </p> </section> </section> <section id="CD007003-sec-0076"> <h4 class="title">Pegylated interferon: high versus low dose</h4> <p>See <a href="./full#CD007003-tbl-0003">summary of findings Table 3</a> </p> <p>Two studies (<a href="./references#CD007003-bbs2-0007" title="Peck-RadosavljevicM , BoletisJ , BesisikF , Lucia FerrazM , AlricL , SamuelD , et al. Low-dose peginterferon alfa-2A (40KD) (PEGASYS®) to treat hepatitis C infected end-stage renal disease patients undergoing haemodialysis: final study results [abstract no: 999]. Journal of Hepatology2008;48(Suppl 2):S374. [CENTRAL: CN-00653069] Peck-RadosavljevicM , BoletisJ , BesisikF , Lucia FerrazM , AlricL , SamuelD , et al. Low-dose peginterferon alfa-2a is safe and produces a sustained virologic response in patients with chronic hepatitis C and end-stage renal disease. Clinical Gastroenterology &amp; Hepatology2011;9(3):242-8. [MEDLINE: 21056689]Peck-RadosavljevicM , BoletisJ , BesisikF , Lucia FerrazM , AlricL , SamuelD , et al. Use of low-dose peginterferon alfa-2a (40 kD) (Pegasys) to treat hepatitis C infected end-stage renal disease patients undergoing haemodialysis: interim results from a randomised study [abstract no: 628]. Journal of Hepatology2007;46(Suppl 1):S237-8. [CENTRAL: CN-00716095] ">HELPS 2011</a>; <a href="./references#CD007003-bbs2-0011" title="RussoMW , GhalibR , SigalS , JoshiV . Randomized trial of pegylated interferon alpha-2b monotherapy in haemodialysis patients with chronic hepatitis C. Nephrology Dialysis Transplantation2006;21(2):437-43. [MEDLINE: 16234288]RussoMW , GhalibR , SigalSH , JoshiV , DetwilerR , AndreoniK , et al. A multi-center randomized trial of pegylated interferon alfa-2B monotherapy (PEG-INTRON) in patients with chronic hepatitis C and end stage kidney disease on dialysis [abstract no: 540]. Hepatology2004;40(4 Suppl 1):399A. [CENTRAL: CN-00507218] ">Russo 2006</a>) compared two doses of PEG interferon. Subgroup analysis was done as two different PEG interferon preparations were used. The duration of treatment was 48 weeks with a follow‐up of 24 weeks after treatment. Doses were 135 µg/week and 90 µg/week of PEG interferon alpha‐2a in <a href="./references#CD007003-bbs2-0007" title="Peck-RadosavljevicM , BoletisJ , BesisikF , Lucia FerrazM , AlricL , SamuelD , et al. Low-dose peginterferon alfa-2A (40KD) (PEGASYS®) to treat hepatitis C infected end-stage renal disease patients undergoing haemodialysis: final study results [abstract no: 999]. Journal of Hepatology2008;48(Suppl 2):S374. [CENTRAL: CN-00653069] Peck-RadosavljevicM , BoletisJ , BesisikF , Lucia FerrazM , AlricL , SamuelD , et al. Low-dose peginterferon alfa-2a is safe and produces a sustained virologic response in patients with chronic hepatitis C and end-stage renal disease. Clinical Gastroenterology &amp; Hepatology2011;9(3):242-8. [MEDLINE: 21056689]Peck-RadosavljevicM , BoletisJ , BesisikF , Lucia FerrazM , AlricL , SamuelD , et al. Use of low-dose peginterferon alfa-2a (40 kD) (Pegasys) to treat hepatitis C infected end-stage renal disease patients undergoing haemodialysis: interim results from a randomised study [abstract no: 628]. Journal of Hepatology2007;46(Suppl 1):S237-8. [CENTRAL: CN-00716095] ">HELPS 2011</a> and 1 µg/kg/week and 0.5 µg/kg/week of PEG interferon alpha‐2b in <a href="./references#CD007003-bbs2-0011" title="RussoMW , GhalibR , SigalS , JoshiV . Randomized trial of pegylated interferon alpha-2b monotherapy in haemodialysis patients with chronic hepatitis C. Nephrology Dialysis Transplantation2006;21(2):437-43. [MEDLINE: 16234288]RussoMW , GhalibR , SigalSH , JoshiV , DetwilerR , AndreoniK , et al. A multi-center randomized trial of pegylated interferon alfa-2B monotherapy (PEG-INTRON) in patients with chronic hepatitis C and end stage kidney disease on dialysis [abstract no: 540]. Hepatology2004;40(4 Suppl 1):399A. [CENTRAL: CN-00507218] ">Russo 2006</a>. Doses were reduced or stopped in the event of adverse events. Stratification by country and HCV genotype were done in <a href="./references#CD007003-bbs2-0007" title="Peck-RadosavljevicM , BoletisJ , BesisikF , Lucia FerrazM , AlricL , SamuelD , et al. Low-dose peginterferon alfa-2A (40KD) (PEGASYS®) to treat hepatitis C infected end-stage renal disease patients undergoing haemodialysis: final study results [abstract no: 999]. Journal of Hepatology2008;48(Suppl 2):S374. [CENTRAL: CN-00653069] Peck-RadosavljevicM , BoletisJ , BesisikF , Lucia FerrazM , AlricL , SamuelD , et al. Low-dose peginterferon alfa-2a is safe and produces a sustained virologic response in patients with chronic hepatitis C and end-stage renal disease. Clinical Gastroenterology &amp; Hepatology2011;9(3):242-8. [MEDLINE: 21056689]Peck-RadosavljevicM , BoletisJ , BesisikF , Lucia FerrazM , AlricL , SamuelD , et al. Use of low-dose peginterferon alfa-2a (40 kD) (Pegasys) to treat hepatitis C infected end-stage renal disease patients undergoing haemodialysis: interim results from a randomised study [abstract no: 628]. Journal of Hepatology2007;46(Suppl 1):S237-8. [CENTRAL: CN-00716095] ">HELPS 2011</a>. After randomisation, four patients in <a href="./references#CD007003-bbs2-0007" title="Peck-RadosavljevicM , BoletisJ , BesisikF , Lucia FerrazM , AlricL , SamuelD , et al. Low-dose peginterferon alfa-2A (40KD) (PEGASYS®) to treat hepatitis C infected end-stage renal disease patients undergoing haemodialysis: final study results [abstract no: 999]. Journal of Hepatology2008;48(Suppl 2):S374. [CENTRAL: CN-00653069] Peck-RadosavljevicM , BoletisJ , BesisikF , Lucia FerrazM , AlricL , SamuelD , et al. Low-dose peginterferon alfa-2a is safe and produces a sustained virologic response in patients with chronic hepatitis C and end-stage renal disease. Clinical Gastroenterology &amp; Hepatology2011;9(3):242-8. [MEDLINE: 21056689]Peck-RadosavljevicM , BoletisJ , BesisikF , Lucia FerrazM , AlricL , SamuelD , et al. Use of low-dose peginterferon alfa-2a (40 kD) (Pegasys) to treat hepatitis C infected end-stage renal disease patients undergoing haemodialysis: interim results from a randomised study [abstract no: 628]. Journal of Hepatology2007;46(Suppl 1):S237-8. [CENTRAL: CN-00716095] ">HELPS 2011</a> and five in <a href="./references#CD007003-bbs2-0011" title="RussoMW , GhalibR , SigalS , JoshiV . Randomized trial of pegylated interferon alpha-2b monotherapy in haemodialysis patients with chronic hepatitis C. Nephrology Dialysis Transplantation2006;21(2):437-43. [MEDLINE: 16234288]RussoMW , GhalibR , SigalSH , JoshiV , DetwilerR , AndreoniK , et al. A multi-center randomized trial of pegylated interferon alfa-2B monotherapy (PEG-INTRON) in patients with chronic hepatitis C and end stage kidney disease on dialysis [abstract no: 540]. Hepatology2004;40(4 Suppl 1):399A. [CENTRAL: CN-00507218] ">Russo 2006</a> were not analysed as they did not receive any dose of the study medication. <a href="./references#CD007003-bbs2-0011" title="RussoMW , GhalibR , SigalS , JoshiV . Randomized trial of pegylated interferon alpha-2b monotherapy in haemodialysis patients with chronic hepatitis C. Nephrology Dialysis Transplantation2006;21(2):437-43. [MEDLINE: 16234288]RussoMW , GhalibR , SigalSH , JoshiV , DetwilerR , AndreoniK , et al. A multi-center randomized trial of pegylated interferon alfa-2B monotherapy (PEG-INTRON) in patients with chronic hepatitis C and end stage kidney disease on dialysis [abstract no: 540]. Hepatology2004;40(4 Suppl 1):399A. [CENTRAL: CN-00507218] ">Russo 2006</a> was designed to enrol 50 participants but terminated after recruiting 16 due to adverse events and modifications in the study design. Both were industry‐funded. </p> <section id="CD007003-sec-0077"> <h5 class="title">Death</h5> <p>High‐dose PEG interferon probably makes little or no difference to death compared to low dose (<a href="./references#CD007003-fig-0016" title="">Analysis 3.1</a> (2 studies, 97 participants): RR 4.30, 95% CI 0.76 to 24.33; I² = 0%; moderate certainty evidence). </p> </section> <section id="CD007003-sec-0078"> <h5 class="title">Relapse</h5> <p><a href="./references#CD007003-bbs2-0007" title="Peck-RadosavljevicM , BoletisJ , BesisikF , Lucia FerrazM , AlricL , SamuelD , et al. Low-dose peginterferon alfa-2A (40KD) (PEGASYS®) to treat hepatitis C infected end-stage renal disease patients undergoing haemodialysis: final study results [abstract no: 999]. Journal of Hepatology2008;48(Suppl 2):S374. [CENTRAL: CN-00653069] Peck-RadosavljevicM , BoletisJ , BesisikF , Lucia FerrazM , AlricL , SamuelD , et al. Low-dose peginterferon alfa-2a is safe and produces a sustained virologic response in patients with chronic hepatitis C and end-stage renal disease. Clinical Gastroenterology &amp; Hepatology2011;9(3):242-8. [MEDLINE: 21056689]Peck-RadosavljevicM , BoletisJ , BesisikF , Lucia FerrazM , AlricL , SamuelD , et al. Use of low-dose peginterferon alfa-2a (40 kD) (Pegasys) to treat hepatitis C infected end-stage renal disease patients undergoing haemodialysis: interim results from a randomised study [abstract no: 628]. Journal of Hepatology2007;46(Suppl 1):S237-8. [CENTRAL: CN-00716095] ">HELPS 2011</a> reported high‐dose PEG interferon may make little or no difference to the number of patients relapsing compared to the low‐dose group (<a href="./references#CD007003-fig-0017" title="">Analysis 3.2</a> (1 study, 81 participants, 43 having relapse): RR 1.11, 95% CI 0.45 to 2.77; low certainty evidence). </p> <p><a href="./references#CD007003-bbs2-0011" title="RussoMW , GhalibR , SigalS , JoshiV . Randomized trial of pegylated interferon alpha-2b monotherapy in haemodialysis patients with chronic hepatitis C. Nephrology Dialysis Transplantation2006;21(2):437-43. [MEDLINE: 16234288]RussoMW , GhalibR , SigalSH , JoshiV , DetwilerR , AndreoniK , et al. A multi-center randomized trial of pegylated interferon alfa-2B monotherapy (PEG-INTRON) in patients with chronic hepatitis C and end stage kidney disease on dialysis [abstract no: 540]. Hepatology2004;40(4 Suppl 1):399A. [CENTRAL: CN-00507218] ">Russo 2006</a> reported one relapse amongst three responders in the high‐dose group, but data could not be analysed as there were no responders in the low‐dose group. </p> </section> <section id="CD007003-sec-0079"> <h5 class="title">End‐of‐treatment response</h5> <p>High‐dose PEG interferon probably makes little or no difference to end‐of‐treatment virological response compared to the low‐dose group (<a href="./references#CD007003-fig-0018" title="">Analysis 3.3</a> (2 studies, 97 participants): RR 1.42, 95% CI 0.51 to 3.90; I² = 20%; moderate certainty evidence). </p> </section> <section id="CD007003-sec-0080"> <h5 class="title">Sustained virological response</h5> <p>High‐dose PEG interferon probably makes little or no difference to SVR compared to the low‐dose group (<a href="./references#CD007003-fig-0019" title="">Analysis 3.4</a> (2 studies, 97 participants): RR 1.19, 95% CI 0.68 to 2.07; I² = 0%; moderate certainty evidence). </p> </section> <section id="CD007003-sec-0081"> <h5 class="title">Treatment discontinuation</h5> <p>High‐dose PEG interferon probably makes little or no difference to the number of patients discontinuing treatment compared to the low‐dose group (<a href="./references#CD007003-fig-0020" title="">Analysis 3.5</a> (2 studies, 97 participants): RR 1.20, 95% CI 0.63 to 2.28; I² = 0%; moderate certainty evidence). </p> </section> <section id="CD007003-sec-0082"> <h5 class="title">Adverse events</h5> <p>High‐dose PEG interferon probably makes little or no difference to the number of patients with adverse events compared to the low‐dose group (<a href="./references#CD007003-fig-0021" title="">Analysis 3.6</a> (2 studies, 97 participants): RR 1.05, 95% CI 0.61 to 1.83; I² = 27%; moderate certainty evidence). </p> <p>High‐dose PEG interferon probably makes little or no difference to the number of patients with serious adverse events compared to the low‐dose group (<a href="./references#CD007003-fig-0022" title="">Analysis 3.7</a> (2 studies, 97 participants): RR 1.24, 95% CI 0.72 to 2.14; I² = 0%; moderate certainty evidence). Refer to <a href="./appendices#CD007003-sec-0104">Appendix 3</a> for details of adverse events. </p> </section> <section id="CD007003-sec-0083"> <h5 class="title">Other outcomes</h5> <p>There were no data on time to recovery, QoL, cost‐effectiveness, and outcomes such as myocardial infarction. </p> </section> </section> <section id="CD007003-sec-0084"> <h4 class="title">Standard or pegylated interferon alone or in combination with ribavirin</h4> <p>See <a href="./full#CD007003-tbl-0004">summary of findings Table 4</a>; <a href="./full#CD007003-tbl-0005">summary of findings Table 5</a> </p> <p>Three studies compared interferons in combination with ribavirin against interferon alone. <a href="./references#CD007003-bbs2-0013" title="TuglularS , Karadayi h, KarakullukcuF , ErmanM , YukselS , CelikM , et al. Preliminary results of interferon compared to interferon combined with ribavirin in the treatment of chronic HCV in patients on chronic hemodialysis [abstract no: A2147]. Journal of the American Society of Nephrology2001;12(Program &amp; Abstracts):416-7A. [CENTRAL: CN-00543899] ">Tuglular 2001</a> compared standard interferon dose (3 million units, 3 times/week) combined with ribavirin (400 mg/day, reducing to 200 mg/day if side effects present) against standard interferon alone. <a href="./references#CD007003-bbs2-0010" title="LuxonBA , MuirAJ , HeneghanMA . Safety and tolerability of pegylated interferon with or without low dose ribavirin for treatment of hepatitis C in hemodialysis patients [abstract no: 1281]. Hepatology2005;42(4 Suppl 1):703-4A. [CENTRAL: CN-00581669] ">Luxon 2005</a> compared PEG interferon alfa‐2b (1 µg/kg/week) combined with ribavirin (200 mg/week increased to two or three times/week if tolerated) against PEG interferon alone. <a href="./references#CD007003-bbs2-0010" title="LuxonBA , MuirAJ , HeneghanMA . Safety and tolerability of pegylated interferon with or without low dose ribavirin for treatment of hepatitis C in hemodialysis patients [abstract no: 1281]. Hepatology2005;42(4 Suppl 1):703-4A. [CENTRAL: CN-00581669] ">Luxon 2005</a> reported results together for both groups in a pooled manner with 7/10 patients discontinuing treatment due to side effects and no virological response in three at the end of treatment. <a href="./references#CD007003-bbs2-0006" title="LiuCH , HuangCF , LiuCJ , DaiCY , LiangCC , HuangJF , et al. Peginterferon alfa-2a with or without low dose ribavirin for hemodialysis patients with hepatitis C virus genotype 2 infection: a randomized trial [abstract no: 1851]. Hepatology2013;58(4 Suppl 1):1096A. [EMBASE: 71237851]LiuCH , HuangCF , LiuCJ , DaiCY , LiangCC , HuangJF , et al. Pegylated interferon-alpha2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 1 receiving hemodialysis: a randomized trial. Annals of Internal Medicine2013;159(11):729-38. [MEDLINE: 24297189]LiuCH , LiangCC , SuTH , HungPH , TsaiHB , LiuCJ , et al. Peginterferon alfa-2a plus low dose ribavirin versus peginterferon alfa-2a monotherapy for dialysis patients with hepatitis C virus genotype 1 infection: a randomized trial [abstract no: 1722]. Hepatology2012;56(4 Suppl 1):993A. [EMBASE: 70943304]LiuCH , LiuCJ , HuangCF , LinJW , DaiCY , LiangCC , et al. Peginterferon alfa-2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 2 receiving haemodialysis: a randomised trial. Gut2015;64(2):303-11. [MEDLINE: 24747867]">HELPER 2013</a> compared PEG interferon alfa‐2a (35 µg/week) combined with ribavirin (200 mg/day) for 24 to 48 weeks (genotype 1: 48 weeks; genotype 2: 24 weeks) against PEG interferon alone. </p> <p><a href="./references#CD007003-bbs2-0013" title="TuglularS , Karadayi h, KarakullukcuF , ErmanM , YukselS , CelikM , et al. Preliminary results of interferon compared to interferon combined with ribavirin in the treatment of chronic HCV in patients on chronic hemodialysis [abstract no: A2147]. Journal of the American Society of Nephrology2001;12(Program &amp; Abstracts):416-7A. [CENTRAL: CN-00543899] ">Tuglular 2001</a> reported a combination of standard interferon with ribavirin may lead to higher treatment discontinuation compared to standard interferon alone (<a href="./references#CD007003-fig-0023" title="">Analysis 4.1</a> (1 study, 52 participants): RR 2.97, 95% CI 1.19 to 7.36; low certainty evidence). Data for other outcomes were not reported. Refer to <a href="./appendices#CD007003-sec-0104">Appendix 3</a> for details of adverse events. </p> <p>In low certainty evidence, <a href="./references#CD007003-bbs2-0006" title="LiuCH , HuangCF , LiuCJ , DaiCY , LiangCC , HuangJF , et al. Peginterferon alfa-2a with or without low dose ribavirin for hemodialysis patients with hepatitis C virus genotype 2 infection: a randomized trial [abstract no: 1851]. Hepatology2013;58(4 Suppl 1):1096A. [EMBASE: 71237851]LiuCH , HuangCF , LiuCJ , DaiCY , LiangCC , HuangJF , et al. Pegylated interferon-alpha2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 1 receiving hemodialysis: a randomized trial. Annals of Internal Medicine2013;159(11):729-38. [MEDLINE: 24297189]LiuCH , LiangCC , SuTH , HungPH , TsaiHB , LiuCJ , et al. Peginterferon alfa-2a plus low dose ribavirin versus peginterferon alfa-2a monotherapy for dialysis patients with hepatitis C virus genotype 1 infection: a randomized trial [abstract no: 1722]. Hepatology2012;56(4 Suppl 1):993A. [EMBASE: 70943304]LiuCH , LiuCJ , HuangCF , LinJW , DaiCY , LiangCC , et al. Peginterferon alfa-2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 2 receiving haemodialysis: a randomised trial. Gut2015;64(2):303-11. [MEDLINE: 24747867]">HELPER 2013</a> reported combination therapy may improve SVR (<a href="./references#CD007003-fig-0024" title="">Analysis 5.1</a> (1 study, 377 participants): RR 1.80, 95% CI 1.46 to 2.21), may increase the number of patients with adverse events (<a href="./references#CD007003-fig-0028" title="">Analysis 5.5</a> (1 study, 377 participants): RR 1.10, 95% CI 1.01 to 1.19), may make little or no difference to the end‐of‐treatment response (<a href="./references#CD007003-fig-0025" title="">Analysis 5.2</a> (1 study, 377 participants): RR 1.01, 95% CI 0.94 to 1.09) and treatment discontinuation (<a href="./references#CD007003-fig-0027" title="">Analysis 5.4</a> (1 study, 377 participants): RR 1.71, 95% CI 0.69 to 4.24), and may reduce the number of relapses (<a href="./references#CD007003-fig-0026" title="">Analysis 5.3</a> (1 study, 377 participants): RR 0.33, 95% CI 0.23 to 0.48) compared to PEG interferon alone. </p> <p>Data on death and other outcomes were not reported.</p> </section> <section id="CD007003-sec-0085"> <h4 class="title">Direct‐acting antivirals</h4> <section id="CD007003-sec-0086"> <h5 class="title">Grazoprevir and elbasvir versus placebo</h5> <p>See <a href="./full#CD007003-tbl-0006">summary of findings Table 6</a> </p> <p><a href="./references#CD007003-bbs2-0004" title="ArduinoJM , ZhangB , JacksonB , RothD , BruchfeldA , khawajaS , et al. Impact of grazoprevir plus elbasvir on health-related quality of life in patients with hepatitis C virus genotype 1 infection and chronic kidney disease stages 4 and 5 [abstract no: TH-PO667]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):242A. BarrE , RothD , BruchfeldA , MartinP , NelsonDR , SilvaM , et al. Elbasvir (EBR)/grazoprevir (GZR) treatment of hepatitis C virus (HCV) infection in patients with chronic kidney disease stage 4/5: final results of the C-SURFER phase 3 study [abstract]. Journal of Gastroenterology &amp; Hepatology2016;31(Suppl 2):65-6. [EMBASE: 612983742]BruchfeldA , RothD , MartinP , NelsonD , StanislasP , LondonoMC , et al. Elbasvir/Grazoprevir (EBR/GZR) treatment of hepatitis C Virus (HCV) infection in patients with chronic kidney disease (CKD) stage 4/5: clinical, virological, and health-related quality of life outcomes in the C-SURFER study [abstract]. Swiss Medical Weekly2016;146(Suppl 221):23S. [EMBASE: 626845823]BruchfeldA , RothD , MartinP , NelsonDR , PolS , LondonoMC , et al. Elbasvir plus grazoprevir in patients with hepatitis C virus infection and stage 4-5 chronic kidney disease: clinical, virological, and health-related quality-of-life outcomes from a phase 3, multicentre, randomised, double-blind, placebo-controlled trial. The Lancet. Gastroenterology &amp; Hepatology2017;2(8):585-94. [MEDLINE: 28576451]BruchfeldA , RothD , NelsonD , LiapakisAM , SilvaM , MonsourH , et al. C-surfer: Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and chronic kidney disease [abstract no: FP267]. Nephrology Dialysis Transplantation2015;30(Suppl 3):iii156. [EMBASE: 72206687]RothD , BruchfeldA , MartinP , NelsonDR , SilvaM , MonsourH , et al. Grazoprevir(GZR)/elbasvir (EBR) treatment of hepatitis C virus (HCV) infection in patients with chronic kidney disease stage 4/5:final results of the C -SURFER phase 3 study [abstract no: SA-PO1100]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):B5. RothD , NelsonD , BruchfeldA , LiapakisA , SilvaM , MonsourHJ , et al. C-SURFER: grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and chronic kidney disease [abstract no: LP02]. Journal of Hepatology2015;62(Suppl 2):S263-4. [EMBASE: 71936662]RothD , NelsonDR , BruchfeldA , LiapakisA , SilvaM , MonsourH , et al. Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination phase 3 study [Erratum in: Lancet. 2015 Nov 7;386(10006):1824; PMID: 26843312]. Lancet2015;386(10003):1537-45. [MEDLINE: 26456905]">C‐SURFER 2015</a> compared a combination of grazoprevir (100 mg) and elbasvir (50 mg) once/day for 12 weeks with placebo. The end‐of‐treatment response was higher for grazoprevir plus elbasvir compared to placebo (<a href="./references#CD007003-fig-0029" title="">Analysis 6.1</a> (1 study 235 participants): RR 174.99, 95% CI 11.03 to 2775.78; low certainty of evidence). </p> <p>Other outcomes could not be assessed for participants on dialysis as the placebo group was crossed over to the intervention arm four weeks after the end of treatment and there were no responses in dialysis patients on placebo. </p> </section> </section> <section id="CD007003-sec-0087"> <h4 class="title">Direct‐acting antivirals in combination with pegylated interferon and ribavirin (different doses and duration) </h4> <p>See <a href="./full#CD007003-tbl-0007">summary of findings Table 7</a> </p> <p><a href="./references#CD007003-bbs2-0012" title="BasuP , ShahN , SirikiR , RahamanM , FarhatS . Telaprevir with adjusted dose of ribavirin in naive CHC-G1: efficacy and treatment in CHC in hemodialysis population target C trial: a placebo randomized control clinical trial [abstract no: 513]. American Journal of Gastroenterology2013;108(Suppl 1):S152. [EMBASE: 71220810]BasuP , SirikiR , ShahNJ , FarhatS , MittimaniK , AtluriS , et al. Telaprevir with adjusted dose of ribavirin in naive CHC-G1: Efficacy and treatment in CHC in hemodialysis population. Target C trial-A placebo randomized control clinical trial [abstract no: 517]. Gastroenterology2013;144(5 Suppl 1):S950. [EMBASE: 71119328]BasuPP , ShahNJ , Ashfique, FarhatS , SirikiR . Telaprevir with adjusted dose of ribavirin in naive CHC-G1: efficacy and treatment in CHC in hemodialysis population. Target C trial-a placebo randomized control clinical trial [abstract no: P196]. Surgical Endoscopy2014;28(1 Suppl):S362. [EMBASE: 71480241]BasuPP , ShahNJ , SirikiR , RahamanM . Telaprevir with adjusted dose of ribavirin in Naive CHC-G1: Efficacy and treatment in CHC in hemodialysis population. TARGET C Trial-a placebo randomized control clinical trial [abstract no: P-298]. Liver Transplantation2014;20(Suppl 1):S244. [EMBASE: 71562627]BasuPP , SinkiR , ShahNJ , FarhatS , MittimaniK , AtluriS , et al. Telaprevir with adjusted dose of ribavirin in naive CHC-G1: efficacy and treatment in CHC in hemodialysis population. TARGET C (RCT) [abstract no: 67]. Journal of Hepatology2013;58(Suppl 1):S30-1. [EMBASE: 71054340]">TARGET C 2013</a> compared a combination of telaprevir, PEG interferon and different initial doses of ribavirin for differing durations. It is uncertain whether a combination of telaprevir, a higher initial dose of ribavirin and PEG interferon for 24 weeks leads to an end‐of‐treatment response (<a href="./references#CD007003-fig-0030" title="">Analysis 7.1</a> (1 study, 35 participants): RR 1.02, 95% CI 0.67 to 1.56; very low certainty evidence) or improved SVR (<a href="./references#CD007003-fig-0031" title="">Analysis 7.2</a> (1 study, 35 participants): RR 1.02, 95% CI 0.67 to 1.56; very low certainty evidence) compared to telaprevir, a lower initial dose of ribavirin and PEG interferon for 48 weeks. </p> <p>Data for other outcomes were not reported.</p> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD007003-sec-0088" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD007003-sec-0088"></div> <section id="CD007003-sec-0089"> <h3 class="title" id="CD007003-sec-0089">Summary of main results</h3> <p>In this update, three new studies met our inclusion criteria (<a href="./references#CD007003-bbs2-0004" title="ArduinoJM , ZhangB , JacksonB , RothD , BruchfeldA , khawajaS , et al. Impact of grazoprevir plus elbasvir on health-related quality of life in patients with hepatitis C virus genotype 1 infection and chronic kidney disease stages 4 and 5 [abstract no: TH-PO667]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):242A. BarrE , RothD , BruchfeldA , MartinP , NelsonDR , SilvaM , et al. Elbasvir (EBR)/grazoprevir (GZR) treatment of hepatitis C virus (HCV) infection in patients with chronic kidney disease stage 4/5: final results of the C-SURFER phase 3 study [abstract]. Journal of Gastroenterology &amp; Hepatology2016;31(Suppl 2):65-6. [EMBASE: 612983742]BruchfeldA , RothD , MartinP , NelsonD , StanislasP , LondonoMC , et al. Elbasvir/Grazoprevir (EBR/GZR) treatment of hepatitis C Virus (HCV) infection in patients with chronic kidney disease (CKD) stage 4/5: clinical, virological, and health-related quality of life outcomes in the C-SURFER study [abstract]. Swiss Medical Weekly2016;146(Suppl 221):23S. [EMBASE: 626845823]BruchfeldA , RothD , MartinP , NelsonDR , PolS , LondonoMC , et al. Elbasvir plus grazoprevir in patients with hepatitis C virus infection and stage 4-5 chronic kidney disease: clinical, virological, and health-related quality-of-life outcomes from a phase 3, multicentre, randomised, double-blind, placebo-controlled trial. The Lancet. Gastroenterology &amp; Hepatology2017;2(8):585-94. [MEDLINE: 28576451]BruchfeldA , RothD , NelsonD , LiapakisAM , SilvaM , MonsourH , et al. C-surfer: Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and chronic kidney disease [abstract no: FP267]. Nephrology Dialysis Transplantation2015;30(Suppl 3):iii156. [EMBASE: 72206687]RothD , BruchfeldA , MartinP , NelsonDR , SilvaM , MonsourH , et al. Grazoprevir(GZR)/elbasvir (EBR) treatment of hepatitis C virus (HCV) infection in patients with chronic kidney disease stage 4/5:final results of the C -SURFER phase 3 study [abstract no: SA-PO1100]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):B5. RothD , NelsonD , BruchfeldA , LiapakisA , SilvaM , MonsourHJ , et al. C-SURFER: grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and chronic kidney disease [abstract no: LP02]. Journal of Hepatology2015;62(Suppl 2):S263-4. [EMBASE: 71936662]RothD , NelsonDR , BruchfeldA , LiapakisA , SilvaM , MonsourH , et al. Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination phase 3 study [Erratum in: Lancet. 2015 Nov 7;386(10006):1824; PMID: 26843312]. Lancet2015;386(10003):1537-45. [MEDLINE: 26456905]">C‐SURFER 2015</a>; <a href="./references#CD007003-bbs2-0006" title="LiuCH , HuangCF , LiuCJ , DaiCY , LiangCC , HuangJF , et al. Peginterferon alfa-2a with or without low dose ribavirin for hemodialysis patients with hepatitis C virus genotype 2 infection: a randomized trial [abstract no: 1851]. Hepatology2013;58(4 Suppl 1):1096A. [EMBASE: 71237851]LiuCH , HuangCF , LiuCJ , DaiCY , LiangCC , HuangJF , et al. Pegylated interferon-alpha2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 1 receiving hemodialysis: a randomized trial. Annals of Internal Medicine2013;159(11):729-38. [MEDLINE: 24297189]LiuCH , LiangCC , SuTH , HungPH , TsaiHB , LiuCJ , et al. Peginterferon alfa-2a plus low dose ribavirin versus peginterferon alfa-2a monotherapy for dialysis patients with hepatitis C virus genotype 1 infection: a randomized trial [abstract no: 1722]. Hepatology2012;56(4 Suppl 1):993A. [EMBASE: 70943304]LiuCH , LiuCJ , HuangCF , LinJW , DaiCY , LiangCC , et al. Peginterferon alfa-2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 2 receiving haemodialysis: a randomised trial. Gut2015;64(2):303-11. [MEDLINE: 24747867]">HELPER 2013</a>; <a href="./references#CD007003-bbs2-0012" title="BasuP , ShahN , SirikiR , RahamanM , FarhatS . Telaprevir with adjusted dose of ribavirin in naive CHC-G1: efficacy and treatment in CHC in hemodialysis population target C trial: a placebo randomized control clinical trial [abstract no: 513]. American Journal of Gastroenterology2013;108(Suppl 1):S152. [EMBASE: 71220810]BasuP , SirikiR , ShahNJ , FarhatS , MittimaniK , AtluriS , et al. Telaprevir with adjusted dose of ribavirin in naive CHC-G1: Efficacy and treatment in CHC in hemodialysis population. Target C trial-A placebo randomized control clinical trial [abstract no: 517]. Gastroenterology2013;144(5 Suppl 1):S950. [EMBASE: 71119328]BasuPP , ShahNJ , Ashfique, FarhatS , SirikiR . Telaprevir with adjusted dose of ribavirin in naive CHC-G1: efficacy and treatment in CHC in hemodialysis population. Target C trial-a placebo randomized control clinical trial [abstract no: P196]. Surgical Endoscopy2014;28(1 Suppl):S362. [EMBASE: 71480241]BasuPP , ShahNJ , SirikiR , RahamanM . Telaprevir with adjusted dose of ribavirin in Naive CHC-G1: Efficacy and treatment in CHC in hemodialysis population. TARGET C Trial-a placebo randomized control clinical trial [abstract no: P-298]. Liver Transplantation2014;20(Suppl 1):S244. [EMBASE: 71562627]BasuPP , SinkiR , ShahNJ , FarhatS , MittimaniK , AtluriS , et al. Telaprevir with adjusted dose of ribavirin in naive CHC-G1: efficacy and treatment in CHC in hemodialysis population. TARGET C (RCT) [abstract no: 67]. Journal of Hepatology2013;58(Suppl 1):S30-1. [EMBASE: 71054340]">TARGET C 2013</a>), bringing the total number of included studies to 13 (997 randomised participants). </p> <p>Five studies (152 participants) with low to moderate certainty of evidence and overall unclear to low risk of bias compared standard interferon with placebo or control. Standard interferon was relatively more effective than placebo or control in producing an end‐of‐treatment response and was well tolerated, but was not more effective in producing a SVR (<a href="./full#CD007003-tbl-0001">summary of findings Table 1</a>). </p> <p>One study (50 participants) with low certainty of evidence and overall low risk of bias compared standard interferon and PEG interferon. PEG interferon was reported to be better in producing an end‐of‐treatment response but not a better SVR than standard interferon, and both were equally tolerated (<a href="./full#CD007003-tbl-0002">summary of findings Table 2</a>). </p> <p>Two studies (97 participants) with low to moderate certainty of evidence and overall low risk of bias compared two doses of PEG interferon in two different preparations. Increasing doses of PEG interferon improved end‐of‐treatment response but not a better SVR. Higher doses were equally tolerated. The addition of ribavirin to standard interferon resulted in more treatment discontinuation in one small study (<a href="./full#CD007003-tbl-0003">summary of findings Table 3</a>; <a href="./full#CD007003-tbl-0004">summary of findings Table 4</a>). </p> <p>One study (377 participants) with low certainty of evidence and low risk of bias showed that the combination of PEG interferon and ribavirin had higher SVR and fewer relapses, but a higher number of adverse events (<a href="./full#CD007003-tbl-0005">summary of findings Table 5</a>). </p> <p>Compared to placebo, the combination of direct‐acting antivirals (grazoprevir and elbasvir) produced a higher end‐of‐treatment response in one study (235 participants, 179 on dialysis, 173 analysed) with low certainty evidence and low risk of bias (<a href="./full#CD007003-tbl-0006">summary of findings Table 6</a>). </p> <p>Compared to a combination of telaprevir for 12 weeks with PEG interferon and ribavirin for 24 weeks it is unclear whether a combination of telaprevir for 12 weeks, PEG interferon 48 weeks and initial low dose ribavirin for 12 weeks followed by 36 weeks of regular dose produced a SVR in one study (35 participants) with very low certainty evidence and unclear risk of bias (<a href="./full#CD007003-tbl-0007">summary of findings Table 7</a>). </p> </section> <section id="CD007003-sec-0090"> <h3 class="title" id="CD007003-sec-0090">Overall completeness and applicability of evidence</h3> <p>The studies included in this review investigated different interventions for HCV infection in CKD patients on dialysis. Direct‐acting antivirals have now replaced interferons in the treatment of HCV in view of better tolerability and near‐universal efficacy, which also may be the reason for their use without RCT evidence. The review highlights the small number of RCTs available and the small number of participants in most. The included studies addressed outcomes such as death, relapse of disease, end‐of‐treatment response, SVR, treatment discontinuation and adverse events. The primary outcome measure in the included studies was SVR. However, the utility of SVR as a valid surrogate for long‐term outcomes including death is not confirmed by RCT evidence. In this review, most included studies had a short follow‐up duration, while some did not report death data resulting in a lack of high‐certainty evidence in this area. Health‐related QoL was reported in <a href="./references#CD007003-bbs2-0004" title="ArduinoJM , ZhangB , JacksonB , RothD , BruchfeldA , khawajaS , et al. Impact of grazoprevir plus elbasvir on health-related quality of life in patients with hepatitis C virus genotype 1 infection and chronic kidney disease stages 4 and 5 [abstract no: TH-PO667]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):242A. BarrE , RothD , BruchfeldA , MartinP , NelsonDR , SilvaM , et al. Elbasvir (EBR)/grazoprevir (GZR) treatment of hepatitis C virus (HCV) infection in patients with chronic kidney disease stage 4/5: final results of the C-SURFER phase 3 study [abstract]. Journal of Gastroenterology &amp; Hepatology2016;31(Suppl 2):65-6. [EMBASE: 612983742]BruchfeldA , RothD , MartinP , NelsonD , StanislasP , LondonoMC , et al. Elbasvir/Grazoprevir (EBR/GZR) treatment of hepatitis C Virus (HCV) infection in patients with chronic kidney disease (CKD) stage 4/5: clinical, virological, and health-related quality of life outcomes in the C-SURFER study [abstract]. Swiss Medical Weekly2016;146(Suppl 221):23S. [EMBASE: 626845823]BruchfeldA , RothD , MartinP , NelsonDR , PolS , LondonoMC , et al. Elbasvir plus grazoprevir in patients with hepatitis C virus infection and stage 4-5 chronic kidney disease: clinical, virological, and health-related quality-of-life outcomes from a phase 3, multicentre, randomised, double-blind, placebo-controlled trial. The Lancet. Gastroenterology &amp; Hepatology2017;2(8):585-94. [MEDLINE: 28576451]BruchfeldA , RothD , NelsonD , LiapakisAM , SilvaM , MonsourH , et al. C-surfer: Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and chronic kidney disease [abstract no: FP267]. Nephrology Dialysis Transplantation2015;30(Suppl 3):iii156. [EMBASE: 72206687]RothD , BruchfeldA , MartinP , NelsonDR , SilvaM , MonsourH , et al. Grazoprevir(GZR)/elbasvir (EBR) treatment of hepatitis C virus (HCV) infection in patients with chronic kidney disease stage 4/5:final results of the C -SURFER phase 3 study [abstract no: SA-PO1100]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):B5. RothD , NelsonD , BruchfeldA , LiapakisA , SilvaM , MonsourHJ , et al. C-SURFER: grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and chronic kidney disease [abstract no: LP02]. Journal of Hepatology2015;62(Suppl 2):S263-4. [EMBASE: 71936662]RothD , NelsonDR , BruchfeldA , LiapakisA , SilvaM , MonsourH , et al. Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination phase 3 study [Erratum in: Lancet. 2015 Nov 7;386(10006):1824; PMID: 26843312]. Lancet2015;386(10003):1537-45. [MEDLINE: 26456905]">C‐SURFER 2015</a> but not separately for those on dialysis. </p> <p>This update identified one study <a href="./references#CD007003-bbs2-0006" title="LiuCH , HuangCF , LiuCJ , DaiCY , LiangCC , HuangJF , et al. Peginterferon alfa-2a with or without low dose ribavirin for hemodialysis patients with hepatitis C virus genotype 2 infection: a randomized trial [abstract no: 1851]. Hepatology2013;58(4 Suppl 1):1096A. [EMBASE: 71237851]LiuCH , HuangCF , LiuCJ , DaiCY , LiangCC , HuangJF , et al. Pegylated interferon-alpha2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 1 receiving hemodialysis: a randomized trial. Annals of Internal Medicine2013;159(11):729-38. [MEDLINE: 24297189]LiuCH , LiangCC , SuTH , HungPH , TsaiHB , LiuCJ , et al. Peginterferon alfa-2a plus low dose ribavirin versus peginterferon alfa-2a monotherapy for dialysis patients with hepatitis C virus genotype 1 infection: a randomized trial [abstract no: 1722]. Hepatology2012;56(4 Suppl 1):993A. [EMBASE: 70943304]LiuCH , LiuCJ , HuangCF , LinJW , DaiCY , LiangCC , et al. Peginterferon alfa-2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 2 receiving haemodialysis: a randomised trial. Gut2015;64(2):303-11. [MEDLINE: 24747867]">HELPER 2013</a> using PEG interferon with or without ribavirin which had no data on death or cost‐effectiveness. Two studies tested direct‐acting antivirals against a placebo or in combination with interferons. One was available only as five conference abstracts (<a href="./references#CD007003-bbs2-0012" title="BasuP , ShahN , SirikiR , RahamanM , FarhatS . Telaprevir with adjusted dose of ribavirin in naive CHC-G1: efficacy and treatment in CHC in hemodialysis population target C trial: a placebo randomized control clinical trial [abstract no: 513]. American Journal of Gastroenterology2013;108(Suppl 1):S152. [EMBASE: 71220810]BasuP , SirikiR , ShahNJ , FarhatS , MittimaniK , AtluriS , et al. Telaprevir with adjusted dose of ribavirin in naive CHC-G1: Efficacy and treatment in CHC in hemodialysis population. Target C trial-A placebo randomized control clinical trial [abstract no: 517]. Gastroenterology2013;144(5 Suppl 1):S950. [EMBASE: 71119328]BasuPP , ShahNJ , Ashfique, FarhatS , SirikiR . Telaprevir with adjusted dose of ribavirin in naive CHC-G1: efficacy and treatment in CHC in hemodialysis population. Target C trial-a placebo randomized control clinical trial [abstract no: P196]. Surgical Endoscopy2014;28(1 Suppl):S362. [EMBASE: 71480241]BasuPP , ShahNJ , SirikiR , RahamanM . Telaprevir with adjusted dose of ribavirin in Naive CHC-G1: Efficacy and treatment in CHC in hemodialysis population. TARGET C Trial-a placebo randomized control clinical trial [abstract no: P-298]. Liver Transplantation2014;20(Suppl 1):S244. [EMBASE: 71562627]BasuPP , SinkiR , ShahNJ , FarhatS , MittimaniK , AtluriS , et al. Telaprevir with adjusted dose of ribavirin in naive CHC-G1: efficacy and treatment in CHC in hemodialysis population. TARGET C (RCT) [abstract no: 67]. Journal of Hepatology2013;58(Suppl 1):S30-1. [EMBASE: 71054340]">TARGET C 2013</a>), and another placebo‐controlled RCT (<a href="./references#CD007003-bbs2-0004" title="ArduinoJM , ZhangB , JacksonB , RothD , BruchfeldA , khawajaS , et al. Impact of grazoprevir plus elbasvir on health-related quality of life in patients with hepatitis C virus genotype 1 infection and chronic kidney disease stages 4 and 5 [abstract no: TH-PO667]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):242A. BarrE , RothD , BruchfeldA , MartinP , NelsonDR , SilvaM , et al. Elbasvir (EBR)/grazoprevir (GZR) treatment of hepatitis C virus (HCV) infection in patients with chronic kidney disease stage 4/5: final results of the C-SURFER phase 3 study [abstract]. Journal of Gastroenterology &amp; Hepatology2016;31(Suppl 2):65-6. [EMBASE: 612983742]BruchfeldA , RothD , MartinP , NelsonD , StanislasP , LondonoMC , et al. Elbasvir/Grazoprevir (EBR/GZR) treatment of hepatitis C Virus (HCV) infection in patients with chronic kidney disease (CKD) stage 4/5: clinical, virological, and health-related quality of life outcomes in the C-SURFER study [abstract]. Swiss Medical Weekly2016;146(Suppl 221):23S. [EMBASE: 626845823]BruchfeldA , RothD , MartinP , NelsonDR , PolS , LondonoMC , et al. Elbasvir plus grazoprevir in patients with hepatitis C virus infection and stage 4-5 chronic kidney disease: clinical, virological, and health-related quality-of-life outcomes from a phase 3, multicentre, randomised, double-blind, placebo-controlled trial. The Lancet. Gastroenterology &amp; Hepatology2017;2(8):585-94. [MEDLINE: 28576451]BruchfeldA , RothD , NelsonD , LiapakisAM , SilvaM , MonsourH , et al. C-surfer: Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and chronic kidney disease [abstract no: FP267]. Nephrology Dialysis Transplantation2015;30(Suppl 3):iii156. [EMBASE: 72206687]RothD , BruchfeldA , MartinP , NelsonDR , SilvaM , MonsourH , et al. Grazoprevir(GZR)/elbasvir (EBR) treatment of hepatitis C virus (HCV) infection in patients with chronic kidney disease stage 4/5:final results of the C -SURFER phase 3 study [abstract no: SA-PO1100]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):B5. RothD , NelsonD , BruchfeldA , LiapakisA , SilvaM , MonsourHJ , et al. C-SURFER: grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and chronic kidney disease [abstract no: LP02]. Journal of Hepatology2015;62(Suppl 2):S263-4. [EMBASE: 71936662]RothD , NelsonDR , BruchfeldA , LiapakisA , SilvaM , MonsourH , et al. Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination phase 3 study [Erratum in: Lancet. 2015 Nov 7;386(10006):1824; PMID: 26843312]. Lancet2015;386(10003):1537-45. [MEDLINE: 26456905]">C‐SURFER 2015</a>) included CKD stages 4 and 5 reported data on SVR, relapse, treatment discontinuation and adverse events; analysis could only be done for the end‐of‐treatment response for participants on dialysis. No studies comparing different combinations of direct‐acting antivirals or direct‐acting antivirals compared to interferon‐based regimens were found. However, recent guidelines have recommended interferon‐free therapy for those with CKD on dialysis. </p> <p>For standard interferon versus placebo or control, data were not available for relapses in two studies (<a href="./references#CD007003-bbs2-0001" title="AlfurayhO , ChaabanA , PallA , Al MutawaN , EllisM , Al MeshariK , et al. Long-term follow up of haemodialysis (HD) patients with chronic hepatitis C (HCV) infection - favorable outcome with a-interferon (IFN) followed by kidney transplantation [abstract no: M221]. Nephrology Dialysis Transplantation2002;17(Suppl 1):110. [CENTRAL: CN-00509051] AlfurayhO , ChaabanA , PallA , EllisM , ChaudryT , AlmeshariK . Randomised controlled trial of interferon-alpha (IFNalpha) in patients with chronic hepatitis C (HCV) on haemodialysis (HD) [abstract]. Nephrology Dialysis Transplantation2000;15(9):A106. [CENTRAL: CN-00497910] AlfurayhOI , ChaabanAM , PallAA , EllisME , AlmeshariK , Al QuaizMN , et al. IFN-alpha for chronic hepatitis C infection (HCV) in haemodialysis (HD) patients - a prospective, randomised, controlled study [abstract]. Journal of the American Society of Nephrology2000;11(Sept):255A. [CENTRAL: CN-00517117] ">Alfurayh 2000</a>; <a href="./references#CD007003-bbs2-0002" title="CampistolJM , CasellasJ , CuevasX , LatorreB , MartínezJ , ModolJ , et al. Efficacy and tolerability of a-2b interferon in the treatment of virus C chronic hepatitis in an hemodialysis population [abstract no: 309] [Eficacia y tolerancia del interferon a-2b en el tratamiento de la hepatitis cronica por virus C (VHC) en la población en hemodialisis (HD)]. Nefrología1996;16(Suppl 1):80. [CENTRAL: CN-00400461] ">Campistol 1996</a>), SVR in one study (<a href="./references#CD007003-bbs2-0002" title="CampistolJM , CasellasJ , CuevasX , LatorreB , MartínezJ , ModolJ , et al. Efficacy and tolerability of a-2b interferon in the treatment of virus C chronic hepatitis in an hemodialysis population [abstract no: 309] [Eficacia y tolerancia del interferon a-2b en el tratamiento de la hepatitis cronica por virus C (VHC) en la población en hemodialisis (HD)]. Nefrología1996;16(Suppl 1):80. [CENTRAL: CN-00400461] ">Campistol 1996</a>), and treatment discontinuation in one study (<a href="./references#CD007003-bbs2-0001" title="AlfurayhO , ChaabanA , PallA , Al MutawaN , EllisM , Al MeshariK , et al. Long-term follow up of haemodialysis (HD) patients with chronic hepatitis C (HCV) infection - favorable outcome with a-interferon (IFN) followed by kidney transplantation [abstract no: M221]. Nephrology Dialysis Transplantation2002;17(Suppl 1):110. [CENTRAL: CN-00509051] AlfurayhO , ChaabanA , PallA , EllisM , ChaudryT , AlmeshariK . Randomised controlled trial of interferon-alpha (IFNalpha) in patients with chronic hepatitis C (HCV) on haemodialysis (HD) [abstract]. Nephrology Dialysis Transplantation2000;15(9):A106. [CENTRAL: CN-00497910] AlfurayhOI , ChaabanAM , PallAA , EllisME , AlmeshariK , Al QuaizMN , et al. IFN-alpha for chronic hepatitis C infection (HCV) in haemodialysis (HD) patients - a prospective, randomised, controlled study [abstract]. Journal of the American Society of Nephrology2000;11(Sept):255A. [CENTRAL: CN-00517117] ">Alfurayh 2000</a>).  </p> <p>No data were available in any of the included studies for cost‐effectiveness, QoL and outcomes such as myocardial infarction. There were no studies comparing different durations of therapy or PEG interferon versus placebo or control. Most of the studies had considerable exclusion criteria in view of the known adverse events of the earlier used interventions namely interferons limiting their use to a select group amongst CKD patients. Hence, the evidence may only be valid for a group of patients who fit the inclusion and exclusion criteria of these studies. The previous practice of preferring PEG interferon over standard interferon may not be valid, and the addition of ribavirin along with standard interferon may result in more treatment discontinuation in this population. </p> </section> <section id="CD007003-sec-0091"> <h3 class="title" id="CD007003-sec-0091">Quality of the evidence</h3> <p><a href="#CD007003-fig-0002">Figure 2</a> and <a href="#CD007003-fig-0003">Figure 3</a> summarise the quality of evidence. Studies comparing standard interferon with placebo or control were of low to moderate certainty evidence and had unclear to low risk of bias. Due to the small number of participants in the studies, data on relapses could only be analysed in <a href="./references#CD007003-bbs2-0003" title="CampistolJM , EsforzadoN , MartinezJ , RoselloL , VecianaL , ModolJ , et al. Efficacy and tolerance of interferon-alpha(2b) in the treatment of chronic hepatitis C virus infection in haemodialysis patients. Pre- and post-renal transplantation assessment. Nephrology Dialysis Transplantation1999;14(11):2704-9. [MEDLINE: 10534516]">Campistol 1999a</a>. Follow‐up after treatment was not available in <a href="./references#CD007003-bbs2-0002" title="CampistolJM , CasellasJ , CuevasX , LatorreB , MartínezJ , ModolJ , et al. Efficacy and tolerability of a-2b interferon in the treatment of virus C chronic hepatitis in an hemodialysis population [abstract no: 309] [Eficacia y tolerancia del interferon a-2b en el tratamiento de la hepatitis cronica por virus C (VHC) en la población en hemodialisis (HD)]. Nefrología1996;16(Suppl 1):80. [CENTRAL: CN-00400461] ">Campistol 1996</a> which prevented assessment of SVR. Only <a href="./references#CD007003-bbs2-0009" title="LiuCH , LiangCC , LinJW , ChenSI , TsaiHB , ChangCS , et al. Pegylated interferon alpha-2a versus standard interferon alpha-2a for treatment-naive dialysis patients with chronic hepatitis C: a randomised study. Gut2008;57(4):525-30. [MEDLINE: 17881538]">Liu 2008a</a> compared PEG interferon with standard interferon, and this had moderate certainty evidence and a low risk of bias. Two studies (<a href="./references#CD007003-bbs2-0007" title="Peck-RadosavljevicM , BoletisJ , BesisikF , Lucia FerrazM , AlricL , SamuelD , et al. Low-dose peginterferon alfa-2A (40KD) (PEGASYS®) to treat hepatitis C infected end-stage renal disease patients undergoing haemodialysis: final study results [abstract no: 999]. Journal of Hepatology2008;48(Suppl 2):S374. [CENTRAL: CN-00653069] Peck-RadosavljevicM , BoletisJ , BesisikF , Lucia FerrazM , AlricL , SamuelD , et al. Low-dose peginterferon alfa-2a is safe and produces a sustained virologic response in patients with chronic hepatitis C and end-stage renal disease. Clinical Gastroenterology &amp; Hepatology2011;9(3):242-8. [MEDLINE: 21056689]Peck-RadosavljevicM , BoletisJ , BesisikF , Lucia FerrazM , AlricL , SamuelD , et al. Use of low-dose peginterferon alfa-2a (40 kD) (Pegasys) to treat hepatitis C infected end-stage renal disease patients undergoing haemodialysis: interim results from a randomised study [abstract no: 628]. Journal of Hepatology2007;46(Suppl 1):S237-8. [CENTRAL: CN-00716095] ">HELPS 2011</a>; <a href="./references#CD007003-bbs2-0011" title="RussoMW , GhalibR , SigalS , JoshiV . Randomized trial of pegylated interferon alpha-2b monotherapy in haemodialysis patients with chronic hepatitis C. Nephrology Dialysis Transplantation2006;21(2):437-43. [MEDLINE: 16234288]RussoMW , GhalibR , SigalSH , JoshiV , DetwilerR , AndreoniK , et al. A multi-center randomized trial of pegylated interferon alfa-2B monotherapy (PEG-INTRON) in patients with chronic hepatitis C and end stage kidney disease on dialysis [abstract no: 540]. Hepatology2004;40(4 Suppl 1):399A. [CENTRAL: CN-00507218] ">Russo 2006</a>) compared two doses of PEG interferon both with moderate certainty evidence and an overall low risk of bias. Two studies (<a href="./references#CD007003-bbs2-0010" title="LuxonBA , MuirAJ , HeneghanMA . Safety and tolerability of pegylated interferon with or without low dose ribavirin for treatment of hepatitis C in hemodialysis patients [abstract no: 1281]. Hepatology2005;42(4 Suppl 1):703-4A. [CENTRAL: CN-00581669] ">Luxon 2005</a>; <a href="./references#CD007003-bbs2-0013" title="TuglularS , Karadayi h, KarakullukcuF , ErmanM , YukselS , CelikM , et al. Preliminary results of interferon compared to interferon combined with ribavirin in the treatment of chronic HCV in patients on chronic hemodialysis [abstract no: A2147]. Journal of the American Society of Nephrology2001;12(Program &amp; Abstracts):416-7A. [CENTRAL: CN-00543899] ">Tuglular 2001</a>) with low certainty evidence comparing standard or PEG interferon alone or in combination with ribavirin did not have follow‐up data. Considering the small number of studies and the small number of participants, findings should be viewed with caution. </p> <p>Studies comparing combination PEG interferon with or without ribavirin and direct‐acting antivirals with placebo had low to very low certainty evidence and a low risk of bias. <a href="./references#CD007003-bbs2-0004" title="ArduinoJM , ZhangB , JacksonB , RothD , BruchfeldA , khawajaS , et al. Impact of grazoprevir plus elbasvir on health-related quality of life in patients with hepatitis C virus genotype 1 infection and chronic kidney disease stages 4 and 5 [abstract no: TH-PO667]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):242A. BarrE , RothD , BruchfeldA , MartinP , NelsonDR , SilvaM , et al. Elbasvir (EBR)/grazoprevir (GZR) treatment of hepatitis C virus (HCV) infection in patients with chronic kidney disease stage 4/5: final results of the C-SURFER phase 3 study [abstract]. Journal of Gastroenterology &amp; Hepatology2016;31(Suppl 2):65-6. [EMBASE: 612983742]BruchfeldA , RothD , MartinP , NelsonD , StanislasP , LondonoMC , et al. Elbasvir/Grazoprevir (EBR/GZR) treatment of hepatitis C Virus (HCV) infection in patients with chronic kidney disease (CKD) stage 4/5: clinical, virological, and health-related quality of life outcomes in the C-SURFER study [abstract]. Swiss Medical Weekly2016;146(Suppl 221):23S. [EMBASE: 626845823]BruchfeldA , RothD , MartinP , NelsonDR , PolS , LondonoMC , et al. Elbasvir plus grazoprevir in patients with hepatitis C virus infection and stage 4-5 chronic kidney disease: clinical, virological, and health-related quality-of-life outcomes from a phase 3, multicentre, randomised, double-blind, placebo-controlled trial. The Lancet. Gastroenterology &amp; Hepatology2017;2(8):585-94. [MEDLINE: 28576451]BruchfeldA , RothD , NelsonD , LiapakisAM , SilvaM , MonsourH , et al. C-surfer: Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and chronic kidney disease [abstract no: FP267]. Nephrology Dialysis Transplantation2015;30(Suppl 3):iii156. [EMBASE: 72206687]RothD , BruchfeldA , MartinP , NelsonDR , SilvaM , MonsourH , et al. Grazoprevir(GZR)/elbasvir (EBR) treatment of hepatitis C virus (HCV) infection in patients with chronic kidney disease stage 4/5:final results of the C -SURFER phase 3 study [abstract no: SA-PO1100]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):B5. RothD , NelsonD , BruchfeldA , LiapakisA , SilvaM , MonsourHJ , et al. C-SURFER: grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and chronic kidney disease [abstract no: LP02]. Journal of Hepatology2015;62(Suppl 2):S263-4. [EMBASE: 71936662]RothD , NelsonDR , BruchfeldA , LiapakisA , SilvaM , MonsourH , et al. Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination phase 3 study [Erratum in: Lancet. 2015 Nov 7;386(10006):1824; PMID: 26843312]. Lancet2015;386(10003):1537-45. [MEDLINE: 26456905]">C‐SURFER 2015</a> included CKD stages 4 and 5. <a href="./references#CD007003-bbs2-0012" title="BasuP , ShahN , SirikiR , RahamanM , FarhatS . Telaprevir with adjusted dose of ribavirin in naive CHC-G1: efficacy and treatment in CHC in hemodialysis population target C trial: a placebo randomized control clinical trial [abstract no: 513]. American Journal of Gastroenterology2013;108(Suppl 1):S152. [EMBASE: 71220810]BasuP , SirikiR , ShahNJ , FarhatS , MittimaniK , AtluriS , et al. Telaprevir with adjusted dose of ribavirin in naive CHC-G1: Efficacy and treatment in CHC in hemodialysis population. Target C trial-A placebo randomized control clinical trial [abstract no: 517]. Gastroenterology2013;144(5 Suppl 1):S950. [EMBASE: 71119328]BasuPP , ShahNJ , Ashfique, FarhatS , SirikiR . Telaprevir with adjusted dose of ribavirin in naive CHC-G1: efficacy and treatment in CHC in hemodialysis population. Target C trial-a placebo randomized control clinical trial [abstract no: P196]. Surgical Endoscopy2014;28(1 Suppl):S362. [EMBASE: 71480241]BasuPP , ShahNJ , SirikiR , RahamanM . Telaprevir with adjusted dose of ribavirin in Naive CHC-G1: Efficacy and treatment in CHC in hemodialysis population. TARGET C Trial-a placebo randomized control clinical trial [abstract no: P-298]. Liver Transplantation2014;20(Suppl 1):S244. [EMBASE: 71562627]BasuPP , SinkiR , ShahNJ , FarhatS , MittimaniK , AtluriS , et al. Telaprevir with adjusted dose of ribavirin in naive CHC-G1: efficacy and treatment in CHC in hemodialysis population. TARGET C (RCT) [abstract no: 67]. Journal of Hepatology2013;58(Suppl 1):S30-1. [EMBASE: 71054340]">TARGET C 2013</a> assessed the combination of PEG interferon, ribavirin and telaprevir and had very low certainty evidence and unclear risk of bias. </p> </section> <section id="CD007003-sec-0092"> <h3 class="title" id="CD007003-sec-0092">Potential biases in the review process</h3> <section id="CD007003-sec-0093"> <h4 class="title">Strengths</h4> <p>This review was conducted as per protocol following pre‐specified inclusion criteria and included comprehensive literature searches to find all relevant studies. Three authors screened all titles, abstracts and full papers to avoid selection bias. </p> </section> <section id="CD007003-sec-0094"> <h4 class="title">Limitations</h4> <p>Four studies were available only as abstracts (<a href="./references#CD007003-bbs2-0001" title="AlfurayhO , ChaabanA , PallA , Al MutawaN , EllisM , Al MeshariK , et al. Long-term follow up of haemodialysis (HD) patients with chronic hepatitis C (HCV) infection - favorable outcome with a-interferon (IFN) followed by kidney transplantation [abstract no: M221]. Nephrology Dialysis Transplantation2002;17(Suppl 1):110. [CENTRAL: CN-00509051] AlfurayhO , ChaabanA , PallA , EllisM , ChaudryT , AlmeshariK . Randomised controlled trial of interferon-alpha (IFNalpha) in patients with chronic hepatitis C (HCV) on haemodialysis (HD) [abstract]. Nephrology Dialysis Transplantation2000;15(9):A106. [CENTRAL: CN-00497910] AlfurayhOI , ChaabanAM , PallAA , EllisME , AlmeshariK , Al QuaizMN , et al. IFN-alpha for chronic hepatitis C infection (HCV) in haemodialysis (HD) patients - a prospective, randomised, controlled study [abstract]. Journal of the American Society of Nephrology2000;11(Sept):255A. [CENTRAL: CN-00517117] ">Alfurayh 2000</a>; <a href="./references#CD007003-bbs2-0002" title="CampistolJM , CasellasJ , CuevasX , LatorreB , MartínezJ , ModolJ , et al. Efficacy and tolerability of a-2b interferon in the treatment of virus C chronic hepatitis in an hemodialysis population [abstract no: 309] [Eficacia y tolerancia del interferon a-2b en el tratamiento de la hepatitis cronica por virus C (VHC) en la población en hemodialisis (HD)]. Nefrología1996;16(Suppl 1):80. [CENTRAL: CN-00400461] ">Campistol 1996</a>; <a href="./references#CD007003-bbs2-0010" title="LuxonBA , MuirAJ , HeneghanMA . Safety and tolerability of pegylated interferon with or without low dose ribavirin for treatment of hepatitis C in hemodialysis patients [abstract no: 1281]. Hepatology2005;42(4 Suppl 1):703-4A. [CENTRAL: CN-00581669] ">Luxon 2005</a>; <a href="./references#CD007003-bbs2-0013" title="TuglularS , Karadayi h, KarakullukcuF , ErmanM , YukselS , CelikM , et al. Preliminary results of interferon compared to interferon combined with ribavirin in the treatment of chronic HCV in patients on chronic hemodialysis [abstract no: A2147]. Journal of the American Society of Nephrology2001;12(Program &amp; Abstracts):416-7A. [CENTRAL: CN-00543899] ">Tuglular 2001</a>), one of which reported outcomes in a pooled manner (<a href="./references#CD007003-bbs2-0013" title="TuglularS , Karadayi h, KarakullukcuF , ErmanM , YukselS , CelikM , et al. Preliminary results of interferon compared to interferon combined with ribavirin in the treatment of chronic HCV in patients on chronic hemodialysis [abstract no: A2147]. Journal of the American Society of Nephrology2001;12(Program &amp; Abstracts):416-7A. [CENTRAL: CN-00543899] ">Tuglular 2001</a>). Older studies which considered HCV as non‐A non‐B hepatitis were excluded. This may lead to a loss of data and influence the results as the number of studies and participants is small. The review included only RCTs which may result in loss of data on rare events. Stratification according to known predictors of treatment response such as HCV genotype, HCV viral load, age, race, genetic polymorphisms, co‐infection, body mass index, and alcohol intake was not done due to lack of data or a small number of participants. The review limited itself to dialysis patients, and kidney transplant outcomes were not assessed. </p> <p>Due to direct‐acting antivirals having efficacy in nearly all studies and treatment durations of three months, present outcome definitions do not consider the end‐of‐treatment response, and SVR is assessed at 12 weeks. Our review included both interferon and direct antiviral agent studies and definitions as per protocol were used.  </p> <p>The update identified one study which was available as an abstract, one which included CKD 4 and 5, and which assessed SVR at 12 weeks instead of 24 weeks. </p> </section> </section> <section id="CD007003-sec-0095"> <h3 class="title" id="CD007003-sec-0095">Agreements and disagreements with other studies or reviews</h3> <p>We found eight published reviews of interventions for HCV in dialysis patients five with interferon therapy and three with direct‐acting antivirals. All included both uncontrolled and controlled studies and presented results of pooled data. </p> <p> <ul id="CD007003-list-0022"> <li> <p><a href="./references#CD007003-bbs2-0019" title="AlavianSM , TabatabaeiSV . Meta-analysis of factors associated with sustained viral response in patients on hemodialysis treated with standard or pegylated interferon for hepatitis C infection. Iranian Journal of Kidney Diseases2010;4(3):181-94. [MEDLINE: 20622305]">Alavian 2010</a> assessed factors associated with SVR to standard interferon and PEG interferon in patients on HD with HCV infection. Twenty‐one studies using standard interferons (491 patients) found an SVR of 39.1% (95% CI 32.1 to 46.1) and 12 studies on PEG interferons (279 patients) found an SVR of 39.3% (95% CI 26.5 to 2.1) and treatment discontinuation in 22.6% (95% CI 10.4 to 34.8) and 29.7% (95% CI 21.7 to 37.7), respectively. Two RCTs were included in this meta‐analysis. In agreement with the present review, no additional benefit was found for PEG interferon. </p> </li> <li> <p><a href="./references#CD007003-bbs2-0036" title="FabriziF , DulaiG , DixitV , BunnapradistS , MartinP . Meta-analysis: interferon for the treatment of chronic hepatitis C in dialysis patients. Alimentary Pharmacology &amp; Therapeutics2003;18(11-12):1071-81. [MEDLINE: 14653826]">Fabrizi 2003</a> considered monotherapy with interferon and included 14 clinical trials (269 participants) of which two were RCTs. The mean overall estimate for SVR and the drop‐out rate was 37% (95% CI 28% to 48%) and 17% (95% CI 10% to 28%), respectively, with heterogeneity with regard to both outcomes. They concluded that tolerance to interferon monotherapy was lower in dialysis and this may be due to no comparative analysis being provided with a placebo/control group. </p> </li> <li> <p><a href="./references#CD007003-bbs2-0039" title="FabriziF , GaneshanSV , LunghiG , MessaP , MartinP . Antiviral therapy of hepatitis C in chronic kidney diseases: meta-analysis of controlled clinical trials. Journal of Viral Hepatitis2008;15(8):600-6. [MEDLINE: 18444984]">Fabrizi 2008a</a> included 13 studies with 539 unique patients, 10 of which concerned patients on maintenance dialysis, three being RCTs. SVR was significantly more in patients receiving antiviral therapy with a pooled odds ratio (OR) of failure to obtain an SVR being 0.08 (95% CI 0.03 to 0.23) including in the subgroup of studies with interferon monotherapy. The pooled OR of drop‐out rate was significantly increased in the study versus control patients (OR 0.39, 95% CI 0.16 to 0.96) but not significant in the subgroup of six studies considering interferon monotherapy. The studies were heterogeneous with regard to viral response and drop‐out rate. As compared to the present review response to treatment was better. This may reflect a publication bias as the review did not include RCTs published as abstracts and included uncontrolled studies. </p> </li> <li> <p><a href="./references#CD007003-bbs2-0040" title="FabriziF , DixitV , MessaP , MartinP . Interferon monotherapy of chronic hepatitis C in dialysis patients: meta-analysis of clinical trials. Journal of Viral Hepatitis2008;15(2):79-88. [MEDLINE: 18184190]">Fabrizi 2008b</a> included 28 studies (645 unique patients) of which three were RCTs including monotherapy with either standard or PEG interferon. For standard interferon, SVR was seen in 39% (95% CI 32% to 46%) and treatment discontinuation in 19% (95% CI 13% to 26%). For PEG interferon, SVR was seen in 31% (95% CI 7% to 55%) and treatment discontinuation in 27% (95% CI 1% to 52%). In agreement with the present review monotherapy with PEG interferon was not of additional benefit. </p> </li> <li> <p><a href="./references#CD007003-bbs2-0072" title="RussoMW , GoldsweigCD , JacobsonIM , Brown RS Jr. Interferon monotherapy for dialysis patients with chronic hepatitis C: an analysis of the literature on efficacy and safety. American Journal of Gastroenterology2003;98(7):1610-5. [MEDLINE: 12873587]">Russo 2003</a> included 11 studies (213 participants) two being RCTs for standard interferon monotherapy. Of the eight studies using 3 million units, 3 times/week dose, the pooled SVR was 33% (95 CI 21% to 51%) with a 29.6% treatment discontinuation rate. They concluded that response to standard interferon was more than in the normal population with more adverse events, but no comparative analysis was provided. </p> </li> <li> <p><a href="./references#CD007003-bbs2-0060" title="LiT , QuY , GuoY , WangY , WL. Efficacy and safety of direct-acting antivirals-based antiviral therapies for hepatitis C virus patients with stage 4-5 chronic kidney disease: a meta-analysis. Liver International2017;37(7):974-81. [MEDLINE: 27943605]">Li 2017</a> included 11 studies (264 participants) with one RCT. Sofosbuvir regimens were compared to other direct‐acting antivirals assessing SVR 12 weeks after treatment, adverse and serious adverse events in CKD stages 4 and 5. They found a pooled SVR12 of 93.2%, serious adverse events of 12.1% and treatment discontinuation of 2.2%. </p> </li> <li> <p><a href="./references#CD007003-bbs2-0075" title="ShehadehF , KalligerosM , ByrdK , SheminD , MylonakisE , MartinP , et al. Efficacy and safety of Sofosbuvir in the treatment of hep C among patients on hemodialysis: a systematic review and meta-analysis. Scientific Reports2020;10(1):14332. [MEDLINE: 32868869]">Shehadeh 2020</a> included 20 studies (514 participants) with no RCTs and concluded that sofosbuvir regimens in HD patients with HCV produced an SVR in 95% (73 to 100%) with adverse events of fatigue, anaemia, nausea vomiting in 16%, 15% and 14%, respectively. </p> </li> <li> <p><a href="./references#CD007003-bbs2-0062" title="Majd JabbariS , MaajaniK , MeratS , PoustchiH , SepanlouSG . An updated systematic review and meta-analysis on efficacy of Sofosbuvir in treating hepatitis C-infected patients with advanced chronic kidney disease. PloS ONE2021;16(2):e0246594. [MEDLINE: 33566846]">Majd Jabbari 2021</a> reviewed sofosbuvir regimens in advanced CKD and found 27 studies (1464 participants). The types of studies were not mentioned, and they found an SVR at 24 weeks after treatment of 95% (89% to 99%) and a serious adverse event incidence of 0.11. </p> </li> </ul> </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD007003-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007003.pub3/media/CDSR/CD007003/urn:x-wiley:14651858:media:CD007003:CD007003-FIG-01" target="_blank"><b></b></a></p> </div><img alt="PRISMA flow diagram including previous review and update" data-id="CD007003-fig-0001" src="/cdsr/doi/10.1002/14651858.CD007003.pub3/media/CDSR/CD007003/image_n/nCD007003-FIG-01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007003.pub3/media/CDSR/CD007003/image_t/tCD007003-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>PRISMA flow diagram including previous review and update</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007003.pub3/full#CD007003-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007003.pub3/media/CDSR/CD007003/image_n/nCD007003-FIG-01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007003-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007003.pub3/media/CDSR/CD007003/urn:x-wiley:14651858:media:CD007003:CD007003-FIG-02" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies" data-id="CD007003-fig-0002" src="/cdsr/doi/10.1002/14651858.CD007003.pub3/media/CDSR/CD007003/image_n/nCD007003-FIG-02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007003.pub3/media/CDSR/CD007003/image_t/tCD007003-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007003.pub3/full#CD007003-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007003.pub3/media/CDSR/CD007003/image_n/nCD007003-FIG-02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007003-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007003.pub3/media/CDSR/CD007003/urn:x-wiley:14651858:media:CD007003:CD007003-FIG-03" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study" data-id="CD007003-fig-0003" src="/cdsr/doi/10.1002/14651858.CD007003.pub3/media/CDSR/CD007003/image_n/nCD007003-FIG-03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007003.pub3/media/CDSR/CD007003/image_t/tCD007003-FIG-03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007003.pub3/full#CD007003-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007003.pub3/media/CDSR/CD007003/image_n/nCD007003-FIG-03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007003-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007003.pub3/media/CDSR/CD007003/urn:x-wiley:14651858:media:CD007003:CD007003-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Standard interferon versus placebo or control, Outcome 1: Death" data-id="CD007003-fig-0004" src="/cdsr/doi/10.1002/14651858.CD007003.pub3/media/CDSR/CD007003/image_n/nCD007003-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007003.pub3/media/CDSR/CD007003/image_t/tCD007003-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: Standard interferon versus placebo or control, Outcome 1: Death</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007003.pub3/references#CD007003-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007003.pub3/media/CDSR/CD007003/image_n/nCD007003-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007003-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007003.pub3/media/CDSR/CD007003/urn:x-wiley:14651858:media:CD007003:CD007003-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Standard interferon versus placebo or control, Outcome 2: Relapse" data-id="CD007003-fig-0005" src="/cdsr/doi/10.1002/14651858.CD007003.pub3/media/CDSR/CD007003/image_n/nCD007003-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007003.pub3/media/CDSR/CD007003/image_t/tCD007003-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: Standard interferon versus placebo or control, Outcome 2: Relapse</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007003.pub3/references#CD007003-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007003.pub3/media/CDSR/CD007003/image_n/nCD007003-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007003-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007003.pub3/media/CDSR/CD007003/urn:x-wiley:14651858:media:CD007003:CD007003-CMP-001.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Standard interferon versus placebo or control, Outcome 3: End‐of‐treatment response" data-id="CD007003-fig-0006" src="/cdsr/doi/10.1002/14651858.CD007003.pub3/media/CDSR/CD007003/image_n/nCD007003-CMP-001.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007003.pub3/media/CDSR/CD007003/image_t/tCD007003-CMP-001.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1: Standard interferon versus placebo or control, Outcome 3: End‐of‐treatment response </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007003.pub3/references#CD007003-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007003.pub3/media/CDSR/CD007003/image_n/nCD007003-CMP-001.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007003-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007003.pub3/media/CDSR/CD007003/urn:x-wiley:14651858:media:CD007003:CD007003-CMP-001.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Standard interferon versus placebo or control, Outcome 4: Sustained virological response" data-id="CD007003-fig-0007" src="/cdsr/doi/10.1002/14651858.CD007003.pub3/media/CDSR/CD007003/image_n/nCD007003-CMP-001.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007003.pub3/media/CDSR/CD007003/image_t/tCD007003-CMP-001.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1: Standard interferon versus placebo or control, Outcome 4: Sustained virological response </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007003.pub3/references#CD007003-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007003.pub3/media/CDSR/CD007003/image_n/nCD007003-CMP-001.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007003-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007003.pub3/media/CDSR/CD007003/urn:x-wiley:14651858:media:CD007003:CD007003-CMP-001.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Standard interferon versus placebo or control, Outcome 5: Treatment discontinuation" data-id="CD007003-fig-0008" src="/cdsr/doi/10.1002/14651858.CD007003.pub3/media/CDSR/CD007003/image_n/nCD007003-CMP-001.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007003.pub3/media/CDSR/CD007003/image_t/tCD007003-CMP-001.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1: Standard interferon versus placebo or control, Outcome 5: Treatment discontinuation </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007003.pub3/references#CD007003-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007003.pub3/media/CDSR/CD007003/image_n/nCD007003-CMP-001.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007003-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007003.pub3/media/CDSR/CD007003/urn:x-wiley:14651858:media:CD007003:CD007003-CMP-001.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Standard interferon versus placebo or control, Outcome 6: Adverse events" data-id="CD007003-fig-0009" src="/cdsr/doi/10.1002/14651858.CD007003.pub3/media/CDSR/CD007003/image_n/nCD007003-CMP-001.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007003.pub3/media/CDSR/CD007003/image_t/tCD007003-CMP-001.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1: Standard interferon versus placebo or control, Outcome 6: Adverse events</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007003.pub3/references#CD007003-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007003.pub3/media/CDSR/CD007003/image_n/nCD007003-CMP-001.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007003-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007003.pub3/media/CDSR/CD007003/urn:x-wiley:14651858:media:CD007003:CD007003-CMP-002.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: PEG interferon versus standard interferon, Outcome 1: Death" data-id="CD007003-fig-0010" src="/cdsr/doi/10.1002/14651858.CD007003.pub3/media/CDSR/CD007003/image_n/nCD007003-CMP-002.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007003.pub3/media/CDSR/CD007003/image_t/tCD007003-CMP-002.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2: PEG interferon versus standard interferon, Outcome 1: Death</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007003.pub3/references#CD007003-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007003.pub3/media/CDSR/CD007003/image_n/nCD007003-CMP-002.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007003-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007003.pub3/media/CDSR/CD007003/urn:x-wiley:14651858:media:CD007003:CD007003-CMP-002.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: PEG interferon versus standard interferon, Outcome 2: Relapse" data-id="CD007003-fig-0011" src="/cdsr/doi/10.1002/14651858.CD007003.pub3/media/CDSR/CD007003/image_n/nCD007003-CMP-002.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007003.pub3/media/CDSR/CD007003/image_t/tCD007003-CMP-002.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2: PEG interferon versus standard interferon, Outcome 2: Relapse</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007003.pub3/references#CD007003-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007003.pub3/media/CDSR/CD007003/image_n/nCD007003-CMP-002.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007003-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007003.pub3/media/CDSR/CD007003/urn:x-wiley:14651858:media:CD007003:CD007003-CMP-002.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: PEG interferon versus standard interferon, Outcome 3: End‐of‐treatment response" data-id="CD007003-fig-0012" src="/cdsr/doi/10.1002/14651858.CD007003.pub3/media/CDSR/CD007003/image_n/nCD007003-CMP-002.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007003.pub3/media/CDSR/CD007003/image_t/tCD007003-CMP-002.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2: PEG interferon versus standard interferon, Outcome 3: End‐of‐treatment response </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007003.pub3/references#CD007003-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007003.pub3/media/CDSR/CD007003/image_n/nCD007003-CMP-002.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007003-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007003.pub3/media/CDSR/CD007003/urn:x-wiley:14651858:media:CD007003:CD007003-CMP-002.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: PEG interferon versus standard interferon, Outcome 4: Sustained virological response" data-id="CD007003-fig-0013" src="/cdsr/doi/10.1002/14651858.CD007003.pub3/media/CDSR/CD007003/image_n/nCD007003-CMP-002.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007003.pub3/media/CDSR/CD007003/image_t/tCD007003-CMP-002.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2: PEG interferon versus standard interferon, Outcome 4: Sustained virological response </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007003.pub3/references#CD007003-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007003.pub3/media/CDSR/CD007003/image_n/nCD007003-CMP-002.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007003-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007003.pub3/media/CDSR/CD007003/urn:x-wiley:14651858:media:CD007003:CD007003-CMP-002.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: PEG interferon versus standard interferon, Outcome 5: Treatment discontinuation" data-id="CD007003-fig-0014" src="/cdsr/doi/10.1002/14651858.CD007003.pub3/media/CDSR/CD007003/image_n/nCD007003-CMP-002.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007003.pub3/media/CDSR/CD007003/image_t/tCD007003-CMP-002.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2: PEG interferon versus standard interferon, Outcome 5: Treatment discontinuation</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007003.pub3/references#CD007003-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007003.pub3/media/CDSR/CD007003/image_n/nCD007003-CMP-002.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007003-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007003.pub3/media/CDSR/CD007003/urn:x-wiley:14651858:media:CD007003:CD007003-CMP-002.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: PEG interferon versus standard interferon, Outcome 6: Serious adverse events" data-id="CD007003-fig-0015" src="/cdsr/doi/10.1002/14651858.CD007003.pub3/media/CDSR/CD007003/image_n/nCD007003-CMP-002.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007003.pub3/media/CDSR/CD007003/image_t/tCD007003-CMP-002.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.6</div> <div class="figure-caption"> <p>Comparison 2: PEG interferon versus standard interferon, Outcome 6: Serious adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007003.pub3/references#CD007003-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007003.pub3/media/CDSR/CD007003/image_n/nCD007003-CMP-002.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007003-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007003.pub3/media/CDSR/CD007003/urn:x-wiley:14651858:media:CD007003:CD007003-CMP-003.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: PEG interferon: high versus low dose, Outcome 1: Death" data-id="CD007003-fig-0016" src="/cdsr/doi/10.1002/14651858.CD007003.pub3/media/CDSR/CD007003/image_n/nCD007003-CMP-003.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007003.pub3/media/CDSR/CD007003/image_t/tCD007003-CMP-003.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3: PEG interferon: high versus low dose, Outcome 1: Death</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007003.pub3/references#CD007003-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007003.pub3/media/CDSR/CD007003/image_n/nCD007003-CMP-003.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007003-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007003.pub3/media/CDSR/CD007003/urn:x-wiley:14651858:media:CD007003:CD007003-CMP-003.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: PEG interferon: high versus low dose, Outcome 2: Relapse" data-id="CD007003-fig-0017" src="/cdsr/doi/10.1002/14651858.CD007003.pub3/media/CDSR/CD007003/image_n/nCD007003-CMP-003.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007003.pub3/media/CDSR/CD007003/image_t/tCD007003-CMP-003.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3: PEG interferon: high versus low dose, Outcome 2: Relapse</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007003.pub3/references#CD007003-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007003.pub3/media/CDSR/CD007003/image_n/nCD007003-CMP-003.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007003-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007003.pub3/media/CDSR/CD007003/urn:x-wiley:14651858:media:CD007003:CD007003-CMP-003.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: PEG interferon: high versus low dose, Outcome 3: End‐of‐treatment response" data-id="CD007003-fig-0018" src="/cdsr/doi/10.1002/14651858.CD007003.pub3/media/CDSR/CD007003/image_n/nCD007003-CMP-003.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007003.pub3/media/CDSR/CD007003/image_t/tCD007003-CMP-003.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3: PEG interferon: high versus low dose, Outcome 3: End‐of‐treatment response</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007003.pub3/references#CD007003-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007003.pub3/media/CDSR/CD007003/image_n/nCD007003-CMP-003.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007003-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007003.pub3/media/CDSR/CD007003/urn:x-wiley:14651858:media:CD007003:CD007003-CMP-003.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: PEG interferon: high versus low dose, Outcome 4: Sustained virological response" data-id="CD007003-fig-0019" src="/cdsr/doi/10.1002/14651858.CD007003.pub3/media/CDSR/CD007003/image_n/nCD007003-CMP-003.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007003.pub3/media/CDSR/CD007003/image_t/tCD007003-CMP-003.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.4</div> <div class="figure-caption"> <p>Comparison 3: PEG interferon: high versus low dose, Outcome 4: Sustained virological response </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007003.pub3/references#CD007003-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007003.pub3/media/CDSR/CD007003/image_n/nCD007003-CMP-003.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007003-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007003.pub3/media/CDSR/CD007003/urn:x-wiley:14651858:media:CD007003:CD007003-CMP-003.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: PEG interferon: high versus low dose, Outcome 5: Treatment discontinuation" data-id="CD007003-fig-0020" src="/cdsr/doi/10.1002/14651858.CD007003.pub3/media/CDSR/CD007003/image_n/nCD007003-CMP-003.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007003.pub3/media/CDSR/CD007003/image_t/tCD007003-CMP-003.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.5</div> <div class="figure-caption"> <p>Comparison 3: PEG interferon: high versus low dose, Outcome 5: Treatment discontinuation</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007003.pub3/references#CD007003-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007003.pub3/media/CDSR/CD007003/image_n/nCD007003-CMP-003.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007003-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007003.pub3/media/CDSR/CD007003/urn:x-wiley:14651858:media:CD007003:CD007003-CMP-003.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: PEG interferon: high versus low dose, Outcome 6: Adverse events" data-id="CD007003-fig-0021" src="/cdsr/doi/10.1002/14651858.CD007003.pub3/media/CDSR/CD007003/image_n/nCD007003-CMP-003.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007003.pub3/media/CDSR/CD007003/image_t/tCD007003-CMP-003.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.6</div> <div class="figure-caption"> <p>Comparison 3: PEG interferon: high versus low dose, Outcome 6: Adverse events</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007003.pub3/references#CD007003-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007003.pub3/media/CDSR/CD007003/image_n/nCD007003-CMP-003.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007003-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007003.pub3/media/CDSR/CD007003/urn:x-wiley:14651858:media:CD007003:CD007003-CMP-003.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: PEG interferon: high versus low dose, Outcome 7: Serious adverse events" data-id="CD007003-fig-0022" src="/cdsr/doi/10.1002/14651858.CD007003.pub3/media/CDSR/CD007003/image_n/nCD007003-CMP-003.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007003.pub3/media/CDSR/CD007003/image_t/tCD007003-CMP-003.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.7</div> <div class="figure-caption"> <p>Comparison 3: PEG interferon: high versus low dose, Outcome 7: Serious adverse events</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007003.pub3/references#CD007003-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007003.pub3/media/CDSR/CD007003/image_n/nCD007003-CMP-003.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007003-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007003.pub3/media/CDSR/CD007003/urn:x-wiley:14651858:media:CD007003:CD007003-CMP-004.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Standard interferon + ribavirin versus standard interferon, Outcome 1: Treatment discontinuation" data-id="CD007003-fig-0023" src="/cdsr/doi/10.1002/14651858.CD007003.pub3/media/CDSR/CD007003/image_n/nCD007003-CMP-004.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007003.pub3/media/CDSR/CD007003/image_t/tCD007003-CMP-004.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4: Standard interferon + ribavirin versus standard interferon, Outcome 1: Treatment discontinuation </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007003.pub3/references#CD007003-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007003.pub3/media/CDSR/CD007003/image_n/nCD007003-CMP-004.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007003-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007003.pub3/media/CDSR/CD007003/urn:x-wiley:14651858:media:CD007003:CD007003-CMP-005.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: PEG interferon + ribavirin versus PEG interferon, Outcome 1: Sustained virological response" data-id="CD007003-fig-0024" src="/cdsr/doi/10.1002/14651858.CD007003.pub3/media/CDSR/CD007003/image_n/nCD007003-CMP-005.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007003.pub3/media/CDSR/CD007003/image_t/tCD007003-CMP-005.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.1</div> <div class="figure-caption"> <p>Comparison 5: PEG interferon + ribavirin versus PEG interferon, Outcome 1: Sustained virological response </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007003.pub3/references#CD007003-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007003.pub3/media/CDSR/CD007003/image_n/nCD007003-CMP-005.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007003-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007003.pub3/media/CDSR/CD007003/urn:x-wiley:14651858:media:CD007003:CD007003-CMP-005.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: PEG interferon + ribavirin versus PEG interferon, Outcome 2: End‐of‐treatment response" data-id="CD007003-fig-0025" src="/cdsr/doi/10.1002/14651858.CD007003.pub3/media/CDSR/CD007003/image_n/nCD007003-CMP-005.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007003.pub3/media/CDSR/CD007003/image_t/tCD007003-CMP-005.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.2</div> <div class="figure-caption"> <p>Comparison 5: PEG interferon + ribavirin versus PEG interferon, Outcome 2: End‐of‐treatment response </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007003.pub3/references#CD007003-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007003.pub3/media/CDSR/CD007003/image_n/nCD007003-CMP-005.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007003-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007003.pub3/media/CDSR/CD007003/urn:x-wiley:14651858:media:CD007003:CD007003-CMP-005.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: PEG interferon + ribavirin versus PEG interferon, Outcome 3: Relapse" data-id="CD007003-fig-0026" src="/cdsr/doi/10.1002/14651858.CD007003.pub3/media/CDSR/CD007003/image_n/nCD007003-CMP-005.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007003.pub3/media/CDSR/CD007003/image_t/tCD007003-CMP-005.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.3</div> <div class="figure-caption"> <p>Comparison 5: PEG interferon + ribavirin versus PEG interferon, Outcome 3: Relapse</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007003.pub3/references#CD007003-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007003.pub3/media/CDSR/CD007003/image_n/nCD007003-CMP-005.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007003-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007003.pub3/media/CDSR/CD007003/urn:x-wiley:14651858:media:CD007003:CD007003-CMP-005.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: PEG interferon + ribavirin versus PEG interferon, Outcome 4: Treatment discontinuation" data-id="CD007003-fig-0027" src="/cdsr/doi/10.1002/14651858.CD007003.pub3/media/CDSR/CD007003/image_n/nCD007003-CMP-005.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007003.pub3/media/CDSR/CD007003/image_t/tCD007003-CMP-005.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.4</div> <div class="figure-caption"> <p>Comparison 5: PEG interferon + ribavirin versus PEG interferon, Outcome 4: Treatment discontinuation </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007003.pub3/references#CD007003-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007003.pub3/media/CDSR/CD007003/image_n/nCD007003-CMP-005.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007003-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007003.pub3/media/CDSR/CD007003/urn:x-wiley:14651858:media:CD007003:CD007003-CMP-005.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: PEG interferon + ribavirin versus PEG interferon, Outcome 5: Adverse events" data-id="CD007003-fig-0028" src="/cdsr/doi/10.1002/14651858.CD007003.pub3/media/CDSR/CD007003/image_n/nCD007003-CMP-005.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007003.pub3/media/CDSR/CD007003/image_t/tCD007003-CMP-005.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.5</div> <div class="figure-caption"> <p>Comparison 5: PEG interferon + ribavirin versus PEG interferon, Outcome 5: Adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007003.pub3/references#CD007003-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007003.pub3/media/CDSR/CD007003/image_n/nCD007003-CMP-005.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007003-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007003.pub3/media/CDSR/CD007003/urn:x-wiley:14651858:media:CD007003:CD007003-CMP-006.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Direct‐acting antivirals (grazoprevir, elbasvir) versus placebo, Outcome 1: End‐of‐treatment response" data-id="CD007003-fig-0029" src="/cdsr/doi/10.1002/14651858.CD007003.pub3/media/CDSR/CD007003/image_n/nCD007003-CMP-006.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007003.pub3/media/CDSR/CD007003/image_t/tCD007003-CMP-006.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.1</div> <div class="figure-caption"> <p>Comparison 6: Direct‐acting antivirals (grazoprevir, elbasvir) versus placebo, Outcome 1: End‐of‐treatment response </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007003.pub3/references#CD007003-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007003.pub3/media/CDSR/CD007003/image_n/nCD007003-CMP-006.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007003-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007003.pub3/media/CDSR/CD007003/urn:x-wiley:14651858:media:CD007003:CD007003-CMP-007.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: PEG interferon + ribavirin (24 weeks) + initial telepravir (12 weeks) versus PEG interferon (48 weeks) + initial telepravir (12 weeks) + initial low dose ribavirin (12 + 36 weeks) , Outcome 1: End‐of‐treatment response" data-id="CD007003-fig-0030" src="/cdsr/doi/10.1002/14651858.CD007003.pub3/media/CDSR/CD007003/image_n/nCD007003-CMP-007.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007003.pub3/media/CDSR/CD007003/image_t/tCD007003-CMP-007.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.1</div> <div class="figure-caption"> <p>Comparison 7: PEG interferon + ribavirin (24 weeks) + initial telepravir (12 weeks) versus PEG interferon (48 weeks) + initial telepravir (12 weeks) + initial low dose ribavirin (12 + 36 weeks) , Outcome 1: End‐of‐treatment response </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007003.pub3/references#CD007003-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007003.pub3/media/CDSR/CD007003/image_n/nCD007003-CMP-007.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007003-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007003.pub3/media/CDSR/CD007003/urn:x-wiley:14651858:media:CD007003:CD007003-CMP-007.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: PEG interferon + ribavirin (24 weeks) + initial telepravir (12 weeks) versus PEG interferon (48 weeks) + initial telepravir (12 weeks) + initial low dose ribavirin (12 + 36 weeks) , Outcome 2: Sustained virological response" data-id="CD007003-fig-0031" src="/cdsr/doi/10.1002/14651858.CD007003.pub3/media/CDSR/CD007003/image_n/nCD007003-CMP-007.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007003.pub3/media/CDSR/CD007003/image_t/tCD007003-CMP-007.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.2</div> <div class="figure-caption"> <p>Comparison 7: PEG interferon + ribavirin (24 weeks) + initial telepravir (12 weeks) versus PEG interferon (48 weeks) + initial telepravir (12 weeks) + initial low dose ribavirin (12 + 36 weeks) , Outcome 2: Sustained virological response </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007003.pub3/references#CD007003-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007003.pub3/media/CDSR/CD007003/image_n/nCD007003-CMP-007.02.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD007003-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Standard interferon versus placebo or control for haemodialysis patients with hepatitis C virus infection</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Standard interferon versus placebo or control for HD patients with HCV infection</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> patients on HD with HCV infection<br/><b>Settings:</b> outpatients<br/><b>Intervention:</b> standard interferon<br/><b>Comparison:</b> placebo or control </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>No. of participants<br/>(RCTs)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="table-header separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p>Risk with p<b>lacebo or control</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p>Risk with s<b>tandard interferon</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Death</b><br/>Follow‐up: 6 to 52 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>17 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>15 per 1000</b><br/>(1 to 224) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.89 </b><br/>(0.06 to 13.23) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>134 (5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Standard interferon may make little or no difference to death compared to a placebo or control  </p> <p>Out of 5 studies only 1 reported death. This evidence should be read with caution due to the low certainty of the evidence </p> <p>In 2 studies data was not available for 18 participants total. Hence, 134/152 were analysed </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Relapse</b><br/>(recurrence after stopping intervention)<br/>Follow‐up: 46 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>1000 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>720 per 1000</b><br/>(280 to 1000) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.72 </b><br/>(0.28 to 1.88) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>1,2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Standard interferon may make little or no difference to the number of relapses compared to placebo or control. This evidence should be read with caution due to the low certainty of the evidence </p> <p>Out of 5 studies only 1 reported relapse. Data was not available in 1 study; 2 studies had no responses in the placebo/control group and could not be analysed, and 1 study did not report follow‐up data </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>End‐of‐treatment response</b><br/>Follow‐up: 6 to 12 months </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population<sup>3</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>RR 8.62 </b><br/>(3.03 to 24.55) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>132 (5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>⊕⊕⊕⊝<br/><b>Moderate</b><sup>1,4</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>Standard interferon probably leads to more end‐of‐treatment response compared to the placebo or control </p> <p>Two studies had events in the control group hence second highest and lowest control group risks also expressed to represent varying levels of risk </p> <p>In 2 studies data was not available for 20 participants</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>34 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>292 per 1000</b><br/>(103 to 832) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate<sup>3</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>59 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>507 per 1000</b><br/>(178 to 1000) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>High<sup>3</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>62 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>539 per 1000</b><br/>(189 to 1000) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Sustained virological response 6 months after stopping treatment</b><br/>Follow‐up: 6 to 12 months </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population<sup>3</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 3.25 </b><br/>(0.81 to 13.07) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>98 (4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝<br/><b>Moderate</b><sup>1,4</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Standard interferon probably makes little or no difference to sustained virological response compared to placebo or control </p> <p>This outcome could not be assessed in 1 study as there was no follow‐up data and data was not available for 18 participants in 2 studies </p> <p>Two studies had events in the control group hence absolute effects for the second highest and lowest control group risks also expressed to represent varying levels of risk </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>116 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>378 per 1000</b><br/>(94 to 1000) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Low<sup>3</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>59 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>192 per 1000</b><br/>(48 to 771) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Treatment discontinuation</b><br/>Follow‐up: 6 to 12 months </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population<sup>3</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 4.59 </b><br/>(0.49 to 42.69) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>116 (4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝<br/><b>Moderate</b><sup>1,4</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Standard interferon probably makes </p> <p>little or no difference in the number of patients discontinuing treatment compared to placebo or control </p> <p>The control group had events in 1 study hence absolute effects at 2 levels of risk were given to represent varying control group risks </p> <p>Data was not available for 1 study and for 18 participants in 2 studies</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>38 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>177 per 1000</b><br/>(19 to 1000) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>High<sup>3</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>222 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>1000 per 1000</b><br/>(109 to 1000) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Adverse events</b><br/>Follow‐up: 24 to 52 months </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population<sup>3</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 3.56 </b><br/>(0.98 to 13.01) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>143 (5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝<br/><b>Moderate</b><sup>1,4</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Standard interferon probably makes little or no difference to the number of patients experiencing adverse events compared to placebo or control </p> <p>The control group had events in 1 study hence absolute effects at 2 levels of risk were given to represent varying control group risks. Data was not available for 9 participants in 1 study </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>31 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>110 per 1000</b><br/>(30 to 400) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>High<sup>3</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>222 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>790 per 1000</b><br/>(218 to 1000) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI)<br/><b>CI:</b> confidence interval; <b>HCV:</b> hepatitis C virus; <b>HD:</b> haemodialysis; <b>RR:</b> risk ratio; <b>RCT:</b> randomised controlled trial </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High certainty:</b> Further research is very unlikely to change our confidence in the estimate of effect<br/><b>Moderate certainty:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate<br/><b>Low certainty:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate<br/><b>Very low certainty:</b> We are very uncertain about the estimate </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>  Number of events is low<br/><sup>2</sup>  One study<br/><sup>3</sup> Based on the second lowest and highest control group risks; events occurred in the control group in some studies for some outcomes hence absolute effects are presented for varying levels of risk </p> <p><sup>4</sup> Risk of bias for random sequence generation was unclear, and allocation concealment was unclear to high </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Standard interferon versus placebo or control for haemodialysis patients with hepatitis C virus infection</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007003.pub3/full#CD007003-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD007003-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Pegylated interferon alpha‐2a versus standard interferon for haemodialysis patients with hepatitis C virus infection</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>PEG interferon alpha‐2a versus standard interferon for HD patients with HCV infection</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> patients on HD with HCV infection<br/><b>Settings:</b> outpatients<br/><b>Intervention:</b> PEG interferon alpha‐2a <br/><b>Comparison:</b> standard interferon alpha‐2a </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> </b>(95% CI) </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>No. of participants<br/>(RCTs)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p>Risk with s<b>tandard interferon</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p>Risk with <b>PEG interferon</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Death</b><br/>Follow‐up: mean 24 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>40 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>13 per 1000</b><br/>(1 to 312) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.33 </b><br/>(0.01 to 7.81) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>1,2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PEG interferon may make little or no difference to death compared to standard interferon</p> <p>This evidence should be read with caution due to the low certainty of the evidence</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Relapse</b><br/>(recurrence after stopping)<br/>Follow‐up: 72 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>667 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>480 per 1000</b><br/>(273 to 833) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.72 </b><br/>(0.41 to 1.25) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>1,2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PEG interferon may make little or no difference to the number of relapses compared to standard interferon </p> <p>This evidence should be read with caution due to the low certainty of the evidence</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>End‐of‐treatment response</b><br/>Follow‐up: 24 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>600 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>918 per 1000</b><br/>(654 to 1000) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.53 </b><br/>(1.09 to 2.15) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>1,2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PEG interferon may lead to more end‐of‐treatment response compared to standard interferon</p> <p>This evidence should be read with caution due to the low certainty of the evidence</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Sustained virological response 6 months after stopping treatment</b><br/>Follow‐up: 48 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>200 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>480 per 1000</b><br/>(198 to 1000) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 2.4 </b><br/>(0.99 to 5.81) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>1,2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PEG interferon may make little or no difference to the number of patients having sustained virological response compared to standard interferon </p> <p>This evidence should be read with caution due to the low certainty of the evidence</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Treatment discontinuation</b><br/>Follow‐up: 24 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>160 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>18 per 1000</b><br/>(2 to 314) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.11 </b><br/>(0.01 to 1.96) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>1,2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PEG interferon may make little or no difference to the number of patients discontinuing treatment compared to standard interferon </p> <p>This evidence should be read with caution due to the low certainty of the evidence</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events </b><br/>Follow‐up: 24 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>160 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>18 per 1000</b><br/>(2 to 314) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.11 </b><br/>(0.01 to 1.96) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>1,2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PEG interferon may make little or no difference to the number of patients having major adverse events requiring treatment withdrawal compared to standard interferon </p> <p>This evidence should be read with caution due to the low certainty of the evidence</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI)<br/><b>CI:</b> confidence interval; <b>HCV:</b> hepatitis C virus; <b>HD:</b> haemodialysis; <b>PEG:</b> pegylated; <b>RR:</b> risk ratio; <b>RCT:</b> randomised controlled trial </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High certainty:</b> Further research is very unlikely to change our confidence in the estimate of effect<br/><b>Moderate certainty:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate<br/><b>Low certainty:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate<br/><b>Very low certainty:</b> We are very uncertain about the estimate </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Number of events is low </p> <p><sup>2</sup> One study  </p> <p>Zero events in the PEG interferon group for death, treatment discontinuation, and number of participants having adverse events </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Pegylated interferon alpha‐2a versus standard interferon for haemodialysis patients with hepatitis C virus infection</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007003.pub3/full#CD007003-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD007003-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">High versus low dose pegylated interferon alpha‐2a or alpha‐2b for haemodialysis patients with hepatitis C virus infection</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>High versus low dose PEG interferon for HD patients with HCV infection</b><br/>(separate and combined results of two preparations: alpha‐2a and alpha‐2b) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> patients on HD with HCV infection<br/><b>Settings:</b> outpatients<br/><b>Intervention 1:</b> high dose PEG interferon alpha‐2a (135 µg/week)<br/><b>Comparison 1:</b> low dose PEG interferon alpha‐2a (90 µg/week) </p> <p><b>Intervention 2:</b> high dose PEG interferon alpha‐2b (1 µg/kg/week) </p> <p><b>Comparison 2:</b> low dose PEG interferon alpha‐2b (0.5 µg/kg/week) </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> </b>(95% CI) </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>No. of participants<br/>(RCTs)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p>Risk with <b>low dose PEG interferon </b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p>Risk with <b>high dose PEG interferon </b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell" colspan="7" rowspan="1" scope="col" valign="top"> <p><b>Death</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>PEG interferon alpha‐2a</b><br/>Follow‐up: 24 week </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>23 per 1000</b><sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>132 per 1000</b><br/>(16 to 1000) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 5.66 </b><br/>(0.69 to 46.31) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>81 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>1,2,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>A high dose of PEG interferon probably makes little or no difference to death compared to a low dose of PEG interferon  </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>PEG interferon alpha‐2b</b> </p> <p>Follow‐up: 72 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>0 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>0 per 1000</b> </p> <p>(0 to 0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 2.40</b> (0.11 to 51.32) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>1,2,3</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>PEG interferon (combined)</b> </p> <p>Follow‐up: 24 to 72 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>20 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>86 per 1000</b><br/>(15 to 487) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 4.30</b> (0.76 to 24.33) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>97 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/><b>Moderate</b><sup>1,3</sup> </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="7" rowspan="1" scope="col" valign="top"> <p><b>Relapse (recurrence after stopping treatment)</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>PEG interferon alpha‐2a</b> </p> <p>Follow‐up: 24 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>286 per 1000</b><sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>320 per 1000</b><br/>(114 to 631) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.12 </b><br/>(0.4 to 2.21) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>1,2,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>A high dose of PEG interferon may make little or no difference to the number of patients having a disease relapse compared to a low dose of PEG interferon. In one study there were no events in the control group and could not be analysed </p> <p>This should be viewed with caution due to the low certainty of the evidence</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>PEG interferon alpha‐2b </b> </p> <p>Follow‐up: 72 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>No data</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p> ‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> ‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> ‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> ‐‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>PEG interferon (combined)</b> </p> <p>Follow‐up; 24 to 72 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>286 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>320 per 1000</b><br/>(114 to 631) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 1.12 </b><br/>(0.4 to 2.21) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>43 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>1,2,3</sup> </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="7" rowspan="1" scope="col" valign=""> <p><b>End‐of‐treatment response</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>PEG interferon alpha‐2a</b><br/>Follow‐up: 24 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>488 per 1000</b><sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>581 per 1000</b><br/>(386 to 869) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.19 </b><br/>(0.79 to 1.78) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>81 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>1,2,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>A high dose of PEG interferon probably makes little or no difference to end‐of‐treatment virological response compared to a low dose of PEG interferon </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>PEG interferon (alpha‐2b)</b> </p> <p>Follow‐up: 72 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>0 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>0 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 5.60</b><br/>(0.34 to 93.35) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>1,2,3</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>PEG interferon (combined)</b> </p> <p>Follow‐up: 24 to 72 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>20 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>28 per 1000</b> </p> <p>(10 to 78)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 1.42</b> (0.51 to 3.90) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>97 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/><b>Moderate</b><sup>2,3</sup> </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="7" rowspan="1" scope="col" valign=""> <p><b>Sustained virological response</b> after stopping treatment </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>PEG interferon alpha‐2a</b><br/>Follow‐up: 72 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>349 per 1000</b><sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>394 per 1000</b><br/>(223 to 698) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.13 </b><br/>(0.64 to 2) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>81 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>1,2,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>A high dose of PEG interferon probably makes little or no difference to sustained virological response compared to a low dose of PEG interferon  </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>PEG interferon alpha‐2b</b> </p> <p>Follow‐up: 72 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>0 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>0 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 4.00</b><br/>(0.22 to 72.01) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>1,2,3</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>PEG interferon (combined)</b> </p> <p>Follow‐up: 24 to 72 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>300 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>357 per 1000</b> </p> <p>(204 to 621)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 1.19</b> </p> <p>(0.68 to 2.07)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>97 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/><b>Moderate</b><sup>2,3</sup> </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="7" rowspan="1" scope="col" valign=""> <p><b>Treatment discontinuation</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>PEG interferon alpha‐2a</b><br/>Follow‐up: 24 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>256 per 1000</b><sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>263 per 1000</b><br/>(125 to 550) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.03 </b><br/>(0.49 to 2.15) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>81 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>1,2,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>A high dose of PEG interferon probably makes little or no difference to the number of patients discontinuing treatment compared to a low dose of PEG interferon </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>PEG interferon alpha‐2b</b> </p> <p>Follow‐up: 72 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>286 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>554 per 1000</b><br/>(151 to 1000) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 1.94</b><br/>(0.53 to 7.2) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>1,2,3</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>PEG interferon (combined)</b> </p> <p>Follow‐up: 24 to 72 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>260 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>3112 per 1000</b> </p> <p>(164 to 593)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 1.20</b> </p> <p>(0.63 to 2.28)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>97 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/><b>Moderate</b><sup>2,3</sup> </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="7" rowspan="1" scope="col" valign=""> <p><b>Adverse events</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>PEG interferon alpha‐2a</b><br/>Follow‐up: 24 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>860 per 1000</b><sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>817 per 1000</b><br/>(671 to 990) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.95 </b><br/>(0.78 to 1.15) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>81 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>1,2,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>A high dose of PEG interferon probably makes little or no difference to the number of patients with adverse events compared to a low dose of PEG interferon </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>PEG interferon alpha‐2b</b> </p> <p>Follow‐up: 72 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>286 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>554 per 1000</b><br/>(151 to 1000) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 1.94</b><br/>(0.53 to 7.20) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>1,2,3</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>PEG interferon (combined)</b> </p> <p>Follow‐up 24 to 72 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>780 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>819 per 1000</b> </p> <p>(476 to 1000)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 1.05</b> (0.61 to 1.83) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>97 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/><b>Moderate</b><sup>2,3</sup> </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="7" rowspan="1" scope="col" valign=""> <p><b>Serious adverse events</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>PEG interferon alpha‐2a</b><br/>Follow‐up: 24 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>326 per 1000</b><sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>368 per 1000</b><br/>(202 to 671) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.13 </b><br/>(0.62 to 2.06) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>81 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>1,2,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>A high dose of PEG interferon probably makes little or no difference to the number of patients with serious adverse events compared to a low dose of PEG interferon </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>PEG interferon alpha‐2b</b> </p> <p>Follow‐up: 72 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>286 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>554 per 1000</b><br/>(151 to 1000) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 1.94</b><br/>(0.53 to 7.2) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>1,2,3</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>PEG interferon (combined)</b> </p> <p>Follow‐up: 24 to 72 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>320 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>397 per 1000</b> </p> <p>(230 to 685)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 1.24</b> </p> <p>(0.72 to 2.14)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>97 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/><b>Moderate</b><sup>2,3</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI)<br/><b>CI:</b> confidence interval; <b>HCV:</b> hepatitis C virus; <b>HD:</b> haemodialysis; <b>PEG:</b> pegylated; <b>RR:</b> risk ratio; <b>RCT:</b> randomised controlled trial </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High certainty:</b> Further research is very unlikely to change our confidence in the estimate of effect<br/><b>Moderate certainty:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate<br/><b>Low certainty:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate<br/><b>Very low certainty:</b> We are very uncertain about the estimate </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> One study </p> <p><sup>2</sup> Number of events low </p> <p><sup>3</sup> Risk of bias high for blinding of participants and personnel </p> <p>Two studies compared different preparations of PEG interferon. Hence, each outcome is presented as three entries with results of each RCT and combined analysis result </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">High versus low dose pegylated interferon alpha‐2a or alpha‐2b for haemodialysis patients with hepatitis C virus infection</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007003.pub3/full#CD007003-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD007003-tbl-0004"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Standard interferon plus ribavirin versus standard interferon alone for haemodialysis patients with hepatitis C virus infection</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Standard interferon plus ribavirin versus standard interferon alone for HD patients with HCV infection</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Patient or population:</b> patients on HD with HCV infection<br/><b>Settings:</b> outpatients<br/><b>Intervention:</b> standard interferon plus ribavirin<br/><b>Comparison:</b> standard interferon  </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> </b>(95% CI) </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>No. of participants<br/>(RCTs)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p>Risk with s<b>tandard interferon</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p>Risk with s<b>tandard interferon plus ribavirin</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Death</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>No data</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Relapse</b><br/>(recurrence after stopping) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>No data</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>End‐of‐treatment response</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>No data</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Sustained virological response</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>No data</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Treatment discontinuation</b><br/>Follow‐up: 16 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>163 per 1000</b><br/>(67 to 402) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>484 per 1000</b> </p> <p>(194 to 1000)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 2.97 </b><br/>(1.19 to 7.36) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>1,2</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Adverse events</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>No data</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI)<br/><b>CI:</b> confidence interval; <b>HCV:</b> hepatitis C virus; <b>HD:</b> haemodialysis; <b>RR:</b> risk ratio; <b>RCT:</b> randomised controlled trial </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High certainty:</b> Further research is very unlikely to change our confidence in the estimate of effect<br/><b>Moderate certainty:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate<br/><b>Low certainty:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate<br/><b>Very low certainty:</b> We are very uncertain about the estimate </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup> One study </p> <p><sup>2</sup> Risk of bias unclear </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Standard interferon plus ribavirin versus standard interferon alone for haemodialysis patients with hepatitis C virus infection</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007003.pub3/full#CD007003-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD007003-tbl-0005"> <div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Pegylated interferon plus ribavirin versus pegylated interferon alone for haemodialysis patients with hepatitis C infection</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>PEG interferon plus ribavirin versus PEG interferon alone for HD patients with HCV infection</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> HD patients with HCV infection <br/><b>Setting:</b> outpatients <br/><b>Intervention:</b> PEG interferon alpha‐2a (135 μg/week) plus ribavirin (200 mg/day) for 48 weeks<br/><b>Comparison:</b> PEG interferon alpha‐2a (135 μg/week) for 48 weeks </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>No. of participants<br/>(RCTs)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with PEG interferon</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with PEG interferon plus ribavirin</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Death</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>No data</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Relapse</b><br/>(recurrence after stopping) </p> <p>Follow‐up: mean 18 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>463 per 1,000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>153 per 1,000</b><br/>(106 to 222) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.33</b><br/>(0.23 to 0.48) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>377 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>1,2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The number of relapses of HCV infection was low in HD patients on PEG interferon with ribavirin therapy. This evidence was reported for HCV 1 and HCV 2 genotypes at 24 weeks and 48 weeks after intervention respectively. This effect should be read with caution because of the low certainty of the evidence </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>End‐of‐treatment response</b><br/>Follow‐up: mean 18 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>867 per 1,000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>876 per 1,000</b><br/>(815 to 945) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.01</b><br/>(0.94 to 1.09) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>377 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>1,2,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The end‐of‐treatment response was more likely in patients treated with PEG interferon with ribavirin, with some limitations for the certainty of the evidence </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Sustained virological response</b><br/>Follow‐up: mean 18 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>383 per 1,000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>689 per 1,000</b><br/>(559 to 846) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.80</b><br/>(1.46 to 2.21) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>377 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Patients on PEG interferon with ribavirin were more likely to have sustained virologic response after treatment. The evidence reported is for both HCV genotype 1 and HCV genotype 2 with 24 weeks and 48 weeks of treatment, respectively </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Treatment discontinuation</b><br/>Follow‐up: mean 18 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>37 per 1,000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>64 per 1,000</b><br/>(26 to 158) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.71</b><br/>(0.69 to 4.24) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>377 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>1,2,3,4</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HD patients with HCV infection on PEG interferon with ribavirin were more likely to discontinue the treatment than patients on PEG interferon monotherapy. However, this evidence should be read with caution, due to the low certainty of the evidence </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events</b><br/>Follow‐up: mean 18 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>819 per 1,000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>901 per 1,000</b><br/>(827 to 975) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.10</b><br/>(1.01 to 1.19) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>377 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HD patients with HCV on PEG interferon with ribavirin therapy had a slightly higher risk of experiencing adverse events when compared to patients on PEG interferon alone. However, this evidence should be read with caution, due to the low certainty of the evidence </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI)<br/><b>CI:</b> confidence interval; <b>HCV:</b> hepatitis C virus; <b>HD:</b> haemodialysis; <b>PEG:</b> pegylated; <b>RR:</b> risk ratio; <b>RCT:</b> randomised controlled trial </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Less number of events </p> <p><sup>2</sup> Only one study was available for analysis; <a href="./references#CD007003-bbs2-0010" title="LuxonBA , MuirAJ , HeneghanMA . Safety and tolerability of pegylated interferon with or without low dose ribavirin for treatment of hepatitis C in hemodialysis patients [abstract no: 1281]. Hepatology2005;42(4 Suppl 1):703-4A. [CENTRAL: CN-00581669] ">Luxon 2005</a> reported pooled outcomes for both groups and could not be meta‐analysed </p> <p><sup>3</sup> Risk estimate includes the null effect </p> <p><sup>4</sup> High risk for blinding of participants  </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Pegylated interferon plus ribavirin versus pegylated interferon alone for haemodialysis patients with hepatitis C infection</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007003.pub3/full#CD007003-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD007003-tbl-0006"> <div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">Direct antivirals (grazoprevir and elbasvir) versus placebo for haemodialysis patients with hepatitis C infection</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Direct antivirals (grazoprevir and elbasvir) versus placebo for HD patients with HCV infection</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> HD patients with HCV infection <br/><b>Setting:</b> outpatients, international, multicentre <br/><b>Intervention:</b> Direct antivirals (grazoprevir 100 mg/day and elbasvir 50 mg/day) <br/><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>No. of participants<br/>(RCTs)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with direct‐acting antivirals</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Death</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>No data</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Relapse</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>No data</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>End‐of‐treatment response</b> </p> <p>Follow‐up: mean 28 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>6 per 1,000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>1000 per 1,000</b><br/>(63 to 1000) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR <b>174.99</b><br/>(11.03 to 2775.78) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>173 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low <sup>1,2</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Patients on direct‐acting antivirals were more likely to report an end‐of‐treatment response when compared to patients on placebo Evidence should be considered with caution as the certainty of the evidence is low. </p> <p>Out of 235 participants, those on dialysis (173) were analysed</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Sustained virological response</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>No data</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Treatment discontinuation</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>No data</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Adverse events</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>No data</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI)<br/><b>CI:</b> confidence interval; <b>HCV:</b> hepatitis C virus; <b>HD:</b> haemodialysis; <b>RR:</b> risk ratio; <b>RCT:</b> randomised controlled trial </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Placebo group also received the treatment after 4 weeks of study. Difficult to determine the directness of evidence for end‐of‐treatment response </p> <p><sup>2</sup> Number of events low; wide 95% CI </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">Direct antivirals (grazoprevir and elbasvir) versus placebo for haemodialysis patients with hepatitis C infection</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007003.pub3/full#CD007003-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD007003-tbl-0007"> <div class="table-heading"><span class="table-label">Summary of findings 7.</span> <span class="table-title">Pegylated interferon + ribavirin (24 weeks) + initial telepravir (12 weeks) versus pegylated interferon (48 weeks) + initial telepravir (12 weeks) + initial low dose ribavirin (12 + 36 weeks) for haemodialysis patients with hepatitis C infection</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>PEG interferon + ribavirin (24 weeks) + initial telepravir (12 weeks) versus PEG interferon (48 weeks) + initial telepravir (12 weeks) + initial low dose ribavirin (12 + 36 weeks) for HD patients with HCV infection</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> HD patients with HCV infection <br/><b>Setting:</b> outpatients <br/><b>Intervention:</b> PEG interferon + ribavirin (24 weeks) + initial telaprevir (12 weeks)<br/><b>Comparison:</b> PEG interferon (48 weeks) + initial telaprevir (12 weeks) + initial low dose ribavirin (12 + 36 weeks) </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>No. of participants<br/>(RCTs)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with PEG interferon + teleprevir + initial low dose ribavirin (12 + 48 weeks)</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with PEG interferon + telaprevir + ribavirin (36 weeks)</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Death</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>No data</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Relapse</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>No data</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Sustained virological response</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>706 per 1,000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>720 per 1,000</b><br/>(473 to 1,000) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.02</b><br/>(0.67 to 1.56) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low<sup>1,2,3</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HD patients with HCV in the intervention group were more likely to have sustained virological response when compared to control. </p> <p>Evidence should be read with caution due to the very low certainty of the evidence</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>End‐of‐treatment response</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>706 per 1,000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>720 per 1,000</b><br/>(473 to 1,000) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.02</b><br/>(0.67 to 1.56) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low<sup>1.2.3</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HD patients with HCV in the intervention groups were more likely to report end‐of‐treatment response when compared to the control group. Evidence should be read with caution due to the very low certainty of the evidence </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Treatment discontinuation</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>No data</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>No data</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI)<br/><b>CI:</b> confidence interval; <b>PEG:</b> pegylated; <b>HCV:</b> hepatitis C virus; <b>HD:</b> haemodialysis; <b>RR:</b> risk ratio; <b>RCT:</b> randomised controlled trial </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Unclear risk of bias for allocation random sequence generation, allocation concealment, blinding of participants and personnel </p> <p><sup>2</sup> Evidence is reported from a single study for which only an abstract is available </p> <p><sup>3</sup> Low number of events and low sample size. CI including no effect </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 7.</span> <span class="table-title">Pegylated interferon + ribavirin (24 weeks) + initial telepravir (12 weeks) versus pegylated interferon (48 weeks) + initial telepravir (12 weeks) + initial low dose ribavirin (12 + 36 weeks) for haemodialysis patients with hepatitis C infection</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007003.pub3/full#CD007003-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD007003-tbl-0008"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Standard interferon versus placebo or control</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 Death <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>134</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.06, 13.23]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 Relapse <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.72 [0.28, 1.88]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.3 End‐of‐treatment response <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>132</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>8.62 [3.03, 24.55]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.4 Sustained virological response <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>98</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.25 [0.81, 13.07]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.5 Treatment discontinuation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>116</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.59 [0.49, 42.69]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.6 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>143</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.56 [0.98, 13.01]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Standard interferon versus placebo or control</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007003.pub3/references#CD007003-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD007003-tbl-0009"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">PEG interferon versus standard interferon</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.1 Death <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.01, 7.81]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.2 Relapse <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.72 [0.41, 1.25]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.3 End‐of‐treatment response <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.53 [1.09, 2.15]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.4 Sustained virological response <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.40 [0.99, 5.81]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.5 Treatment discontinuation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.11 [0.01, 1.96]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.6 Serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.11 [0.01, 1.96]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">PEG interferon versus standard interferon</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007003.pub3/references#CD007003-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD007003-tbl-0010"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">PEG interferon: high versus low dose</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.1 Death <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>97</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.30 [0.76, 24.33]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1.1 1 µg/kg/week versus 0.5 µg/kg/week</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.40 [0.11, 51.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1.2 135 µg/week versus 90 µg/week</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>81</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.66 [0.69, 46.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.2 Relapse <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2.1 135 µg/week versus 90 µg/week</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.11 [0.45, 2.77]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.3 End‐of‐treatment response <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>97</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.42 [0.51, 3.90]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3.1 1 µg/kg/week versus 0.5 µg/kg/week</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.60 [0.34, 93.35]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3.2 135 µg/week versus 90 µg/week</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>81</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.19 [0.79, 1.78]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.4 Sustained virological response <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>97</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.19 [0.68, 2.07]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.4.1 1 µg/kg/week versus 0.5 µg/kg/week</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.00 [0.22, 72.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.4.2 135 µg/week versus 90 µg/week</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>81</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.13 [0.64, 2.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.5 Treatment discontinuation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>97</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.20 [0.63, 2.28]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.5.1 1 µg/kg/week versus 0.5 µg/kg/week</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.94 [0.53, 7.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.5.2 135 µg/week versus 90 µg/week</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>81</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.49, 2.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.6 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>97</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.61, 1.83]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.6.1 1 µg/kg/week versus 0.5 µg/kg/week</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.94 [0.53, 7.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.6.2 135 µg/week versus 90 µg/week</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>81</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.78, 1.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.7 Serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>97</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.24 [0.72, 2.14]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.7.1 1 µg/kg/week versus 0.5 µg/kg/week</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.94 [0.53, 7.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.7.2 135 µg/week versus 90 µg/week</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>81</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.13 [0.62, 2.06]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">PEG interferon: high versus low dose</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007003.pub3/references#CD007003-tbl-0010">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD007003-tbl-0011"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Standard interferon + ribavirin versus standard interferon</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.1 Treatment discontinuation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>54</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.97 [1.19, 7.36]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Standard interferon + ribavirin versus standard interferon</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007003.pub3/references#CD007003-tbl-0011">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD007003-tbl-0012"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">PEG interferon + ribavirin versus PEG interferon</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.1 Sustained virological response <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>377</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.80 [1.46, 2.21]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.2 End‐of‐treatment response <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>377</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.94, 1.09]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.3 Relapse <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>377</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.23, 0.48]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.4 Treatment discontinuation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>377</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.71 [0.69, 4.24]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.5 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>377</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.10 [1.01, 1.19]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">PEG interferon + ribavirin versus PEG interferon</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007003.pub3/references#CD007003-tbl-0012">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD007003-tbl-0013"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Direct‐acting antivirals (grazoprevir, elbasvir) versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.1 End‐of‐treatment response <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>173</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>174.99 [11.03, 2775.78]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Direct‐acting antivirals (grazoprevir, elbasvir) versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007003.pub3/references#CD007003-tbl-0013">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD007003-tbl-0014"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">PEG interferon + ribavirin (24 weeks) + initial telepravir (12 weeks) versus PEG interferon (48 weeks) + initial telepravir (12 weeks) + initial low dose ribavirin (12 + 36 weeks) </span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.1 End‐of‐treatment response <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.67, 1.56]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.2 Sustained virological response <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.67, 1.56]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">PEG interferon + ribavirin (24 weeks) + initial telepravir (12 weeks) versus PEG interferon (48 weeks) + initial telepravir (12 weeks) + initial low dose ribavirin (12 + 36 weeks) </span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007003.pub3/references#CD007003-tbl-0014">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD007003.pub3&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD007003-note-0016">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD007003-note-0021">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD007003-note-0014">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD007003-note-0013">Hrvatski</a> </li> <li class="section-language"> <a class="" href="hu#CD007003-note-0015">Magyar</a> </li> <li class="section-language"> <a class="" href="id#CD007003-note-0020">Bahasa Indonesia</a> </li> <li class="section-language"> <a class="" href="ja#CD007003-note-0019">日本語</a> </li> <li class="section-language"> <a class="" href="ko#CD007003-note-0011">한국어</a> </li> <li class="section-language"> <a class="" href="ms#CD007003-note-0012">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pl#CD007003-note-0022">Polski</a> </li> <li class="section-language"> <a class="" href="ru#CD007003-note-0010">Русский</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD007003-note-0017">简体中文</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD007003-note-0018">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007003\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007003\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007003\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD007003\x2epub3"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007003\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007003\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007003\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007003\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007003\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD007003\x2epub3"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007003\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007003\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007003\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD007003\x2epub3"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007003\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007003\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007003\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD007003\x2epub3"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=18M35a5z&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD007003.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD007003.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD007003.pub3/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD007003.pub3/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD007003.pub3%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740727341291"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD007003.pub3/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740727341295"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD007003.pub3/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918ea9af7c1b9377',t:'MTc0MDcyNzM0MS4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 